What if you could run an entire #drugdiscovery pipeline from a single chat?
In our Q3 pharma.ai webinar, we showed how Chemistry42 #mcp connects a compatible chat application to the platform’s scientific tools, so you can describe a workflow, review the setup, and work with the results in one conversation.
In this clip, the example workflow goes like this:
• Fetch and prepare a protein structure (PDB 9WGU)
• Generate molecules
• Profile their #admet properties
• Select compounds for further evaluation with Alchemistry, #retrosynthesis, and MDFlow
The key is the connection between steps: results from one experiment become inputs to the next, while the conversation retains the project, structures, and selection criteria.
Watch the 1-minute walkthrough here.
#chemistry42 #drugdiscovery #generativeai #mcp #insilicomedicine
Insilico Medicine
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company applies genomics, big data analysis, and deep learning for in silico drug discovery. More on Wikipedia
-
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🎬 Watch Longevity Grok tackle a real research case, from start to finish.
One question. An entire AI-powered research team. Every claim backed by sources.
Built for researchers, in collaboration with @davidasinclair.
👉 Explore Longevity Grok: longevitygrok.siThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧪 Insilico Medicine’s updated ADMET specialist achieved state-of-the-art performance on 17 benchmark tasks.
Trained through MMAI Gym, the model predicts properties related to absorption, distribution, metabolism, excretion, and toxicity, helping researchers better understand compounds throughout drug discovery.
🔬 Try it for free: playground.insilico.com -
Insilico Medicine
@InSilicoMeds
🧬 What if you could make a prediction about your health and then check how accurate it was?
Longevity Grok, developed by Insilico Medicine with @davidasinclair’s lab, brings together a team of agents on @bot to help you explore your health data and longevity research. It can create prediction cards for biomarkers and compare them with future measurements.
An exciting step toward more personalized, evidence-driven longevity research. 🔬
Try it here: longevitygrok.si -
Insilico Medicine
@InSilicoMeds
🌍 The complete longevity ecosystem, with citizen scientists, longevity medicine doctors, and institutional researchers working together around the clock with frontier AI systems, has long been a personal dream.
🧬 Its goal is to extend and improve life for everyone on the planet in a sustainable, maximally beneficial way, with full individual control. Grok Bot (@bot) made this possible.
🚀 When infrastructure and intelligence from the planet’s strongest technology and engineering team, with rigorous data security, privacy, and real flexibility, meet the strongest longevity AI research teams, always-on longevity superintelligence becomes reality.
Set up your own Longevity Grok: longevitygrok.si
Insilico Medicine 🤝 @davidasinclairThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Since its founding, Insilico Medicine has been dedicated to extending healthy, productive longevity and pushing the boundaries of human lifespan.
Proud to see our founder interviewed for @JoinLifespan by @davidasinclair, one of the most prominent academics in longevity biotechnology.
lifespan.com/blogs/magazine/im-fine-with-dying-not-with-d… -
Insilico Medicine
@InSilicoMeds
🆕 In the latest issue of Lifespan Magazine, Dr. David Sinclair sat down with our CEO, Dr. Alex Zhavoronkov, for a conversation on a profound new bottleneck in medicine: an excess of potential breakthrough medicines.
Historically, finding a single viable drug candidate took years of grueling trial and error. Today, AI allows scientists to scan tens of billions of molecules, spot hidden patterns across terabytes of data, and fast-track discovery at an unprecedented scale.
Read the latest issue here: lifespan.com/blogs/magazine/the-race-to-cure-all-diseases -
Insilico Medicine
@InSilicoMeds
We are proud to announce we’ve hit the early drug discovery milestone in our AI-powered oncology collaboration with Servier, just 10 months in!
This triggers a milestone payment from Servier and underscores the power of combining Insilico’s generative AI capabilities with Servier’s deep clinical expertise to accelerate the discovery of novel small-molecule therapeutics.
Thank you to Drug Discovery World for the coverage: www.ddw-online.com/partnership-advances-ai-driven-rd-coll…
#drugdiscovery #aidd #partnerships -
Insilico Medicine
@InSilicoMeds
A model is only as well evaluated as the benchmark used to test it.
In AI for drug discovery, we talk a lot about model performance. We talk far less about whether the benchmarks behind those numbers are the right ones.
That's the idea behind #o3dc, the Open Drug Discovery & Development Consortium, and its Benchmark Index: a community resource for finding, comparing and debating open benchmarks in drug discovery. Check out the latest video and let us know, which benchmark in your field deserves a closer look?
#insilicomedicine #drugdiscovery -
Insilico Medicine
@InSilicoMeds
What if #artificialintelligence could help humans not only reach 150 years of age, but spend those extra decades healthy, active, and biologically resilient?
Insilico Medicine Founder and CEO Dr. Alex Zhavoronkov recently joined @FoxNews Saturday in America to discuss how generative AI is shifting longevity medicine from science fiction to clinical reality. -
Insilico Medicine
@InSilicoMeds
#inclinico Agent: The Next Generation of Clinical Trial Intelligence
inClinico Agent is an advanced AI agent built to automate and accelerate clinical trial intelligence. By translating natural language queries into structured analytical workflows, inClinico Agent compresses months of manual trial landscape analysis into minutes.
Read our latest blog here: insilico.com/blog/inclinico-agent-clinical-trial-intellig… -
Insilico Medicine reposted
Rim
@RimShayakhmetov
We're presenting the accepted LFM+MMAI Gym paper at the ongoing EMNLP 2026 conference. Come talk to @AjMizera!
x.com/AjMizera/status/2115061296001409418
Congrats @InSilicoMeds teams and @liquidai (@ramin_m_h @xanamini) on making it possible - it was such a great LFM models transformation in MMAI Gym to become fluent in molecular formats and drug discovery tasks!
Paper: arxiv.org/abs/2603.03517
Here's the full poster 👇
Mikołaj Mizera
@AjMizera
How do you make a foundation model fluent in drug discovery? 🧬💊
Excited to present our paper at #emnlp2026:
“MMAI Gym for Science: Training Liquid Foundation Models for Drug Discovery”
400+ tasks. One goal: teach Liquid AI models the language of drug discovery.
Come chat! -
Insilico Medicine
@InSilicoMeds
📊 Introducing DDDBench Core: 59 essential drug discovery benchmarks across five R&D domains, selected from over 300 benchmarks in Foundations.
🔹Generalist Models: See how leading frontier models perform across core drug discovery tasks. GPT-6 Astra currently tops the leaderboard.
🔹Specialist Models: Our compact 2.6B and 4B MMAI Gym models outperform dedicated tools and generalist models on specific tasks, including single-step retrosynthesis, ADMET, Kinome, and GPCR predictions.
🏆 Which models lead in AI-driven drug discovery?
Explore the live benchmarks and leaderboards:
👉 dddbench.insilico.com
#dddbench #insilicosotafm -
Insilico Medicine
@InSilicoMeds
🚀 Introducing #inclinico Agent: an agentic AI system that predicts clinical trial outcomes.
📊 Efficacy AUROC: 0.828 | Safety AUROC: 0.809
🔍 Built on over 100,000 trial records, live clinicaltrials.gov queries
🎯 A head-to-head prospective benchmark with 5 frontier LLMs for 3,235 ongoing Phase I–III clinical trials.
Now available to industry partners: pharma.ai/inclinico -
Insilico Medicine
@InSilicoMeds
🎥 From molecular design to human testing.
An important moment for Insilico’s oncology team as we share early Phase 1 findings for ISM6331 at #esmo2026.
Thank you to the participants, families and clinical teams.
Investigational; dose escalation ongoing. Release ↓This media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine introduces #inclinico Agent: An agentic AI system designed to accelerate clinical trial intelligence and predict trial outcomes
Read the latest release here: insilico.com/news/pr0f93d4df1efbf84e2ded-insilico-medicin… -
Insilico Medicine reposted
𝔸𝕦𝕝𝕒𝕤 𝕀𝕟𝕥𝕖𝕝𝕚𝕘𝕖𝕟𝕥𝕖𝕤
@AulasInteligent
Avances realmente interesantes en #esmo2026 en Madrid. Destacamos este avance publicado por @InSilicoMeds del posible uso de ISM6331 para el tratamiento de mesotelioma y otros tumores sólidos avanzados, en el que el diseño molecular se apoyó en el uso de la IA (Chemistry42).
-
Insilico Medicine
@InSilicoMeds
🚨 Can we predict clinical trial success?
Introducing inClinico Agent by Insilico Medicine. 🧬
⚡ Months of analysis → minutes
🧠 100,000+ clinical trials
🎯 AI-powered outcome predictions
Clinical development is going agentic. 🧵This media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
How accurate is it? 📊
Validated on 939 clinical trials completed in 2025:
🎯 78% accuracy in Phase 3
📈 0.805 overall AUROC
✅ 73.4% overall accuracy
Predicting trial outcomes using data available before results are known.
Insilico Medicine
@InSilicoMeds
🤖 Are frontier models too optimistic?
We benchmarked 5 leading frontier models against inClinico Agent on 3,311 ongoing trials.
🔹 Frontier models predicted 75–82% would meet their endpoints.
🔹 inClinico Agent predicted ~50%.
Historical test-set success rate? 53%.
Predictions are locked. Results will reveal who's right. 🔒
Insilico Medicine
@InSilicoMeds
And it's more than a prediction. 🚀
🔬 Competitive trial intelligence
🧬 Biomarker analysis
💊 Safety assessments
📋 Clinical protocol design
📝 Regulatory documentation
From drug discovery to clinical development.
📄 doi.org/10.64898/2026.10.13.26365373 -
Insilico Medicine
@InSilicoMeds
🧪 Introducing #chemcensor: now in #chemistry42 #retrosynthesis.
A precedent-based score (0-5) that checks whether a proposed reaction is actually chemically plausible: same reaction center, same functional-group compatibility, backed by real documented precedent. Not pattern-matching, chemist logic, systematized.
Introduced at ICML 2026, Seoul. Learn more: insilico.zoom.us/webinar/register/2117878442285/WN_gLMYTG…
#pharmaai2026 -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment insilico.com/news/prae42d246d48ff71179df-insilico-medicin…
-
Insilico Medicine
@InSilicoMeds
Up to $888M. 2 oncology programs. First R&D milestone. 🧬
Insilico Medicine and Servier have reached the first R&D milestone in their AI-driven oncology collaboration, powered by pharma.ai.
Read the press release:
insilico.com/news/prae42d246d48ff71179df-insilico-medicin… -
Insilico Medicine
@InSilicoMeds
🧬 New PandaOmics Agent skill: Single-Cell Signature
Understanding #geneexpression across cell types and disease states is core to target validation and biomarker discovery, but digging through single-cell datasets by hand is slow.
PandaOmics now includes 1,700+ single-cell RNA-seq datasets, searchable with a simple text request. In this clip: we ask about #rheumatoidarthritis and a short list of genes of interest (S100A8, S100A9, IL1B, TNFAIP3, JAK3, IRF1), and the agent:
🔹 Automatically locates the relevant datasets
🔹 Identifies case vs. control groups
🔹 Compares expression across cell types
🔹 Outputs a split dot plot (cases vs. controls side by side), dot size = % of cells expressing each gene, color = average expression level
🔹 Delivers a DE heatmap, full expression tables, and a written biological summary highlighting the most interesting changes
From a one-line question to a complete, cell-type-resolved differential expression report.
👉 Watch the full clip.
#pandaomics #singlecellrnaseq #drugdiscovery #targetvalidationThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
📺 Our Founder & CEO on @FoxBusiness: #ai, #aging, and what Phase III actually means
Alex Zhavoronkov, PhD sat down with Fox Business to talk about where Insilico Medicine stands today: 40+ drug candidates in the pipeline, and one, a treatment for idiopathic pulmonary fibrosis (#ipf), a deadly lung disease with an average onset age of 65, now in Phase III clinical trials, the final stage before approval.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Event Recap 📽️
At the 13th Aging Research & Drug Discovery Meeting (#ardd2026) at Harvard University, Dr. Andrew Brack, Program Manager for Proactive Health at ARPA-H, presented an inside look at PROSPR, a landmark 5-year, up to $144 million federal initiative engineered to establish the #clinical, #regulatory, and data infrastructure required to turn healthspan therapeutics into an actionable industry.
Check out his presentation in this video below.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧪 New #featurefriday in #chemistry42: Typed Excluded Volumes
Excluded volumes aren’t new, but typed ones are. Instead of just blocking a region of space, you can now specify exactly what’s not allowed there: no aromatic rings, no H-bond donors, no positively charged groups, whatever the medicinal chemistry calls for.
In this short clip, we walk through a real B-RAF growth-vector example.
#pharmaai #generativechemistryThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
Access the full recording here: insilico.zoom.us/webinar/register/3817878442258/WN_gLMYTG…
-
Insilico Medicine
@InSilicoMeds
67 kinases. What else could your molecule hit? 🎯
Meet MMAI KINOME, Insilico Medicine’s specialist AI model for predicting kinase activity and exploring selectivity.
Bring your molecule. Explore the predictions. FREE to try.
👉 playground.insilico.com -
Insilico Medicine
@InSilicoMeds
In the Virtual Cell forum, Petrina Kamya, Global Head of AI Platforms at Insilico Medicine, presented the company's Virtual Aging Cell simulation framework. Built upon 12 years of proprietary data and benchmarking, the Virtual Aging Cell operates as a multi-agent system spanning five biological scales, including molecular, intracellular, intercellular, tissue/organ, and organism levels.
The system utilizes approximately 43 specialized AI agents per biological layer to simulate post-intervention cell state transitions against patient-seeded baseline graphs. Kamya emphasized that prospective validation in Insilico’s fully automated robotic laboratory, testing novel molecules with unknown mechanisms, is currently being executed to rigorously validate predictions and rule out literature memorization.This media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
🚀 Explore the Virtual Cell today virtualcell.insilico.com
-
Insilico Medicine
@InSilicoMeds
ARDD 2026 Signals a New Era for Longevity Biotechnology as Frontier AI, Big Pharma, and Scientific Pioneers Converge at Harvard firstwordpharma.com/story/8206940
-
Insilico Medicine
@InSilicoMeds
We are thrilled to announce that Insilico Medicine’s Founder and CEO, Dr. Alex Zhavoronkov, will be speaking at the Abu Dhabi Future Health Summit 2026 next week!
Join him on the Forum Stage on October 21st (11:35 – 12:15) for the highly anticipated panel: "The Future of Drug Discovery." -
Insilico Medicine
@InSilicoMeds
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted #vav1 Degrader as PCC for Autoimmune Diseases
insilico.com/news/pr2ac063260245a3ca0cea-ai-driven-molecu… -
Insilico Medicine
@InSilicoMeds
1 model. 28 predictions about your molecule. 🧪
Will it be absorbed by the body? Could it be toxic? How might it behave as a potential drug?
Meet MMAI ADMET, part of our family of SOTA models for drug discovery. 🧪
🚀 Now FREE to try!
👉 playground.insilico.com -
Insilico Medicine
@InSilicoMeds
4 state-of-the-art drug discovery models. FREE to try. 🧪
Got compounds? Put them to the test.
💊 ADMET. Kinase selectivity. GPCR interactions. Synthetic chemistry.
Your compounds. Real-time predictions. Zero cost to try.
👉 playground.insilico.comThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
Want to explore our models' performance in more detail?
Visit dddbench.insilico.com to see the benchmark results. -
Insilico Medicine
@InSilicoMeds
11 preclinical drug candidates in 10 months. 🧬
Meet ISM9546, our AI-designed molecular glue that degrades VAV1, a regulator of immune-cell activation.
An orally bioavailable drug candidate for autoimmune diseases, including rheumatoid arthritis and IBD.
More here:This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Event Recap 📽️
At the 13th Aging Research & Drug Discovery Meeting (ARDD 2026) at Harvard University, Insilico Medicine CEO Dr. Alex Zhavoronkov took the main stage to present our latest clinical findings: the first demonstration of biological age reduction in a #phase2a clinical trial using six independent proteomic #aging clocks.
Catch the 15-minute cut of Alex’s keynote, exploring how Insilico is bridging the gap between acute disease treatment and healthy #longevity.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Three days at Harvard. Aging scientists, AI researchers, big pharma and regulators. 🧬
#ardd2026 brought them together to discuss longevity research and drug discovery.
Full recap in the comments 👇
Insilico Medicine
@InSilicoMeds
ARDD 2026 recap: insilico.com/news/pr7568d8c5d757d0bcfd61-ardd-2026-signal…
-
Insilico Medicine
@InSilicoMeds
Insilico picks AI-designed GIPR blocker for next obesity drug
longevity.technology/news/insilico-picks-ai-designed-gipr… -
Insilico Medicine
@InSilicoMeds
Insilico Medicine CEO & CBO, Dr. Alex Zhavoronkov, recently took the stage at the Aging Research & Drug Discovery Meeting (ARDD) 2026 to present groundbreaking data on how we are leveraging generative AI to pioneer a new era of "aging-first" drug discovery.
In his presentation, Alex detailed the remarkable seven-year journey of our lead anti-fibrotic program, a story recently highlighted in a Harvard Business School case study and supported by a multi-omics Phase 2 analysis published in Springer Nature Biotechnology.
The presentation can be found here 👉www.youtube.com/watch?v=oQt8Cc2SXbg
#ardd2026 #agingresearch #drugdiscovery #bostonbiotech -
Insilico Medicine
@InSilicoMeds
🍁 Excited to see our own Michael Mahdavi, MSc on stage in #montréal.
Michael, Senior BD & Strategic Partnerships Manager for AI Platforms at Insilico Medicine, joins the panel "From Drug Discovery to Clinical Trials" at AI in Life Sciences: From Discovery to Impact, hosted by the Embassy of Spain in Canada and Acerca.
🗓️ Wednesday, October 14, 16:25-17:10
📍 Mila - Quebec Artificial Intelligence Institute
Michael's work on the BD and strategic partnerships side of pharma.ai, which puts him right at the center of this conversation, connecting AI driven discovery with the partners, pipelines, and real-world deployments that get it into the clinic. Looking forward to hearing his perspective on stage.
If you're at the event, don't miss this panel. 🧬 For event information and registration details, please visit: luma.com/6harfmuj -
Insilico Medicine
@InSilicoMeds
📼 Missed pharma.ai Q3 Fall update last week? It's now on demand.
Last Wednesday, we walked through the latest chapter of Pharmaceutical Superintelligence (PSI), one expanding ecosystem, built around a simple arc: Train → Evaluate → Connect → Apply.
What we covered:
🔹 DDD Bench: rigorous evaluation for unseen drug discovery and development problems, with consistent datasets, splits, and metrics for more rigorous comparison [dddbench.insilico.com]
🔹 MMAI Gym: targeted post-training that turns general-purpose language models into scientific specialists [insilico.com/mmai]
🔹 Specialist Models: SOTA-level or superior performance across 70+ benchmark tasks in chemistry and biology
🔹 O3DC: our open benchmark infrastructure for assessing scope, strengths, limitations, and known biases across the field [o3dc.org]
🔹 Virtual Aging Cell: age-aware biological modeling across multi-omics and perturbations [virtualcell.insilico.com]
🔹 MCP Connectivity: natural-language access to multi-step pharma.ai workflows, enabling scientific agents to execute real tasks through conversation
Plus live updates across our three flagship platforms: Generative Biologics, Chemistry42, and PandaOmics.
If you missed the event, the full session is now available on demand.
👉 [Watch now insilico.zoom.us/webinar/register/2117878442285/WN_gLMYTG…]
#pharmaceuticalsuperintelligence #pharma.AI #aiforscience #drugdiscovery -
Insilico Medicine
@InSilicoMeds
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist insilico.com/news/prfc6c0d56cc3e2211e1d0-ism1354-gipr-ant…
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine CEO Alex Zhavoronkov discusses longevity therapeutics and pipeline progress on BiotechTV. 🧬 Topics include biomarkers and the longevity component of Insilico's IPF trials. 🔬 #longevity #clinicaltrials
Insilico Medicine
@InSilicoMeds
BiotechTV interview:
www.biotechtv.com/post/insilico-medicine-october-5-2026 -
Insilico Medicine
@InSilicoMeds
🇦🇪 AI-powered drug discovery in the UAE is in the spotlight on @DubaiEye1038FM
Ahmad Al Ghaith, an organic chemist at Insilico Medicine, joined @georgiatolley to discuss how the UAE’s support for research and innovation helps advance the development of new medicines.
He then explored the science behind our team’s use of AI to discover potential treatments for blood cancers, following our recent publication in the Journal of Medicinal Chemistry.
▶️ Watch the interview below. -
Insilico Medicine
@InSilicoMeds
📅 Insilico Medicine will make an appearance at BioJapan 2026, held from October 7 to 9 at PACIFICO Yokohama, at Booth D74. Insilico’s Business Development team will be on-site to engage in face-to-face meetings with attendees and potential partners. We look forward to discussing emerging trends in AI-driven drug discovery, sharing practical insights on generative AI across the entire drug development lifecycle, and exploring multifaceted strategic partnering opportunities.
About BioJapan 2026 👇
Founded in 1986, BioJapan is Asia's oldest and largest premier biotechnology event. The 2026 edition will take place from October 7 to 9 at PACIFICO Yokohama.
The event convenes global pharmaceutical leaders, innovative biotech companies, renowned academic institutions, and investors, focusing on frontier areas such as generative AI for drug discovery, cell and gene therapy, precision oncology, and longevity biology. Through its open innovation platform, BioJapan connects global pharma with Asian innovation sources, serving as a key benchmark for expanding global life science footprints and forging strategic licensing and R&D partnerships.
You can catch the latest release here: www.eurekalert.org/news-releases/1146037
#biojapan #innovation #biopartnering -
Insilico Medicine
@InSilicoMeds
🇦🇪 Insilico Medicine’s UAE research is featured in The National!
Our colleague Ahmad Al Ghaith, an organic chemist at Insilico Medicine, spoke to Daniel Bardsley from @TheNationalNews about how our team in the UAE used AI to advance the discovery of potential treatments for blood cancers.
The feature follows our recent publication in the Journal of Medicinal Chemistry and highlights the UAE’s growing capabilities in developing new medicines.
Want to learn more about Insilico’s work to develop new treatments in the UAE?
🔗 Link to the full story in the comments.
Insilico Medicine
@InSilicoMeds
Read the full story: www.thenationalnews.com/news/uae/2026/10/04/uae-scientist…
-
Insilico Medicine
@InSilicoMeds
🧬 Cracking the Code of Life with AI
Our Founder & Co-CEO, Alex Zhavoronkov, PhD, is heading to the Abundance Longevity Trip in #sanfrancisco to talk about using frontier AI to develop longevity therapeutics.
Alex has been invited to attend the Abundance Longevity Trip, founded by Dr. Peter H. Diamandis.
As a recognized thought leader in #aging research and #longevity biotechnology, Dr. Zhavoronkov will join top global longevity scientists and biotech founders. Drawing from Insilico's pioneering breakthroughs, he will share insights into AI biology of aging, anti-aging interventions, and longevity drug discovery, joining fellow delegates to usher in a new era of AI-driven longevity medicine.
If you're there, don't miss this session! For more information, please visit: longevity.abundance360.com -
Insilico Medicine
@InSilicoMeds
Insilico Medicine shared rentosertib updates for idiopathic pulmonary fibrosis at the 10th IPF Summit. 🫁 In focus: Phase III GENESIS-IPF-3 in China and the inhaled clinical program. 🔬 #insilicomedicine #clinicaltrials
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine is helping convene ARDD 2026, which opened today at the David Rubenstein Treehouse at Harvard University. 🧬 Aging research meets AI and clinical medicine. In Boston? Meet our team. 🤝 #longevity #drugdiscovery
Insilico Medicine
@InSilicoMeds
ARDD 2026 program 📋
agingpharma.org/program2026 -
Insilico Medicine
@InSilicoMeds
Insilico Medicine nominates ISM1354, an AI-driven small-molecule GIPR antagonist, as a preclinical candidate for obesity.
🧬 Preclinical findings support its advancement into further safety studies. 🔬 #aidrugdiscovery #drugdevelopment
Insilico Medicine
@InSilicoMeds
Full announcement:
insilico.com/news/prfc6c0d56cc3e2211e1d0-ism1354-gipr-ant… -
Insilico Medicine
@InSilicoMeds
🤖 Taking place next week! Ai Everything Abu Dhabi "The Machines Curing Us"
Join our Co-founder & President, Alex Aliper, PhD, on October 6, 2026 at T3 Frontier, ADNEC Center, Abu Dhabi for a session on how AI is reshaping the path from molecule to medicine.
At AI Everything Abu Dhabi, discover how AI is transforming biology into the next trillion-dollar innovation platform, from decoding biology and accelerating drug discovery to turning genomics into strategic assets and building the AI-powered bioeconomy. Ai Everything Abu Dhabi
🗓️ October 6, 2026
🕑 2:00 PM – 2:30 PM
📍 T3 Frontier, ADNEC Center, Abu Dhabi
If you're attending AI Everything, don't miss this one! Event details can be found here: visit.aieverythingabudhabi.com
#aieverything #abudhabi -
Insilico Medicine
@InSilicoMeds
Ready to see how Agentic AI is transforming drug discovery? 💻
Our software team at Insilico Medicine has been hard at work behind the scenes preparing an insightful session, and we’re excited to welcome our community in just a few hours.
Join us live as we dive into real-world applications, agentic workflows, and the future of AI-driven therapeutics.
🗓️ Beginning this morning at 10:00 AM ET
🔗 Register: insilico.zoom.us/webinar/register/2117878442285/WN_gLMYTG…
#pharmaai2026 #pharmaaieventsThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Sign up here: insilico.zoom.us/webinar/register/2117878442285/WN_gLMYTG…
Join Insilico Medicine’s pharma.ai Fall Event to explore the benchmarks, specialized models, and research platforms advancing AI-driven drug discovery.
Our Open Science and New Research Platforms session will cover:
📊 DDD Benchmarks: A unified platform featuring 300+ drug discovery benchmarks, bringing curated datasets and specialized evaluations together to assess scientific AI.
🎯 SOTA Models: Specialist and multi-task models achieving SOTA+ performance on 57 drug discovery tasks, built for biological and chemical applications and complex scientific reasoning.
🏋️ MMAI Gym for Science: A post-training environment delivering up to 10× performance gains over general models on selected drug discovery tasks. Explore LFM2-2.6B-MMAI, developed with Liquid AI, for lightweight, on-premise deployment.
🌐 O3DC Consortium: A free, open-access community index evaluating benchmark quality across 15 consortia and 10 categories, making evaluation limitations easier to identify.
🔬 Virtual Aging Cell: A multi-agent cellular modeling platform simulating biological age, cell fate, and responses to compound perturbations.
Connect with pharmaceutical leaders, computational biologists, and medicinal chemists as we explore Pharmaceutical Superintelligence and the practical deployment of agentic research workflows.
#insilicomedicine #pharmaai #mmaigym -
Insilico Medicine
@InSilicoMeds
Don't miss Petrina Kamya, Ph.D. (Global Head of AI Platforms & VP, Insilico Medicine; President, Insilico Medicine Canada) as she kicks off with The Model Validation to Clinical Translation featured presentation today. Happening at #bostondot26!
Event details: www.discoveryontarget.com/ai-machine-learning-driven-drug…
#discoveryontarget -
Insilico Medicine
@InSilicoMeds
🚀 NEXT WEEK: Agentic AI takes the wheel of pharmaceutical intelligence. Register here: insilico.zoom.us/webinar/register/2117878442285/WN_gLMYTG…
The next leap in AI-driven drug discovery isn't one bigger model, it’s an ecosystem of specialized engines, scientific agents, and rigorous benchmarks working as one.
Join us on Wednesday, September 30, at 10:00 AM ET for the pharma.ai 2026 Q3 Fall Update as we unveil the future of autonomous drug discovery.
What We’ll be presenting:
pharma.ai Speaks MCP: With Model Context Protocol (MCP) servers integrated across the stack, autonomous agents can now connect directly into our biology, chemistry, and biologics engines—automating multi-step workflows inside the AI tools researchers already use.
Generative Biologics Upgrade: Design novel, high-affinity biologics against complex targets in under 72 hours, backed by epitope prediction workflows and end-to-end agentic screening.
Next-Gen PandaOmics Agent Skills: Introducing Single-Cell Signature analysis, automated Indication Prioritization, and CADD Structural Review to streamline target validation.
Open Science & AI Evaluation: Premiering open-access evaluation resources including the O3DC Consortium, DDD Benchmarks, and a preview of our multi-agent Virtual Aging Cell platform.
"With pharma.ai now speaking MCP, researchers can plug our platforms directly into their own AI environments and let autonomous agents run real discovery workflows, from target evaluation to antibody design. That is how we move beyond AI-powered tools to true pharmaceutical superintelligence."
- Alex Aliper, PhD, President of Insilico Medicine -
Insilico Medicine
@InSilicoMeds
Bridging the gap between #targetdiscovery and autonomous chemistry pipelines is critical to the future of AI drug discovery, and Discovery on Target remains one of the premier events where the #drugdiscovery community tackles these challenges head-on.
Don't miss Petrina Kamya, Ph.D. (Global Head of AI Platforms & VP, Insilico Medicine; President, Insilico Medicine Canada) as she presents: 📍 "Building Agentic AI Workflows for Drug Discovery: From LLM Tools to Autonomous Discovery Pipelines"
Join us in Boston (Sept 28 - Oct 1) at the Sheraton Boston to see how autonomous agentic workflows inside pharma.ai are streamlining target identification (PandaOmics) and de novo molecular generation (Chemistry42).
👉 Details & Session Info: www.linkedin.com/posts/petrinakamya_discoveryontarget-bos… -
Insilico Medicine reposted
Rim
@RimShayakhmetov
Thought pharma was too complex for Jev-like models? Don't think twice.
A plain-language guide to System 1 in drug discovery: what Jev actually does, why new molecules are the hard part, and how small language models answer, fast and accurately, today. x.com/i/article/2102322860299599872 -
Insilico Medicine reposted
Stefan N.
@stefan_neymark
AgingJev we published in 2023 x.com/i/article/2103062526569177088
-
Insilico Medicine
@InSilicoMeds
Agentic AI takes the wheel of pharmaceutical intelligence.
AI can answer questions. What happens when it starts coordinating drug discovery?
Our pharma.ai 2026 Fall Update Preview explores where agentic AI is heading and what it could mean for pharmaceutical R&D.
Read the article for a closer look. ↓
#pharmaai #agenticai #drugdiscovery #pharmaceuticalresearch #ai
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🕐 The Aging Research & Drug Discovery Meeting begins on October 1!
The 13th Aging Research & Drug Discovery Meeting kicks off at the David Rubenstein Treehouse, Harvard University, and two of our own will be on stage across four sessions.
Alex Zhavoronkov, PhD (Founder, CEO, CBO) opens on October 2nd:
🔹 9:30 AM - Aging-first Drug Discovery with #mmai and Longevity Foundation Models (AI in Drug Discovery Forum)
🔹 10:20 AM - Longevity Therapeutics as the Most Impactful Trillion-Dollar Industry in Biotechnology (Main Stage)
Petrina Kamya, Ph.D., (Global Head of AI Platforms, VP; President of Insilico Medicine Canada) covers the Virtual Aging Cell across two days:
🔹 Oct 2, 3:35 PM - Introducing Insilico Medicine's Virtual Aging Cell (Virtual Cell in Time Forum)
🔹 Oct 3, 4:15 PM - Science Panel: Aging as a Stress Test of the Virtual Cell (Virtual Cell in Time Forum)
If you're in Boston, come join us and support our mission to help cure #aging.
See you there
#ardd2026 #agingresearch #longevity #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Aging remains one of the most complex challenges in biological science. In a landmark study selected as the cover story for Cell (September 17, 2026), Insilico Medicine and international research partners introduced a complete open-source AI toolkit designed to evaluate and accelerate longevity research.
This short documentary explores how domain-specific language models and multi-agent platforms move beyond conventional chatbots to autonomously plan research workflows, evaluate multi-omics data, and identify candidate targets for anti-aging interventions.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧪 Great model. Or a generous data split?
In one solubility study, changing the split moved CV R² from 0.73 to 0.83. Test R² stayed between 0.81 and 0.83.
The split changed the story more than the test performance.
Before you trust the metric, check the split. 👇Post not available here, view on X
Insilico Medicine
@InSilicoMeds
The average score tells only part of the story.
CV R² standard deviation:
Scaffold: 0.06
Balanced scaffold: 0.06
Random: 0.02
Radial: 0.01
Balancing scaffolds raised the average score, but didn’t make it more consistent across folds in this experiment.
Insilico Medicine
@InSilicoMeds
Choose the split for the question you need answered. Scaffold splits test the jump to unfamiliar scaffolds.
Radial led here, but the test set used radial splitting too. The next check: a test set built with an independent criterion.
👉 insilico.com/blog/data-splitting -
Insilico Medicine
@InSilicoMeds
📊 DDD Benchmarks: 300+ drug discovery benchmarks.
🧬 SOTA models: SOTA+ performance on 57 drug discovery tasks.
Join Insilico Medicine’s pharma.ai Fall Event to explore the platforms advancing scientific AI.
Here’s what’s on the agenda. 👇Post not available here, view on X
Insilico Medicine
@InSilicoMeds
🔬 Explore biology. Build scientific specialists.
Virtual Aging Cell models biological age, cell fate, and compound responses through multi-agent simulation.
Our SOTA models tackle targeted biological and chemical tasks.
Insilico Medicine
@InSilicoMeds
🏋️ Also on the agenda: MMAI Gym for Science, with up to 10× gains over general models on selected drug discovery tasks.
Discover LFM2-2.6B-MMAI, developed with Liquid AI. -
Insilico Medicine
@InSilicoMeds
🧬 Longevity science is moving toward medicines. The people who can make that happen are coming to Harvard.
📅 @ARDD_Meeting 2026: October 1–3.
Global pharma. FDA and ARPA-H representatives. Aging research pioneers.
The program is live: agingpharma.org/program2026
#ardd2026
Insilico Medicine
@InSilicoMeds
What’s on the agenda?
💊 Pharma leadership panel
🏛️ FDA + ARPA-H discussion on trials and regulation
🏆 11 XPRIZE Healthspan finalist teams
🔬 Forums on AI drug discovery, pet longevity and virtual cells that model aging
Insilico Medicine
@InSilicoMeds
How do we turn advances in aging biology into therapies that reach patients?
Join the conversation at ARDD 2026.
📍 October 1–3 | David Rubenstein Treehouse at Harvard University
🎟️ Program + registration: agingpharma.org -
Insilico Medicine
@InSilicoMeds
26 drug safety tasks. 1 model.
Potency gets the headlines.
Safety decides whether the molecule can become a drug. 🧪
Our 4B InsilicoMMAI-Chem-ADMET model predicts safety, metabolism and PK endpoints across a single specialist model.
🚀 SOTA+ on 7 tasks
🧬 Trained on 140K+ datapoints in MMAI Gym for Science
#insilicosotafm
Insilico Medicine
@InSilicoMeds
The 7 SOTA+ tasks answer some very practical drug discovery questions:
🧬 Will it inhibit CYP1A2, CYP2C9, CYP2C19 or CYP3A4?
☠️ Is it cytotoxic in HEK293 cells?
🩸 How strongly does it bind plasma proteins in humans and mice?
Same data. Same split. Better than Chemeleon, MapLight, MapLight+GNN, and MiniMol.
🔬 Results: dddbench.insilico.com
📩 Try it on your own task: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
Insilico Launches AI-Driven Longevity Vaccines Research Program www.biopharminternational.com/view/insilico-ai-driven-lon…
-
Insilico Medicine
@InSilicoMeds
New from Insilico in Cell! 🤖 @biogerontology and Fedor Galkin discuss our latest publication: an ecosystem of AI tools for #aging research, including Longevity Benchmarks, Longevity LLMs, and the Longevity Claw multi-agent system.
Explore the tools: www.longevitybenchmarks.org
Watch the video: www.youtube.com/watch?v=9oL6Rlubs0w
#longevity #ai #biotechThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Aging has a language. 🧬 We’re teaching AI to read it.
On the cover of Cell: compact Longevity-LLMs, jointly trained by Insilico Medicine and @liquidai, demonstrate SOTA performance on LongevityBench.
Powered by these models, Longevity Claw nominated 328 candidate gene targets for aging research.
Small model. Big questions. Open source. 🧵👇
#insilicosotafm
Insilico Medicine
@InSilicoMeds
And the work is featured on the cover of Cell, one of the leading scientific journals. 🧬
A special moment for the team, and a great way to mark the release of LongevityBench, Longevity-LLMs, and Longevity Claw.Post not available here, view on X
Insilico Medicine
@InSilicoMeds
Longevity-LLMs: Small model. Big result. 🤖
Our compact Longevity-LLM, trained in the MMAI Gym for Science, ranks #1 overall across all 17 tasks and 5 domains, ahead of every frontier model we evaluated, at a fraction of the size.
Explore the open-source model:
🔗
Insilico Medicine
@InSilicoMeds
Longevity Claw puts the Longevity-LLMs to work. 🧬🔎
It identified 328 candidate gene targets across 14 aging-related research categories, achieving up to 5.6× enrichment over an independent set of experimentally validated targets.
Explore the code:
🔗 github.com/Insilico-org/longeclaw -
Insilico Medicine reposted
Alexander Amini
@xanamini
A foundation model for aging biology 🧬
Our LFMs are now matching or beating frontier models across clinical data, genetics, methylation, transcriptomics, and proteomics – using a single model family across the full biological stack.
Published today on the cover of @CellCellPress!
Read more and play with the model 👉 www.liquid.ai/blog/longevitybench
Full paper 👉 doi.org/10.1016/j.cell.2026.08.026This media couldn't be displayed. See it on the original post.
Liquid AI
@liquidai
In a new article published today on the cover of @CellCellPress, we obtained Liquid Foundation Model instances that establish state-of-the-art performance on biological longevity tasks, outperforming the best frontier models such as Gemini-3.1-Pro, GPT-5, and Claude Opus.
In partnership with @InSilicoMeds, we built and released:
> A comprehensive eval suite of 17 biological longevity tasks (i.e., LongevityBench), to assess whether a general-purpose language model can interpret aging data spanning clinical records, DNA methylation, transcriptomics, plasma proteomics, and genetic evidence.
> LFM2-1.2B-Longevity and LFM2-2.6B-Longevity: two compact models specialized for interpreting structured aging data across these tasks.
These results are important! 🧵 -
Insilico Medicine
@InSilicoMeds
From measuring biological age in patients to opening the next generation of longevity discovery.
In a new Cell Press cover special edition, Insilico Medicine and collaborators introduce an open AI toolkit built to accelerate aging research worldwide:
🔹 LongevityBench: the first open benchmark for AI reasoning across multiple domains of aging biology
🔹 Longevity-LLMs: compact, specialized models, with the top model ranking first among 26 AI systems tested
🔹 Longevity Claw: an agentic research platform that autonomously nominated 328 potential longevity targets across 14 hallmarks of aging
Following our recent Nature Biotechnology paper of biological aging signatures in the rentosertib Phase IIa trial, this work takes the next step: giving researchers open tools to identify and develop future longevity interventions.
Read our Cell study and access the open-source resources: www.cell.com/cell/fulltext/S0092-8674(26)00999-2
#longevity #artificialintelligence #drugdiscovery #agingresearch #generativeai #openscience -
Insilico Medicine
@InSilicoMeds
[News Release 🚀] Insilico Medicine Strengthens Its Middle East Presence with potential Blood Cancer treatment, generated by AI, first of its kind in the #uae
insilico.com/news/btk170926en-insilico-medicine-uae-btk-p… -
Insilico Medicine
@InSilicoMeds
🇦🇪 New AI drug discovery milestone from the UAE: BTK-targeting PROTACs for potential applications in blood cancers.
Our UAE team used AI to help design a new series of BTK degraders.
🧬 Lead compounds showed picomolar BTK degradation
💊 Oral bioavailability in mice
🎯 Activity against wild-type and mutated BTK
🤖 Novel building blocks designed with Chemistry42
The research was published in the Journal of Medicinal Chemistry and builds on Insilico Medicine’s growing drug discovery efforts in the UAE.
From designing molecules locally to publishing internationally, this is another step toward building AI-powered drug discovery capabilities in Abu Dhabi. 🇦🇪
Insilico Medicine
@InSilicoMeds
The team synthesized and tested 40+ compounds, systematically optimizing linker design, BTK degradation, activity against resistant BTK mutants, safety, and pharmacokinetics.
Two lead compounds stood out:
🧬 ISM-PR25: DC₅₀ 0.04 nM, nearly 10× stronger antiproliferative activity than the clinical-stage reference NX-5948, with 26% oral bioavailability in mice.
🧬 ISM-PR44: DC₅₀ 0.05 nM, high HSC safety index of 205, low clearance, and 29% oral bioavailability.
Insilico Medicine
@InSilicoMeds
Link to the study: doi.org/10.1021/acs.jmedchem.6c01136
Link to the press release: insilico.com/news/btk170926en-insilico-medicine-uae-btk-p… -
Insilico Medicine
@InSilicoMeds
What if we could eliminate the cellular drivers of age-related disease before they take hold?
Insilico Medicine has launched Longevity Vaccines, a new research initiative combining generative AI with programmable RNA medicine to develop single-administration, self-limiting in vivo cell therapies.
Powered by pharma.ai, aging foundation models, and the Virtual Aging Cell, the program is designed to direct a patient’s own immune cells to identify and clear senescent, fibrotic, and autoreactive cells—starting with immune system rejuvenation.
This marks an important expansion of our aging-first discovery strategy: from treating established disease to targeting its earliest cellular causes.
Read more: insilico.com/news/lgv150926en-ai-driven-longevity-vaccines
#longevity #healthyaging #generativeai #rnamedicine #celltherapy #drugdiscovery -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:750603248067…
📍Heading to Boston for #discoveryontarget2026? 🧬
We’re excited to connect with the Discovery on Target community from September 28-October 1 at the Sheraton Boston.
As #drugdiscovery evolves from standalone computational tools to autonomous, #agenticai pipelines, #chemistry42 continues to push the boundaries of generative chemistry and 3D molecular design.
Catch Petrina Kamya, Ph.D. Kamya, PhD, Global Head of AI Platforms & VP, Insilico Medicine; President, Insilico Medicine Canada, as she shares insights on building agentic AI workflows, bridging the gap between multi-omics data and automated molecular optimization.
Sessions: Swipe through the graphic to view Petrina’s scheduled talks.
Interested in seeing how Chemistry42 can supercharge your pipeline? Drop a comment below or email us [Pharma.ai@insilicomedicine.com] to schedule a 1-on-1 meeting.
See you in Boston!
#bostondot #bostonbiotech #drugdiscoveryevents -
Insilico Medicine
@InSilicoMeds
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧬 Introducing Longevity Vaccines.
Building on experience from the Rentosertib program, Insilico’s new research initiative extends its strategy of tackling both disease and biological aging into preventive cell clearing.
🛡️ Combining AI and circular mRNA, the approach aims to equip the body’s own T cells to remove selected aging immune cells.
🎯 Advancing the science of longevity.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
One molecule. What else does it hit? 🧬
That’s one of the hardest questions in kinase drug discovery.
We’re releasing InsilicoMMAI-4B-Chem-Kinome, a 4B specialist language model for kinase potency prediction.
Trained on 210,000+ data samples and achieved SOTA performance on 31 diverse kinase targets. 🚀
#insilicosotafmThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
🔬 Check the benchmark results:
dddbench.insilico.com
Want to test it on your own task?
📩 MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
🚀 Happening today, Insilico Medicine's executive leadership takes the stage in #newyork and #montreal to highlight our clinical-stage AI pipeline and scalable platform capabilities.
Morgan Stanley 24th Annual Global Healthcare Conference
Speaker: Alex Zhavoronkov, PhD (Founder & Co-CE
Format: In-Person Fireside Chat | New York, NY
Time: 2:35 PM - 3:10 PM EDT
ALL IN 2026 / Montreal AI Showcase
Speaker: Petrina Kamya, PhD (Head of AI Platforms)
Location: Montreal, QC Montréal International
Connect with our team on-site in NYC and Montreal or follow our updates throughout the day.
#morganstanley #allin2026 #aidrugdiscovery #generativeai #biotech -
Insilico Medicine
@InSilicoMeds
Recently, Alex Zhavoronkov, Founder and CEO of Insilico Medicine, attended the Nature Conference Redefining Healthcare in the Age of AI at the Sorbonne in Paris.
During his presentation, Alex reflected on his entrepreneurial journey, from founding Insilico Medicine in 2014 after recognizing the potential of deep learning, to establishing a sustainable AI-driven drug discovery model and advancing rentosertib into Phase III clinical development.
He also shared recent progress in generative AI-powered drug discovery, including findings from a Phase IIa study involving proteomic aging clocks and changes in biological age. Alex further discussed how biotechnology companies can balance commercial viability with the long-term goal of advancing aging research.
The findings discussed remain investigational and should not be considered medical or investment advice.This media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
I trained a fly to present at the @InSilicoMeds webinar. 🪰🎤
On September 30, it will cover:
🧪 DDD benchmarks
🤖 GPT-6 Astra results
🚀 #insilicosotafm models
…and much more.
Yes, the fly can present too.
Registration link in the comments. 👇 -
Insilico Medicine
@InSilicoMeds
It’s been a few weeks since the Open Drug Discovery & Development Consortium (#o3dc) went live. Have you explored the index yet?
For the first time, 100+ benchmarks across 10 categories and 15 global initiatives are unified in a single open-access platform.
Why O3DC matters for AI R&D:
-Know the Limitations: Evaluate hidden benchmark caveats, from data leakage and scaffold bias to reproducibility challenges, before trusting a model's evaluation score.
-Find, Compare, Challenge: Flawed benchmarks stall real-world progress.
-O3DC allows the community to flag dataset contamination, propose alternative splits, and continuously update caveats in real time.
Open to Everyone: Built for researchers across academia, Big Pharma, biotech, and independent AI labs.
If you are developing or evaluating foundation models for biology and chemistry, know what you are benchmarking against.
👉 Explore the index & join the consortium: o3dc.org
#aidrugdiscovery #o3dc #openscience #generativeai #modelvalidationThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
This tiny ion channel can kill an otherwise great drug. ❤️⚡
It’s called hERG.
A molecule may be potent, selective, and beautifully designed, but if it blocks hERG too strongly, it can disrupt the heart’s electrical rhythm.
That’s why hERG is one of the most important ADMET predictions. 🧪
The goal is simple: Find dangerous molecules as early as possible.
This is exactly the kind of task the InsilicoMMAI-4B-Chem-ADMET model is built for. 🤖
#insilicosotafmThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
Evaluate the predictions:
dddbench.insilico.com
Try it out:
MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Founder and Co-CEO Alex Zhavoronkov, PhD, will be featured at the Morgan Stanley 24th Annual Global Healthcare Conference next week in New York.
Alex will participate in an in-person fireside chat to discuss how generative AI is transforming therapeutic discovery and clinical execution, from our Phase 2a trial momentum with #rentosertib to the commercialization of dual-purpose geroprotective assets.
Session Details:
🗓️ Date: Tuesday, September 15, 2026
⏰ Time: 2:35 PM – 3:10 PM EDT
📍 Format: In-Person Fireside Chat
🎤 Speaker: Alex Zhavoronkov, PhD (Founder & Co-CEO)
If you are attending the conference, please join this session and hear about the future of Pharmaceutical Superintelligence (PSI).
#morganstanley #globalhealthcare #aidrugdiscovery #biotech #techbio #insilicomedicine -
Insilico Medicine
@InSilicoMeds
🚀 Have you joined #o3dc yet?
www.linkedin.com/posts/in-silico-medicine_o3dc-academics-…
We are excited to share the launch of the Open Drug Discovery & Development Consortium (#o3dc).
Our first shared resource is now public: a living Benchmark Index that already includes 115 open benchmarks across 10 categories and 15 consortia & initiatives, and is being updated and populated every day.
What you’ll find:
✅ What each benchmark actually measures
✅ Who maintains it
✅ Live GitHub status (so you know if it’s still actively updated)
✅ Known weaknesses, biases, and caveats that official papers often leave out
The evaluation landscape for AI-driven drug discovery has been scattered across dozens of repositories, challenge pages, and frozen leaderboards. O3DC aims to fix that by creating one open, community-curated home for better evaluation.
Anyone can join: #academics, industry #researchers, independent developers. No fee. No exclusivity. If you care about how computational #drugdiscovery is evaluated, you’re welcome.
Looking forward to building this together. 🧬 -
Insilico Medicine
@InSilicoMeds
🚀For over a decade, Insilico Medicine has pioneered a paradigm shift in biopharma: using generative AI to target the shared drivers of aging and disease simultaneously.
Watch the full paper trail and clinical timeline of rentosertib (formerly ISM001-055), the world's first generative AI-discovered drug for idiopathic pulmonary fibrosis (IPF), from initial dual-purpose target discovery on PandaOmics to human biological age reversal validated in Phase 2a clinical trials.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Yesterday, the first patient was dosed with Rentosertib in Phase III. 🧬
In Phase II, Rentosertib showed something unexpected: across 6 independent aging clocks, patients treated with the drug showed a shift toward a younger predicted biological age. 👀
Now, the first generative-AI-discovered drug to reach Phase III is taking its next step.
And so are we.
We’re introducing a suite of Insilico SOTA+ models for drug discovery, achieving top performance across 70+ drug discovery tasks. 🚀
We made the first step.
Now it’s your turn.
Test your models. Explore the benchmarks.
#insilicosotafmThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
Take retrosynthesis as one example. ⚗️
We just added GPT-6 Astra to our benchmark, and it performs extremely well, making it the best-performing frontier model.
But our specialist LFM2-MMAI-Chem-SSRS-2.0 retrosynthesis model still scores higher, outperforming the frontier models and specialist suites in our benchmark. 👀
The model was trained on 45M+ chemical reactions collected by the Insilico team.
Insilico Medicine
@InSilicoMeds
How do we build these specialists?
🏋️ MMAI Gym for Science.
We train compact language models across related scientific tasks, then benchmark them directly against frontier models and established specialist methods.
Want to test the models or bring your own scientific task?
📩 MMAIGym@insilicomedicine.com
🧪 dddbench.insilico.com
We built the gym. Bring us the next problem. -
Insilico Medicine
@InSilicoMeds
Dopamine. 🧠 Serotonin. 🙂 Glucagon. 🍬
Very different biology, but all of these signals can run through GPCRs.
Predicting how strongly a molecule interacts with them is a classic molecular modeling problem.
Now, a 4B specialist language model is winning 11 of those tasks. 🤯
#insilicosotafm
Insilico Medicine
@InSilicoMeds
We trained InsilicoMMAI-4B-Chem-GPCR, and across 11 GPCR IC50 targets, it achieved a lower MAE than every specialist model in the comparison:
🧪 Chemeleon
🗺️ MapLight
🧬 MapLight+GNN
🔬 MiniMol
Same data. Same split. ✅
Insilico Medicine
@InSilicoMeds
The most exciting part is, again, the same:
A relatively small language model trained in MMAI Gym can become a strong specialist in a scientific domain and compete directly with models designed specifically for molecular prediction. 🚀
🔬 Results: dddbench.insilico.com
🧪 Try your own task: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
📽️ Can NVIDIA help solve aging?
That question became Rentosertib.
Not starting from a disease. Starting from aging biology. PandaOmics identified TNIK as a target connecting aging and fibrosis. Generative chemistry designed the molecule. Target to preclinical candidate in 18 months. Phase 1, Phase 2A, now Phase 3.
And this month, published in Nature Biotechnology, we asked a new question: is Rentosertib slowing aging itself?
We applied six independently developed proteomic aging clocks to Phase 2A trial data. Six clocks from multiple independent groups, sharing neither features nor training data. All six agreed. Treated patients saw predicted biological age go down by up to six years. Placebo did not.
This study is early and we say so plainly. But the template is clear. Find a target in aging biology. Purpose it toward a disease. Demonstrate it works. Then measure aging.
Rentosertib cannot yet be called a proven human longevity drug. But it may mark the beginning of a new era. From treating diseases of aging to actively intervening in aging itself.
We hope other companies and researchers repeat this template. 🧬
#rentosertib #insilicomedicine #longevity #agingclock
#naturebiotechnology #ipf #tnikThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
📽️ Following our breakthrough publication in Springer @NatureBiotech, Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD, joined @Bloomberg's The China Show with Yvonne Man and Avril Hong to discuss how our AI-discovered candidate for Idiopathic Pulmonary Fibrosis (#ipf) reduced participants' biological age by 3 to 6 years.
Watch the full Bloomberg interview to learn how aging-first target discovery is reshaping clinical developmen. ⤵️
#bloomberg #insilicoannouncement #ipf #agingThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧬 Rentosertib, the first AI-designed drug, is now in Phase 3 and inhibits TNIK
TNIK is a kinase, a molecular switch inside the cell.
The challenge with kinases is selectivity. Many of their binding pockets are remarkably similar, so a molecule designed for one kinase may also hit others.
Today we’re releasing InsilicoMMAI-4B-Chem-Kinome, our 4B specialist language model with SOTA+ performance on 31 kinase targets.
#insilicosotafm
Insilico Medicine
@InSilicoMeds
The human kinome contains 500+ kinases.
Because many of their binding pockets are so similar, activity can extend beyond the intended target.
Sometimes that extra activity is useful.
Sometimes it is exactly what you do not want.
That is why kinase drugs are profiled across broad panels.
Insilico Medicine
@InSilicoMeds
InsilicoMMAI-4B-Chem-Kinome was trained on 210,000+ data samples and achieved SOTA performance across 31 diverse kinase targets, outperforming other specialist models.
🔬 Check the results: dddbench.insilico.com
Now run your own: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
🧬 Insilico’s latest blog on Automated Train-Test Leakage Audit is now available.
We address a growing challenge in computational #biopharma: benchmark contamination and data leakage that may overestimate the model’s quality. Standard public evaluation sets often allow foundation models to achieve impressive scores simply by recognizing familiar training patterns, without demonstrating the ability to navigate the complex, sequential decisions required in real-world drug discovery.
In this case study, we demonstrate how Claude Code (powered by Claude Opus 5) connects to Insilico Medicine’s #cheminformatics Engine, MolTools, via the Model Context Protocol (#mcp) to automate an end-to-end train–test leakage detection on the Therapeutics Data Commons (TDC) P-glycoprotein (Pgp) Inhibition benchmark (Broccatelli et al., J. Med. Chem. 2011, 54, 1740–1751; DOI: 10.1021/jm101421d).
Read the full article to learn how rigorous validation is shifting focus from vanity benchmark scores to measurable R&D progress: insilico.com/blog/model-validation?pi_content=dea485773f2…
#aidrugdiscovery #generativeai #modelvalidation -
Insilico Medicine
@InSilicoMeds
Live from the Insilico Medicine Media Lab. Hear the #rentosertib talk with Fedor Galkin, PhD, and Alex Zhavoronkov, PhD, of Insilico Medicine. www.youtube.com/watch?v=0DF6WlyxmN4
-
Insilico Medicine
@InSilicoMeds
🚀 Join Insilico Medicine for our exclusive Pharma AI Q3 Fall Update, where we will continue to showcase the acceleration of pharma.ai leading platforms: Generative Biologics, Chemistry42, and PandaOmics.
Experience an exclusive preview of our newest launches designed to power autonomous, agentic R&D workflows:
Virtual Aging Cell (VAC) (virtualcell.insilico.com Multi-agent cellular modeling platform simulating biological age, cell fate steering, and compound perturbation dynamics.
O3DC Consortium (o3dc.org/An open-access index evaluating benchmark quality and documenting model caveats across 15 consortia and 10 categories.
DDD Benchmarks (dddbench.insilico.com Standardized Benchmark-as-a-Service testing whether foundation models can make real-world decisions across biology, chemistry, and clinical development.
SOTA Specialist Models: Compact, purpose-built #llms delivering state-of-the-art performance across 70+ #drugdiscovery tasks.
Register here 👉insilico.zoom.us/webinar/register/3817878442258/WN_gLMYTG…
#pharmaaiq3 #pharmaai2026 -
Insilico Medicine
@InSilicoMeds
🧬 Rentosertib went from an AI-designed molecule to patients and recently showed shifts toward younger predicted biological age across 6 proteomic aging clocks.
The first experiment is done. Now you can try our new SOTA+ drug discovery models yourself.
InsilicoMMAI-Chem-ADMET achieves SOTA+ performance on 7 drug safety and metabolism prediction tasks. 🚀
It’s a 4B language model trained on 140K+ datapoints in our MMAI Gym for Science.
#insilicosotafmPost not available here, view on X
Insilico Medicine
@InSilicoMeds
Here’s the interesting part 👀
Small-data ADMET has been dominated by graph and descriptor models for years. Language models were barely part of the conversation.
This is a 4B dense LM trained as an ADMET specialist.
And it beats every frontier model we tested.
Insilico Medicine
@InSilicoMeds
Rentosertib is a reminder of where all these predictions are supposed to lead.
Novel target. Novel molecule. AI-designed. Now in patients.
The first experiment is done.
🔬 Check the benchmark: dddbench.insilico.com
Access the model: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧬 Rentosertib just turned back biological age in people.
⏱️ 6 aging clocks. 6 independent groups.
After 12 weeks, all 6 clocks read them 3 to 4 years younger.
🚀 The first AI-designed drug. The first clinical demonstration of 3–4 year biological age reversal.
The first experiment is done. 🔬 Now run your own with Insilico’s SOTA models.
#insilicosotafmPost not available here, view on X
Insilico Medicine
@InSilicoMeds
Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry:
“6 proteomic clocks from 6 independent groups, applied to the same 42 patients, all reported a younger biological age in the treated arms. What convinces me is not the size of the effect but the agreement, because these models share neither their features nor their training data. This trial cannot yet separate slower aging from a treated lung, and the authors say so plainly. The experiment in healthy volunteers is the one I want to see next.”
Insilico Medicine
@InSilicoMeds
The first experiment is done.
Now try Insilico’s drug discovery models, demonstrating SOTA performance across 50+ tasks 🧬
Benchmark: dddbench.insilico.com
🔑 Access: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
Nature Biotechnology | Insilico’s AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks www.nature.com/articles/s41587-026-03286-y
First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment).
First Universal Consensus Across Six Independently-Developed Proteomic Aging Clocks: Analyzing 12-week longitudinal Olink proteomic data from 42 IPF patients, six aging clock models (including ProtAge, OrganAge, and PAC) independently developed by the leading groups from Harvard, Oxford, PKU, and Insilico, unanimously indicated that rentosertib reversed predicted biological age.
First Scalable Blueprint for Dual-Purpose Clinical Trials: The study is the first demonstration of a novel drug for a novel target discovered using aging research purposed to the age-related disease with aging biomarkers applied in a context of a clinical study. It establishes a standardized framework for embedding geroscience endpoints into standard disease trials, aligned with FDA Biomarker/BEST guidelines for dual-purpose aging and disease therapeutics.
CAMBRIDGE, Mass. — Monday, September 7, 2026 (5AM EST) — Insilico Medicine (“Insilico”), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.
Using longitudinal Olink proteomic data (CNCB OMIX accession: OMIX008341) collected during a Phase IIa clinical trial of rentosertib, researchers evaluated biological age using six internationally recognized, independently developed proteomic aging clocks. All six models consistently indicated a reduction in predicted biological age among patients treated with rentosertib. In addition, the Forced Vital Capacity (FVC), the essential measure of lung function declining with age, showed promising dose-dependent reversal compared to placebo aligning with the proteomic aging clock age reversal.
Recently published in Nature Biotechnology, the study represents the first clinical evaluation of a potentially first-in-class drug candidate featuring both an AI-discovered target with relevance to aging and disease biology and an AI-designed molecule, rather than a repurposed generic drug such as rapamycin or metformin. The findings also provide a proof-of-concept framework for integrating aging biomarkers into standard clinical trials to accelerate the discovery of geroprotective drugs and longevity therapeutics.
The results will be presented by first author Alex Zhavoronkov, founder and CEO of Insilico Medicine, at the Nature conference: Redefining Healthcare in the Age of AI, to be held at Sorbonne University in Paris on September 8, 2026.
From aging biology to a clinical drug
Unlike traditional geroscience studies that rely on repurposed drugs like rapamycin or metformin, Insilico pursued a different approach by incorporating aging biology into its drug discovery strategy from the outset.
Using its AI-powered target discovery platform, Insilico identified TNIK as a novel target implicated in aging and fibrosis and performed hallmarks of aging assessment where TNIK scored highly in 6 hallmarks. TNIK was subsequently prioritized as a dual-purpose target relevant to both underlying aging biology and idiopathic pulmonary fibrosis (IPF). Insilico’s generative chemistry platform, Chemistry42, was then deployed to design the small-molecule candidate rentosertib targeting TNIK. The program progressed from target identification to preclinical candidate nomination in approximately 18 months, with the preclinical findings published in Nature Biotechnology in 2024.
In June 2025, Insilico reported the results of a Phase IIa trial of Rentosertib for IPF (NCT05938920) in Nature Medicine. The trial met its primary safety endpoint and demonstrated a promising dose-dependent trend in efficacy. One of the common efficacy outcome measures is Forced Vital Capacity (FVC), the essential measure of lung function. The typical age of onset of IPF is around 65 years. Interestingly, in healthy individuals older than 65, FVC declines as well typically at the rate of 20-50 mL/year and may also serve as a potential physiological biomarker of aging. In the previous publication, it was revealed that in the 60-mg once-daily group, patients experienced a mean improvement in forced vital capacity (FVC) of +98.4 mL, compared with a mean decline of -20.3 mL in the placebo group (-62.3 excluding outlier).
Crucially, the trial protocol prospectively included longitudinal serum proteomic screening for exploratory biomarker analyses, which proved consistent with the drug’s proposed anti-fibrotic and anti-inflammatory activity. All data collected from the trial were subsequently deposited with the China National Center for Bioinformation (CNCB), enabling the current investigation of biological aging biomarkers.
Six different clocks point to strong biological age reversal measured by proteomics
In the current study, researchers evaluated serum proteome profiles from 42 trial participants across 2,841 proteins. The team applied six independently developed proteomic aging clocks, including ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT, and PAOPAC. Despite relying on diverse methodologies and training criteria, all six clocks consistently exhibited a trend toward reversed biological age among rentosertib-treated patients compared to placebo. The peak effect is observed at Week 4 in participants receiving 30 mg BID with approximately 3–4 years reversal in biological age and up to 6 years in a certain aging clock.
📷
Rentosertib decreases predicted biological age across various regimens as measured by most aging clocks, most significantly in the 30 mg BID group and in week 4.
Beyond changes in biological age scores, the study showed that rentosertib’s anti-aging effects operate partially independent of its respiratory benefits. Notably, the dose associated with the greatest improvement in lung function differed from that producing the strongest age-reversal signal, suggesting that the drug’s geroprotective activity was not merely a downstream consequence of disease improvement.
This systemic impact was further validated through comparisons with 55,319 UK Biobank profiles, which showed that rentosertib directly reversed the typical age-related protein-expression trajectories. Mechanistically, the drug acted as a senomorphic agent, suppressing key drivers of cellular senescence, including EREG, ESM1, IGFBP4, ITGA2, MMP10, MMP13, and SPP1 while downregulating growth-factor signaling pathways associated with accelerated aging, including RTK–PI3K and RAS–ERK, and modulating antioxidant and cholesterol metabolisms.
A framework for the future
To support reproducibility and further research, all research data have been deposited at CNCB (accession OMIX008341), and the underlying pipeline code has been published as the open-source Python library on GitHub.
Beyond these specific findings, the study lays out a scalable blueprint for embedding geroscience endpoints into disease-focused drug development. The research proposes a stepwise framework: collecting aging and senescence biomarkers prospectively as exploratory endpoints in disease trials, and ultimately pursuing biomarker qualification or composite clinical endpoints under the FDA Biomarker Qualification Program and FDA–NIH BEST framework. Such an approach could surface geroprotective candidates years or even decades earlier than the traditional path of post-approval drug repurposing.
Insilico’s dual-purpose therapeutic strategy is also proving its viability as a sustainable commercial model. Recently, Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing, with an adjusted net profit exceeding $51 million. This milestone was driven by a series of out-licensing, co-development, and R&D collaborations with global partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the latest practicable date, the total contract value of transactions announced by Insilico in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 approximately $11 billion.
On the AI-driven R&D front, Insilico nominated nine development candidates within nine months of 2026 as of late August, setting a new company record for annual pipeline productivity and achieving eight clinical milestones across its proprietary and co-developed programs. Leading this progress is rentosertib (ISM001-055), the world's first drug candidate discovered and developed using generative AI, which has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF). In addition, Insilico Medicine launched a comprehensive set of benchmarks that allow foundation models to be evaluated in all tasks needed for drug discovery and launched state of the art (SOTA) foundation models outperforming other models and even internal tools in benchmarks. Using this new capability Insilico hopes to expand and accelerate longevity drug discovery and development both in terms of scale, therapeutic modalities, and indications.
Industry Commentary
"Six proteomic clocks from six independent groups, applied to the same 42 patients, all reported a younger biological age in the treated arms. What convinces me is not the size of the effect but the agreement, because these models share neither their features nor their training data.” said Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry. “This trial cannot yet separate slower aging from a treated lung, and the authors say so plainly. The experiment in healthy volunteers is the one I want to see next."
“Insilico Medicine was built with one purpose – to develop a credible and sustainable business model for the development of frontier deep learning technology and its application to practical aging research and drug discovery with the purpose of developing using AI and practical discovery and development of longevity therapeutics. This first program demonstrates the first proof of concept for the novel dual-purpose therapeutic targeting aging but proposed toward the age-related disease discovered in record time making exploratory development in multiple indications commercially viable.
Today, the majority of Insilico’s 40+ drug programs have dual purpose targeting aging and disease in a broad range of therapeutic areas. By pursuing a credible biotechnology business model, the company reached profitability and established the longevity board, which is rare for the publicly-traded frontier biotechnology company. I am also happy that the drug carries the name of the true hero of the AI drug discovery revolution, our co-CEO, Dr. Ren.
The social and economic opportunity for drugs reversing biological age is vast - trillions of dollars and billions of life years. If you add just 3 extra years to everyone’s lifespan, that translates into roughly 25 billion life years on the global scale - at current life expectancy, that is roughly 340 million human lifetimes. More lifetimes than humanity lost in all the wars ever fought. If you manage to add 3 years to everyone’s life, the drug should be able to significantly extend the healthy portion of life as well translating into trillions of dollars in productivity and savings”, said Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine.
“In this study, we evaluated clinical trial data to compare the blood proteomic profiles of pulmonary fibrosis patients treated with Rentosertib versus placebo”, said Ludger Goeminne, Research Fellow in Medicine at Harvard Medical School, and co-author of the paper. “Using six proteomic aging clocks including models our team published in Cell Metabolism, we observed significant reductions in predicted biological age across multiple organ-specific clocks, and further pathway analysis confirmed that Rentosertib’s biological impact extends far beyond merely reducing fibrosis.”
“As the developer of PAOPAC (Proteome-Aware Organ Proxy Aging Clock), I am thrilled to see our tool applied to the analysis of the Phase IIa clinical trial for rentosertib. Dr. Zhavoronkov and his colleagues are the first to systematically evaluate a novel drug candidate using multiple proteomic aging clocks within a single clinical trial cohort. The methodologies underlying these clocks range from traditional machine learning (OrganAge, PAOPAC, PAC) to deep learning (ProtAge, ipfP3GPT), with training targets encompassing both chronological age (ProtAge, OrganAgechrono, ipfP3GPT, PAOPAC) and mortality risk (PAC, OrganAgemortality). Across the board, these clocks consistently predicted a reduction in biological age within the rentosertib treatment group. This cross-model consistency demonstrates that rentosertib's effect on aging-related proteomic signals is not a model-specific artifact, but rather a highly robust biological phenomenon.”, said Professor Jing-Dong Jackie Han, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Center for Quantitative Biology (CQB), China. “Furthermore, this study establishes a relatively comprehensive workflow for the standardized application of aging clocks in clinical trials, covering cohort establishment, omics profiling, multi-clock parallel analysis, result cross-validation, and mechanistic interpretation. It also introduces an innovative practical approach to clinical trial design: evaluating aging biomarkers in parallel during trials targeting specific indications, particularly age-related diseases. This strategy holds great promise for accelerating the discovery and validation of longevity interventions.
Finally, my congratulations on the breakthrough achieved with rentosertib—an innovative drug discovered in China and clinically evaluated primarily in Chinese patient cohorts. As a domestic Chinese research team behind the development of aging clocks, we look forward to witnessing more industry-academia-research collaborations driving future clinical trials in aging interventions.”
Reference
[1] Zhavoronkov, A., Galkin, F., Chen, S. et al. Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nat Biotechnol (2026). doi.org/10.1038/s41587-026-03286-y
[2] Pun, F. W., Leung, G. H. D., Leung, H. W. et al. Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging (Albany NY) 14, 2475–2506 (2022). doi.org/10.18632/aging.203960
[3] Tang, Q., Xiao, D., Veviorskiy, A. et al. AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent. Aging Dis 17, 432–451 (2026). doi.org/10.14336/AD.2024.1492
[4] Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol 43, 63–75 (2025). doi.org/10.1038/s41587-024-02143-0
[5] Xu, Z., Ren, F., Wang, P. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 31, 2602–2610 (2025). doi.org/10.1038/s41591-025-03743-2
About Rentosertib (ISM001-055)
Rentosertib is a potentially first-in-class small molecule targeting TNIK, developed using Insilico Medicine's generative AI platform pharma.ai. TNIK was identified through AI-powered target discovery as a gene involved in six hallmarks of aging, making it a dual-purpose target for both aging biology and idiopathic pulmonary fibrosis (IPF). The drug's discovery, design, preclinical validation, and Phase I results were published in Nature Biotechnology in March 2024. Phase IIa results were published in Nature Medicine in June 2025. Rentosertib has entered Phase III clinical development in China.
About Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a chronic, scarring lung disease characterized by progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis with a median survival of 3–4 years. Current approved treatments can slow disease progression but cannot stop or reverse it, leaving a significant unmet need for disease-modifying therapies.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.hk.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
🧪 NEW SOTA in chemical synthesis
Building molecules is hard. There are countless possible routes, but only some actually work. We trained a 2.6B LFM model by @liquidAI in #mmaigym to find them.
📈 +7% vs. the best specialist tool
🚀 +27% vs. frontier LLMs
💥 2.6B punches way above its weight
#insilicosotafm -
Insilico Medicine
@InSilicoMeds
9 in 10 drugs fail. Often, because the target is wrong.
🎯 We introduce SOTA models for target identification. TargetPro picks the right target 83% of the time.
The best frontier model manages just 34%.
That’s 2.4× better and a new SOTA across all 8 disease areas.
#insilicosotafm
Insilico Medicine
@InSilicoMeds
🧪 TargetBench 1.0 scores target discovery systems by asking how many of their top picks are already clinical-stage drug targets.
🥇 TargetPro+ 83%
GPT-5.6 Sol 34%
GPT-5.5 33%
Gemini 3.1 Pro 30%
Claude Opus 5 30%
Grok 4.5 29%
Insilico Medicine
@InSilicoMeds
📊 100 diseases. 8 disease areas. 19,291 protein-coding genes scored for every disease.
📄 Method paper: doi.org/10.1038/s41598-026-47765-3
🔬Check the results:dddbench.insilico.com
🔑 Access: MMAIGym@insilicomedicine.com -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Collaborator Discover Novel Alzheimer’s Disease Targets Through AI and Rigorous Experimental Validation
insilico.com/news/2mfo0649d1-insilico-medicine-and-collab… -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Releases SOTA MMAI Specialist Models to Redefine AI Application in Drug Discovery
insilico.com/news/tvb0jud0y1-insilico-medicine-releases-s… -
Insilico Medicine
@InSilicoMeds
🚀 5 new drug-discovery specialist LLMs. SOTA-level performance across 70+ benchmark tasks.
Insilico Medicine has released a series of frontier Specialist Language Models for chemistry and biology, trained through MMAI Gym.
They cover drug safety, potency prediction, chemical synthesis, and biology.
🧬 From general-purpose models to scientific specialists.This media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
To try out the model, send an email to mmaigym@insilicomedicine.com
Post not available here, view on X
Insilico Medicine
@InSilicoMeds
⚗️ The single-step retrosynthesis specialist delivers SOTA-level performance, including on challenging out-of-distribution benchmarks.
The results were recently published in a new paper: arxiv.org/abs/2608.18940
Insilico Medicine
@InSilicoMeds
🧬 The Chemistry Specialist Models are now available.
Want to put them to the test? Contact us to explore the models and benchmark their performance on DDD Benchmark: dddbench.insilico.com
#insilicosotafm -
Insilico Medicine
@InSilicoMeds
Can a language model become SOTA in chemical synthesis? 🧪🔥
We put a 2.6B-parameter @liquidai model into MMAI Gym.
It now sets the state of the art in single-step retrosynthesis. 🚀
#insilicosotafm
Insilico Medicine
@InSilicoMeds
To try out the model, send an email to mmaigym@insilicomedicine.com
Post not available here, view on X
Insilico Medicine
@InSilicoMeds
The result: SOTA performance. 🏆
Best specialist model,
- MHNreact: 1.28 → +7%
- Gemini 3.1 Pro: 1.08 → +27%
- GPT 5.5: 1.05 → +30%
And the gains hold across multiple metrics, not just the headline one. 📈
Insilico Medicine
@InSilicoMeds
A 2.6B open-weight model beats both dedicated chemistry tools and frontier LLMs on chemistry it has never seen. 🧪🚀
Small models don't lose to big models.
Try it: dddbench.insilico.com 🔗 -
Insilico Medicine
@InSilicoMeds
AI hunts new uses for Phase 3 metabolic drug
longevity.technology/news/ai-hunts-new-uses-for-phase-3-m… -
Insilico Medicine
@InSilicoMeds
Just one week until AIM Congress 2026 in Dubai! Insilico Medicine Co-Founder and President Alex Aliper, PhD, will be featured across two high-impact sessions focusing on longevity therapeutics and the future of the AI innovation economy.
Where to catch Alex next week:
Panel Discussion: The Longevity Thesis: Investing in the human lifespan
🗓️ Date: Monday, September 7
⏰ Time: 4:55 PM – 5:30 PM GST
📍 Location: Room 1 - Plenary Room - Hall 1
Special Spotlight Fireside: AI for Science: Building the Next Trillion-Dollar Innovation Economy
🗓️ Date: Tuesday, September 8
⏰ Time: 3:50 PM – 4:05 PM GST
📍 Location: Room 3 - Future Economies' Room - Hall 1
📍 Venue: Dubai World Trade Centre, United Arab Emirates
If you are attending AIM Congress 2026, we hope you will join these sessions and connect with Alex and the Insilico Medicine team.
#aimcongress2026 #aidrugdiscovery #longevity -
Insilico Medicine
@InSilicoMeds
🚀 Amazon Web Services (AWS) AI League: Drug Discovery Challenge - a hands-on build event happening during Boston AI Week on October 2!
This event is a competitive, challenge where your team will fine-tune a Small Language Model (like Amazon Nova Micro via Amazon SageMaker AI) to predict #drugdiscovery properties lipophilicity, permeability, and clearance with higher accuracy than frontier-scale models, and at lower cost. This follows the same approach Nimbus Therapeutics used to build their Novus model on AWS.
Why attend?
•Hands-on SageMaker AI experience — Walk away with a fine-tuned model you built yourself, plus practical experience with serverless model fine-tuning on Amazon SageMaker AI and deployment to Amazon Bedrock
•Compete for up to $5K in AWS credits — Prizes for the top 6 teams, plus a special recognition award for Best Competitive Intel Answer
•Learn a proven approach — Apply the same supervised fine-tuning methodology that Nimbus Therapeutics used in production, using tens of thousands of labeled molecules
•Network with builders and founders — Connect with fellow practitioners, startup founders, and Amazonians working at the intersection of AI and drug discovery
RSVP: awsaileaguedrugdiscoveryqachal.splashthat.com
#bostonaiweek #bostonbiotech #awsevents -
Insilico Medicine
@InSilicoMeds
Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
insilico.com/news/s11n46hx31-commercialization-roadmap-va… -
Insilico Medicine
@InSilicoMeds
In our latest video, Insilico Medicine Founder and CEO Alex Zhavoronkov sits down with Andrew Aiginin and Evgeny Kirilin to discuss the critical importance of the Open Drug Discovery and Development Consortium (#o3dc).
While foundation models continue to scale rapidly, many still fall short on highly specialized tasks crucial to moving a molecule to the clinic, such as predicting toxicity, pharmacokinetics (PK), and permeability. And even when models claim state-of-the-art performance, they often suffer from benchmark leakage (where test data was already seen during training).
Watch the full conversation to learn how O3DC is helping the industry build AI systems that actually deliver. www.youtube.com/watch?v=J5tKiSG3H-0&t=908s -
Insilico Medicine
@InSilicoMeds
Can one remarkable AI breakthrough be turned into a repeatable system for drug discovery? 🧪
In his feature, @BernardMarr explores how Insilico Medicine is moving beyond proof-of-concept to build a scalable, end-to-end generative AI system for novel therapeutics.
Read more ⤵️ bernardmarr.com/how-insilico-medicine-is-using-ai-to-rein…
#aidrugdiscovery #generativeai #techbio #insilicomedicine -
Insilico Medicine
@InSilicoMeds
What if Alzheimer’s disease begins with the cell’s power plants?
A new study published in Alzheimer’s & Dementia reveals a pivotal connection between mitochondrial health, brain aging, and neurodegeneration.
Using Insilico Medicine’s PandaOmics platform followed by rigorous experimental validation, researchers prioritized five potential Alzheimer’s disease targets within the NAD⁺-mitophagy axis—opening new directions for biomarkers and future treatments.
Read the study: alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71680
#alzheimersdisease #artificialintelligence #drugdiscovery #neuroscience #healthyaging -
Insilico Medicine
@InSilicoMeds
What if you could watch a cell age in real time, and see the molecular response as it happens? ⏳
Set the age, add a compound, then read the transcriptome, proteome and methylome that come back. Each profile comes with a predicted biological age.
Check out our Virtual Aging Cell: virtualcell.insilico.com -
Insilico Medicine
@InSilicoMeds
📽️ Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD, joined Bloomberg’s The China Show with David Ingles and Yvonne Man to discuss our 1H 2026 financial performance, pipeline milestones, and the evolving business model driving AI in #drugdiscovery. Check out the latest interview here.
www.youtube.com/watch?v=4GokBLybPog
#insilicomedicine #financials #insilicoupdatesThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🔥 The Drug Discovery & Development (DDD) Benchmarks is a standardized framework designed to test whether AI foundation models and agents can make true, real-world decisions across #targetidentification, generative #chemistry, SAR analysis, and clinical predictions.
If you are developing domain-specific #llms, multi-modal foundation models, or autonomous AI agents for life sciences, see how your architecture stacks up against SOTA industry baselines.
Submit your model and benchmark your performance today ⤵️
dddbench.insilico.com?pi_content=0370f755f6e29e24d1e214d8… -
Insilico Medicine
@InSilicoMeds
Next week, Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD, takes the stage at LEAP 2026 in Riyadh to share insights on how generative AI is transforming healthcare from target discovery to late-stage clinical progress.
Where to catch Alex on Wednesday, September 2:
Deep Dive: Rewriting Healthcare with Predictive Intelligence
⏰ Time: 15:10
How multimodal predictive models are unlocking hidden biology and accelerating discovery timelines.
Beyond the Horizon: Breakthroughs at the Edge of Market Entry
⏰ Time: 18:05
Translating AI-designed therapeutics into clinical milestones and commercial readiness.
📍 Location: Riyadh, Saudi Arabia
If you are attending LEAP 2026, connect with Alex and the Insilico team to explore how predictive intelligence is redefining drug discovery.
#leap2026 #aidrugdiscovery #generativeai #insilicomedicine -
Insilico Medicine
@InSilicoMeds
🤝 Welcome to Insilico's latest #o3dc, a community resource for finding, comparing and addressing open benchmarks in #drugdiscovery.
O3DC doesn't just index existing benchmarks, it allows members to share their experiences and learnings, and also provides a means for authors of new benchmarks to add them to index.
O3DC is open to researchers across #academia, industry, and independent practice with no membership fees or exclusivity. The #consortium is actively seeking contributors to update existing entries, catalog new benchmarks, and lead the curation of specific categories.
Join us here: o3dc.orgThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine is proud to support the upcoming Springer Nature Conference: "Redefining Healthcare in the Age of AI." 🇫🇷
As AI transitions from theoretical promise to real-world clinical application, bringing together global leaders across biopharma, academia, and digital health is essential to defining the next generation of patient care.
Event Details:
-Dates: 8–10 September 2026
-Location: Paris, France (Grand Amphithéâtre de la Sorbonne)
Join global scientific and clinical leaders in Paris as we explore how artificial intelligence is reshaping medicine.
🔗 Register and view the full agenda: natureconferences.streamgo.live/healthcare-ai/lobby
#natureconferences #aiinhealthcare #drugdiscovery #generativeai -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
One MCP. 7× Higher Hit Rate 🚀
What does Agentic Drug Discovery look like?
PLI Mapper MCP, part of the upcoming Chemistry42 MCP Hub, allows an agent to filter molecules based on their interactions with a protein.
Same CDK2 DUD-E set. Same docking. Same top-50 cutoff.
Adding Leu83 + Glu81 hinge H-bonds as a filter took the hit rate from 4% to 28%. 📈
One MCP. One additional layer of information.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
www.linkedin.com/pulse/insilico-medicine-announces-2026-i… -
Insilico Medicine reposted
Petrina Kamya
@petrinak_ISM
Most benchmark catalogues tell you what a test measures.
Ours also tells you what's wrong with it.
129 drug discovery benchmarks. Each with its documented caveat. Updated daily. Every entry has a discussion thread where you can argue with us.
Not a catalogue. A community.
@InSilicoMeds
#drugdiscovery
#compchem
#openscience
#aidrugdiscovery
#machinelearning
o3dc.org -
Insilico Medicine
@InSilicoMeds
[New Demo Video] 🐼
#cadd Structural Review lets you choose the pocket and interface and which site to design against, and the review already knows which questions fit the target.
See how the analysis and report steps work in this video here.
#pandaomics #targetid #explainervideosThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🚀 Join Insilico Medicine Application Scientist Stefania Evoli this Thursday for a deep dive into "Benchmarking Antibody-Antigen Affinity Prediction Across Sequence-, Structure-, & Physics-Based Methods."
Key Seminar Highlights:
-Structure-Aware Superiority: Explicit 3D epitope–paratope interactions remain crucial, structure-aware models consistently outperform sequence-only representations.
-The Limits of #llms & PLMs: Why Protein Language Models and Large Language Models underperform when predicting binding affinity without physical 3D context.
-The Path Forward: How hybrid approaches combining physics-based data with structural insights deliver the most reliable predictive accuracy.
Event details are here: cdd-ai-biologics.com/speaker/stefania-evoli/
#bostonbiotech #biologics -
Insilico Medicine
@InSilicoMeds
[New Demo Video] 🐼
#cadd Structural Review lets you choose the pocket and interface and which site to design against, and the review already knows which questions fit the target.
See how the analysis and report steps work in this video here.
#pandaomics #targetid #explainervideosThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
A joint study by Insilico Medicine, the University of Copenhagen, and academic partners identifies #ndrg1 as a key regulator of DNA damage repair, demonstrating that targeting this pathway via the antimalarial drug quinacrine triggers synthetic lethality in specific cancer subtypes.
insilico.com/news/ok6co4kgd1-science-signaling-insilico-m… -
Insilico Medicine
@InSilicoMeds
🚀 #o3dc is live: Stop scrolling 40 repos
The Open #drugdiscovery & Development Consortium just dropped its first shared resource:
-115 benchmarks indexed across 10 categories and 15 consortia.
-Live GitHub status checks + honest notes on the caveats papers usually hide.
Open to academics, industry, and independents. Free to join.
Link in the commentsThis media couldn't be displayed. See it on the original post.
Insilico Medicine
@InSilicoMeds
Visit it: o3dc.org
-
Insilico Medicine
@InSilicoMeds
Insilico advances virtual cell research
Insilico Medicine has introduced biological age as a core condition in virtual cell research with the launch of its Virtual Aging Cell (VAC) Webpage and a preview of its Multi-Agent driven VAC platform.
Read more here: www.ddw-online.com/insilico-advances-virtual-cell-researc…
#vac #virtualagingcell -
Insilico Medicine reposted
Petrina Kamya
@petrinak_ISM
A decade in the making: 2014 "can AI solve aging?" → embryonic.ai (COX7A1) → PreciousGPT (1/2/3) → the Virtual Aging Cell. From reading a cell's age to reshaping its fate → virtualcell.insilico.com
@InSilicoMeds @precious_gpt @vovalive @VladAladin @biogerontology @AlexAliper -
Insilico Medicine
@InSilicoMeds
From Molecular Lego to High-Quality Data: Insilico Medicine and Saudi Aramco Advance AI-Driven MOF Discovery with sorbaMOF DB
We are proud to introduce #sorbamof DB, a validated and extensible materials database, together with a benchmarked computational protocol designed to ensure reliable CO₂ adsorption predictions. The research has been submitted as a preprint paper on ChemRxiv under the title “sorbaMOF DB: An Extensible MOF Adsorption Database Platform with a Case Study on Direct Air Capture of CO₂.”
For more information, visit: insilico.com/news/5kip5kk0s1-from-molecular-lego-to-high-…
#chemrxiv @ChemRxiv #chemistry #casestudy -
Insilico Medicine
@InSilicoMeds
Can AI uncover a new path to non-opioid pain relief? www.drugdiscoverynews.com/can-ai-uncover-a-new-path-to-no…
-
Insilico Medicine
@InSilicoMeds
Recorded live from the podcast pavilion at @Ai4 Las Vegas, Sam sits down with Alex Zhavoronkov, Founder & CEO of Insilico Medicine, for one of the most wide-ranging conversations on AI drug discovery you'll hear this year - from why most "AI drug discovery" companies are shoemakers without shoes, to a pain drug discovered by sheer luck that outperformed morphine, to a philosophical closing argument about being kind to a future "AI God."
Listen to the new podcast here: www.youtube.com/watch?v=D8D1-e4ZXUo
#profitableai #profitableaidd -
Insilico Medicine
@InSilicoMeds
BIO Asia−Taiwan 2026 interview featuring @biogerontology . Watch it here www.youtube.com/watch?v=d0UCqHM_q2A
-
Insilico Medicine reposted
Evgeny Kirilin
@EvgenyKirilin
🧬At @InSilicoMeds , one of our drugs, Rentosertib, works by switching off a protein called TNIK.
Here's the fun part: a 2025 @Nature study found that 12 weeks of resistance training left a similar fingerprint in human muscle, less TNIK activity, just from lifting weights.
Same target, hit two completely different ways. One is a molecule designed by #ai. The other is a workout.
Drug discovery meets exercise science, with a real overlap into longevity research too.
Simulation on one side. A TT bike on Hudayriyat🇦🇪 on the other (just a few hours before completing another #dddbenchmarks task)
@TeamEmiratesUAE - thanks for the inspiration to keep riding even through hot summer mornings
#aidrugdiscovery #tnik #exercisescience #longevity #proteinsimulation #cycling #ttbike #hudayriyat #abudhabiThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven #vac Generation Platform
insilico.com/news/r94oegijt1-insilico-medicine-introduces… -
Insilico Medicine
@InSilicoMeds
Introducing the 32nd developmental candidate: #ism9077.
And this one went in a direction we did not fully expect. We started by applying PandaOmics to rank targets across ocular diseases and create high-confidence disease-target associations.
Target Y came up strongly implicated in dry AMD, uveitis, and dry eye disease. But also in multiple age-related diseases beyond ophthalmology. The efficacy signal in ophthalmic models was the clearest, so we made a significant bet on this program completely from scratch. Multi-parameter optimized structure, balancing activity, potency, safety, pharmacokinetics, and drug delivery.
Many companies have been chasing targets in this space for years without finding a molecule with a balanced profile. We designed and selected ISM9077 using Chemistry42 and it delivers. Preclinical studies showed encouraging efficacy across dry AMD, uveitis, and dry eye disease models. Three species, 28-day DRFs in rat, rabbit, and monkey. Large therapeutic window. And the molecule can be administered as an eye drop or orally. Both.
Target Y has not been previously associated with multiple ocular diseases, especially dry AMD. We have patented many molecules for this indication. ISM9077 is our 32nd PCC since 2021. 13 of those have received IND clearance. And consistent with our dual-purpose strategy, Target Y is also implicated in aging and age-related diseases. Ophthalmology is the initial focus. The biology points further. We are in no rush to license this one out. We have high confidence in this asset. But we are always open to in-depth discussions with the right partner.
#insilicomedicine #drugdiscovery #ai #ophthalmology #amd #uveitis #dryeye #longevity #aging #generativeai #pandaomicsThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
NEW Video 📽️Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual #aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
Following a decade of exploration from the 2014 NVIDIA #gtc to the @precious_gpt model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell(#vac) platform with #biological age as a core condition.
Hear the story behind our latest launch in this video, and preview Virtual Aging Cell here: virtualcell.insilico.com
#insilicolaunch #virtualaging #longevity @petrinak_ISMThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine's #pandaomics Enables AI-Driven Indication Expansion Strategy for THPharm's Phase 3 Metabolic Disease Program
Read the latest release announcement here: insilico.com/news/h9zeln8cc1-insilico-medicines-pandaomic… -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico’s 32nd PCC nominated since 2021.
insilico.com/news/insilico-medicine-nominates-ism9077-as-pcc -
Insilico Medicine
@InSilicoMeds
RT @petrinak_ISM: Introducing @InSilicoMeds Virtual Aging Cell (VAC) - the first #virtualcell that takes #aging seriously!
The Virtual Ag… -
Insilico Medicine reposted
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM
@agingdoc1
After billions in deals, Insilico CEO promises: ‘You haven’t seen anything yet’
@biogerontology @InSilicoMeds
www.biospace.com/business/after-billions-in-deals-insilic… @biospace -
Insilico Medicine reposted
Petrina Kamya
@petrinak_ISM
Aging is a key factor in our overall health. And when we're trying to understand disease biology, we must take it seriously. #virtualcells #aging @InSilicoMeds Watch this space...we're about to annouce something pretty awesome!
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine introduces the Virtual Aging Cell
We think of age as a number. 🔢 Biology doesn’t. 🧬
The Virtual Aging Cell (VAC) is built to explore how cellular states change across time ⏳ and how those changes shape response to intervention.
The goal isn’t just to measure aging. It’s to predict what comes next 🔬
🧵1/5Post not available here, view on X
Insilico Medicine
@InSilicoMeds
4/5 Under the hood: a swarm of AI agents reasoning across six biological scales. Molecular, intracellular, intercellular, tissue, organ, organism. 🧠
Master agents coordinate top-down and bottom-up, and every agent shares one context where biological age comes first.
Insilico Medicine
@InSilicoMeds
5/5 “Every computational model needs a first principle, and ours is biological age.”
Alex Zhavoronkov, Founder & Co-CEO
VAC is an early preview. Bench validation is the work ahead, and we’re opening it to collaborators. 🤝
🔗 virtualcell.insilico.com
📍 More at ARDD 2026, Boston -
Insilico Medicine
@InSilicoMeds
📽️ MCP-Powered AI Engine for Drug Discovery & R&D
In this video, you will see how the MCP Loop turns a single prompt into an automated, multi-step scientific workflow. You ask in natural language, and the agent plans the steps to pull the right tools, runs them, and returns results that you can act on.
See a researchers' example in this video here 👇
#chemistry42 #drugdiscovery #mcp -
Insilico Medicine
@InSilicoMeds
Insilico Medicine nominates AI-designed candidate for #oculardiseases
“ISM9077 marks our 32nd preclinical candidate nominated since 2021, so this is an example of how generative AI delivers at scale,” said Alex Zhavoronkov, Found, CEO and CBO of Insilico Medicine.
“This candidate features a moderately novel target, a novel molecule designed from scratch and a novel formulation possibility of eye drop. Beyond offering a non-invasive, highly effective option for millions of patients suffering from blinding ocular diseases, ISM9077 further enhances Insilico’s dual-purpose strategy to treat specific diseases while targeting ageing and extending healthspan, as Target Y is strongly implicated in ageing, longevity and multiple age-related conditions.”
Read the latest article from @DrugTargetRev here: www.drugtargetreview.com/insilico-medicine-nominates-ai-d… -
Insilico Medicine
@InSilicoMeds
Thank you Bernard Marr and @Forbes for highlighting Insilico Medicine’s mission to reinvent drug discovery through end-to-end generative AI.
From novel target ID to generative chemistry and clinical outcome prediction, we are proud to lead the charge in making AI-native drug discovery an industry reality.
📖 Read the full feature on Forbes:
www.forbes.com/sites/bernardmarr/2026/08/07/how-insilico-… -
Insilico Medicine reposted
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
What happens to a pill 💊 after it reaches the liver and why it is so important?
The liver breaks drugs down so the body can get rid of them.
Swallowed → Absorbed → Broken down → Cleared
One way we measure this is Clint MLM (intrinsic clearance in mice liver microsomes) -- how quickly a drug is broken down by mouse liver enzymes in a lab test 🧪. The faster 🏃♂️clearance, the less drug is left in the body, the less the effect of the drug.
Can frontier models predict this from molecular structure alone with no tools/orchestration❓
Opus 5 came out on top 🏆 for Clint MLM prediction, with a Spearman correlation of 0.425. Check our #dddbench site to see how better is Opus 5 compared to other frontier models. -
Insilico Medicine
@InSilicoMeds
📹Our mission is to help people live longer, healthier lives. Hear from the experts behind the #generativeai story.
#tnik #longevity #rentoserib #nvidia #gtcThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Alex Zhavoronkov, CEO of Insilico Medicine, on why we’re opening our core AI benchmarking tools to the entire industry.
It’s not about competing on model parameters – it’s about:
✅ Teaching cutting‑edge AI how to do drug discovery
✅ Validating with real‑world experimental data
✅ Making intelligence flow between algorithms and wet labs
“Our moat is the bridge that connects AI to real medicines.”
Our roadmap is clear:
🔹 Open benchmarks to help more models get smarter
🔹 Feed real drug R&D data back into AI
🔹 Turn breakthroughs into out‑licensable assets
At the end of the day, we just want AI to genuinely accelerate drug development – and get better treatments to patients sooner.
That’s not a slogan. It’s what we experiment on and iterate every single day.
🔬 We invite all AI teams to join us at dddbench.insilico.com – let’s build that bridge together.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
⚡ Co-folding models, a new feature now available in the #generativebiologics platform.
The dedicated scoring function allows you to achieve a 70% hit rate within the top 10 predictions. See the preliminary results in this video here. 👇
#biologics #generativeai #scoringfunction #platformupdates -
Insilico Medicine
@InSilicoMeds
🚀 How do frontier AI models differ across drug discovery?
We just updated our Drug Discovery & Development Benchmark portal with two new frontier models: GPT-5.6-Sol and Claude Opus-5.
The surprising result: there is no single winner across all categories.
🧪 Claude Opus-5 leads in clinical trial prediction @AnthropicAI
🧬 GPT-5.6-Sol dominates large therapeutic molecules @OpenAI
⏳ Grok 4.5 takes longevity @SpaceXAI
However, in many categories, frontier models have not yet surpassed specialist models.
Explore the benchmark, compare performance, and test your own models.
Insilico Medicine
@InSilicoMeds
Benchmark your model at: dddbench.insilico.com
-
Insilico Medicine
@InSilicoMeds
On stage today! ⏰
Attending #ai42026 at The Venetian? Head over to Palazzo Ballroom M at 2:50 PM to catch Alex Zhavoronkov, PhD for his talk:
🧠 "Cracking the Code of Life with AI: Using Frontier AI to Develop Therapies Addressing Diseases and Aging at the Same Time"
Discover how Insilico Medicine uses frontier AI to discover novel targets, generate optimized molecules, and target disease and aging simultaneously.
📌 Palazzo Ballroom M | 2:50 PM – 3:10 PM
See you there! 🚀
#ai4 #aiinpharma #techbio #longevity #insilicomedicine -
Insilico Medicine
@InSilicoMeds
🐼 Today, we’re excited to introduce PandaOmics #mcp (Model Context Protocol): a standardized communication bridge that seamlessly connects your local agentic tools (like Claude Code, Cursor, or CodeX) directly to Insilico Medicine’s advanced biological ecosystem.
🛜 By connecting PandaOmics directly to your favorite AI agents and tools, users can access target discovery, pathway analysis, and biomedical intelligence seamlessly.
In our latest demo video, watch how Claude Code uses the PandaOmics MCP integration to analyze single-cell gene expression patterns across cell types in rheumatoid arthritis, automatically delivering a publication-ready HTML report.
Join the future of agent driven discovery here: pharma.ai/pandaomics, or contact our team today to get started: Pharma.ai@insilicomedicine.com.
#agenticai #pandaomics #mcp #modelcontextprotocolThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
How Is AI Reshaping Innovative Drug Development? Alex Zhavoronkov in Conversation with CGTN
From artificial intelligence and robotics to next-generation biotechnology, China’s “new new trio” is accelerating convergence across these fields.
In an exclusive interview with CGTN, Alex Zhavoronkov, Founder and CEO of Insilico Medicine, discusses how generative AI is improving the efficiency of drug discovery, advancing innovative drug development, and exploring the unique strengths of China’s biotechnology industry.
In the face of aging and disease—shared challenges for all humanity—what truly matters is not competition alone, but global collaboration, ensuring that technological progress ultimately benefits everyone.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Thank you to @GeneOnlineNews 🤝 for the latest coverage.
Alex Zhavoronkov Maps a Path Forward for #longevitymedicine
At #bio Asia–Taiwan 2026 in #taipei, Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine, argued that longevity medicine has entered a pivotal stage of transformation. In an exclusive interview with GeneOnline, Zhavoronkov discussed how the convergence of GLP-1 therapies, AI-powered drug discovery, aging biomarkers, and next-generation pharmaceutical strategies is driving the development of longevity therapeutics and redefining how medicine approaches aging.
Continue reading here: www.geneonline.com/alex-zhavoronkov-maps-a-path-forward-f… -
Insilico Medicine
@InSilicoMeds
Tackling the PROTAC linker challenge: How multi-stage automated extraction is solving the structural decomposition puzzle 🧬
While most teams maintain robust libraries of warheads and E3 ligands, almost nobody keeps a dedicated library of linkers, even though linker length and composition drive ternary-complex geometry, permeability, and degradation efficiency.
Extracting these linkers from existing PROTAC sets manually is notoriously difficult, often resulting in broken rings, fragmented pieces, and lost attachment point bookkeeping.
By leveraging our MolTools MCP connector, drug hunters can systematically dissect PROTACs using plain-language prompts, guaranteeing ring integrity and retaining explicit attachment points for practical linker-region SAR analysis.
In our newest blog, we break down:
-Multi-Stage Pipeline: Navigating auto-cleaning, strict substructure matching, and boundary extension
-Data Integrity & Bookkeeping: Unambiguous preservation of attachment points for future enumerations
-AI-Driven Automation: Decomposing 949 distinct PROTACs in just four minutes with full visual validation and an exhaustive audit trail
Stop wrestling with custom, undocumented decomposition scripts and bring computational precision to your Targeted Protein Degraders design pipeline.
📖 Read the technical breakdown here: insilico.com/blog/protac-decomposition
#medicinalchemistry #compchem #protacs #targetedproteindegradation #chemistry42 -
Insilico Medicine
@InSilicoMeds
How do we know whether an AI-generated molecule is actually good?
Insilico Medicine Founder and CEO Alex Zhavoronkov introduces the company’s Drug Discovery and Development Benchmarks initiative.
Built on real drug discovery programs, experimental results, and years of industry-level validation, the initiative aims to help frontier AI developers evaluate where their models perform well—and where further improvement is needed.
Visit: dddbench.insilico.comThis media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
Qwen3.8-Max just entered our antibody developability benchmark.
It landed just behind the GPT models, essentially tied with Gemini 3.1 Pro, and ahead of Grok 4.5, Opus 5, and Opus 4.8.
That's an impressive result for an open-weights (soon) model on a wet-lab antibody prediction benchmark. Meanwhile, Kimi K3 (also open-weights) scored 0.075 and finished last.
Not an open-vs-closed story. A Qwen story 💪. @Alibaba_Qwen
#dddbenchmarks
Qwen
@Alibaba_Qwen
📢Meet Qwen3.8-Max — our most capable model to date.
Next week, the open weights of Qwen3.8-Max will be released, and Qwen3.8-27B is also going open-weights to meet you all!🎉
Qwen3.8-Max, a new bar for coding and cowork at 2.4T parameters:
- Autonomous coding: 10+ days of self-evolving development, from empty folder to production without hand-holding, complete project trace in the GitHub:github.com/qwen-code-dev-bot/oh-my-cli
- Real work, real results: Production-quality deliverables across hundreds of professions.
- Long-horizon mastery: System-level autonomous planning with closed-loop adaptive learning, driving 500+ turns of chip design optimization and 365 days of e-commerce strategy.
- Native multimodal intelligence: Vision isn't just input — it's a continuous feedback loop for planning, execution, and self-correction.
💰Pricing:
Input: $2.0 / M tokens
Output: $6.0 / M tokens
Implicit Caching: $0.25 / M tokens
Start building with Qwen3.8-Max! 🚀
📖 Blog: qwen.ai/blog?id=qwen3.8
✅ Qwen Studio: chat.qwen.ai?models=qwen3.8-max
⚡ API: www.qwencloud.com/models/qwen3.8-max -
Insilico Medicine reposted
Vladimir Aladinskiy
@VladAladin
Opus 5 shows a clear step-change on small molecule logD prediction in DDDBench.
Spearman 0.72 | R² 0.50 | MAE 0.692 — leading across the board.
Notable improvement on this key physchem property compared with previous Opus versions and the rest of the current field.
@AnthropicAI @jackclarkSF @mgdurrant
dddbench.insilico.com #tripledbench -
Insilico Medicine reposted
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
Everyone is asking: how is new Qwen 3.8-Max in #ursabench for synthesis planning ⁉️
1⃣ Well, it is much better than new Kimi K3
2⃣ Winter ❄️ (3.5) to summer, ☀️ Qwen's performance boosted +650% 🚀 , while Kimi is only +60%
3⃣ Qwen reached the level of Grok 4.5 (not bad), but beyond Opus (19%) and Sol 5.6 (26%).
Great job so far @Ali_TongyiLab @Alibaba_Qwen 👏
For more details, check our Benchmark Explorer at #dddbench by @InSilicoMeds ⬇️ -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Launches the Industry's First Drug Discovery and Development (#ddd) Benchmark as a Service, to Evaluate Frontier AI and #foundationmodels on Real-World Science
insilico.com/news/hxjtp34a41-insilico-medicine-launches-t… -
Insilico Medicine reposted
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
I am not a specialist in all of these disproved/proved conjectures and Erdős problems. But as a chemist I can see decisive improvements by the frontier models by @AnthropicAI to solve synthesis planning without ANY tools/orchestration.
Opus 5.0 has jumped 90% ! (10 to 19) on our hardest #ursabench set from Opus 4.8! Amazing progress 🚀! Kudos to @mgdurrant @nc_frey @dagarfield @AlecTPhD 👏 -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
We tested how reasoning effort impacts performance across the GPT-5.6 family (☀️ Sol, 🌎 Terra, 🌓 Luna) on the antibody developability benchmark.
The biggest gain (26%) came from GPT-5.6 High, but at a cost of $342.
Surprising result: Luna Medium outperformed Sol Medium 🧐
The frontier models are improving, but they are not there yet. Some signals may still be noise. Hydrophobicity is handled well, but other developability properties remain challenging, which may explain this behavior.
A glimpse into where AI stands today in antibody design. #dddbenchmarks -
Insilico Medicine
@InSilicoMeds
Big update to the Insilico #dddbenchmark (Drug Discovery and Development) portal.🧪
The portal now includes purpose-built specialist models alongside the latest frontier models, including Opus 5 and the GPT 5.6 family (☀️Sol, 🌎Terra, 🌓Luna), giving a more complete view of how general-purpose and domain-specific AI compare across drug discovery tasks.
The results are especially striking on our multi-step synthesis planning #ursabench. GPT 5.6 Sol (High) is now the top-ranked LLM and ranks 🥉 #3 overall, behind only two dedicated retrosynthesis planners, @maggie_hott @OpenAI.
General-purpose models are closing the gap fast. But the specialist leader still sets the pace: #retrochimera by @marwinsegler @MaziarzKris from @Microsoft remains the only model to break 30 points and continues to hold the 🥇#1 spot 💪. #aizynthfinder by @AstraZeneca takes 🥈. -
Insilico Medicine reposted
Vladimir Aladinskiy
@VladAladin
GPT-5.6 Family on Antibody Developability Prediction
Luna is remarkably close at a fraction of the cost. But looking at these results I thought: would I pay $400 for a higher chance of submitting the right molecule to synthesis and testing?
In the field of drug design, the cost of a mistake is extremely punishing. This is why building proper evals is so important.
dddbench.insilico.com
@OpenAI @joyjiao12 @thekaransinghal -
Insilico Medicine reposted
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
Meet our #dddbench for synthetic chemistry 🧪! Here are new results for Opus 5.0, Kimi K3, 5.6 Sol ☀️, Luna 🌒 and Terra🌎 ! The Insilico Index is heavily dependent on our #ursabench with primary focus on multi-step synthesis planning. Kudos 🏆 to @sama @maggie_hott @joyjiao12
-
Insilico Medicine
@InSilicoMeds
New Interview 📽️: How did China evolve from a biomedical service provider into a global biotechnology powerhouse?
In this excerpt from a recent Cure. webinar, Seema Kumar, CEO of Cure, speaks with Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, about China’s growing hashtag#biotechnology ecosystem, the evolution of AI-driven drug discovery and what Insilico has learned from operating across the U.S., China and other global markets.
Get a 15 minute preview here: www.youtube.com/watch?v=M-GbrnZzo3Y -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
GPT-5.6 Luna is one of the strongest frontier models we've tested for antibody developability prediction. 🔥
New pricing: 20× cheaper than GPT-5.6 Sol, with almost the same performance!
That's impressive! @OpenAI @sama -
Insilico Medicine
@InSilicoMeds
Think your foundation model is good at drug discovery?🧪
Prove it on clean data and earn your place on the leaderboard.
Every frontier model is already there. None of them wins everything.
Insilico DDD Benchmark. Submissions are open.
1/ 🧵Post not available here, view on X
Insilico Medicine
@InSilicoMeds
5/ The baselines aren't expert opinion.
Drug Candidate Essentials is grounded in proprietary data from multiple programs that reached the preclinical stage, an unprecedented benchmark, and the most important one for measuring the impact of frontier foundation models on real drug discovery programs.
Insilico Medicine
@InSilicoMeds
6/ Any model on a standard chat-completions API can be scored: private report, or published on the public board.
Your model. Your place on the board. Submit. -
Insilico Medicine reposted
Evgeny Kirilin
@EvgenyKirilin
🧬 At @InSilicoMeds, we give frontier AI models a protein and ask one deceptively simple question. Actually, thousands.
Which parts can change, and which absolutely can't?
Some amino acids are tolerable for mutation. Others are so important that changing just one can break the protein.
Our Structural Biology benchmark measures how well AI can tell the difference using only the protein's structure and sequence context.
🏆 Grok led this run at predicting which changes proteins can tolerate, well done @grok
🛡️ Opus was close behind and stood out at identifying the amino acids most critical to protein function, strong result @AnthropicAI
Plenty of room for the leaderboard to change with the right structural and evolutionary training data. You know where to find it. 😉 -
Insilico Medicine
@InSilicoMeds
Our 31st developmental candidate. And this one is special.
ISM9528 is a potential first-in-class, brain-penetrant, orally available non-opioid molecule for pain management. Novel target, novel molecule, novel mechanism. All three. Identified by PandaOmics, designed and optimized using our generative chemistry platform Chemistry42, with only 60 to 200 molecules synthesized and tested.
In preclinical models, it outperformed morphine. When the results came back, the teams were blown away. They didn't believe it, so we redid the experiments. Confirmed.
To see a non-opioid candidate outperform morphine in preclinical models is perhaps one of the most remarkable and unexpected results in our company's history. A result of frontier AI, human ingenuity, and scientific serendipity.
More than 20% of the global population suffers from chronic pain. The standard of care still relies heavily on opioids and NSAIDs, limited by inadequate efficacy, toxicity, and serious risks of dependence and addiction. ISM9528 offers a genuinely new path.
31 PCCs since 2021. 13 INDs approved or cleared. Average time to PCC nomination: 12 to 18 months versus the industry standard of 2.5 to 4 years. We are fast-tracking ISM9528 toward clinical trials in 2027.
We welcome pharmaceutical companies to review the preclinical package.
#insilicomedicine #drugdiscovery #painmanagement #generativeai #ism9528 #longevityThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Kimi K3 ranks near the bottom on our in-house drug discovery benchmark.
On ADMET prediction, it achieves a mean Spearman of 0.25 across 28 endpoints, not significantly better than K2.5 (0.23).
GPT and Opus lead at 0.45.
Good job @nc_frey @joyjiao12 -
Insilico Medicine
@InSilicoMeds
Frontier models are getting measurably better at real drug discovery tasks with every generation.
📷 Grok 4.5 reached #1 on drug-induced liver injury prediction. It is one of the most important safety benchmarks in drug development.
This is exactly the kind of progress our Insilico Medicine benchmark was built to capture. Want to test your model?
Great job @grok @SpaceXAI
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
Grok 4.5 just took the crown. 🚀
On DILI, the challenge of predicting drug-induced liver toxicity and one of the biggest causes of drug 💊failures, Grok 4.5 is now the #1 🥇model, outperforming every frontier flagship of the same LLM's generation.
Looking forward to seeing what Grok 4.6 can do in comparison to 5.6 Sol and Opus 5.0. @elonmusk -
Insilico Medicine
@InSilicoMeds
The evolution of the Opus model is fascinating to follow.
Its performance on Tm prediction suggests a meaningful signal, but the variation across other antibody developability #assays highlights the complexity of evaluating #llms for scientific applications.
Andrew Aiginin
@andrewaiginin
🏆 Opus 4.8 tops the frontier LLMs on antibody thermostability
Across the Melting temperature assay, Anthropic's Opus 4.8 leads every frontier LLM. Spearman ρ = 0.366 (p = 0.0014), ahead of GPT-5.5 (0.277) and GPT-5.6-sol (0.216). A real, statistically significant signal, not noise.
🧬 By the way, this is quite close to specialized models trained on public data.
Would be great to test #fable on this @nc_frey @mgdurrant -
Insilico Medicine
@InSilicoMeds
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC #ism9528 for Pain Management
Read the latest release here: insilico.com/news/3hbxchsjl1-targeting-the-100-billion-ma… -
Insilico Medicine
@InSilicoMeds
The Regular Webcast series continues 👇
Get an exclusive tour from Alex Zhavoronkov at the #insilicolab.
#ceoseries #labtour #insilicomedicineThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
AI isn't just transforming drug discovery anymore—it's transforming the entire biopharma value chain. 🚀
Generative AI platforms have already proven they can compress preclinical discovery timelines from years into months. But the real breakthrough happens when you connect that AI discovery engine directly to global drug development, CDMO capabilities, and manufacturing scale.
That was the core focus of our recent strategic signing ceremony in Taipei between Insilico Medicine and Bora Pharmaceuticals! 🤝
We are thrilled to announce a multi-target strategic alliance—a landmark framework with a potential collaboration value exceeding $2.5 Billion.
What this next-generation model brings to the table:
🔬 End-to-End Synergy: Linking Insilico’s pharma.ai platform (target discovery, generative chemistry, molecule optimization) with Bora’s global leadership in CMC, formulation, scale-up, and commercial manufacturing.
⚡ Operational Transformation: Upskilling workforce AI literacy and applying AI tools to optimize manufacturing, supply chain, and quality systems.
💊 Faster Delivery to Patients: Closing the gap between de novo molecule design and reliable, high-quality delivery for patients with unmet medical needs.
Watch the video recap featuring Alex Zhavoronkov (Founder & co-CEO, Insilico Medicine) and Bobby Sheng Sheng (Chairman & CEO, Bora Pharmaceuticals)!
Video: www.linkedin.com/posts/in-silico-medicine_insilico-medici…
#aidrugdiscovery #pharmaai #biotech #cdmo #drugdevelopment #pharmainnovation #insilicomedicine #borapharmaceuticals @BoraPharma
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Great insights on how AI models are evolving. 📷
Claude Opus is showing steady progress in synthesis planning, moving beyond understanding molecules toward helping scientists figure out how to make them.
While specialized chemistry tools are still ahead, the continued improvement is encouraging. It’s exciting to see AI becoming a stronger partner for scientific discovery.
Great job @sumrexromanus
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
🧪Making Claude a synthesis planner ⚗️?
We tested whether Claude Opus can do more than understand molecules 💊 or their NMR spectra – can it help scientists figure out how to make them?
With our #ursa (Utilitarian RetroSynthesis Assessment) framework, it is now possible to benchmark different LLMs on retrosynthesis. Interestingly, some models improve their coding abilities at the expense of domain-specific skills, but that doesn’t seem to be the case for #opus. Its performance on #retrosynthesis has been steadily improving with each new version
It is still far behind dedicated tools like #retrochimera and #aizynthfinder, but the progress is encouraging. If this trend 📈 continues, I believe Opus could become a strong competitor in synthesis planning. FYI @nc_frey
@mgdurrant @AlecTPhD @janleike @dagarfield
Unfortunately, #fable remains reluctant to discuss synthesis planning, so we couldn’t benchmark it properly this time 🙂. Looking forward to seeing what Opus 5.0 brings. Hopefully, it will not only be more capable but also a little more friendly.
💻Test your LLM using URSA: github.com/insilicomedicine/URSA
📜URSA preprint: arxiv.org/pdf/2607.04688
📊Checkout our LLMs’ dashboard for Drug Discovery tasks: ddb.insilico.com -
Insilico Medicine reposted
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
You know, generative chemistry has been our key domain at @InSilicoMeds for a long time. Remember MOSES? This time our colleagues translated their expertise into a novel #benchmark for 3D generative chemistry. Meet and try 3D-Fit! GitHub repo and preprint are in the thread 🧵
Maksim Kuznetsov
@Max__Kuznetsov
🧬LLMs are getting better at chemistry. But can they design molecular binders in 3D?
At @InSilicoMeds we test whether LLMs can generate ligands directly in a protein pocket while following spatial constraints such as fixed fragments, pharmacophores and required interactions.
🧵 -
Insilico Medicine reposted
Andrew Aiginin
@andrewaiginin
🏆 GPT-5.5 isn’t done yet: still dominating biologics developability
The newer 5.6-sol model brings fresh capabilities, but historical developability prediction benchmarks show the older GPT-5.5 model leading across most tasks.
🧬 Scientific AI is about fit, not just scale.
Congrats @OpenAI @joyjiao12 🚀 -
Insilico Medicine
@InSilicoMeds
📷 Can LLMs really design molecules in 3D?
We put them to the test by asking whether they can generate ligands inside protein pockets while following complex structural constraints.
The results are exciting. LLMs can handle more than we expected, but there is still a long way to go when it comes to physical realism.
A fascinating look at what AI can do today and where the next breakthroughs are needed in molecular design.
Maksim Kuznetsov
@Max__Kuznetsov
🧬LLMs are getting better at chemistry. But can they design molecular binders in 3D?
At @InSilicoMeds we test whether LLMs can generate ligands directly in a protein pocket while following spatial constraints such as fixed fragments, pharmacophores and required interactions.
🧵 -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
My friends, I would like to report a true breakthrough in my life and career - the nomination of our 31st developmental candidate that is very special. Novel Mechanism, Novel Target, Novel Oral Brain-penetrant Multi-parameter Optimized Molecule for... Pain. The target is undisclosed and carries the first letter of my family name - Target Z.
This is also our AI Eureka! Moment - the combination of Luck, AI, and curious human experts. I will post the press release and my blog story behind this drug separately but for this special moment, I recorded the video for you.
My goal is to solve aging. But if in the process we solve pain - this life was also worth living. The beauty of Target Z is that it is also implicated in aging (and no, it is not our brain-penetrant NLRP3).This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🚀 A major breakthrough in non-opioid pain management!
Insilico Medicine has officially nominated ISM9528, our 31st Preclinical Candidate Compound (PCC) since 2021—offering a potential first-in-class, non-opioid approach to pain management.
Key Breakthroughs:
🟢 Novel Biological Target: Identified by PandaOmics, ISM9528 targets a previously unexplored mechanism ("Target Z").
🟢 Superior Efficacy: Preclinical models demonstrated superior efficacy compared to current standards of care, with rapid-acting results and high blood-brain barrier permeability.
🟢 Favorable Safety: Orally available with a promising safety and DMPK profile.
Fast-tracking toward clinical trials in 2027.
hashtag#AIDrugDiscovery hashtag#Biotech hashtag#FirstInClass hashtag#PharmaAI hashtag#InsilicoMedicine
www.linkedin.com/posts/in-silico-medicine_aidrugdiscovery…
AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management.
Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated superior efficacy compared to the standard of care, along with a favorable safety profile as an oral treatment, and promising DMPK properties.
Proven Reproducibility and Scale: As Insilico's 31st PCC nominated since 2021, ISM9528 further validates the capabilities of Insilico's proprietary pharma.ai platform to consistently accelerate and empower drug R&D innovation.
CAMBRIDGE, Mass., July 22, 2026 -- Despite the widespread availability of analgesics, pain management remains one of the most significant and pervasive challenges in modern medicine, with more than 20% of the global population suffering from chronic pain, especially chronic neuropathic pain characterized by central sensitization. However, the standard of care currently continues to rely heavily on opioids and NSAIDs, which are limited by inadequate efficacy, gastrointestinal toxicity, and the serious risks of dependence and addiction, calling for novel, effective, non-addictive, brain-penetrant analgesics.
Insilico Medicine ("Insilico", HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, is addressing this critical unmet need by using AI to uncover novel biological mechanisms and develop innovative therapies. The company recently announced the nomination of ISM9528 as a Preclinical Candidate Compound (PCC) for pain management. Identified by PandaOmics, ISM9528 is a potential first-in-class, brain-penetrant, orally available inhibitor of Target Z that offers a novel, non-opioid treatment approach by acting on a previously unexplored biological mechanism. Notably, this marks the 31st PCC nominated by Insilico since 2021, further validating the company's AI-driven R&D capabilities.
"To see a non-opioid candidate outperform morphine in preclinical models is an unprecedented milestone, perhaps one of the most remarkable and unexpected results in our company's history, a result of frontier AI, human ingenuity and scientific serendipity." says Alex Zhavoronkov, PhD, Founder, CEO, and CBO of Insilico Medicine. "Target discovery for highly complex human mechanisms like chronic pain and migraine historically takes over a decade, but PandaOmics precisely mapped this pathway, driving us to our 31st PCC since 2021. By understanding the biology behind, we are not only addressing pain management, but moving one step closer to our ultimate ambition: decoding the biology of aging through our dual-purpose strategy."
To find a new path forward for pain management, the team leveraged PandaOmics, Insilico's AI engine for identification and prioritization of therapeutic targets. By analyzing massive datasets of omics, textual and multimodal data, PandaOmics helped the team uncover a new pain-related pattern, highlighting the potential of Target Z in Insilico's current portfolio, a novel target not systematically linked to pain management before, and driving their attention to a compound they had already developed.
Subsequent bioinformatics analyses of human and animal model data showed high expression of Target Z in pain-related cell types, strengthening the team's confidence to advance into wet lab testing. Moving swiftly into in vivo validation, The research utilized specialized mice models to imitate human pain mechanisms, demonstrating robust, dose-dependent pain management efficacy, with potential comparable or surpassing current solutions, including morphine.
Following target validation, the team aimed at brain-penetrant properties and a balance between efficacy and safety, deploying Chemistry42, Insilico's generative chemistry platform compassing 40+ selective models integrated into several affiliated applications to re-generate compounds with optimized selectivity and ADMET properties for pain indication. After iterative cycles of AI generation, human feedback and refinement, ISM9528 was selected as the lead compound for the project.
"The nomination of ISM9528 as the 31st drug candidate of Insilico validates the reproducibility and precision of our end-to-end AI platform," says Feng Ren, PhD, Co-CEO and CSO of Insilico Medicine, "Featuring both a novel mechanism of action and a highly distinct chemical structure, ISM9528 delivers superior efficacy and a favorable safety profile, with promising brain penetrant traits. Looking ahead, we are confident that our continuous integration of generative AI and automation will set new standards, deliver solid proof of concept, and introduce real-world clinical benefits for patients."
In preclinical studies, ISM9528 demonstrated superior efficacy compared to standard of care in validated models of acute postsurgical pain and neuropathic pain, as an oral treatment. Moreover, comprehensive in vitro and in vivo safety screenings across multiple panels and animal models confirmed exceptional safety properties, while rapid systemic absorption and excellent blood-brain barrier permeability support a favorable DMPK profile.
In the Spinal Nerve Ligation (SNL) rat model for neuropathic pain, ISM9528 dose-dependently restored mechanical allodynia. The middle dose delivered a significant analgesic effect across all time points up till 6h post dosing, which was comparable to Pregabalin, a standard of care for pain at similar dose level.
In the postsurgical acute pain model, in addition to the dose dependent efficacy, ISM9528 demonstrated a rapid-acting efficacy at 0.5-hour post-dosing outperforming the equivalent dose of Pregabalin.
"There is a tremendous unmet need for non-opioid pain medications, and the preclinical data for ISM9528 is quite promising," saysCarol Satler, MD, PhD, Senior Vice President for Clinical Development, Non-Oncology, Insilico Medicine, "This is what we call a 'Eureka' moment, the kind of discovery that completely changes the landscape of how we treat patients. We are fast-tracking this exciting program toward clinical trials in 2027, driven to deliver a medicine that will genuinely transform patient care."
As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard for the industry. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached preclinical candidate (PCC) nomination in an average of just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per program. Since 2021, the company has nominated 31 PCCs, 13 of which have received IND approval or clearance.
While expanding the practical applications of its technology in drug discovery and life science research, Insilico is also continuously enhancing the performance of its AI platform. Drawing on extensive experience and datasets from its training platform, the company has distilled thousands of benchmarks and integrated them into MMAI Gym. Serving as both a "trainer and benchmark" for scientific AI, MMAI Gym enables organizations to train models for domain-specific reasoning while rigorously evaluating their performance on real-world tasks, advancing the path toward pharma superintelligence. To date, Human Longevity and Liquid AI have collaborated with Insilico, joining as partners of MMAI Gym.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.hk.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com -
Insilico Medicine
@InSilicoMeds
New from the Insilico #scienceaibench: a remarkable turnaround
On our 28-task ADMET suite, Claude Opus climbed from #10 of 13 (v4.6) to tied for #1 (v4.8) — matching the best LLM in the field on both prediction accuracy and compound ranking.
This is why we benchmark every version, not just the flagship.
Great Job @AnthropicAI @claudeai
See the full results 📷
Bogdan A. Zagribelnyy, PhD
@sumrexromanus
🤖Claude Opus 4.8 ranks among the top LLMs for drug ADMET prediction. 📈
Claude Opus 4.8's ADMET comeback is incredible: version 4.6 stumbled, finishing #10 out of 13 on prediction error and near the bottom on compound ranking on our #admet benchmark sets that we thoroughly collect and curate at @InSilicoMeds
Two releases later, Opus 4.8 is tied for #1 🥇 across 28 ADMET drug-property tasks, matching the best frontier LLM in the field on both prediction accuracy and compound ranking.
For example, on predicting volume of distribution (how a drug spreads through the body), it reached an R² of 0.88.
It would be interesting to benchmark Fable too, but it still refuses to talk on bio/chemistry🙂. Anyway, great job @AnthropicAI @claudeai -
Insilico Medicine
@InSilicoMeds
Should we aim for ‘world-first’ or strive for ‘best-in-class’?
@biogerontology has summarized the common approaches into three categories:
1) Both the target and the molecule are highly novel
2) The novelty of both the target and the molecule is moderate
3) The target is relatively nonnovel, but the molecule itself is highly innovative. Each of these approaches has its own merits.
The question is: as an AI-driven pharmaceutical company, how do we weigh up these options?
And why do we make such choices? The answer lies in this video.
#openclaw #aidrivenpharma #openclaw #novelty #targetThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧪 How do you know an AI is any good? You test it on things it has never seen, just like a real #exam.
For drug discovery AI, that means predicting properties of new molecules, not ones it already learned from.
We checked whether the standard "exams" for small molecule activity prediction actually contain new molecules.
Mostly, they don't. 👀
Continue reading👇
#benchmark #insilicobenchPost not available here, view on X
Insilico Medicine
@InSilicoMeds
Even perfect separation isn't enough.
The exact same molecule can appear about 12× stronger or weaker simply because different labs measured it under different conditions.
If you ignore that, you're training AI on noisy, contradictory answers.
Insilico Medicine
@InSilicoMeds
🚀 Bottom line:
A record score on a benchmark full of leaked molecules doesn't tell you much.
Stop rewarding memorization.
If a benchmark is 90% copies, the leaderboard is measuring memory, not discovery.
At @InSilicoMeds, we build training and evaluation datasets to be genuinely separate and aware of experimental differences. That's the first step toward AI that can help discover new medicines. -
Insilico Medicine
@InSilicoMeds
Excited to share our latest work presented at #icml2026, where we introduce a new perspective on evaluating and training LLMs for retrosynthesis.
By moving beyond the “single correct answer” paradigm, we aim to enable more realistic, scalable approaches for AI-driven chemistry.
Continue reading👇
#benchmark #insilicobench
Maksim Kuznetsov
@Max__Kuznetsov
🧪At #icml2026, we presented our new paper from @InSilicoMeds:
“When a Single Answer Is Not Enough: Rethinking Single-Step Retrosynthesis Benchmarks for LLMs”
📄 Paper: arxiv.org/abs/2602.03554
🧵👇 -
Insilico Medicine
@InSilicoMeds
🧪 Retrosynthesis #benchmarks are broken.
For ~9 years, they’ve rewarded patent matching or “reaching” purchasable building blocks, even through chemistry no chemist would trust.
The real test is simple: would a chemist take this route to the lab?
That’s why we built #ursa 🧵
Continue reading 👇Post not available here, view on X
Insilico Medicine
@InSilicoMeds
“Can the system reach purchasable starting materials?” is also not enough.
A route can look solved on paper while relying on impossible selectivity, incompatible functional groups, or invalid reaction logic.
That is the risk: a benchmark may say “success,” while a chemist would say “do not run this.”
Insilico Medicine
@InSilicoMeds
This is the deeper problem: benchmarks optimize what is easy to count (exact match), not what chemists actually need. Also they need ingeniously novel target molecules, not like in the conventional USPTO-190 benchmark, where some clusters are enormously big, making the entire set non-diverse (see this cluster of 19! compounds).
Insilico Medicine
@InSilicoMeds
At @InSilicoMeds, we built #ursa to benchmark retrosynthesis closer to how chemists evaluate routes. Kudos to @sumrexromanus !
#chemcensor #icml2026 evaluates reaction plausibility. URSA then scores full routes hierarchically using Solv-N metrics: from formal validity (Solv-0 🔴) to reaction-center logic (Solv-1 🟠) and functional-group compatibility (Solv-2 🟢). For more details: read our preprint: arxiv.org/pdf/2607.04688
Insilico Medicine
@InSilicoMeds
The gap is striking: Some systems formally “solve” ~95% of targets, but only ~9% survive chemical plausibility checks. LLMs like GPT, Claude, Gemini, and Grok still lag behind conventional CASP tools. Even the best systems solve fewer than one-third of our novel expert targets, anyway, 🥇great job @marwinsegler with their RetroChimera!
Try URSA here: you can all try benchmarking URSA via our GitHub: github.com/insilicomedicine/URSA -
Insilico Medicine
@InSilicoMeds
Day 72 of #scienceaibench! 🧪 Can a model plan chemistry it has never seen? We score single-step retrosynthesis on the OOD URSA-expert-2026 targets using ChemCensor plausibility metrics.
📋 Benchmark Specifications:
- Tasks: Max-CC, Top-3, Top-5, Top-10.
- Metric: ChemCensor APT (↑)
- Models Evaluated: Opus 4.8, GPT 5.5, Grok 4.3, and Gemini 3.1 Pro.
📊 Observed Performance:
- Opus 4.8 leads the board: it posts the strongest average signal, winning 4 of 4 metrics and peaking at 1.700 on Max-CC.
- GPT 5.5 follows: a steady second at a mean of 0.875, without topping any individual board while tracking the leader across the family.
- Top-10 is the toughest metric: no model clears 0.362 on it, whereas Max-CC is the most tractable, reaching 1.700.
- Gemini 3.1 Pro trails the field: it posts the weakest scores (down to 0.253), struggling to capture the underlying signal.
💡 The Takeaway: On truly novel targets, retrosynthetic plausibility separates the models clearly — generalization beyond memorized reactions is the real test.
🔄 Our daily series continues tomorrow.
#scienceai #drugdiscovery #retrosynthesis #insilicobench #mmai #mmaigym #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
New Video 📹Longevity Claw vs. Longevity Lobster
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Yesterday we talked about benchmarking and TargetPro. Today we are covering PandaClaw, Longevity Lobster, and Longevity Claw.
PandaClaw is the biggest new feature in PandaOmics 6.0. A smart AI agent for target identification, target evaluation, drugability, safety, and competitive landscape analysis, all in real time. Good reception so far from our BD, biology, and chemistry teams.
Then we got into longevity. Two tools we quietly released that people are already using.
Longevity Lobster identifies dual purpose targets that can fight aging and disease at the same time. Fully integrated with our PandaOmics database, 244 aging clocks, GeneAge, GeroProtector, and more.
Longevity Claw uses Qwen and Liquid AI foundation models post-trained on longevity tasks including age prediction, target ID, disease modeling, dual purpose targets, mortality, comorbidity, and anti-aging signatures from potential geroprotectors.
Two different tools. Both focused on the same mission: extend healthy, productive longevity for everybody on the planet.
#insilicomedicine #longevity #drugdiscovery #ai #pandaomics #longevityresearch #targetdiscovery #aging #biotech #aiforscience #generativeaiThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Day 71 of #scienceaibench! 🧠 Back to GPCRs with the dopamine receptors D1–D4, where the line between antipsychotic efficacy and side effects is drawn by subtype selectivity.
📋 Benchmark Specifications:
- Targets: D1, D2, D3, D4.
- Metric: Spearman (↑)
- Models Evaluated: GPT 5.5, Gemini 3.1 Pro, Opus 4.8, and Grok 4.3.
📊 Observed Performance:
- GPT 5.5 leads the board: it posts the strongest average signal, winning 3 of 4 subtypes and peaking at 0.627 on D2.
- Gemini 3.1 Pro follows: a steady second at a mean of 0.301, taking 1 subtype while tracking the leader across the family.
- D4 is the toughest subtype: no model clears 0.228 on it, whereas D2 is the most tractable, reaching 0.627.
- Grok 4.3 trails the field: it posts the weakest scores (down to 0.030), struggling to capture the underlying signal.
💡 The Takeaway: The frontier ranks dopamine potency respectably, but the spread across D1–D4 shows subtype-specific SAR is still only partly captured.
🔄 Our daily series continues tomorrow.
#scienceai #drugdiscovery #gpcr #insilicobench #mmai #mmaigym #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Thank you to the International Telecommunication Union (ITU) organizers, who put on an incredible AI for Good Summit. Insilico President Alex Aliper joined an engaging panel discussing how we can expand healthcare through AI-enabled science.
Let's achieve "AI for Good" together. 🤝
#geneva #aiforgood #pharmaevents -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development.
Read the latest release: www.linkedin.com/pulse/insilico-medicine-bora-pharmaceuti… -
Insilico Medicine
@InSilicoMeds
Alex Zhavoronkov came to Taipei to answer the question the longevity industry keeps avoiding: not whether ageing can be treated, but who is going to pay for finding out
www.biospectrumasia.com/influencers/41/28025/bio-asiataiw… -
Insilico Medicine
@InSilicoMeds
What I want to do is more than just help people live longer 🧬
Over the years, I’ve been pondering one question: Can we truly understand aging and use science to change it?
From the founding of ARDD in 2014 to ARDD2026, which we’re about to host this year, I’ve come to realize time and again that longevity research is no longer just a topic of discussion in the lab.
Scientists, pharmaceutical companies, and investors are coming together to turn hypotheses about aging into testable targets, drugs, and clinical studies.
For me, what truly matters has never been the word “longevity” itself, but rather enabling more people to maintain their health, mobility, and quality of life as they age.
We’re using AI to gain new insights into disease and aging, and we’re working to bridge the gap between discovery and drug development.
There’s still a long way to go, but at least we’ve begun to turn “healthy longevity” from a vision into reality, one step at a time.
#createinfinitepossibilities #dowhatyouwantThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Over the past year and a half, benchmarking has been Insilico's main focus in AI. We benchmark everything, from target ID and disease modeling to clinical trial outcome prediction. With 31 developmental candidates, we can now use our own programs as benchmarks. About 1,200 benchmarks per developmental candidate from start to nomination.
We introduced TargetPro, our new advanced target discovery model built on those benchmarks. Frontier LLMs like ChatGPT 5.5 and Opus 4.8 are about 10 to 20% worse than our best-in-class specialist tools. But when we post-train open source models like Qwen using MMAI Gem, they outperform those frontier models by more than 10 to 15%. Dramatically.
PandaOmics 6.0 is also out. Biggest update since launch. Full single cell data analysis, fully connected to target ID. This is exactly how we identified TNIK as the best target for IPF.
#insilicomedicine #longevity #drugdiscovery #ai #pandaomics #benchmarking #targetdiscovery #generativeai #longevityresearch #biotech #drugdevelopment #aiforscience #aging #lifesciences #hongkongThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
How can a line of code become a clinical drug candidate with the potential to transform patients’ lives?
The journey of Rentosertib (INS018_055) answers that very question.
It began in 2019 with our landmark GENTRL study published in Nature Biotechnology, which first demonstrated the power of generative AI to design novel small molecules.
By integrating our proprietary, end-to-end pharma.ai platform, we turned theory into a reality:
🎯 PandaOmics identified and prioritized the novel biological target.
🧪 Chemistry42 drove the generative chemistry and molecular optimization.
From nominating Rentosertib as a preclinical candidate for idiopathic pulmonary fibrosis (IPF), through Phase 0 and Phase I safety studies, to publishing positive Phase IIa patient data in Nature Medicine—every step has been a leap forward.
Now, with the initiation of our Phase III clinical trial this month (July 2026), Rentosertib represents far more than the advancement of a single drug program.
Rentosertib stands as a public, traceable, and fully validated evidence chain showing how AI-driven target discovery and generative molecular design move seamlessly from algorithms to late-stage clinical trials.
For the entire AI drug discovery industry, this is no longer just a proof of concept. This is a historic step toward late-stage clinical validation, patient-first data, and a fundamental shift in how tomorrow's medicines are discovered and developed.
#generativeai #drugdiscovery #biotech #clinicaltrials #pharmaai #insilicomedicine #phase3This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
The CEO #dailychats with Alex series continue. Check out the latest #openclaw video here 👇
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Now Available 👇
Rentosertib Encyclopedia: From Target Discovery and Generative Chemistry to Phase III Clinical Trials rentosertib.net -
Insilico Medicine
@InSilicoMeds
Day 69 of #scienceaibench! 💧 We open the ADMET stretch with the most fundamental physicochemical properties — lipophilicity and solubility — that shape a molecule's entire fate in the body.
📋 Benchmark Specifications:
- Tasks: LogP, LogD, Kinetic Solubility, Thermodynamic Solubility.
- Metric: Spearman (↑)
- Models Evaluated: GPT 5.5, Gemini 3.1 Pro, Opus 4.8, and Grok 4.3.
📊 Observed Performance:
- GPT 5.5 leads the board: it posts the strongest average signal, winning 4 of 4 properties and peaking at 0.925 on LogP.
- Gemini 3.1 Pro follows: a steady second at a mean of 0.641, without topping any individual board while tracking the leader across the family.
- Kinetic Solubility is the toughest property: no model clears 0.314 on it, whereas LogP is the most tractable, reaching 0.925.
- Grok 4.3 trails the field: it posts the weakest scores (down to 0.177), struggling to capture the underlying signal.
💡 The Takeaway: Lipophilicity is nearly solved for frontier models, but aqueous solubility remains meaningfully harder — a reminder that not all physicochemical endpoints are created equal.
🔄 Our daily series continues tomorrow.
#scienceai #drugdiscovery #admet #insilicobench #mmai #mmaigym #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
What does the future of medicine look like? It looks like the world’s first fully documented generative AI-designed drug entering Phase III clinical trials.
Following our recent Phase III announcement for rentosertib (ISM001-055), we aren't just celebrating a clinical milestone—we are looking at a paradigm shift in how life-saving medicines are discovered, designed, and delivered.
By utilizing our proprietary pharma.ai platform, we are actively proving that the timeline and cost of traditional drug discovery can be drastically reduced, ultimately aiming to extend healthy life expectancy for everyone.
Rentosertib was discovered and designed using Insilico’s pharma.ai platform. The continued advancement of pharma.ai is supported by Insilico’s AI-driven biotechnology R&D centre in Abu Dhabi. Through our strategic partnership with the Abu Dhabi Investment Office مكتب أبوظبي للاستثمار (ADIO), Insilico has expanded its presence in Abu Dhabi as a member of the HELM cluster and established its R&D centre in Masdar City.
By bringing together global scientific talent, proprietary algorithms, and clinical expertise, Insilico is proud to catalyze the UAE’s rapidly growing pharmaceutical innovation hub.
The future isn’t coming; it’s being built right now.
👇 Read the full breakdown of our Phase III milestone and partnership details in the comments below.
#insilicomedicine #generativeai #biotechinnovation #rentosertib #phaseiii #abudhabi #masdarcity #adio #pharmaai #futureofmedicineThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Day 68 of #scienceaibench! 🧬 Today we probe subtype selectivity on the opioid receptors — Delta, Kappa and Mu. Hitting the right subtype is the whole game in designing painkillers that relieve pain without the addiction liability of classic Mu agonists.
📋 Benchmark Specifications:
- Targets: OPRD1, OPRK1, OPRM1.
- Metric: Spearman (↑)
- Models Evaluated: GPT 5.5, Gemini 3.1 Pro, Opus 4.8, and Grok 4.3.
📊 Observed Performance:
- GPT 5.5 leads the board: it posts the strongest average signal, winning 3 of 3 subtypes and peaking at 0.639 on OPRD1.
- Gemini 3.1 Pro follows: a steady second at a mean of 0.356, without topping any individual board while tracking the leader across the family.
- OPRM1 is the toughest subtype: no model clears 0.330 on it, whereas OPRD1 is the most tractable, reaching 0.639.
- Grok 4.3 trails the field: it posts the weakest scores and dips negative (down to -0.037), struggling to capture the underlying signal.
💡 The Takeaway: Frontier models can rank Delta-opioid potency well, but the collapse on the Mu receptor shows that selective potency prediction — the crux of safer analgesic design — is far from solved.
🔄 Our daily series continues tomorrow.
#scienceai #drugdiscovery #gpcr #insilicobench #mmai #mmaigym #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
⚡ New #profiling updates announced at our latest #pharmaai2026 Q2 Webinar: Expanded Kinase Inhibitor Models and New Prediction Reliability Indicators. Check out this preview video here which shows how we evaluated 67 kinase targets using around 261,000 bioactivity records.
The full version is available here 👉 insilico.zoom.us/webinar/register/9117803176869/WN_hxGDHR…
#chemistry42 #profilingresults #regressiontasks -
Insilico Medicine
@InSilicoMeds
Phase III is where innovation meets validation. We're proud to announce the initiation of the Phase III clinical trial for Rentosertib, our lead AI-powered program for idiopathic pulmonary fibrosis—the world's first end-to-end AI-discovered drug candidate to reach this stage. #clinicaltrials #ai #drugdiscovery #ipf
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
"For example, Insilico Medicine’s average timeline to nominate a preclinical candidate is between nine and 12 months vs the industry average of four to six years. Increasingly, the biopharma industry is seeing improved probability of success in phase one trials indicating higher quality candidates are coming through from AI."
Read the latest "Capgemini: How AI is Transforming Pharma Drug Discovery" here: aimagazine.com/news/capgemini-how-ai-transforms-drug-disc… -
Insilico Medicine
@InSilicoMeds
How is AI transforming the future of drug discovery and healthcare?
Alex Aliper, Co-Founder & President of Insilico Medicine, joins Ana Blanquart at the FII TV Studio during FII PRIORITY Europe 2026 in Rome to discuss how artificial intelligence is accelerating pharmaceutical innovation and enabling the development of targeted therapies.
Watch the full interview for insights on AI in healthcare, drug discovery, biotechnology, and the future of medicine.
www.youtube.com/watch?v=kqL3Matm8h0 -
Insilico Medicine
@InSilicoMeds
pharma.ai Q2 2026 Summer Webinar: A Deep Dive into Insilico Medicine’s Latest Platform Upgrades
As AI reshapes the pharmaceutical industry, it is opening a new chapter of opportunities in drug discovery, design, and development. To help accelerate the advent of Pharmaceutical Superintelligence, Insilico Medicine welcomed over 600 scientific professionals worldwide, part of the pharma.ai 2026 Quarterly Webinar Series.
Find all the release notes across our platforms here: insilico.com/news/er6gnm3741-pharmaai-q2-2026-summer-webi…
#pharmaai2026 #newfeatures #webinarseries -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic #aidrugdiscovery
The collaboration is designed to identify clinically differentiated drug candidates for promising therapeutic targets. Using advanced generative models from the earliest stages of design, the teams aim to improve the quality of candidate molecules and optimize them to achieve best-in-class efficacy and safety criteria.
Read the latest release here: insilico.com/news/4ifuiaal01-insilico-medicine-announces-… -
Insilico Medicine
@InSilicoMeds
🚀 Heading to #icml2026? The Insilico Medicine team is on the ground and excited to share our latest research at the intersection of #machinelearning and drug discovery! [ICML] Int'l Conference on Machine Learning
We are presenting our recent developments in establishing robust benchmarks for ML solutions in synthetic chemistry. Stop by our poster session to chat about turning digital AI predictions into real-world bench #chemistry.
📍 Poster Session 3
Topic: When Single Answer Is Not Enough: Rethinking Single-Step #retrosynthesis Benchmarks for LLMs
When: Wednesday, July 8, 2026 • 10:30 AM – 12:15 PM KST
Where: HALL A #1103
💡 Why This Matters
As #generativeai and predictive models scale, standardized benchmarks are absolutely critical. Our team has been working on framework developments that help validate ML solutions in synthetic chemistry, bridging the gap between digital design and successful chemical synthesis.
Whether you want to dive deep into molecular graphs, discuss generative chemistry, or explore potential collaborations, we’d love to see you there.
Drop by HALL A #1103 to chat with the team! 🔬✨
#icml2026 #machinelearning #syntheticchemistry #aiindrugdiscovery #generativeai #insilicomedicine -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:747634828946…
In Part 3 of our Bits to Bio series, Insilico Medicine CEO Alex Zhavoronkov and 01.ai CEO Kai-Fu Lee tackle one of the most critical, yet unspoken bottlenecks in the deep tech industry: the AI adoption gap.
Dr. Lee highlighted a stark reality that many organizations face when deploying advanced technology: "The gap between the model and the rate of adoption is pretty significant."
Here are the core takeaways from their discussion on bridging that divide:
🟢 The 1-Year Bottleneck: It often takes six months to develop a frontier AI model, and another six months for scientists to learn and adopt it. Shortening this 12-month lag between development and actual utility is where true operational efficiency is won or lost.
🟢 Moving Beyond Chatbots: True enterprise transformation isn’t about just tweaking a chatbot to give slightly better answers. It’s about taking AI into action. This requires a rigorous, multi-step deployment framework: setting a data foundation, building a specific domain ontology, fine-tuning agents, and ensuring safe environment execution.
🟢 Streamlining the Pipeline: When taking open-source or closed models and tailoring them for industry-specific applications, the goal must be compression. By systemizing the path from model to everyday workflow, 01.ai works to radically shorten the time to real customer satisfaction.
We aren't just building faster models; we are engineering the seamless pipelines required to get those models out of the lab and into the hands of scientists who are changing the world.
Stay tuned for more in our series: Bits to Bio with Alex Zhavoronkov & Dr. Kai-Fu Lee! 🎬
How does your organization bridge the gap between building an advanced tool and actually getting your team to adopt it? Let’s discuss in the comments. 👇
#artificialintelligence #biotech #generativeai #drugdiscovery #deeptech #aiadoption -
Insilico Medicine
@InSilicoMeds
Today, not a single approved therapeutic on the market can extend human life by even a single year.
At InSilico Medicine, we want to change that—not by chasing headline-grabbing numbers, but by shifting the focus to "Peakspan."
Our true mission is to extend the time people spend in their healthiest, most vibrant, and most productive zones.
In a recent feature article, our CEO, Alex Zhavoronkov, spoke with Jason Chau at The Wall Street Journal about how we are combining generative AI, clinical execution, and a bold global strategy to redefine the boundaries of human health:
🇨🇳 Competing at the Epicenter of Global Innovation
We are intentionally doubling down on our presence in China because it has become a powerhouse for rapid biopharma innovation. While traditional drug discovery can take over 4 years to move from a novel target to preclinical trials, the ecosystem in China compresses that to roughly 2.5 years. By using our proprietary generative AI platform to shorten that window to as little as 9 months, we are uniquely positioned to compete and deliver at the frontlines of global medicine.
💰 Validated Commercial Growth
A grand vision requires sustainable execution. On the heels of our recent $2.75 billion Eli Lilly deal and a $2.5 billion partnership with SK Biopharmaceuticals, we have secured a comfortable 5-to-6-year cash runway. This financial momentum positions us to achieve profitability within the next three years as we scale our pipeline.
⚠️ A Healthy Reality Check on the AI Bubble
True leadership requires clear eyes. Alex also shared a realistic outlook on the broader AI sector, warning of an impending market correction for overvalued startups that lack deep domain expertise. At InSilico, we have built our foundation on real revenue, tangible assets, and clinical-stage pipelines to ensure long-term value creation.
A sincere thank you to Jason Chau for this deep dive into our work, our strategy, and the next frontier of human health. Link to the WSJ article in the comments. 👇
www.wsj.com/business/insilico-is-on-a-mission-be-no-1-in-…
#insilicomedicine #biotech #artificialintelligence #peakspan #longevity #aipharma #generativeai #innovation #globalbusiness -
Insilico Medicine
@InSilicoMeds
Quantum: The best and worst of the next computing revolution www.ubs.com/global/en/investment-bank/insights-and-data/a…
-
Insilico Medicine
@InSilicoMeds
www.linkedin.com/pulse/frontier-transformation-scale-insi… Frontier Transformation at Scale: Inside Asia’s Reimagined Experience Center
-
Insilico Medicine
@InSilicoMeds
🤝 We are incredibly honored to be featured by Katy Brown (Corporate Vice President of Americas Markets and Industries at Microsoft) in her recent piece, "A New Frontier for Experience Centers: Transformation at Scale in Silicon Valley."
The feature highlights how Insilico Medicine is leveraging Microsoft Azure AI Foundry within our pharma.ai suite to move past standard automation and achieve true pipeline autonomy. By combining advanced physics-based models with specialized scientific AI agents, we are fundamentally reshaping the traditionally slow, costly, and complex R&D process.
Read the full article here 👉 www.linkedin.com/pulse/new-frontier-experience-centers-tr… -
Insilico Medicine
@InSilicoMeds
Follow along on all of our BIO Coverage this week 👇
Insilico Medicine to showcase AI-driven drug breakthroughs at #bio2026 International Convention
www.news-medical.net/news/20260618/Insilico-Medicine-to-s… -
Insilico Medicine
@InSilicoMeds
#bio2026 Day 1 and 2 recap video! www.linkedin.com/posts/zhavoronkov_bio2026-activity-74755…
-
Insilico Medicine
@InSilicoMeds
🐼#pandaclaw operates through a seamless autonomous workflow powered by a cutting-edge agent architecture utilizing LangChain and LangGraph frameworks. When presented with a research objective, the Agent Core autonomously formulates a multi-step analytical workflow, parsing natural language requests into distinct tasks.
To ensure scientific integrity, the agent autonomously diagnoses and self-corrects formatting issues or data anomalies within an isolated local sandbox. Finally, the platform produces high-quality, figure-rich reports while maintaining strict data provenance and scientific transparency. Learn more here: pharma.ai/pandaomicsThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and SK Biopharmaceuticals Announce Up to $2.5 Billion AI Neuroimmune Drug Collaboration www.geneonline.com/insilico-medicine-and-sk-biopharmaceut…
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
If you would like to acquire FIC/BIC preclinical/clinical drugs with maximally-optimized molecular properties or SOTA AI that was used to discover these drugs or the platform that was used to develop that SOTA AI - find one of these team members or visit our booth at #bio2026. Booth #4021
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
AI is the most frequently used word at #bio2026. Happy to see fresh perspectives from Christopher Arendt, PhD of Takeda and being very humble. In my book, Takeda is in top 3 pharma companies in the world in terms of AI competence and productivity.
-
Insilico Medicine
@InSilicoMeds
🚀 Insilico Medicine & SK Biopharmaceuticals Forge $2.5B AI Drug Discovery Alliance
We are pleased to share that Fortune has featured our landmark multi-program partnership with South Korea’s SK Biopharmaceuticals to develop novel neuroimmune therapies for the central nervous system (CNS).
The agreement—valued at up to $2.5 billion in milestones and royalties ($18 million near-term)—marks Insilico’s largest partnership to date in the Asia-Pacific region. This is our second multi-billion-dollar deal this year, following our $2.75 billion collaboration with Eli Lilly. Reflecting strong investor confidence, Insilico’s shares rose 5.6% in Hong Kong trading following the announcement, extending total gains to 35% since our recent IPO.
📈 Strategic Insights from the Fortune Feature
The Macro AI Boom: The alliance capitalizes on South Korea's surging AI hardware ecosystem. With SK Group's affiliate SK Hynix recently becoming South Korea’s most valuable company due to the AI chip boom, substantial resources are flowing directly into the region's pharmaceutical innovation.
Chasing Ultra-High Novelty: As Insilico co-CEO Alex Zhavoronkov noted, Korean companies have the appetite and capital to take calculated risks for ultra-high novelty in neuroimmunology—a domain poised to become a trillion-dollar therapeutic opportunity.
Unprecedented Preclinical Speed: By leveraging optimized global discovery platforms, Insilico aims to drastically compress early R&D timelines, gaining up to two years of speed at the preclinical stage.
Scalable Architecture: SK Biopharmaceuticals plans to combine our target discovery engine with their proven U.S. commercial infrastructure. As DH (Donghoon) Lee, President and CEO of SK Biopharmaceuticals, stated, this collaboration serves as a "scalable and repeatable growth platform" for future CNS therapies.
🚀 Reaching "Escape Velocity"
"We want to be the SpaceX of the pharmaceutical industry," Dr. Zhavoronkov told Fortune. "The more I scale, the better my AI gets. I want to get to this escape velocity where nobody can even compete."
By continuously scaling our pharma.ai platform, we are breaking traditional R&D bottlenecks to deliver innovative assets to the market faster, maximizing value for our shareholders and bringing real hope to patients.
Our sincere thanks to Asia Editor Nicholas Gordon for capturing the scope of this milestone.
👉 Read the full exclusive on Fortune: fortune.com/2026/06/22/insilico-sk-biopharmaceuticals-sou…
#ai #drugdiscovery #biotech #pharma #cns #neuroscience #innovation #insilicomedicine #skbiopharmaceuticals #generativeai #biotechinvesting -
Insilico Medicine
@InSilicoMeds
🌐 Live from #bio2026
Yesterday at the BIO International Convention in San Diego, Insilico Medicine’s Founder, CEO, and CBO, Dr. Alex Zhavoronkov, joined an exceptional panel of industry leaders for a deep dive into: "ADCs, GLP-1s, and Beyond: How China is Impacting the 2026 BD Landscape." Thank you to Lilly Asia Ventures 礼来亚洲基金 for moderating.
The discussion centered on the explosive growth of high-value modalities specifically antibody-drug conjugates (ADCs) and GLP-1 metabolic therapies, and how cross-border collaborations are becoming more dynamic than ever.
🎪 Onsite in San Diego? Stop by Booth #4021 to meet the Insilico team, see live demos of our new scientific agent PandaClaw, or discuss potential pipeline partnerships. -
Insilico Medicine
@InSilicoMeds
Big news out of @BIOConvention today! 🚀
Insilico Medicine and SK Biopharmaceuticals have officially entered into a $2.5 billion AI-powered drug discovery collaboration to tackle neuroimmune disorders.
By uniting our pharma.ai engine with SK Biopharmaceuticals’ world-class CNS expertise, we are aiming to dramatically accelerate discovery timelines and deliver next-generation therapies to patients suffering from complex neurological conditions.
This record-setting partnership represents a massive milestone for Insilico as our largest APAC deal to date, but more importantly, it shows how generative AI is shifting from industry hype to multi-billion-dollar clinical validation.
Heading to BIO this week? Let's talk about where scientific AI is moving next. Catch the team at our panel sessions or swing by the Insilico Booth #4021!
#biopharma #ai #digitalhealth #cns #innovation #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Follow along throughout the week at #bio2026. Book a partnering meeting with our team or visit booth 4021! www.linkedin.com/feed/update/urn:li:activity:747493472988…
-
Insilico Medicine
@InSilicoMeds
👉 4 days until Biotechnology Innovation Organization 2026 kicks off! Our team will be on the floor ready to discuss our latest pipeline advancements, pharma.ai features, and more.
Book a #partnering meeting with us in the #bio2026 Partnering app, or email: BD@insilico.com.
See you in San Diego next week! @BIOConvention -
Insilico Medicine
@InSilicoMeds
Join us on June 30 at 10 am ET for the next quarterly webinar from pharma.ai!
This virtual webinar gathers Pharma Executives, Computational Biologists and Medicinal Chemists to explore the frontier of Pharmaceutical Superintelligence (PSI). We will share our progress in achieving Pharmaceutical Superintelligence (PSI) through the MMAI Gym, and all the new features we have added to our pharma.ai platform
Register here:
insilico.zoom.us/webinar/register/9117803176869/WN_hxGDHR… -
Insilico Medicine
@InSilicoMeds
Just announced: Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969 with Hygtia Therapeutics
Read the release here: www.linkedin.com/pulse/insilico-completes-first-in-human-… -
Insilico Medicine
@InSilicoMeds
Teaching AI the Language of Molecules: How MMAI Gym and Liquid Intelligence are Solving the “Brute Force” Crisis in Drug Discovery
#drugdiscovery is often described as searching for a needle in a haystack, with only a tiny number of drug compounds simultaneously safe, effective, and synthesizable. The reality is far more daunting–it's like finding a needle in a whole galaxy. Chemists estimate the number of potential drug-like molecules at 1060, more than the number of atoms in the Milky Way. We have traditionally relied on two things to navigate this virtually infinite landscape: the intuition of master chemists and, more recently, the brute force of massive #artificialintelligence.
Continue reading our latest blog: insilico.com/blog/mmai-liquid-ai
#mmaigym -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:747234598052…
What happens when one of the world’s ultimate pioneers in artificial intelligence steps into a fully automated, robotic drug discovery lab?
Insilico Medicine CEO, Alex Zhavoronkov had the absolute privilege of hosting Dr. Kai-Fu Lee at our Shanghai facilities for an exclusive, deep-dive conversation.
This kickoff marks the start of an exciting new series where we bridge the gap between pure tech and biological breakthroughs. We didn't just talk about code; we talked about the tangible future of human health.
If you want to know where the next decade of deep tech is going, you won’t want to miss this series.
Stay tuned for more in our series: Bits to Bio with Alex Zhavoronkov & Dr. Kai-Fu Lee! 🎬
What do you think will be AI's most disruptive contribution to healthcare over the next 5 years? Let’s discuss in the comments. 👇
#artificialintelligence #biotech #generativeai #drugdiscovery #deeptech #innovation #healthcare -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the Morgan Stanley China #biopharma Symposium 2026 in Shanghai on June 18. He will deliver a speech during the morning session from 10:00 to 10:50 AM at the "AI-Driven Drug Discovery in China: Accelerating from Hit to Clinic" Forum.
📅 Panel Session Details:
Topic: Global Out-licensing Boom: Structuring Win-Win Partnerships
Date: Thursday, June 18, 2026
Time: 9:00 AM - 9:50 AM
Are you attending the symposium? Let us know in the comments or reach out directly to our team to connect in Shanghai!
#morganstanley #biopharma #outlicensing #insilicomedicine
www.eurekalert.org/news-releases/1131820 -
Post not available here, view on X
Insilico Medicine
@InSilicoMeds
The detailed release can be found here: www.eurekalert.org/news-releases/1131820
-
Insilico Medicine
@InSilicoMeds
GPT 5.5 Deep-Dive
We’ve been running near-daily model evaluations for a while, but those quick reads only scratched the surface. We’re changing the rhythm: fewer reports, deeper insights. This first deep-dive looks at GPT 5.5 across drug discovery and materials science, stacked head-to-head against older versions and Opus 4.7.
🔬 Methodology
• 162 benchmarks across 6 categories
• Raw metric averages aggregated within each metric type — no normalization tricks, no cherry-picking
📈 GPT 5.5 vs legacy models
This isn’t an incremental update; GPT 5.5 lives in a different tier compared to the previous GPT line:
• Materials property prediction: error dropped from ~124–177 to 49.6
• ADMET rank correlation: roughly doubled to 0.47
• Molecular optimization: success rate jumped to 83% vs ~44–54%
• Retrosynthesis: ~2.5× quality of GPT 5.1 and well ahead of GPT 5.2
⚔️ GPT 5.5 vs Claude Opus 4.7
On public benchmarks, it’s a tight race: GPT 5.5 narrowly edges out Opus 4.7, leading 83 to 79 head-to-head.
GPT 5.5 is strongest in ADMET, materials, biologics, and molecular optimization (though at the expense of structural similarity to known references).
🤝 The retrosynthesis challenge
Retrosynthesis is the only category where another model partially keeps pace. Opus 4.7 is slightly more effective than GPT 5.5 in the single-step retrosynthesis task on the key OOD URSA-expert-2026 benchmark, as measured by ChemCensor metrics as a proxy for chemical plausibility.
Interestingly, GPT 5.5 is a bit more capable than Opus 4.7 on the conventional USPTO-50k benchmark with potential data leakage. However, when compared in synthesis planning, i.e. multistep retrosynthesis on OOD target molecules, GPT 5.5 heavily beats Opus 4.7: 23% vs 12% by Solv-2, a solvability metric extended with ChemCensor-based plausibility checks.
Thus, even with Anthropic’s heavy public investment in chemistry, the end goal of retrosynthesis is not resolved by their model. At the same time, we see significant progress in OpenAI models' retrosynthesis performance when comparing previous generations of GPTs to 5.5.
🧪 The wet-lab reality check
When we move to our PCC essentials benchmark, which uses wet-lab ADMET measurements as ground truth, the illusion breaks:
• Rank correlation drops to 0.20–0.28 for every model
• The public benchmark gap vanishes
• No model meaningfully separates itself in the real world
The takeaway: a model scoring 0.47 on a public benchmark but dropping to ~0.28 on unseen experimental data is a major warning sign. It suggests public datasets are measuring recall and memorization just as much as actual reasoning.
Bottom line: GPT 5.5 is a true generational jump and the strongest single model on public benchmarks – but treat those numbers with caution.
The benchmarks that matter most are the ones a model has never seen. On those, the frontier is nowhere near solved. That’s why we’re shifting to deeper, slower evaluations with held-out experimental data. -
Insilico Medicine
@InSilicoMeds
🔇 The Insilico Medicine team is heading to the Biotechnology Innovation Organization International Convention in #sandiego, and we are actively looking to partner with leaders ready to transform targets into therapeutics.
Don't miss the chance to see how our #generativeai and automation are cutting down discovery timelines.
Insilico Medicine will present the following featured BIO 2026 speaking sessions:
-ADCs, GLP-1s, and Beyond: How China is Impacting the 2026 BD Landscape, June 22, 3:00 PM - 4:00PM at 32AB
-Quantum Computing in #drugdiscovery, June 22, 4:15PM - 5:15PM at 28ABCDE
Strategic Innovation: Building Smarter Pipelines for Challenging Targets, June 25, 9:00 AM - 10:00 AM at 29AB
Learn more about our pipeline: insilico.com?pi_content=9a2891f1b28b14684696d9b7ecdbc145a…
👇 Drop a comment below or connect with us in the BIO 1:1 Partnering app to set up a meeting.
#bio2026 #biotech #generativebiology #aiinhealthcare #partnering #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Attending #dhai26? Be sure to catch Petrina Kamya's Healthy Longevity session.
www.linkedin.com/posts/petrinakamya_dhai2026-longevity-ch… -
Insilico Medicine
@InSilicoMeds
At the inaugural Pulmonary Clinical Trials Workshop, Dr. Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joined leaders from academia, biotech, and pharma to discuss the future of therapies for idiopathic pulmonary fibrosis (IPF) and other serious pulmonary diseases.
Reflecting on the meeting, Dr. Satler highlighted the strong interest in Insilico Medicine's generative AI-driven approach to drug discovery, with many recognizing its potential to accelerate development, identify novel targets, and ultimately help transform patient care and clinical outcomes.
Thank you to the organizers and everyone who contributed to these important discussions. We look forward to continuing to advance the next generation of AI-enabled therapeutics through collaboration and innovation.
#insilicomedicine #ipf #pulmonaryfibrosis #generativeai #drugdiscovery #biotech #clinicaltrials -
Insilico Medicine
@InSilicoMeds
Afraid of AI? You‘re Just Too Lazy to Prompt
Want to keep your job? Start with AI. Run faster just to stay in place. Ask your LLM: what should I learn today? Those who fear losing jobs are just too lazy to prompt. Sticking to old skills is no longer an option.
#ai #futureofwork #automation #upskill #productivity #insilicomedicine #alexzhavoronkovThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
📽️ Ending the Farce: AI Pharma Needs a Real Playbook
Hype-based fundraising is toxic to the industry. Drug discovery isn't just another tech trend; it requires rigorous benchmarks and real-world case studies. Progress in pharma might be "boring" and slow, but it's the only path to saving lives. It's time for a playbook based on results, not rhetoric.
#insilicomedicine #alexzhavoronkov #venturecapital #pharmainnovation #healthcareai #integrityinscienceThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Congratulations to our Founder and CEO, Alex Zhavoronkov, PhD, on being named to the inaugural #scw75 list by Scientific Computing World.
The SCW75 recognizes 75 influential leaders advancing high-performance computing, AI infrastructure, laboratory informatics, and simulation across the globe. This recognition reflects Alex's long-standing commitment to applying AI and scientific computing to some of the most complex challenges in biology, chemistry, and human health.
At Insilico Medicine, that vision has helped drive the advancement of 30 developmental candidates, including 13 clinical-stage pipelines, while expanding the impact of AI-powered molecular design beyond healthcare into sustainability applications.
www.linkedin.com/pulse/insilico-medicine-founder-ceo-alex…
#insilicomedicine #ai #drugdiscovery #scientificcomputing #generativeai #biotechnology #longevity #pharmaai -
Insilico Medicine
@InSilicoMeds
🔇 Just announced! Join Insilico Medicine for our exclusive #pharmaai Summer Event, where we bypass the generic AI hype to showcase true industrial-strength execution.
This virtual webinar gathers Pharma Executives, Computational Biologists and Medicinal Chemists to explore the frontier of #pharmaceuticalsuperintelligence (PSI).
We will share our progress in achieving Pharmaceutical Superintelligence (PSI) through the #mmaigym, and all the new features we have added to our pharma.ai platform
Secure your spot today 👉 insilico.zoom.us/webinar/register/9117803176869/WN_hxGDHR…
#pharmaai2026 #webinarseries -
Insilico Medicine
@InSilicoMeds
The Unexpected Challenge of Hiring "Experienced" AI Pharma Talent
"Many experienced hires have been living in a bubble and got used to being unproductive." In AI drug discovery, the real gap isn't credentials, it's the ability to actually produce. We don't need more press releases or research papers; we need drugs that work. It's time to burst the "unproductive bubble."
#alexzhavoronkov #investingtips #pharmaai #biotechreality #venturecapitalThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
📽️ The 4 Common Mistakes in AI Biotech Investing
"Proprietary data and elite scientists don't guarantee a drug." Many investors are blinded by compute and algorithms, forgetting the true goal of AI: speed, cost, and novelty. If a company has no clinical assets after years, its tech might just be PR.
Time to use AI to stress-test your portfolio.
#insilicomedicine #alexzhavoronkov #investingtips #pharmaai #biotechreality #venturecapital #deeptechThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
NEW Video 📽️ Curing Aging: The Ultimate Solution to Everything
When we solve aging, we will have the time to solve everything else. That is the North Star of Insilico Medicine. By leveraging AI for faster, cheaper, and more novel drug discovery, we aren't just treating diseases, we are buying time for humanity.⏳
#insilicomedicine #alexzhavoronkov #longevity #ai #healthtech #innovation #spacexThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Company to deliver three presentations spanning AI drug discovery, quantum computing, and next-generation pipeline strategy @BIOConvention
#bio2026 www.linkedin.com/pulse/insilico-medicine-showcase-ai-driv… -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Saudi Aramco Introduce the “Sanity Pipeline” to Advance AI-driven Discovery of MOFs
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
insilico.com/news/ps2bndbh61-insilico-medicine-and-human-… -
Insilico Medicine
@InSilicoMeds
Thank you to The Infinite Loop for this coverage.
AI drug discovery faces its defining test: clinical trials
infiniteloop.media/p/ai-drug-discovery-faces-its-defining… -
Insilico Medicine
@InSilicoMeds
The "Starship" of Pharma: Scaling AI Drug Discovery:
A real AI pharma company isn't just about the drugs, it's about the "system." Borrowing SpaceX’s "Launch and Learn" philosophy, we're turning drug discovery into a high-frequency, iterative industrial process. Each milestone is a step toward Pharmaceutical Superintelligence
#insilicomedicine #alexzhavoronkov#AI #spacex #curingaging #biotech #drugdiscovery#Starship #innovation #futureofhealthThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:746574209024…
Case Study 📽️
The GLP1R Case Study video will go through the 3 screened #peptides that were tested. These 3 peptides demonstrated single digit #nanomolar activity.
The objective was to improve the activity of the lead candidate, P3.
Read more on the GLP1R case study here: insilico.com/news/o1y20pfyz1-insilico-showcases-advanced-…
#optimization #peptides -
Insilico Medicine
@InSilicoMeds
When AI platforms become commoditized, how do pharmaceutical companies maintain their competitive moat? In a recent CNBC interview, Insilico Medicine CEO Alex Zhavoronkov offered a characteristically "SpaceX-style" answer:
"30 development candidates—it's like a rocket successfully reaching orbit." "Every time you launch, you learn. Launch and learn." The true moat is not the AI software itself, but rather: The continuous generation and out-licensing of candidate drugs.
Accumulating industry-validated data from every single "launch." Rolling the snowball through a dual-engine model (out-licensing +proprietary clinical trials).
The long-term vision is even grander:
-building models of life and taking on aging itself.
-GLP-1 is just the beginning; AI is fundamentally rewriting the logic of drug discovery.
#cnbc #aidrugdiscovery #insilicomedicine #spacex #alexzhavoronkov #longevityThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
www.linkedin.com/pulse/insilico-medicine-human-longevity-… -
Insilico Medicine
@InSilicoMeds
www.bloomberg.com/news/videos/2026-05-22/insilico-on-appl… Insilico on applying AI to Transform Drug Discovery. Check out the latest from @business
-
Insilico Medicine
@InSilicoMeds
⚡ Unlock #mmaigym's latest research by scanning the QR code, or visiting insilico.com/mmai
This quick video will give you an overview of 2 ways to access MMAI Gym membership through #datalicensing or licensing pre-trained models directly. Get started today.
Watch it here: www.linkedin.com/feed/update/urn:li:activity:746361540159… -
Insilico Medicine
@InSilicoMeds
New Article @pharmaboardroom: Hong Kong: Bouncing Back
The city’s long-term bets on innovation – especially in niches like AI-driven drug discovery and robotics – appear to be paying off. For instance, Insilico Medicine – sponsor of the first drug discovered and designed entirely by generative AI to reach human trials – raised USD 292 million in a heavily oversubscribed HKEX IPO in December 2025.
Continue reading here: pharmaboardroom.com/articles/hong-kong-bouncing-back/ -
Insilico Medicine
@InSilicoMeds
Yesterday at #bioitexpo, Petrina Kamya, Ph.D. led an engaging panel on enterprise digital transformation across automated and robotic R&D, bringing together industry leaders from Takeda, Cellares, and Leash Bio.
The conversation highlighted a clear theme: scalable, AI-driven lab and data infrastructure is no longer optional, it’s foundational.
If you’re attending today, don’t miss Petrina’s session at 3:10pm on AI-driven lab automation, where she’ll dive deeper into how integrated platforms are accelerating experimentation, standardizing workflows, and enabling true end-to-end innovation.
#aiforscience #digitaltransformation #biotech #lifesciences #enterpriseai #scientificinnovation -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
The right to live long and healthy life is the fundamental human right regardless of where you are from and the freedom to live longer is the ultimate form of freedom. World leaders must burry their hatchets when it comes to longevity and collaborate. Same goes for climate change - we need to control climate together and collaborate on the development of new technologies that allow us to recover, recycle, and reuse both human and natural pollutants from the environment.
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
📽️ What is the Real Moat for AI Pharma?
Think having AI is a competitive advantage? Think again. Nowadays, anyone can plug into a foundation model. The real moat? It’s passing the grueling "interrogation" of a 60-person Pharma expert team and closing a $2.75 billion licensing deal.
High-quality assets speak louder than algorithms.
#insilicomedicine #alexzhavoronkov #ai #biotech #pharma #licensing #innovation #drugdiscovery #techbusiness #entrepreneurshipThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🔥 Introducing PandaClaw: The AI Agentic Core
🐼 PandaClaw is powered by a state-of-the-art autonomous AI agentic core that handles the entire scientific journey - from complex planning to flawless execution and critical review. By interpreting simple natural language prompts, PandaClaw integrates advanced #bioinformatics workflows to give you fully vetted, comprehensive results. Whether you are querying public knowledge bases or bringing your own datasets, #pandaclaw automates highly sophisticated tasks.
Get started today: pharma.ai/pandaomics
#newlaunch #aiagents #pandaomicsThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
At the HERS Conference, our team showcased how PandaOmics is advancing therapeutic target discovery and drug repurposing in endometriosis. Highlighted by Drug Hunter, the presentation demonstrated how AI-driven analysis can uncover novel biological insights and surface promising targets with greater speed and precision. @drughunter_com
Read the full article: drughunter.com/articles/endometriosis-inspires-re-examina… -
Insilico Medicine
@InSilicoMeds
4.5 Years vs 18 Months: The AI Disruption in Pharma
A silent revolution is happening in the lab. While traditional methods are still at the starting line, AI has already finished the race. Are you ready for the new era of efficiency?
#insilicomedicine #alexzhavoronkov #ai #drugdiscovery #biotech #pharma #artificialintelligence #innovation #futuretech #healthcare #scienceThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
ATS 2026 poster sessions are underway today, and we’re proud to share three presentations highlighting the continued advancement of our AI-driven inhaled Rentosertib (INS018_055) program for pulmonary fibrosis.Presented by Dr. Carol Ann Satler on behalf of the Insilico Medicine team:
🟢 Poster 9800
“Inhaled Rentosertib (INS018_055), a Novel TNIK Inhibitor Discovered Using Generative AI, Exhibits High Safety and Tolerability in Animal Models”
🟢 Poster 9825
“Inhaled Rentosertib (INS018_055), a TNIK Inhibitor Discovered Using Generative AI, Achieves High And Specific Pulmonary Exposure In Healthy And Fibrotic Lungs”
🟢 Poster 9862
“Study Design of a Phase 1, Randomized, Double blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled Rentosertib (INS018_055), A Novel AI-Generated TNIK Inhibitor”
📍 Location: Area E, Halls WA2–WA3 (Level II, OCCC West Concourse)Join Dr. Carol Ann Satler and the Insilico Medicine team today at ATS 2026 to explore how generative AI is helping accelerate the development of next-generation therapies for pulmonary fibrosis and respiratory disease.#ats2026 #pulmonaryfibrosis #ipf #respiratoryinnovation #respiratorymedicine #drugdiscovery #generativeai #biotech #ai -
Insilico Medicine
@InSilicoMeds
AI #drugdiscovery: The Real Metric
AI in drug discovery sounds amazing. But here's the reality check. No real drugs = no real impact. The only metric that matters: how long from idea to developmental candidate. Do you think AI will truly transform drug discovery?
#insilicomedicine #ai #drugdiscovery #biotech #pharma #artificialintelligence #innovationThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and 01.ai debut the #mmaigym chemistry model.
✅ Generate complex molecules + 3D coordinates from text
✅ Predict quantum properties, solubility, retrosynthesis
✅ Works for pharma, agriculture, petrochemistry
What once required expert models and years of training can now be done via a prompt window.
From prompt to code to prompt to drug – pharmaceutical superintelligence is on the horizon.
#aiforscience #drugdiscovery #01aiThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
⚡ The MMAI Gym transforms causal LLMs into domain-specific scientific reasoning engines.
👏 The Highlights:
-Massive Data Scale: Armed with 500M+ data samples and 1,000+ benchmarks across six scientific disciplines.
-Elite Performance: We see up to a 10x increase in performance compared to baseline models.
-Full-Pipeline Integration: From target ID to clinical trial forecasting, we provide the data and reinforcement fine-tuning to turn base models into discovery engines.
Smarter training meets scalable infrastructure. Swipe through the carousel to see how we’re accelerating discovery from pipeline to patient.
#ai #drugdiscovery #generativeai #mmaigym
Visit: insilico.com/mmai for more information. -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:746000400425…
New Target Prioritization Scores 📽️
Check out how to access the upcoming Indication Prioritization scores in #pandaomics. This feature allows you to assess which indications for a given target will have the strongest mechanistic evidence. -
Insilico Medicine
@InSilicoMeds
⚡ We are just a few weeks away from Bio-IT World Conference & Expo in #boston, May 19-21. It’s a fantastic community of scientists, technologists, and innovators sharing the latest advances accelerating discovery, and advancing #precisionmedicine, and a great place to build the collaborations that move ideas into real-world impact.
If you’re planning to attend, please connect with Petrina Kamya, Ph.D. and join her session on May 21, and take advantage of this discount: $150 off registration with code BIT26SPK.
🔗 Explore the agenda and speaker lineup: www.bio-itworldexpo.com
#bioitexpo -
Insilico Medicine
@InSilicoMeds
📅 One week until #pegsummit! Catch Stefania Evoli at Poster C061
In just one week, the 22nd Annual PEGS Boston Summit kicks off, and we are thrilled to highlight the work of our very own Application Scientist, Stefania Evoli!
If you are attending in person, don't miss the chance to discuss the future of antibody engineering. Stefania will be presenting her latest research on how hybrid modeling is changing the game for developability predictions.
Poster Title: Enhancing Antibody Developability Prediction with Hybrid Sequence–Structure Modeling
Poster Number: C061
Date: Thursday, May 14, 2026
Time: 10:50 a.m. – 2:05 p.m.
Location: Omni Boston Hotel at the Seaport
Antibody developability is a critical hurdle in drug discovery. Stop by to see how Insilico Medicine is leveraging hybrid sequence-structure models to predict success earlier and more accurately.
See you in Boston! 🧬#pegsboston #antibodyengineering #drugdiscovery #aiinpharma #biotechnology #insilicomedicine @PEGSboston -
Insilico Medicine
@InSilicoMeds
Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), recently announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (#targetpro) and #targetidentification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.
Published in Scientific Reports, the framework demonstrates strong performance across benchmarking and real-world discovery workflows, reinforcing its role as a standardized foundation for AI-driven target identification.
#drugdiscovery has long been constrained by high failure rates, with nearly 90% of clinical candidates failing—often due to weak or poorly validated biological targets. Insilico's integrated TargetPro–TargetBench framework addresses this challenge by combining disease-specific predictive modeling with rigorous, standardized evaluation.
Read the latest release here: phys.org/news/2026-04-ai-drug-platform-pairs-benchmarking… -
Insilico Medicine
@InSilicoMeds
Insilico Medicine to Present Groundbreaking AI Retrosynthesis Research at ICML 2026: Introducing ChemCensor to Bring Real-World Chemistry to AI Bench
Read the preprint here: arxiv.org/abs/2602.03554 -
Insilico Medicine
@InSilicoMeds
🤝 Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
● For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH) and other prominent ecosystem players .
● ISM0387 is an MTA-cooperative hashtag#PRMT5 inhibitor with AI-powered novel structure, showing improved in vitro activity and selectivity, enhanced brain penetrant properties, and robust, dose-dependent efficacy in disease models.
● The discovery process of hashtag#ISM0387 is local, and it signals that the hashtag#UAE has evolved into a technology-driven powerhouse with a knowledge-based "Falcon Economy."
● Based on Chemistry42 and its 40+ models, Insilico’s team screened 90 AI-powered novel candidates, considering multiple parameters with a focus on CNS-specific traits, completing the lead discovery phase in just six months.
Drug discovery is famously a “game for the brave”: a high-stakes pursuit that demands immense capital, decades of patience, and unwavering technical fortitude. According to research in Nature, bringing a single drug to market typically costs between $900 million and $2.6 billion, spanning over a decade. Even the early phase, from target identification to candidate nomination, can consume 4.5 years of thousands of molecular screening.
For the full release and more onsite coverage, please visit: insilico.com/news/yxenmllx01-generative-ai-leap-insilico-… -
Insilico Medicine
@InSilicoMeds
⚡ 99% of the world’s computers exists outside of data centers. Yet, most #drugdiscovery teams are still tethered to massive, high-latency flagship models that frequently fail to target performance goals for #admet and toxicity.
Insilico Medicine and Liquid AI are changing that.
We’ve partnered to train LFM2-2.6B-MMAI, a model designed for the edge, but better everywhere. After a single training session in the hashtag
#mmaigym, this "tiny" 2.6B model is now outperforming models like TxGemma-27B while maintaining a significantly smaller energy footprint.
Key Benchmarks at a Glance:
-ADMET Supremacy: Surpassed TxGemma-27B across multiple property prediction endpoints.
-94% #retrosynthesis Accuracy: Achieved via specialized SFT+RFT training sessions.
-Undisputed SOTA: Leading performance in functional group reasoning (FGBench) and molecular optimization (MuMO).
-Edge-Ready: Optimized for CPUs, NPUs, and GPUs, providing low-latency, "always-on" intelligence without the need for cloud calls.
🤝 We’re ready to help you integrate these models directly into your DMTA cycle for real-time lead optimization.
See it in action: Test the MMAI Demo today insilico.com/mmai -
Insilico Medicine
@InSilicoMeds
⚡ 10x Smaller, 10x Faster: New SOTA Benchmarks for Pharma #llms
Most frontier models like GPT-4 and Claude 3 continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training.
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a #drugdiscovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
💥 Key Benchmarks at a Glance:
-ADMET Supremacy: Surpassed TxGemma-27B across multiple property prediction endpoints.
-94% #retrosynthesis Accuracy: Achieved via specialized SFT+RFT training sessions.
-Undisputed SOTA: Leading performance in functional group reasoning (FGBench) and molecular optimization (MuMO).
-Edge-Ready: Optimized for CPUs, NPUs, and GPUs, providing low-latency, "always-on" intelligence without the need for cloud calls.
We’re ready to help you integrate these models directly into your DMTA cycle for real-time lead optimization.
See it in action: Test the MMAI Demo here 👉 mmai-demo.liquid.ai/sign-in?redirect_url=https%3A%2F%2Fmm…
Ready to deploy? Contact our team at bd@insilicomedicine.com
#mmaigym -
Insilico Medicine
@InSilicoMeds
Nature Reviews Drug Discovery | #targetidentification and Assessment in the Era of AI
Insilico recently published a comprehensive review that emphasizes key considerations in target selection, summarizes breakthroughs in the application of AI-driven approaches for therapeutic target exploration, and highlights clinical-stage successes in which #ai played a pivotal role in target identification.
The review, titled "Target identification and assessment in the era of AI", was published in Nature Reviews Drug Discovery (doi.org/10.1038/s41573-026-01412-8), a leading journal in the pharmaceutical and biomedical research community known for its peer-reviewed strategic roadmaps and in-depth analysis of emerging trends and breakthroughs in drug discovery and development. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Showcases Preclinical Breakthroughs for Four AI-Powered Oncology Pipelines at #aacr2026 Annual Meeting 2026 @AACR
Read the full release: insilico.com/news/z21rzi2mv1-insilico-medicine-showcases-… -
Insilico Medicine
@InSilicoMeds
NEW Release: Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH) and other prominent ecosystem players.
Read the latest release here: insilico.com/news/yxenmllx01-generative-ai-leap-insilico-…
#pcc #insilicomedicine #uae -
Insilico Medicine
@InSilicoMeds
⏰ Happening tomorrow in Cambridge at Takeda: How AI is transforming the discovery landscape.
There are only 24 hours left until we kick off the PBSS symposium on "Artificial Intelligence and Machine Learning Shaping the Future of Therapeutic Drug Discovery".
Please join Petrina Kamya, Ph.D. VP and Global Head of AI Platforms at Insilico Medicine, with a symposium focused on Therapeutic #drugdiscovery, and a featured presentation as well.
See the full agenda and registration details here: www.pbss.org/eventDetails/1047
#insilicomedicine #pbss #bostonbiotech -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
A new board aims to turn aging into a treatable target, using AI to move from reactive care to longer and healthier lives.
vist.ly/4zwy4
#longevity #geroscience #ai #drugdiscovery #biotech
@InSilicoMeds -
Insilico Medicine reposted
TimePie (focus on anti-aging science)
@TimePieChina
NEWS: Insilico Medicine announces industry’s first longevity board to accelerate AI-driven aging research for drug discovery, with Andrew Adams, Group Vice President of Molecular Discovery at @EliLillyandCo, as the Board Chairman. @InSilicoMeds
insilico.com/news/vxuidy8ph1-insilico-medicine-announces-… -
Insilico Medicine reposted
cGxP Wire
@cGxPWire
🤖🧬 AI Meets Longevity Science
@InSilicoMeds launches a longevity-focused board to drive AI drug discovery.
👉 cgxpwire.com/biopharma/insilico-medicine-launches-longevi…
#ai #longevity #drugdiscovery -
Insilico Medicine
@InSilicoMeds
Check out our Day 3 coverage from #aacr2026!
We had another energetic day at booth #1511. From poster presentations and media interviews on KRAS and TEAD, to strong engagement across both our pipeline and software platforms, the momentum continues to build.
🎤 Today, our team connected with media to share how Insilico Medicine is advancing AI-powered drug discovery—from early target identification through clinical-stage programs—while continuing to scale our pharma.ai platform.
📜 Today’s poster presentations (Poster Section 17):
Abstract Title: CBLB inhibition with ISM3830, a novel AI-generated #smallmolecule, restored innate and adaptive immunity and demonstrated #antitumor activity against solid tumors in vitro and in vivo
Abstract Title: ISM6210, a potent and selective AI-discovered CDK4 inhibitor for the treatment of HR+/HER2- breast cancer
🚀 Across both pipeline and software, we saw strong excitement and engagement—reinforcing the power of generative AI to transform how new medicines are discovered and developed.
Thank you to everyone who stopped by to connect—we look forward to continuing the conversations.
#aacr2026 -
Insilico Medicine
@InSilicoMeds
🫶 Day 3 of #aacr2026 Exhibition begins, and we are ready for a full day at booth #1511. We hope to see everyone after the "Early Onset Cancers" plenary session in the exhibit hall. Posters go from 9-12 PST today, and we will be in Poster Section 17.
📜 Today we will present:
-Abstract Title: Cbl-b inhibition with ISM3830, a novel AI-generated #smallmolecule, restores innate and adaptive immunity and demonstrates #antitumor activity against solid tumors in vitro and in vivo
-Abstract Title: ISM6210, a potent and selective AI-discovered CDK4 inhibitor for the treatment of HR+/HER2- breast cancer
To close out the day, we are looking forward to attending:
“AI in Cancer Research and Care: What We’ve Learned and What Comes Next?” at 5pm PST. Stop by our booth before heading to this special session.
Have a great conference! @aacr -
Insilico Medicine
@InSilicoMeds
Day 3 at #aacr2026! Poster reminders 💡
Insilico will showcase a robust portfolio of four cutting-edge #oncology programs, including two innovative projects originated from its UAE-based R&D center.
In the meantime, we invite all partners and researchers to visit the Insilico team at Booth #1511 in the exhibit hall to explore our latest data and discuss potential #collaborations.
Learn more: www.eurekalert.org/news-releases/1122346 -
Insilico Medicine
@InSilicoMeds
We're gearing up for another busy day at #aacr2026 in San Diego! 🌴
Come see a live demo of Insilico Medicine’s Automated AI-Driven #partneringsystem, designed to put both common and complex scientific and #businessdevelopment questions at your fingertips.
We will be at booth #1511 from 9-5 today and we will be at poster section 17 for our two Novel Antitumor Agents presentations from 9-12. We hope you have a great day at AACR! @AACR -
Insilico Medicine
@InSilicoMeds
As the show closed on Day 2 of #aacr26, the energy at our booth was still going strong.
Our team is hard at work—connecting with partners, showcasing our AI-powered platforms, and sharing the depth of our growing pipeline. From discovery to development, it’s been a full day of meaningful conversations around what’s next for drug discovery.
If you haven’t stopped by yet, there’s still time. Visit us at booth #1511 to see what we’re building.
#aacr2026 #drugdiscovery #ai #biotech
www.linkedin.com/posts/in-silico-medicine_aacr26-aacr2026… -
Insilico Medicine
@InSilicoMeds
Good morning #sandiego and #aacr2026 Day 2 attendees.
Get a close up look at all 4 sides of our #aacr2026 booth, and be on the lookout for our Pharmaceutical Intelligence halo sign 👀
From our latest #mmaigym, to our #oncology program updates, pharma.ai and more, we have a lot to offer this week.
Find us at booth #1511 near the poster sessions at the main Hall B entrance for live demos, giveaways and to meet our team. @AACR -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
#aacr2026 is in full swing and our posters are very popular. And some pharma companies realized that we have clinical data now and the molecules were AI-optimized to avoid the common liabilities. Finally, some genuine interest and we will have a lot of work to do after the AACR.
Another aspect of many of our pipeline choices is indication expansion potential. Ask the team about that on site. We always aim to expand into multiple cancers and beyond oncology and into aging and age-related diseases. These pivots can only be validated after getting enough clinical data. -
Insilico Medicine
@InSilicoMeds
At Insilico Medicine’s booth (#1511), we’re not just training models, we’re training Jedi-level scientific reasoning at the MMAI Gym.
What is #mmaigym? 👇
It is a complete training ecosystem that transforms any #llm into a domain-specific reasoning engine. The MMAI Gym transforms general AI into domain-expert systems for #chemistry, #biology, and #clinicalresearch.
⏰ Book a session here: insilico.com/mmai
📜 Read the paper: arxiv.org/abs/2603.03517
#aacr2026 -
Insilico Medicine
@InSilicoMeds
#aacr2026 reminder 👇
Poster sessions are going on for another hour until 5 pm. Check out our Novel Antitumor Agents 1 poster session in section 17, presentation #425. -
Insilico Medicine
@InSilicoMeds
The #aacr26 exhibit hall is open! ⚡️
Stop by Booth 1511 to meet the Insilico Medicine team and explore our pipeline and oncology program updates.
Our first poster "ISM6166 a novel oral pan-KRAS (ON/OFF) inhibitor discovered with generative AI" will begin at 2 pm, located at section 17, poster number 28.
Whether you’re interested in our pharma.ai platform or our latest oncology posters, we’d love to chat.
📩 Contact: BD@insilico.com 📍 Booth 1511 | San Diego 🌴
#aacr2026 #ai #biotechnology #cancerresearch -
Insilico Medicine
@InSilicoMeds
"The most important market on the planet for everyone is longevity. If you can deliver a therapeutic that addresses this biological process and also gives you some other benefit — that presents a massive opportunity."— Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine from Semafor World Economy
www.linkedin.com/posts/semaformedia_founder-ceo-alex-zhav…
Insilico Medicine
@InSilicoMeds
View the interview here: www.youtube.com/watch?v=6UNIMGTuwGc
-
Insilico Medicine
@InSilicoMeds
LAST CHANCE! 🔇
Please join us today April 14th at 10 AM ET, for our pharma.ai Spring Kickoff.
🐼 We’ll be walking through our latest PandaOmics updates, with a chance to see #pandaclaw, our upcoming agentic AI tool in action, and discover how its natural-language interface allows you to conduct complex, real-time multi-omics analyses and generate research hypotheses effortlessly.
We will also demonstrate how our recent incorporation of comprehensive single-cell datasets provides enhanced resolution for your #targetidentification.
You can register here [insilico.zoom.us/webinar/register/2017745465996/WN_h7tujo…] to secure your spot for the session.
If you aren't able to join us live, make sure you register and be the first to receive the on-demand recording to watch at your convenience.
#pharmaai2026 #q1update #pharmaaiwebinar -
Insilico Medicine
@InSilicoMeds
Event Countdown!
Insilico at AACR: Four Innovative Posters Demonstrating the Power of #generativeai @AACR
Marking its fourth consecutive year of participation, Insilico will showcase a robust portfolio of four cutting-edge oncology programs, including two innovative projects originated from its UAE-based R&D center.
In the meantime, we invite all partners and researchers to visit the Insilico team at Booth #1511 in the exhibit hall to explore our latest data and discuss potential collaborations. If you are interested in setting up a meeting with our team at the conference, please email: BD@insilico.com or visit our booth during the exhibit hall hours.
Learn more about our AACR Poster sessions and how to book a meeting here: insilico.com/events/a82iia5on1-insilico-at-aacr-four-inno…
#aacr26 #oncologyevents #oncologytransformation -
Insilico Medicine
@InSilicoMeds
🧪Recent research published in @Sciencedirect underscores the accelerating role of AI in transforming #drugdiscovery and development workflows.
The paper points to emerging approaches that integrate computational modeling, automation, and real-world data to significantly improve efficiency across the R&D lifecycle.
💡Check out the latest review Article "Integrating #multi-omics and artificial intelligence fuels advanced target identification and drug discovery" here: www.sciencedirect.com/science/article/abs/pii/S0734975025… -
Insilico Medicine reposted
Abu Dhabi Investment Office مكتب أبوظبي للاستثمار
@InvestAbuDhabi
Insilico Medicine and Eli Lilly announce a $2.75B AI-driven R&D collaboration, reinforcing HELM and ADIO’s role in advanced healthcare.
Read the full LinkedIn Article: www.linkedin.com/pulse/insilico-medicine-eli-lilly-announ…
@HelmAbuDhabi @InSilicoMeds
#investwithabudhabi -
Insilico Medicine
@InSilicoMeds
📅 Join the pharma.ai Spring Kickoff Webinar next week, where we will announce the latest updates across the pharma.ai platform and share how next-generation AI systems are accelerating the future of #drugdiscovery.
During the Generative Biologics section, you will hear major updates for peptide design. It introduces a completely new workflow for cyclic peptides, supporting both head-to-tail and disulfide-bond architectures, generating hundreds of candidates in just hours with AI- and physics-based prioritization.
Join us on Tuesday at 10 am ET:
#pharmaai2026 #pharmaaiupdates #generativebiologics -
Insilico Medicine
@InSilicoMeds
📅 We are one week away from the pharma.ai Spring Kickoff, and the response has been big!
Why this is a "Can't Miss" event:
Dive deeper into the #mmaigym for Science. Learn how our SFT/RFT training and benchmarking system can significantly improve the performance of causal LLMs on real drug discovery tasks, and how you can gain access to it!
We’re breaking down a live case study on GLP1R Agonist Optimization, featured in the Generative Biologics section.
See #abfe in #alchemistry, multitarget support for generation and much more.
[Register Now: insilico.zoom.us/webinar/register/2017745465996/WN_h7tujo… ]
#pandaomics #pharmaai2026 #pharmaailaunchevent -
Insilico Medicine
@InSilicoMeds
Teaching AI the Language of Molecules: How MMAI Gym and Liquid Intelligence are Solving the “Brute Force” Crisis in Drug Discovery www.linkedin.com/pulse/teaching-ai-language-molecules-how…
-
Insilico Medicine
@InSilicoMeds
Please join us at the pharma.ai Spring Kickoff event, where we will announce the latest updates across the Pharma AI platform.
👉 Save the date: April 14th at 10 AM EST
This session will highlight the newest developments across the pharma.ai ecosystem, including the launch and capabilities of MMAI Gym for Science, updates across core modules like PandaOmics, Generative Biologics and Chemistry42, and the growing role of foundation models in scientific discovery.
📅 Secure your spot today: insilico.zoom.us/webinar/register/2017745465996/WN_h7tujo…
#chemistry42 #pharmaai2026 #pharmaaiupdates -
Insilico Medicine
@InSilicoMeds
At AACR Journals Annual Meeting 2026, Insilico Medicine is showcasing four novel oncology programs discovered using its end-to-end generative AI platform—highlighting how AI is accelerating the path from data to drug candidates 🚀
From a pan-KRAS inhibitor to next-generation immuno-oncology and precision-targeted therapies, these programs demonstrate the power of integrating generative biology and chemistry to tackle some of the toughest cancer targets 🧬
As AI continues to compress discovery timelines and unlock new therapeutic possibilities, this year’s AACR marks another step toward truly AI-native drug development.
Learn more: www.linkedin.com/pulse/four-innovative-posters-demonstrat…
#aacr2026 #ai #oncology #drugdiscovery #biotech #healthcareinnovation #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Thanks to Brittany Trang, PhD for the sharp and insightful feature.
As our CEO Alex Zhavoronkov shares, AI in drug discovery is rapidly shifting from promise to real-world impact—advancing programs into the clinic and redefining how R&D gets done.
This is just the beginning of truly AI-native drug development.
#ai #biotech #drugdiscovery #insilicomedicine
www.statnews.com/2026/04/01/insilico-medicine-ceo-biotech… @statnews -
Insilico Medicine
@InSilicoMeds
🌍 Insilico Medicine is proud to announce we will be at the upcoming #aacr26 Annual Meeting in San Diego, presenting four posters across solid tumors and epigenetic modulation. As one of the world's most influential gatherings in oncology, this year’s meeting will take place from April 17 to 22 at the San Diego Convention Center in San Diego, California.
Meet the Team in San Diego:
📍 Booth #1511 in the exhibit hall
📊 4 Featured Posters
💬 BD Team on-site
Ready to accelerate your oncology pipeline? Let's connect at the San Diego Convention Center or book a time via BD@insilico.com.
See you in San Diego!
#aidd #aiinpharma #aacr #innovation #oncology -
Insilico Medicine
@InSilicoMeds
We are thrilled to announce that our SVP of Clinical Development, Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP has been invited by Dr. Keith Collins to present to the Beth Israel Lahey Health Artificial Intelligence Interest Group.
BILH is at the forefront of integrating AI into medicine, and we are proud to share the stage with OpenAI this month as they showcase ChatGPT Health and Prism.
What we’ll be discussing:
The current status of AI-enabled drug discovery.
How Insilico successfully navigated regulatory pathways for the first-ever AI-discovered drug to reach Phase II/III (Rentosertib)
Community building and knowledge sharing are vital as we transition from AI-designed molecules to approved commercial therapies. We look forward to an attentive and knowledgeable audience of BILH clinicians and decision-makers!
#ai #pharma #biotech #insilicomedicine #healthcareinnovation #drugdiscovery #openai #bilh -
Insilico Medicine
@InSilicoMeds
Big Pharma Doubles Down on AI—Insilico Medicine Is Redefining Drug Discovery, Securing $2.75B Collaboration with Eli Lilly and Company.
Read the latest release 👇insilico.com/news/uiy12zcjg1-insilico-medicine-announces-…
#ai #biotech #pharma #drugdiscovery #transformation #nextgenmedicine -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health insilico.com/news/2fx40la551-insilico-medicine-and-aska-p…
-
Insilico Medicine
@InSilicoMeds
New Video: www.linkedin.com/posts/chemistry42_scienceai-medicinalche…
Will AI replace medicinal chemists?
The answer is becoming increasingly clear: no.
Drug discovery has historically been a process of massive trial and error. Thousands of molecules are designed, synthesized, and tested before a viable candidate emerges.
📋 Focus Area: AI-assisted medicinal chemistry
Key Question: Does AI replace chemists, or amplify their productivity?
📊 Key Observations:
The traditional model is slow.
Medicinal chemistry has long relied on iterative experimentation with limited exploration of chemical space.
AI accelerates exploration.
Foundation models allow scientists to rapidly generate and evaluate molecular hypotheses.
Human expertise becomes more valuable.
AI removes repetitive work, allowing chemists to focus on strategy, interpretation, and creativity.
Productivity multiplies.
Scientists can explore significantly more molecular ideas than before.
The Takeaway:
AI will not replace chemists. It will enable the most productive generation of medicinal chemists in history.
#scienceai #medicinalchemistry #drugdiscovery #ai #biotech -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million insilico.com/news/99t6vd21h1-insilico-medicine-and-tenaci…
-
Insilico Medicine
@InSilicoMeds
Day 26 of #scienceaibench!
🧬 Last Monday, we observed that frontier models could find a positive correlation when predicting the total number of non-covalent interactions. However, simply knowing that these bonds exist isn't enough to determine a ligand's potency. Today, we are asking a much harder question: Can these models actually "see" where those interactions are in 3D space? We challenged frontier models to analyze structural conformations and predict specific protein-ligand interactions. The results reveal a massive gap between predicting bulk molecular properties and understanding spatial physics.
Today’s benchmark tests whether LLMs can transition from 1D scalar predictions to extracting granular, 3D pharmacophore data directly from structural representations, using the Chemistry42 platform as our definitive ground truth.
📋 Benchmark Specifications:
Task: Predicting specific non-covalent interactions in 3D (interaction type, interaction residue, and interaction power).
Dataset: LP-PDBBind.
Ground Truth: Chemistry42 protein pharmacophores engine.
Metrics: Fraction of restored interactions (↑), Fraction of restored powers (↑), Fraction of fake interactions (↓).
Models Evaluated: Opus 4.5, Opus 4.6, GPT 5.2, Sonnet 4.5, Grok 4.1, GPT 5.1, and Nemotron 3 Nano.
📊 Observed Performance:
The Formatting Collapse: Before even assessing spatial accuracy, models must produce valid answers. While GPT 5.1 achieved perfect validity (1.000) and Opus 4.5 followed closely (0.991), the newer generation struggled immensely. GPT 5.2 suffered a catastrophic formatting collapse, producing valid answers only ~1% of the time (0.011), while Nemotron failed entirely (0.000).
The Best of a Struggling Class: Even when producing valid answers, spatial awareness remains highly limited. Opus 4.6 correctly restored the highest fraction of exact interactions (0.269), while Opus 4.5 was the most accurate at predicting the power/strength of those specific interactions (0.655).
The "Fake Bond" Crisis: The most alarming finding is the massive hallucination rate. The "Fake Ratio" measures interactions the model confidently predicted that do not physically exist in the 3D structure. Even the top-performing Opus 4.5 hallucinated 70.5% of its predicted bonds. Models like Grok 4.1 (0.853) and GPT 5.2 (0.833) hallucinated the vast majority of their outputs.
The 3D Translation Barrier: The data strongly suggests that while current LLMs can count total interactions, they cannot reliably translate textual or 1D string representations into 3D spatial physics. They frequently invent "ghost" hydrogen bonds and interactions that violate basic physical laws.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Most AI companies believe the future is cloud-first. Pharma is different.
In this industry, data is the kingdom.
Experimental data.
Molecular designs.
Clinical insights.
Some of the most valuable intellectual property on Earth.
And in many cases, it cannot leave the lab.
This is where the typical cloud-first AI model becomes a strategic vulnerability.
While building MMAI Gym and collaborating with Liquid AI, we had a realization:
The next phase of scientific AI will be local.
Smaller, highly specialized models deployed directly on-device can:
• protect pharmaceutical IP
• guarantee data privacy
• accelerate experimentation
• enable real-time discovery
The AI industry is obsessed with bigger models.
But in drug discovery, the advantage may come from deploying intelligence exactly where the data lives.
At Insilico Medicine we’ve evolved:
From building individual AI fighters
to becoming the MMA coach for scientific foundation models.
The future of pharma AI will not just be bigger models.
It will be secure intelligence embedded inside the lab.
#ai #drugdiscovery #edgeai #biotechThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Meet PandaClaw — Agentic AI for Biology
Insilico Medicine has launched PandaClaw, a powerful new capability within PandaOmics that enables biologists to run complex multi-omics analyses using simple natural language.
Instead of needing deep AI or bioinformatics expertise, researchers can now ask questions, generate hypotheses, discover targets, and produce figure-ready reports through autonomous AI agents.
With 140+ scientific skills and 1,000+ bioinformatics tools, PandaClaw turns biological data into actionable insights — faster than ever.
A major step toward AI-driven pharmaceutical superintelligence.
#ai #drugdiscovery #biotech #agenticai #longevity #pharmaai
Read the release: insilico.com/news/spjz8fzmb1-insilico-medicine-launches-p… -
Insilico Medicine
@InSilicoMeds
💥 Honored to see Insilico Medicine recognized by Fast Company as the #3 most innovative biotech company of 2026. This recognition reflects the strength of our team and our continued work to advance generative AI powered drug discovery and development. Grateful to everyone helping push this field forward.
👉 Read the full article and rankings here: www.fastcompany.com/91497087/biotech-most-innovative-comp…
#fcmostinnovative -
Insilico Medicine
@InSilicoMeds
🐼 #pandaclaw is here www.linkedin.com/posts/zhavoronkov_insilicomedicine-panda…
-
Insilico Medicine
@InSilicoMeds
⚡Taking place today in Boston! The AI Convergence Conference.
Insilico Medicine's Petrina Kamya, PhD, will present "Harnessing Pharmaceutical Superintelligence & Generative Molecular Design Across the End-to-End Discovery Funnel to Derisk Small Molecule Programs" on March 19th at 3pm. We hope to see you there.
Event details: ai-convergence-small-molecule-discovery.com -
Insilico Medicine
@InSilicoMeds
🧬 PandaOmics Wednesday Target Challenge is LIVE!
Can you guess this week’s target?
🔍 Clues:
• Activated during tissue stress on epithelial surfaces
• Plays a key role in TGF-β signaling
• Implicated in cancer progression and fibrosis
• A promising druggable switch (without blocking TGF-β entirely)
💡 This target sits at the intersection of tumor invasion, fibrosis, and microenvironment remodeling, making it a highly attractive (and nuanced) therapeutic opportunity.
👇 Drop your guess below.
We’ll reveal the answer next week.
#pandaomics #drugdiscovery #targetidentification #ai #biotech #computationalbiology #precisionmedicine -
Insilico Medicine
@InSilicoMeds
💥 Template-based screening, a workflow that allows Generative Biologics users to upload a receptor complex and a peptide library, evaluate mutations against existing binders, review passed and rejected candidates, and compare their scores and structures to the original template.
This video gives you a quick rundown of the latest update to our #peptide workflows from Generative Biologics. Watch it here 💻
www.linkedin.com/feed/update/urn:li:activity:744003738380…
#generativebiologics #softwareupdates #peptideworkflows #biologicsai -
Insilico Medicine
@InSilicoMeds
🧪 Monday’s Molecule Challenge: Can you crack the code?
The "undruggable" label is just a dare to a medicinal chemist with the right tools. Today’s #mondaymolecule features a masterclass in structural biology and covalent design.
The Clues:
✅ Mode of Action: Stabilizes an inactive state to avoid nucleotide competition
✅ Design Logic: Uses a "quiet" electrophile to target a specific cysteine.
✅ The Twist: Atropisomeric orientation is the key to its potency.
Think you know which molecule this is? Drop your best guess in the comments!
#medicinalchemistry #drugdiscovery #chemistry42 #structuralbiology #pharmaai -
Insilico Medicine
@InSilicoMeds
Kicking off this week in Boston 🎤
Petrina Kamya, Ph.D. joins the Inaugural AI Convergence: Small Molecule Discovery Summit.
⚡ Petrina will present "Harnessing Pharmaceutical Superintelligence & Generative Molecular Design Across the End-to-End Discovery Funnel to Derisk Small Molecule Programs" on March 19th at 3pm.
The inaugural AI Convergence: Small Molecule Discovery Summit arrives at this pivotal juncture to immerse you in the applied learnings needed to catalyze the next wave of AI/ML-powered small molecule development.
We are proud to join leaders from PsiThera, OpenADMET, Sanofi, Novo Nordisk, and more.
Are you attending? Let us know below 👇
#techbio #pharmaadopters #bostonbiotech -
Insilico Medicine
@InSilicoMeds
Day 23 of #scienceaibench!
🧫 Moving past efficacy, we arrive at the most critical hurdle in drug discovery: safety. Predicting whether a compound will be toxic to human cells before it ever enters a lab is a holy grail of computational chemistry. Today’s benchmark tests whether frontier models can predict the 50% Cytotoxic Concentration (CC50) for two foundational cell lines: HepG2 for liver toxicity and HEK293 for kidney and general host toxicity. The results reveal a glaring weakness in current AI capabilities.
📋 Benchmark Specifications:
Properties: HepG2 CC50 (hepatotoxicity) and HEK293 CC50 (nephrotoxicity/general cytotoxicity).
Metric: Spearman correlation (ρ).
Models Evaluated: Kimi K2.5, Gemini 3 Flash, GPT 5.2, Grok 4.1, Nemotron, Sonnet 4.5, DeepSeek v3, Opus 4.6, and GPT 5.1.
📊 Observed Performance:
The "Best" of a Weak Field: Kimi K2.5 and Gemini 3 Flash secured the highest nominal scores, but the absolute numbers are remarkably poor. Kimi K2.5 led in HEK293 with a mere ρ = 0.130, while Gemini 3 Flash led HepG2 with an almost non-existent ρ = 0.026.
The Random Noise Barrier: The vast majority of models failed to find any meaningful predictive signal. Scores clustering around 0.000 (like GPT 5.2's -0.004 on HepG2 or Grok 4.1's -0.010 on HEK293) indicate that the models are essentially guessing when ranking compounds for cellular toxicity.
Negative Trajectories: Alarmingly, several top-tier generalist models showed distinctly negative correlations, meaning their predictions were worse than random. GPT 5.1 (ρ = -0.146), Opus 4.6 (ρ = -0.115), and Sonnet 4.5 (ρ = -0.110) all inverted the actual rank order of toxicity for the HepG2 cell line.
The Reality Check: Predicting complex, multifactorial biological outcomes like cell death from chemical structure remains a massive algorithmic challenge. Current sequence and structure-based models do not yet possess the mechanistic understanding required to accurately flag toxic liabilities.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Day 22 of #scienceaibench! 🧪
Today’s benchmark evaluates antibody developability–relevant physicochemical properties using two chromatography-based readouts: heparin affinity chromatography (HAC) and hydrophobic interaction chromatography (HIC) retention time.
HAC reflects surface charge distribution and electrostatic interaction propensity, while HIC reflects exposed hydrophobic surface patches and aggregation risk. Both assays are commonly used to assess nonspecific interaction liability and overall developability.
📋 Benchmark Specifications:
Properties: HAC retention time (charge-driven binding) and HIC retention time (hydrophobic interaction).
Metric: Spearman correlation.
Models Evaluated: Sonnet 4.5, Opus 4.6, Grok 4.1, Gemini 3 Flash, Deepseek 3.2, Opus 4.5, GPT 5.1, GPT 5.2, and Nemotron 30B.
📊 Observed Performance:
The Electrostatic Leaders (HAC): The Anthropic models demonstrated the strongest monotonic agreement for charge-driven behavior. Sonnet 4.5 (ρ = 0.499) and Opus 4.6 (ρ = 0.492) achieved the highest predictive signal, closely followed by Grok 4.1 (ρ = 0.430).
The Hydrophobic Challenge (HIC): Predicting hydrophobic interactions remains notoriously difficult. Grok 4.1 secured the top spot (ρ = 0.339), with Gemini 3 Flash (ρ = 0.215) and Sonnet 4.5 (ρ = 0.140) showing modest, positive alignment.
The Predictability Gap: Across the board, models are vastly better at predicting electrostatic retention (HAC) than hydrophobic aggregation risk (HIC). Sequence-based modeling captures charge much more reliably than hydrophobic patches.
The Laggards: Several prominent models struggled to find any meaningful signal. GPT 5.2 (ρ = –0.067) and Nemotron 30B (ρ = –0.005) showed near-random ordering for HAC, while GPT 5.1 (ρ = –0.128) actually trended negative for HIC, suggesting a partial inversion of rank ordering.
🔄 Our daily series continues next week.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
🚀 The countdown is on for Insilico Medicine at LSX World Congress Europe!
We’re excited to have two Insilico leaders speaking at this year’s LSX World Congress Europe, bringing insights on how AI is transforming #drugdiscovery and healthcare innovation.
🎤 Two sessions you won’t want to miss:
🧠 Petrina Kamya, Ph.D.
📍 Pushing the Boundaries: How Far Can AI Technologies Take Us in Healthcare?
🗓 March 26 | 11:10
🔬 Jue Wang
📍 Silicon Meets Science: AI’s Make-or-Break Moment in Biotech
🗓 March 26 | 14:00
From AI driven target discovery to generative chemistry and foundation models, the conversation around the future of drug discovery is accelerating, and we’re excited to contribute to the dialogue with leaders across biotech, pharma, and investment.
🤝 Attending LSX? Let’s connect.
If you’re interested in exploring collaboration opportunities or learning more about the pharma.ai platform, we’d love to meet.
📩 Email us to schedule a meeting
📅 Or book a partnering meeting directly through the LSX partnering platform
And of course, join us at both sessions and say hello afterward.
Who else will be attending LSX World Congress Europe this year? 👇
#lsxworldcongress #drugdiscovery #partneringone #pharmaai #insilicomedicine -
Insilico Medicine reposted
Aging Journal
@AgingJrnl
🎥 #agingshort:
Abstract #video about the #research paper, "AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging." @InSilicoMeds
🔗 doi.org/10.18632/aging.206295
#aging #trendingwithimpact #ipf #lungfibrosis #proteomics #ai #oa #publishingThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Living longer is possible with AI drug discovery | The latest from @thestandardth
Living a long life is something we all dream of, though it often feels out of reach. Alex Zhavoronkov, founder and chief executive of Insilico Medicine, has been working toward this – pursuing longevity is not simply adding more years to lifespans, but also ensuring those years are healthier and filled with quality.
“I think that AI is a bubble, and this bubble can burst any time, so it’s very important to price yourself conservatively and not to dip if things go traumatic," he said.
Read the latest article here:
www.thestandard.com.hk/people/article/326151/ -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
New Partnership Announcement 🔊
@liquidai and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for #drugdiscovery.
The partnership tackles a critical challenge facing pharmaceutical companies today: how to harness cutting-edge AI capabilities without sending proprietary molecules, assays, and target data to external cloud services.
By combining Liquid AI's efficient #lfm architecture with Insilico's #mmaigym, (a comprehensive training platform with over 1,000 pharmaceutical benchmarks), the work shows that on-premise deployment can deliver competitive results across the full spectrum of drug discovery tasks in a single system.
Read the latest announcement here: insilico.com/news/bo54fkt0e1-liquid-ai-and-insilico-medic…
#partnerships #aipartnerships #insilicomedicine -
Insilico Medicine
@InSilicoMeds
NEW Video: The era of Pharmaceutical Superintelligence has arrived.
Join Alex Zhavoronkov (Insilico Medicine) and Ramin Hasani (@liquidai) for an exclusive fireside chat and live demo of LFM2-2.6B-MMAI. This 2.6B-parameter scientific foundation model is a game-changer for drug discovery. Trained via the Science #mmaigym, it delivers state-of-the-art performance in molecular property prediction and ADMET endpoints—all while running locally on-premise.
Why it matters: Data Sovereignty: High-performance AI that keeps proprietary IP behind your firewall—no cloud transmission required.
Efficiency: Outperforms models 10x its size, reducing compute costs and R&D timelines.
End-to-End Capability: Supports every stage from initial hit discovery to optimization.
Watch it here: www.youtube.com/watch?v=WoLyympszZU
#liquidai #insilicomedicine #biotech #onpremiseai #drugdiscovery #deeptech -
Insilico Medicine
@InSilicoMeds
These diseases were thought to be incurable. Now AI is unlocking new treatments
Artificial intelligence is inventing new drugs against Parkinson's disease, antibiotic-resistant superbugs and many rare diseases – progress that many scientists never dreamed possible.
Read the latest from @BBCWorld www.bbc.com/future/article/20260309-ai-is-finding-treatme… -
Insilico Medicine
@InSilicoMeds
🔬 The Insilico Medicine Intern Spotlight Series Continues!
📽️ Advancing AI Driven #biologics
At Insilico Medicine, we believe the future of drug discovery is built by the next generation of scientists and AI innovators.
Today we’re excited to highlight one of our recent interns, Yusra Ahmed from Khalifa University, who contributed to research and development efforts around Generative Biologics, part of the pharma.ai platform.
Our Generative Biologics engine enables researchers to design and optimize biologics such as antibodies, nanobodies, and peptides using generative AI.
During the internship, Yusra gained hands-on experience exploring how AI can support biologics engineering.
Programs like this reflect our commitment to mentorship, global collaboration, and advancing the next generation of computational biologists.
A big thank you for the hard work, Yusra! 🤝
Learn more about our Generative Biologics platform:
pharma.ai/generativebiologics
#insilicomedicine #pharmaai #generativeai #biologics #computationalbiologyThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Day 18 of #scienceaibench! 📉
Today we hit a "performance wall." We are looking at Metabolic Stability, specifically Microsomal Clearance. Using a challenging proprietary dataset from Chemistry42, we tested whether frontier models can predict how quickly a drug is metabolized by the liver. The short answer? This remains an unsolved problem for general-purpose AI.
Metabolic stability, measured by intrinsic clearance in microsomes (CLint), is a primary step of the ADMET screening, allowing to estimate a drug's half-life and dosing frequency. Predicting clearance is notoriously difficult due to the complexity of CYP450 enzyme interactions and species differences.
📋 Benchmark Specifications:
Task: Intrinsic Microsomal Clearance (CLint(mic)) Prediction.
Data Source: Proprietary dataset from Chemistry42.
Species: Human (HLM), Mouse (MLM), and Rat (RLM).
Metric: Spearman Correlation.
Models Evaluated: Opus 4.6, GPT 5.2, Sonnet 4.5, Gemini 3 Flash, Deepseek 3.2, Grok 4.1, GPT 5.1, and Nemotron 3 Nano.
📊 Observed Performance:
The "Clearance Cliff": This proved to be the hardest task in the entire benchmark series. All models performed poorly, with the highest correlation across the entire board reaching only 0.219. Most models showed little to no predictive signal ( < 0.05).
Best of the Rest: Opus 4.6 was the only model to maintain a consistent positive signal, securing the top spot for Human (0.165) and Rat (0.219) clearance, and ranking second in Mouse (0.131).
Species Anomaly: GPT 5.2 achieved the highest score for Mouse clearance (0.139) but failed to generalize, dropping to 0.021 for Human and 0.072 for Rat.
Signal Failure: Several models, including Nemotron 3 Nano and GPT 5.1, consistently produced negative or near-zero correlations (e.g., Nemotron Human -0.009), indicating they cannot distinguish stable from unstable compounds in this chemical space.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery www.prnewswire.com/news-releases/insilico-medicine-and-li…
-
Insilico Medicine
@InSilicoMeds
Liquid AI and Insilico Launch LFM2-2.6B-MMAI: Lightweight Model for On-Premise Drug Discovery www.geneonline.com/liquid-ai-and-insilico-launch-lfm2-2-6…
-
Insilico Medicine reposted
Aging Journal
@AgingJrnl
🎥 #agingshort:
Abstract #video about this #research perspective #published in Volume 17, Issue 8, titled "Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis." @InSilicoMeds
🔗 doi.org/10.18632/aging.206301
#aging #publishing #oa -
Insilico Medicine
@InSilicoMeds
Day 17 of #scienceaibench! 🎗️ Today we focus on Oncology-related Kinases Inhibition. Protein kinases are the most common drug targets in cancer therapy.
Kinase inhibitors are the backbone of modern targeted cancer therapy. Predicting how a small molecule interacts with specific kinase pockets is essential for designing selective drugs and avoiding off-target toxicity.
Today’s benchmark utilizes the PKIS2 (Published Kinase Inhibitor Set 2) dataset via Polaris Hub, evaluating frontier models on their ability to predict inhibition profiles for three major receptor tyrosine kinases: RET (Thyroid cancer), KIT (GIST/Melanoma), and EGFR (Lung cancer).
📋 Benchmark Specifications:
Task: Kinase Inhibition Prediction.
Dataset: PKIS2 subset v2 (Drewry et al., 2017) via Polaris Hub.
Targets: RET, KIT, and EGFR.
Metric: Spearman Correlation.
Models Evaluated: Opus 4.6, Opus 4.5, Gemini 3 Flash, Deepseek 3.2, Grok 4.1, Sonnet 4.5, GPT 5.1, and GPT 5.2.
📊 Observed Performance:
The Opus Dynasty: The Opus family dominates this benchmark. Opus 4.6 secured the top spot for RET (0.477) and EGFR (0.295), while the previous generation Opus 4.5 surprisingly outperformed the newer model on KIT (0.348), demonstrating robust chemical reasoning across versions.
Strong Contender: Gemini 3 Flash proved to be the only competitive non-Opus model for RET, achieving a correlation of 0.468, virtually tying with the leaders. However, it struggled to generalize to KIT (0.151).
Niche Performance: While generally mid-tier, Grok 4.1 showed surprising strength on EGFR (0.275), ranking third and outperforming Gemini 3 Flash on this specific target.
The GPT Collapse: The GPT 5 series struggled immensely with this specific chemical space. GPT 5.2 failed to identify active compounds entirely, recording negative correlations for both RET (-0.067) and KIT (-0.063), due to a lack of valid outputs.
🔄 Our daily series continues tomorrow. #scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
💥 Taking place this week in Silicon Valley! The #pmwc26 Conference is the World's premier #precisionmedicine Event. @PMWCintl
Insilico Medicine CEO & CBO Alex Zhavoronkov, PhD, will be part of the Precision Aging & #longevity Track.
Session Details:
AI-Driven Biomarkers to Quantify Aging
•Alex Zhavoronkov, Insilico Medicine
We are proud to join leaders from @Harvard University, Albert Einstein College of Medicine, @Stanford University, @OpenAI and many more.
🤝 Stop by our booth #b617 in the main entrance near Hall A/B to speak with our team: pmwcintl.com/exhibition/
Since 2009, recognized as a vital cornerstone for all constituents of the health care and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.
For the full event agenda, please visit: pmwcintl.com/session/mar-6-track-4-precision-aging-and-lo… and let us know if you'll be attending in the comments 👇 -
Insilico Medicine
@InSilicoMeds
As we enter the era of enabling Pharmaceutical Superintelligence, CEO Alex Zhavoronkov outlines his vision for the next five years. 🧬
We are moving away from hundreds of specialized models toward a unified foundation model approach.
At Insilico Medicine, this "Superintelligence" is already delivering:
-27+ candidates moved to IND-enabling studies.
-9–18 month timelines to reach the PCC stage.
-3 Phase II clinical studies currently in progress.
But the most exciting part? We aren’t doing this alone. We’re opening the MMAI Gym to frontier AI developers to help train the future of medicine.
The goal is simple: Most drug discovery tasks run from a prompt window—making life-saving research faster, cheaper, and more precise than ever before.
Big things are coming. Stay tuned. 🚀
#ai #drugdiscovery #genai #biotech #pharmaceuticals #insilicomedicineThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Day 16 of #scienceaibench! 💊 We are back to ADMET properties, specifically Distribution. Plasma Protein Binding (PPB) is a critical determinant of drug distribution and efficacy. Only the unbound ("free") fraction of a drug can cross membranes and engage its target. Predicting species-specific binding differences is also essential for translating preclinical animal data to human trials.
Today’s benchmark utilizes a proprietary high-quality dataset from our Chemistry42 platform to evaluate frontier models on regression tasks for PPB across three species.
📋 Benchmark Specifications:
Task: Plasma Protein Binding prediction (Regression).
Data Source: Proprietary dataset from Chemistry42.
Species: Human, Mouse, and Rat.
Metric: Spearman Correlation .
Models Evaluated: Opus 4.6, Gemini 3 Flash, Sonnet 4.5, GPT 5.2, GPT 5.1, Nemotron, Deepseek 3.2, and Grok 4.1.
📊 Observed Performance:
The Leaders: A distinct "Tier 1" remains clear, consisting of Opus 4.6 and Gemini 3 Flash. These two models significantly outperformed the field across all three species.
Human PPB: Opus 4.6 achieved the highest correlation (0.588), followed closely by Gemini 3 Flash (0.570). Mid-tier models like Sonnet 4.5 (0.469) trailed by over 0.10.
Rodent Models (Mouse & Rat):
Mouse: Gemini 3 Flash took the lead with a score of 0.452, surpassing Opus 4.6 (0.419) and Sonnet 4.5 (0.359).
Rat: Opus 4.6 demonstrated exceptional performance, recording the highest score in the entire benchmark (0.651).
Specific Failures: While GPT 5.1 struggled specifically with Rat PPB (-0.136), the newly evaluated Nemotron showed a "Human-Specific Failure," recording a negative correlation for Human PPB (-0.010) despite maintaining moderate positive signals in Mouse (0.235) and Rat (0.209).
Generalization Gap: Models like Grok 4.1 and Deepseek 3.2 showed consistently limited predictive power, with correlations rarely breaking 0.20 across species.
🔄 Our daily series continues next week.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
🎤 Happening Today at the International House: Chevron Auditorium!
Thank you to The University of California, Berkeley and the AI Summit team for welcoming Alex Zhavoronkov to the lineup.
Catch the "#longevity Tech - Can AI help us live longer, healthier lives?" session today! Check in begins at 430 pm. Reserve your spot here: www.eventbrite.com/e/uc-berkeley-scet-x-international-hou…
#aisummit #longevityevents #physicalai -
Insilico Medicine
@InSilicoMeds
The AI drug discovery industry is often distracted by "Pinocchio walks"—fancy PowerPoints and star-studded boards that mask a lack of substance. If you want to measure true R&D productivity, stop looking at the hype and start looking at Zero to Developmental Candidate (PCC).
🏎️The "Sports Car" Acceleration
Think of drug discovery like a high-performance sports car:
-The Acceleration (0 to PCC): This is where AI excels. Traditional methods take 4.5 years; we’ve shortened this to an average of 13 months.
-The Traffic (Clinical Trials): Once you hit IND-enabling studies, you are in a highly regulated zone. You must move at the "speed of traffic" dictated by regulators. You cannot "AI" your way out of a 28-day toxicity study.
🧮 The Productivity Formula
To compare platforms objectively, use this calculation:
Productivity = Preclinical R&D Budget/Number of PCCs developed x Number of drugs out-licensed
🕵️♂️The Ultimate Lie Detector: Out-Licensing
The "Number of drugs out-licensed" is the most critical variable. When a pharmaceutical company licenses your molecule, 70 experts spend months trying to "kill the deal" by finding flaws in your data. If you pass that rigorous scrutiny, your platform is validated.
🏆Benchmark Against Champions
The real "China Speed" is the new global standard. Local biotechs there are discovering drugs at a scale and speed previously unseen. If you want to lead, don't just develop "fancy algorithms" for isolated problems—compete against the champions who are delivering high-quality candidates to the clinic every single year.
Zero to PCC is the only benchmark that matters. Everything else is just moving with the speed of traffic.
#aidrugdiscovery #drugdiscovery #randdproductivity #preclinical #outlicensingThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Day 14 of #scienceaibench! 🧠
Today, we tackle one of the most complex frontiers in medicine: the #cns.
Target discovery for psychiatric conditions is notoriously difficult due to the lack of distinct biomarkers and complex etiology. Today’s benchmark evaluates the reasoning capabilities of frontier AI models in retrieving established clinical-stage targets for three major mental disorders: Major Depressive Disorder (MDD), Bipolar Disorder, and Schizophrenia.
📋 Benchmark Specifications:
Disease Indications: Major Depressive Disorder, Bipolar Disorder, and Schizophrenia.
Metric: Mean Average Precision (MAP) at TopK (↑).
Models Evaluated: Claude Opus 4.1, Gemini 2.5 Pro, GPT-5, DeepSeek R1, Claude Sonnet 4, and Grok 4.
📊 Observed Performance:
Depression Specialist: Gemini 2.5 Pro achieved the highest single score in the benchmark, recording a MAP of 0.891 for Major Depressive Disorder, significantly outperforming the field in this specific indication.
Consistency Leader: Claude Opus 4.1 demonstrated the most robust performance across all three disorders. It was the only model to maintain high scores in both Schizophrenia (0.848) and the more challenging Bipolar Disorder (0.684).
Schizophrenia Performance: GPT-5 secured the top rank for Schizophrenia target identification with a score of 0.854, narrowly edging out Opus 4.1.
The "Bipolar Gap": Bipolar Disorder proved to be the most discriminatory task. While Opus 4.1 and GPT-5 maintained scores above 0.67, Gemini 2.5 Pro saw a sharp performance drop to 0.567, and Grok 4 recorded the lowest score of 0.546.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym -
Insilico Medicine
@InSilicoMeds
NEW Podcast 🎤 The Future Beyond #aging Metrics
What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?
In this new podcast episode, Alex Zhavoronkov, Founder & CEO of Insilico Medicine, joins Phil Newman from longevity.technology and Dr. Nina Patrick, PhD to discuss how AI is transforming biotech, from target discovery to clinical trials.
In this episode, you’ll learn:
-Why early diagnostics may currently be the most reliable longevity strategy.
-How AI can design drug candidates in months instead of years.
-Why most longevity drugs succeed in animals but fail to prove benefits in humans.
-How disease focused therapeutics could become future aging interventions.
-What GLP-1 drugs reveal about the future of #longevitymedicine.
-The real role of clinical trials in validating AI generated therapies.
-How next generation technologies like brain computer interfaces could extend healthy lifespan.
If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.
This podcast is now available on YouTube and Apple podcasts. Watch here: www.youtube.com/watch?v=lRbEiyjmC9A -
Insilico Medicine
@InSilicoMeds
Day 13 of #scienceaibench!
🧪 Today we are moving from biomedical domain to organic chemistry and specifically single-step retrosynthesis (SSRS). We are assessing how well top-tier LLMs can suggest plausible reactions 🔮 to get a compound from plausible reactants.
In contrast to conventional USPTO-50k-test utilizing ground-truth-based Top-K accuracy metric, the proposed new benchmark assess the models outputs for chemical plausibility framework built on broader chemical context within reaction centers and functional groups compatibility mimicking the way how chemists🧑🔬 review the reactions for their plausibility.
The key data-driven metric for chemical plausibility assessment is ChemCensor, which is a part of URSA (Utilitarian RetroSynthesis Assessment) family of retrosynthesis benchmarks. The brand new URSA-expert-2026 out-of-distribution benchmark set of target molecules is proposed for realistic assessment in real-world medicinal chemistry cases.
📄 Read the ChemCensor for LLMs Preprint: arxiv.org/abs/2602.03554
📋 Benchmark Specifications:
· Datasets:
📑 USPTO-50k-test: 4972 target molecules from conventional USPTO-50k set for SSRS models evaluation
🔥 URSA-expert-2026: 100 novel synthetically accessible target molecules assessed by experts
· Metric: max ChemCensor value, average per target (↑), {Av. PT max CC}
· Metric version: ChemCensor-U2, based on publicly available USPTO full set by D.Lowe
· Models Evaluated: GPT 5.1, GPT 5.2, Claude Sonnet 4.5, Claude Opus 4.5, DeepSeek 3.2, Gemini 2.5 Flash, Gemini 3 Flash and Grok 4.1
📊 Observed Performance:
· OOD leader: Gemini 3 Flash achieved the highest {Av. PT max CC} of 1.82, demonstrating superior plausibility of proposed reactions on the OOD URSA-expert-2026 set.
· LLM versions progress: newer LLM versions show substantial progress on both public and OOD sets (GPT 5.2 over 5.1, Gemini 3 over 2.5).
· Performance Gap: All models fail to perform at the OOD URSA-expert-2026 benchmark set as successfully as they perform at the well-reported data. Best performing Claude 4.5 Sonnet at USPTO-50k-test is only 3rd best at the OOD benchmark.
· Proprietary models win: top-tier proprietary models show much reliable performance rather than open-source models (DeepSeek 3.2). Some open-source models (like Kimi K2) were even not included to the chart due to poor (~0) performance.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #retrosythesis #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Discovering and developing new drugs takes years, costs billions, and fails often.
🌟Did you know the journey from identifying a target to a development candidate takes 2.5-4 years?
We are rewriting the rules of #drugdiscovery with pharma.ai, a proprietary platform that harnesses the full power of #generativeai across #biology, #chemistry, and clinical development.
Built on Amazon Web Services (AWS) secure infrastructure with support from the AWS Global Startup program, pharma.ai seamlessly integrates into R&D pipelines worldwide.
Check out this video to learn more, and partner with our team today to accelerate breakthrough therapies and deliver hope to the patients who need them most.
#aws #insilicomedicine #nach01 #phaseii #aitransformationThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Have we entered a new age of AI-enabled scientific discovery?
AI systems are changing the way we do science. Some scientists are already using AI to generate hypotheses, design experiments or even run tests inside robotic laboratories, such as this one at Insilico Medicine. This lab was based in Suzhou, China, but it has been upgraded and moved to Shanghai.
Read more here: www.sciencenews.org/article/ai-enabled-science-discovery-… -
Insilico Medicine
@InSilicoMeds
🇵🇹 The LSX World Congress Europe takes place next month in Lisbon!
Our team is proud to announce two Leaders from Insilico Medicine, Petrina Kamya, Ph.D., and Jue Wang, PhD, MBA who will be part of multiple presentations throughout the week.
Details below 👇
Pushing The Boundaries: How Far can AI Technologies Take us in #healthcare?
This expert panel cuts through marketing claims to examine where AI is genuinely adding value in healthcare delivery and patient outcomes.
[Session details: informaconnect.com/lsx-world-congress/speakers/petrina-ka…]
Silicon Meets Science: AI's Make-or-Break Moment in Biotech
Panelists will tackle the billion-dollar question: Can AI truly reduce clinical failure rates and deliver on its promise to revolutionize drug development?
[Session details: informaconnect.com/lsx-world-congress/speakers/jue-wang/]
🤝 We look forward to joining other experts from top organizations including Roche, Hexarad, AI Medical Technology, endogene.bio, Nucleome Therapeutics
Will you be attending? Let us know in the comments or email our team: BD@insilico.com
#lsxworldcongress #medtech #aiinbiotech#WomeninScience -
Insilico Medicine
@InSilicoMeds
Insilico Medicine initiates AI driven collaboration with leading global cancer center to identify novel targets for gastroesophageal cancers
Read the release here: insilico.com/news/ncd16c90n1-insilico-medicine-initiates-… -
Insilico Medicine
@InSilicoMeds
How AI is helping solve the labor issue in treating rare diseases techcrunch.com/2026/02/06/how-ai-is-helping-with-the-labo…
-
Insilico Medicine
@InSilicoMeds
Day 10 of #scienceaibench! 🧬 We are shifting from observation to intervention. After analyzing static omics profiles yesterday, today’s benchmark tests the models' ability to predict causal biological outcomes. We are evaluating how well frontier models can forecast the lifespan effects of genetic mutations (Epistasis) and determine the natural expression trajectories of genes during aging.
Predicting the phenotypic outcome of genetic engineering is a "Holy Grail" capability for computational biology. Today’s benchmark evaluates frontier models on two fundamental tasks in genetics:
Multi-mutant Lifespan: Predicting whether a combination of mutations (e.g., in Drosophila) will extend or shorten lifespan compared to wild type.
Aging Trajectories: Classifying whether a specific gene's expression increases or decreases with age in human tissues.
📄 Read the LongevityBench Preprint: www.biorxiv.org/content/10.64898/2026.01.12.698650v2
📋 Benchmark Specifications:
Tasks: Combinatorial Lifespan Prediction (SynergyAge) and Gene Expression Trajectory Classification (Open Genes).
Metric: Accuracy (Random baseline = 0.50).
Models Evaluated: Gemini 3 Pro, DeepSeek R1, Gemini 3 Flash, Grok 4, GPT 5.2, and Claude Sonnet 4.5.
📊 Observed Performance:
Category Leader: Gemini 3 Pro demonstrated state-of-the-art reasoning in genetic tasks, achieving the highest accuracy in both Multi-mutant Lifespan (0.781) and Aging Trajectories (0.742).
Strong Baseline: DeepSeek R1 served as the second-best performer for combinatorial lifespan prediction (0.717), significantly outperforming GPT 5.2 (0.609) in reasoning about genetic interactions.
Trajectory Classification Struggles: Predicting how gene expression changes with age proved difficult for several architectures. Notably, Claude Sonnet 4.5 scored 0.479, performing slightly below random chance.
Model Profiles: Grok 4 showed a reversed competency profile compared to the field, performing better on trajectory classification (0.647) than on lifespan prediction (0.627).
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Day 9 of #scienceaibench! 🧬 Today we enter the era of #longevitybench.
We are testing whether AI models can look at complex biological datasets—DNA methylation, RNA expression, and Protein levels—and correctly identify the biological age of a sample. This benchmark evaluates "Pairwise Age Prediction," asking models to distinguish which of two samples comes.
Reliably interpreting omics data is a prerequisite for AI-driven longevity research. Today’s benchmark evaluates model performance across three distinct biological clocks: Transcriptomic (RNA), Proteomic (Protein), and Methylation (DNAm) aging. The task is a pairwise comparison: given two biological profiles, the model must determine which sample originates from an older individual.
📄 Read the LongevityBench Preprint: www.biorxiv.org/content/10.64898/2026.01.12.698650v2
📋 Benchmark Specifications:
Tasks: Pairwise age prediction from GTEx (Transcriptomics), Olink (Proteomics), and GEO (Methylation) datasets.
Metric: Accuracy (Random baseline = 0.50).
Models Evaluated: Gemini 3 Pro, GPT 5.2, DeepSeek R1, Claude Sonnet 4.5, Grok 4, and Gemini 3 Flash.
📊 Observed Performance:
Methylation (Epigenetics) Leader: Gemini 3 Pro demonstrated superior performance in epigenetic aging, achieving the highest accuracy of 0.724, followed by Gemini 3 Flash at 0.661. Other models struggled to exceed 0.55 in this domain.
Proteomics Specialist: GPT 5.2 (0.676) and DeepSeek R1 (0.673) led the field in proteomic age prediction, significantly outperforming the Gemini family, which hovered near the random baseline (~0.50–0.51).
The Transcriptomic Barrier: Predicting age from gene expression (RNA) remains a universal failure point for current frontier models. No model performed significantly better than random chance, with scores ranging tightly between 0.48 and 0.52.
Domain Heterogeneity: The results highlight distinct "biological senses" in current architectures; no single model demonstrated competency across all three omics modalities.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
Updates continue with #scienceaibench! 🧬
We are making a major shift today from small molecules to biologics. Today’s benchmark evaluates how well frontier models can predict the "manufacturability" of antibody candidates – a critical step in ensuring a drug can actually be produced at scale.
As the industry shifts toward biologics, predicting "developability" becomes essential. High binding affinity is useless if an antibody cannot be stably maintained or produced in sufficient quantities.
Today’s benchmark evaluates frontier models on two critical manufacturing parameters: Melting Temperature (Tm) (a proxy for stability) and Titer (expression yield).
📋 Benchmark Specifications:
Properties: Thermal unfolding midpoint (Tm) and Expression Titer.
Metric: Spearman correlation.
Models Evaluated: GPT 5.2, Gemini 3 Flash, Opus 4.5, Grok 4.1, Sonnet 4.5, GPT 5.1, Deepseek 3.2, and Kimi K2 Thinking.
📊 Observed Performance:
General Challenge: Performance is significantly lower than in small molecule tasks. The peak Spearman correlation is only ~0.21, indicating that current frontier models struggle to capture the complex physicochemical rules governing protein stability and yield.
Stability (Tm) Leader: Claude Sonnet 4.5 achieved the highest correlation (0.210), followed closely by GPT 5.2 (0.204).
Yield (Titer) Leader: GPT 5.2 ranked first in predicting production yield (0.170), with Gemini 3 Flash as the only other model showing comparable positive signal (0.163).
Negative Correlations: Several models, including Kimi K2 Thinking and Deepseek 3.2, produced negative correlations (e.g., Kimi K2 at -0.272 for Tm), suggesting an inverse understanding of the underlying features.
🔄 Our daily series continues tomorrow.
#scienceai #insilicobench #biologics #antibodydiscovery #proteinengineering #ai #developability -
Insilico Medicine
@InSilicoMeds
📣 Insilico Medicine Receives USD 5 Million Milestone Payment from MENARINI Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.
As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.
For the full release, please visit: insilico.com/news/g3l291v091-insilico-medicine-receives-u… -
Insilico Medicine
@InSilicoMeds
Day 5 of #scienceaibench: Target Identification 🎯
We continue our daily release series with Day 5, shifting focus from molecular properties to the complex challenge of biological target discovery. Identifying the right therapeutic target is the most critical step in drug development to avoid costly clinical failures. Today, we dig deeper into bioinformatics and introduce the results for the TargetBench module.
Success in drug discovery begins with the right target. Today's benchmark evaluates the ability of frontier AI models to recover established, clinical-stage targets for complex fibrotic diseases, distinguishing true biological signals from noise.
We have also published a preprint detailing our methodology and full results, available now alongside the live benchmark data on our website.
📄 Read the Preprint: [www.biorxiv.org/content/10.1101/2025.08.06.668866v2] 🌐 View the Benchmark: [www.targetbench.org]
📋 Benchmark Specifications:
Disease Indications: Idiopathic Pulmonary Fibrosis (IPF), Atherosclerosis, and Osteoarthritis.
Metric: Clinical Target Recall (CTR) — the proportion of known clinical-stage targets retrieved in the model's top-ranked predictions.
Models Evaluated: GPT-5, Claude Opus 4, Grok 4, and DeepSeek R1.
📊 Observed Performance:
Top Performer: GPT-5 demonstrated the highest Clinical Target Recall across all tested indications, achieving 0.474 for Atherosclerosis and 0.352 for IPF.
Performance Stratification: A distinct gap exists between models; Claude Opus 4 ranked second (e.g., 0.377 for Atherosclerosis), while Grok 4 and DeepSeek R1 generally showed lower retrieval rates.
Complex Disease Challenge: IPF proved to be the most difficult indication for baselines, with Grok 4 recording its lowest score of 0.199, highlighting the difficulty of reasoning over complex fibrotic pathology.
General Trend: The data reveals significant stratification in reasoning capabilities for biological target discovery, with clear performance tiers between model generations.
🔄 An updated version of TargetBench with expanded disease indications is coming soon. Stay tuned for further insights.
#scienceai #insilicobench #drugdiscovery #ai #targetidentification #bioinformatics #machinelearning -
Insilico Medicine
@InSilicoMeds
Day 4 of #scienceaibench: Toxicity and Safety 🧪
We continue our daily release series with Day 4, moving from foundational properties into critical safety assessment. In drug discovery, early toxicity screening is essential for preventing late-stage failures.
Predicting a drug candidate's safety profile before synthesis is vital to identify high-risk compounds and prevent adverse clinical outcomes. Today's benchmark based on correspondent TDC datasets evaluates frontier models on three fundamental safety tasks: Drug-Induced Liver Injury (DILI), Ames mutagenicity, and hERG cardiotoxicity.
📋 Benchmark Specifications:
Safety Tasks: Drug-induced liver injury (DILI), Ames test (genotoxicity), and hERG inhibition (cardiotoxicity).
Metric: Balanced Accuracy (BA ↑).
Models Evaluated: Gemini 3 Flash, Opus 4.5, Sonnet 4.5, Kimi K2 Thinking, Grok 4.1, GPT 5.1, GPT 5.2, and Deepseek 3.2.
📊 Observed Performance:
Gemini 3 Flash achieved the highest scores across all individual safety tasks, reaching a peak of 0.834 in the DILI category.
Strong Competency: Models generally showed their strongest performance in the DILI category, with both Gemini 3 Flash and Opus 4.5 scoring above 0.70.
Performance Variance: Several models, including GPT 5.1, GPT 5.2, and Deepseek 3.2, remained primarily in the 0.55 – 0.62 range across these tasks.
Predictive Consistency: Opus 4.5 followed as a top-tier performer, showing consistent results above 0.70 for all three safety markers (DILI, hERG, and Ames).
🔄 Our daily benchmark series continues tomorrow. Stay tuned for further insights into model performance across the drug discovery pipeline.
#scienceai #insilicobench #drugdiscovery #ai #toxicity #safetybydesign #biotechnology #machinelearning -
Insilico Medicine
@InSilicoMeds
Thank you to @LongevityTech for the continued coverage🤝
Longevity Technology
@LongevityTech
Phase 1 dosing milestone for MEN2501 signals growing confidence in generative AI drug discovery and its healthspan implications.
longevity.technology/news/insilico-lands-5m-as-ai-designe…
#longevity #aiinbiotech #drugdiscovery #clinicalmilestone #healthspan #insilicomedicine -
Insilico Medicine
@InSilicoMeds
ScienceAI Bench Day 3: Physicochemical Properties (Lipophilicity & Solubility)
Day 3 of #scienceaibench is here! 🚀 We are maintaining our rapid pace, continuing to test the industry's leading models against the most critical challenges in drug discovery. Today, we tackle the fundamental physicochemical properties of molecular design.
Lipophilicity and Solubility are the "gatekeeper" properties of drug discovery. They determine a compound's ability to dissolve in the bloodstream and cross cell membranes to reach its target. Once again we would like to refer to TDC’s datasets to benchmark LLMs.
Today we present the performance of 8 frontier models on these foundational metrics.
📋 Benchmark Specifications:
Properties: Lipophilicity and Solubility.
Metric: Mean Absolute Error (MAE ↓).
Models Evaluated: Gemini 3 Flash, Opus 4.5, GPT 5.2, Sonnet 4.5, Kimi K2 Thinking, Deepseek 3.2, GPT 5.1, and Grok 4.1.
📊 Observed Performance:
Top Performer: Gemini 3 Flash showed the lowest error rates in both categories, achieving scores of 0.788 for Lipophilicity and 0.736 for Solubility.
Opus 4.5 followed closely, being the only other model to score below 0.90 in both categories (0.864 for Lipophilicity and 0.855 for Solubility).
Consistency: GPT 5.2 demonstrated remarkable stability, producing a uniform error score of 0.976 across both tested properties.
High Variance in Solubility: Solubility prediction remains a challenge for several models; GPT 5.1 and Grok 4.1 recorded significantly higher error rates, both exceeding 1.3.
Uniformity in Lipophilicity: Excluding the top performers, Lipophilicity results were largely uniform, with most models clustering between 0.97 and 1.0.
🔄 Our daily series continues tomorrow with a new set of molecular property benchmarks.
#scienceai #insilicobench #drugdiscovery #aibenchmarks #biotechnology #lipophilicity #solubility -
Insilico Medicine
@InSilicoMeds
📆#scienceaibench continues!
Our #dailybenchmark series is moving fast, and we are already expanding our evaluation pool. Today’s update introduces several new models into the mix, including Deepseek 3.2, Gemini 3 Flash, and Kimi K2 Thinking, as we continue to build the most rigorous testing ground for AI in drug discovery.
🔄 Today’s benchmark focuses on Pharmacokinetics (PK) properties from Therapeutic Data Commons ADMET datasets, evaluating models on their ability to predict several main aspects of drug’s journey through the body. Intrinsic clearance in microsomes and hepatocytes from in vitro studies, and then half life (T1/2) and volume of distribution at steady state (Vdss) from in vivo PK are critical for the early selection of preclinical candidates.
📋 Benchmark Specifications:
Properties: T1/2, Vdss, and Clearance (Microsomes/Hepatocytes).
Metric: Spearman correlation.
Models Evaluated: Gemini 3 Flash, Opus 4.5, GPT 5.2, Kimi K2 Thinking, Grok 4.1, Sonnet 4.5, GPT 5.1, and Deepseek 3.2.
📊 Observed Performance:
Best Performance: Gemini 3 Flash achieved the highest Spearman correlation in every category tested, notably reaching 0.867 for T1/2.
Key Discriminator: Predicting T1/2 revealed significant performance gaps; while Gemini 3 Flash and Opus 4.5 maintained strong correlations, Grok 4.1 fell into negative correlation (-0.056).
Predictive Challenges: Predicting Clearance remains a major challenge for the field. Most models, excluding Gemini 3 Flash, showed very low or negative correlations (e.g., GPT 5.2 at -0.008 for Clearance Mic).
Consistency: Models generally demonstrated more consistent positive results when predicting Vdss.
🤖 Daily updates on further molecular properties and model benchmarks will continue throughout the week.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine
@InSilicoMeds
ScienceAI Bench is LIVE!
We are starting a daily series of drug discovery benchmarks with the main drug metabolism machines: CYP450s.
Day 1: CYP450 Profiling (Metric: Balanced Accuracy)
Opus 4.5: 0.704 (CYP2C9 Inh) / 0.691 (CYP2C19 Inh).
Grok 4.1: Lowest scores across all tasks.
Scope: 5 isoforms, substrate & inhibition tasks.
More properties and models coming tomorrow.
#scienceai #ai #drugdiscovery #datascience -
Insilico Medicine
@InSilicoMeds
🚀 Taking Place next week!
Insilico Medicine to Showcase at #whx 2026, Bridging Middle East–Global Partnerships to Accelerate Translational Research
At WHX 2026, Insilico Medicine will exhibit jointly with its strategic partner, the Emirates Drug Establishment مؤسسة الإمارات للدواء (EDE). The joint booth will be located at South Hall, S19J30, Emirates Health, where the company will highlight its latest progress and real-world applications in #ai-driven drug discovery and development.
Dr. Alex Aliper, PhD, President of Insilico Medicine, has been invited to speak on February 9 (local time), 3:10–3:40 PM, at the “Frontiers Stage: Biotechnology & Life Sciences” forum, joining a panel titled “Translational Research and Innovation: From Regional to Global.”
Together with experts and industry leaders from regional research organizations and the global #biotech community, the panel will explore ways to strengthen links between regional institutions and global biotech leaders, enhance translational pathways to move #laboratorybreakthroughs into clinical applications, and attract international capital into regional R&D ecosystems.
Check out the full release here: insilico.com/news/1dtymbokl1-insilico-medicine-to-showcas… -
Insilico Medicine
@InSilicoMeds
New Interview ⚡️
Hear how @Servier will leverage Insilico's proprietary pharma.ai platform to identify new #drugcandidates for complex #oncology targets, by exploring and designing molecules for chemical spaces that were previously difficult to access. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Nominates #ism5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate insilico.com/news/akink88ao1-insilico-medicine-nominates-…
-
Insilico Medicine
@InSilicoMeds
See what The MMAI Gym for Science enables here 👇
Get started today: insilico.com/MMAI?pi_content=5f52f9c3be992998fa09bf69d6b4…
#drugdiscovery #aidd #aimodels -
Insilico Medicine
@InSilicoMeds
World Cancer Day is a reminder to come together to take action against cancer.
Share your story, support those affected, and advocate for people-centered care.
Your voice can inspire change! #worldcancerday
#unitedbyunique -
Insilico Medicine
@InSilicoMeds
“#mmaigym is the next step, a partner-facing training environment that can take any customer-owned, open-source, or proprietary causal #llm and run it through a standardized regimen, curated scientific reasoning datasets, multi-task supervised fine-tuning, reinforcement learning with domain reward models, data decontamination, and robust public plus in-house benchmarking,” Zhavoronkov explained.
Read the full release: www.genengnews.com/topics/artificial-intelligence/no-pain… -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
We just nominated the AI-powered GIPR antagonist ISM0676 showing some impressive weight loss results.
Thanks to @LongevityTech longevity.technology for covering the news ❤️ we think that incretins are amazing longevity targets.
longevity.technology/news/insilicos-ai-obesity-drug-hits-… -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Day 5 of #scienceaibench: Target Identification 🎯
We continue our daily release series with Day 5, shifting focus from molecular properties to the complex challenge of biological target discovery. Identifying the right therapeutic target is the most critical step in drug development to avoid costly clinical failures. Today, we dig deeper into bioinformatics and introduce the results for the TargetBench module.
Success in drug discovery begins with the right target. Today's benchmark evaluates the ability of frontier AI models to recover established, clinical-stage targets for complex fibrotic diseases, distinguishing true biological signals from noise.
We have also published a preprint detailing our methodology and full results, available now alongside the live benchmark data on our website.
📄 Read the Preprint: [www.biorxiv.org/content/10.1101/2025.08.06.668866v2] 🌐 View the Benchmark: [www.targetbench.org]
📋 Benchmark Specifications:
Disease Indications: Idiopathic Pulmonary Fibrosis (IPF), Atherosclerosis, and Osteoarthritis.
Metric: Clinical Target Recall (CTR) — the proportion of known clinical-stage targets retrieved in the model's top-ranked predictions.
Models Evaluated: GPT-5, Claude Opus 4, Grok 4, and DeepSeek R1.
📊 Observed Performance:
Top Performer: GPT-5 demonstrated the highest Clinical Target Recall across all tested indications, achieving 0.474 for Atherosclerosis and 0.352 for IPF.
Performance Stratification: A distinct gap exists between models; Claude Opus 4 ranked second (e.g., 0.377 for Atherosclerosis), while Grok 4 and DeepSeek R1 generally showed lower retrieval rates.
Complex Disease Challenge: IPF proved to be the most difficult indication for baselines, with Grok 4 recording its lowest score of 0.199, highlighting the difficulty of reasoning over complex fibrotic pathology.
General Trend: The data reveals significant stratification in reasoning capabilities for biological target discovery, with clear performance tiers between model generations.
🔄 An updated version of TargetBench with expanded disease indications is coming soon. Stay tuned for further insights.
#scienceai #insilicobench #drugdiscovery #ai #targetidentification #bioinformatics #machinelearning -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Preclinical results spotlight a new AI-driven approach to obesity, one tied less to appetite alone and more to long-term metabolic health.
longevity.technology/news/insilicos-ai-obesity-drug-hits-…
#longevity #aiinmedicine #drugdiscovery #obesityresearch #digitalhealth #biotechnews -
Insilico Medicine
@InSilicoMeds
Insilico’s AI obesity drug hits up to 31.3% weight loss
longevity.technology/news/insilicos-ai-obesity-drug-hits-… -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Day 2 of #scienceaibench!
Our #dailybenchmark series is moving fast, and we are already expanding our evaluation pool. Today’s update introduces several new models into the mix, including Deepseek 3.2, Gemini 3 Flash, and Kimi K2 Thinking, as we continue to build the most rigorous testing ground for AI in drug discovery.
💡 ScienceAI Bench Day 2: In Vitro/In Vivo PK Parameters
Today’s benchmark focuses on Pharmacokinetics (PK) properties from Therapeutic Data Commons ADMET datasets, evaluating models on their ability to predict several main aspects of drug’s journey through the body.
Intrinsic clearance in microsomes and hepatocytes from in vitro studies, and then half life(T1/2) and volume of distribution at steady state (Vdss) from in vivo PK are critical for the early selection of preclinical candidates.
Benchmark Specifications:
•Properties: T1/2, Vdss, and Clearance (Microsomes/Hepatocytes).
•Metric: Spearman correlation.
•Models Evaluated: Gemini 3 Flash, Opus 4.5, GPT 5.2, Kimi K2 Thinking, Grok 4.1, Sonnet 4.5, GPT 5.1, and Deepseek 3.2.
Observed Performance:
•Best Performance: Gemini 3 Flash achieved the highest Spearman correlation in every category tested, notably reaching 0.867 for T1/2.
•Key Discriminator: Predicting T1/2 revealed significant performance gaps; while Gemini 3 Flash and Opus 4.5 maintained strong correlations, Grok 4.1 fell into negative correlation (-0.056).
•Predictive Challenges: Predicting Clearance remains a major challenge for the field. Most models, excluding Gemini 3 Flash, showed very low or negative correlations (e.g., GPT 5.2 at -0.008 for Clearance Mic).
•Consistency: Models generally demonstrated more consistent positive results when predicting Vdss.
Daily updates on further molecular properties and model benchmarks will continue tomorrow.
#scienceai #insilicobench #mmai #mmaigym #drugdiscovery #aibenchmarks #biotechnology -
Insilico Medicine reposted
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM
@agingdoc1
The Next Battlefield in Frontier AI Will Be in AI for Science
The ultimate benchmarks will be experimentally and clinically validated therapeutics
@biogerontology | @InSilicoMeds
🔗www.forever.ai/p/the-next-battlefield-in-frontier -
Insilico Medicine
@InSilicoMeds
⭐ Intern Spotlight
This year, we had the privilege of working with two incredible interns, Sahar Allabban, and Mehdi Marrakchi, who joined our #medicinalchemistry and #bioinformatics teams at Insilico Medicine.
From day one, they jumped into real scientific problems, contributing to data analysis, model development, and research workflows that support our AI driven drug discovery platform.
👏 We’re very grateful for their contributions and proud to have supported them during this stage of their careers. Watching young scientists grow, experiment, and push boundaries is one of the most rewarding parts of our work.
🔬 Stay tuned for more updates from our team!
#internspotlight #futurescientists #aiindrugdiscoveryThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🚀 What is the MMAI Gym?
Insilico Medicine’s MMAI is a training ground for #llms that leverages Insilico Medicine’s proprietary data, reasoning datasets, and validated models to boost the LLM’s intelligence in drug discovery and development related tasks.
The Gym’s curriculum focuses on:
🧪 Medicinal and organic chemistry: Multi-step optimization chains, reaction reasoning, retrosynthesis, and 3D structure-property relationships.
💡 Biology and target discovery: Omics-aware reasoning over gene expression, pathways, disease mechanisms, and multi-objective target scoring.
📰 Clinical development: Interpretation of trial designs, endpoints, and prediction of Phase 2 trial success or failure using proprietary benchmarks like ClinBench.
Explore Science MMAI Gym by booking a session today 👉 insilico.com/MMAI
#mmaigym #targetdiscovery #insilicomedicine #medicinalchemistry -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
But what is the secret of Chinese companies - how do they manage to deliver so quickly and at such incredible scale?
Many of my friends here often talk about "innovative drugs from China" (by the way, I noticed that when I use drugs or China in my posts, LinkedIn algorithm shadow bans the posts 😊 - so please like/share if you would like to break the shadow ban see more of these stories). At this year's JP Morgan, China was mentioned more often than AI - there is a Cambrian explosion of novel medicines... What most of my friends should know is that some of the best drugs are designed using our platform - we do know China very well.
I will try to sit down with some of our partners to help answer this question. Yesterday, we opened our new automated peptide design research lab in the beautiful city of Yixing and showed it to our partners. While having dinner, I talked to our amazing friend, Dr. Houjiang Zhou of Hisun Pharma, the global company with roots in China, one of the largest API manufacturers which was one of the first to go after FIC and innovative BIC therapeutics rapidly building the pipeline. We collaborate with Hisun and recently managed to nominate a PCC that will likely be the true BIC for a very difficult target for BIC in just 8 months.
At dinner, we decided to sit down and discuss this collaboration on video. Unscripted, unfiltered (please excuse any errors, omissions - and accept all proper disclaimers) - for your education and benefit. Check out this video if you would like to learn how leading companies in China manage to achieve such high level of innovation and productivity.
If I get enough likes for this video, I will turn this into a routine. All it takes is our 3 phones and the DJI microphone.
I would like to thank Dr. Zhou and Dr. Ren for this wonderful opportunity.
#ai #drugdiscovery #chinainnovation #pharmaThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact
endpoints.news/insilicos-latest-deal-is-a-120m-cardiometa… -
Insilico Medicine
@InSilicoMeds
Good news keeps coming! 🎉
Insilico Medicine just announced a $120M drug development collaboration with Qilu Pharmaceutical 🤝🧬—combining AI-native discovery 🧠⚗️ with strong pharma development execution 🏥📈 to accelerate new therapies for treating metabolic diseases.
More to watch from this partnership 🚀 insilico.com/news/ckvxca1tu1-insilico-medicine-and-qilu-p…
#insilicomedicine #qilupharmaceutical #metabolicdiseases #aidrugdiscovery #drugdevelopment #biotech #pharma -
Insilico Medicine
@InSilicoMeds
Generative AI models, like Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs), analyze molecular structures and medical images to suggest potential drugs for effective treatment. For instance, Insilico Medicine has successfully explored the advantages of quantum GANs in generative chemistry, enhancing the efficiency and accuracy of drug design.
aws.amazon.com/startups/learn/how-generative-ai-is-changi… -
Insilico Medicine
@InSilicoMeds
#llms are trained in the MMAI Gym using multi-task supervised fine-tuning (SFT), reinforcement fine-tuning (RFT), and proprietary scientific datasets. Reportedly, Insilico draws from over 4 million medicinal chemistry optimization chains, 100 million organic synthesis descriptions, and hundreds of thousands of molecular dynamics simulations.
www.biopharmatrend.com/news/insilico-medicine-launches-ai… -
Insilico Medicine
@InSilicoMeds
Newly Released: Artificial Intelligence for Drug Target and Pathway Identification, Assessment, Validation, and Indication Expansion
The integration of artificial intelligence (AI) into drug discovery has been transformational, particularly in identifying, validating, and assessing novel drug targets, biological pathways, and therapeutic indication expansion of existing compounds.
Continue reading: link.springer.com/chapter/10.1007/978-3-031-98022-0_3 -
Insilico Medicine
@InSilicoMeds
Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance www.fiercebiotech.com/biotech/qilu-programs-path-cardiome…
-
Insilico Medicine
@InSilicoMeds
endpoints.news/fosun-funded-hygtia-therapeutics-licenses-… Fosun Pharma-funded biotech licenses Insilico’s NLRP3 inhibitor
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine launches science MMAI gym to train frontier LLMs into pharmaceutical-grade scientific engines
The New “AI GYM for Science” dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10x performance gains on key drug discovery benchmarks and advancing the company’s vision of Pharmaceutical Superintelligence (PSI).
www.eurekalert.org/news-releases/1113489 -
Insilico Medicine
@InSilicoMeds
Thank you to @biospace for this coverage 🤝
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
www.biospace.com/press-releases/insilico-medicine-launche… -
Insilico Medicine
@InSilicoMeds
🚀 Major Launch Announcement 🚀 PR Newswire
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines (insilico.com/MMAI)
Today, Insilico Medicine launches a powerful platform designed to transform frontier large language models into pharmaceutical-grade scientific engines that accelerate hypothesis generation, experimental planning, and biological insight at scale.
Building on more than a decade of AI research and its own internal pipeline of 27 preclinical candidates, 10+ molecules with IND clearance, and multiple Phase I and Phase IIa clinical trials completed or ongoing, Insilico is now opening its AI training infrastructure to external partners. Science MMAI Gym adapts general-purpose LLMs (such as GPT, Claude, Gemini, Grok, Llama, and Mistral) to reason in medicinal chemistry, biology, and clinical development with the precision required in modern pharma R&D.
💡 The Gym's curriculum focuses on:
-Medicinal and organic chemistry: Multi-step optimization chains, reaction reasoning, retrosynthesis, and 3D structure-property relationships.
-Biology and target discovery: Omics-aware reasoning over gene expression, pathways, disease mechanisms, and multi-objective target scoring.
-Clinical development: Interpretation of trial designs, endpoints, and prediction of Phase 2 trial success or failure using proprietary benchmarks like ClinBench.
🤝 A huge thank you to our team for bringing this vision to life.
Take your model to the MMAI Gym: insilico.com/MMAI
👉 Read the full announcement here: www.prnewswire.com/news-releases/insilico-medicine-launch…
#aiinpharma #aiinscience #pharmaceuticalinnovation #llm -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Launches Science #mmai Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines www.prnewswire.com/news-releases/insilico-medicine-launch…
-
Insilico Medicine
@InSilicoMeds
Insilico inks $66m collab to develop NLRP3 inhibitor for Parkinson’s
longevity.technology/news/insilico-inks-66m-collab-to-dev… -
Insilico Medicine
@InSilicoMeds
AI-Native Drug Discovery using Insilico Medicine’s Nach01 Model and Microsoft Discovery
techcommunity.microsoft.com/blog/azureinfrastructureblog/… -
Insilico Medicine
@InSilicoMeds
Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform www.biopharmatrend.com/news/insilico-deploys-its-chemistr…
-
Insilico Medicine reposted
BiopharmaTrend
@BiopharmaTrend
Just in: Insilico Medicine @InSilicoMeds deployed its chemistry foundation model, Nach01, on Microsoft Discovery, Azure’s AI R&D platform—showing how third-party models can run inside a single enterprise environment for end-to-end drug discovery.
www.biopharmatrend.com/news/insilico-deploys-its-chemistr… -
Insilico Medicine
@InSilicoMeds
🚀 We’re proud to see Fierce Biotech spotlight our strategic collaboration with Hygtia Therapeutics for the co-development and global licensing of #ism8969, a potential best-in-class #nlrp3 inhibitor discovered using Chemistry42.
Under the agreement, Insilico will take the lead on bringing the preclinical asset, dubbed ISM8969, into a phase 1 trial for Parkinson’s disease. Hygtia Therapeutics will then take over for further studies and onward toward regulators and commercialization.
🤝 A big thank-you to Hygtia for their partnership and shared commitment to advancing therapies for central nervous system disorders. Together, we’re accelerating the path from AI discovery to meaningful clinical impact.
For more on this partnership, please visit: www.fiercebiotech.com/biotech/insilico-agrees-66m-deal-sp…
#insilicomedicine #partnership #aiindiscovery #neuroscience -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Very happy to Open Source DORA Community Edition - our first agentic AI scientific research platform we first launched as a service in the summer of 2024. Many of you to use it for target discovery, scientific paper writing, and many other tasks. In this recent collaboration with Microsoft, we open sourced this platform for deployment and modification in your own organizations. Many of the agents and templates in DORA were validated and improved based on the community feedback over the course of over a year. And you can even feed the code into your LLM and distill it 💡.
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
For those who do not know, Insilico Medicine started out of the NVIDIA GTC conference (check out the datestamped link in comments) and many of our early papers thanked NVIDIA for early access to hardware. At that time, we were bootstrapping and every gift of NVIDAI Tesla or early access to DIGITS DevBox made a huge difference. I am very happy to have come that far with 27 developmental candidates and 11 programs that reached clinical stage with the help of deep learning.
It is very important to remember that all of us in AI owe a great debt of gratitude to Jensen because without him, the AI revolution would simply not happen. And huge thanks for the NVIDIA Sparks we got during this JP Morgan ❤️
#jpm2026 -
Insilico Medicine
@InSilicoMeds
888 million — a lucky deal to kick off the year! 🍀💰
Huge congratulations to our incredible BD team, led by Dr Alex Zhavoronkov, on securing Insilico's first major collaboration of 2026.
🎉We're excited to further deepen our partnership with our long-time collaborator Servier and work together to push the frontiers of AI-enabled oncology drug discovery, from tackling some of the most challenging cancer targets to accelerating the development of innovative therapies for patients worldwide. 🔬🤝🌍
Read the full release here: www.linkedin.com/pulse/insilico-medicine-announces-us888-…
#insilico #servier #ai #oncology #aidrugdiscovery #drugdiscovery #biotech #collaboration #partnership #hongkong #03696hk -
Insilico Medicine reposted
BiopharmaTrend
@BiopharmaTrend
A 24-Hour Snapshot of AI Drug Discovery Across Pharma, Biotech, and Research... @IsomorphicLabs, @InSilicoMeds, @LanternPharma, and a new European AI drug design consortium.
www.biopharmatrend.com/news/in-one-day-ai-drug-discovery-… -
Insilico Medicine
@InSilicoMeds
📽️ The upcoming #dora Community Edition will be available under the permissive Apache 2.0 license, offering business-friendly terms for use and modification. #developers and #researchers worldwide can get started with Open-Source DORA by accessing the code on GitHub: github.com/insilicomedicine/DORA
🚀 Deploy it. Modify it. Build on it.
#scientificwriting #aiwritingtools -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase IIa Trial for Garutadustat, the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
insilico.com/news/gyjl5gbtd1-insilico-medicine-completes-… -
Insilico Medicine
@InSilicoMeds
🚀 Coming Soon to PandaOmics! The #singlecell Data Viewer will provide insights into cellular heterogeneity. Cells are colored by cell type, but the display can be switched to other metadata attributes. See how this new feature will work in this 1 minute video 👇
#pandaomics #softwareupdates #datasets -
Insilico Medicine
@InSilicoMeds
🤝 At Insilico Medicine, interns contribute to platforms like #chemistry42 while developing skills that matter in real-world discovery. Andre’s journey reflects our commitment to collaboration and hands-on scientific work.
Thank you to André Hurtado, Computational Scientist Intern, for sharing your experience, and we are proud to work with you!
#workingatinsilico #aidd #earlycareer -
Insilico Medicine
@InSilicoMeds
Happening this week ❗️
✈️ We look forward to joining other #pharma and #medtech leaders this week at Capgemini’s #jpm Detox Breakfast, happening January 14.
Discover how Insilico Medicine and Capgemini are transforming drug discovery by developing an agentic system that leverages domain-specific #llms with Pharmaceutical Superintelligence (PSI).
Stop by our station during the event to explore this groundbreaking collaboration and experience live demos showcasing how we're working together to make Agentic AI in Drug discovery accessible to all.
See the full event details and register here 📷 www.capgemini.com/news/events/jpm-detox-breakfast-2026/
#psi #pharmaceuticalsuperintelligence #jpm2026 -
Insilico Medicine
@InSilicoMeds
New Video from Chemistry42🚀
#pace (Patent Analysis & Chemical Extraction) is an AI-powered system that automates the extraction, structuring, and analysis of chemical, structural, and claim information from patent documents.
We are launching a closed beta program to gather feedback from selected industry professionals in #drugdiscovery, IP analysis, and #computationalchemistry.
Join here 👉 docs.google.com/forms/d/e/1FAIpQLSc89txMUWGIiXmb7ointihAL… -
Insilico Medicine
@InSilicoMeds
📣 Alex Zhavoronkov, Founder, CEO and CBO at Insilico Medicine will deliver the keynote at Modeling Molecules: The Bio Foundation Model Breakfast this Wednesday, January 14.
This event will bring together:
-Pharma R&D leaders actively prioritizing compounds and de-risking pipelines
-Founders and AI model builders are developing biological foundation models
-Investors and platform teams backing frontier tools in translational science
For more information, visit: luma.com/modeling-molecules
#jpm #sanfrancisco #longevityevents -
Insilico Medicine
@InSilicoMeds
📍 Happening this Sunday in #sanfrancisco!
The MSQ-Jones Day Global Biopharma Leadership Forum welcomes Alex Zhavoronkov, CEO and CBO at Insilico Medicine.
-Time: 3:30 PM PST
-Location: Jones Day, San Francisco
On Sunday, January 11, 2026, senior leaders from across global biopharma will gather at the Jones Day office in San Francisco for the 2026 Global Biopharma Leadership Forum, co-hosted by MSQ Ventures and Jones Day. Supported by BioCentury Inc. The BayHelix Group, American Healthcare Executive Association, and KKH Advisors.
For the full event details, please visit: msqventures.com/new-events/global-biopharma-leadership-fo…
#jpm2026 #leadershipevents #biopharmaconferences -
Insilico Medicine
@InSilicoMeds
📽️ New Video
Hear the latest updates to #chemistry42's #alchemistry 2.0. This release focused on advanced accuracy and performance across complex protein ligand systems.
Alchemistry 2.0: A two-stage RBFE engine (equilibrium MD + non-equilibrium switching) that delivers industry-level accuracy and massive scalability, with an interactive trajectory viewer and an upcoming absolute binding #freeenergy module. Compared to the previous version, it improves accuracy by up to 16% and achieves a 2–4× speed-up.
Dive into the full video here 👇 insilico.zoom.us/webinar/register/5917635757230/WN_KBH6zT… -
Insilico Medicine
@InSilicoMeds
NEW Science 42: #dora release! Insilico Open-sources DORA on GitHub, supported by Microsoft Azure, Transforming Scientific Research and Content Creation with Multi-Agent LLMs
insilico.com/news/kv5e80yc41-insilico-open-sources-dora-o… -
Insilico Medicine
@InSilicoMeds
🔊 Breaking News: Insilico Medicine and Zhejiang Hisun Pharmaceutical Co Ltd Nominate a Preclinical Candidate Just 8 Months After Forming a Strategic Collaboration
Read more about the exciting milestone below!
#insilico #hisun #ai #aidrugdiscovery #drugdiscovery -
Insilico Medicine
@InSilicoMeds
AI Drug Discovery Unicorn Insilico Medicine Jumps In Hong Kong Trading Debut www.forbes.com/sites/zinnialee/2025/12/30/ai-drug-discove…
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Here is a long (if 7 min is long) and comprehensive coverage of the state of the AI-drug discovery and development by the @TheEconomist . Check it out ahead of the JP Morgan conference. There is no doubt that AI is delivering and there are solid benchmarks to track this progress. Link to the article in the comments.
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
www.linkedin.com/pulse/insilico-medicine-announces-us888-… -
Insilico Medicine
@InSilicoMeds
Servier taps Insilico’s AI platform for early cancer R&D
endpoints.news/servier-taps-insilicos-ai-platform-for-ear… -
Insilico Medicine reposted
The Pharma Letter
@ThePharmaLetter
@QimingVC’s @InSilicoMeds successfully lists on HKEX www.thepharmaletter.com/pharmaceutical/qiming-venture-par…
-
Insilico Medicine
@InSilicoMeds
📢News release from @EurekAlert
Insilico Medicine lists on Hong Kong Stock Exchange, showing AI drug discovery momentum with 2025’s largest Hong Kong biotech IPO
www.eurekalert.org/news-releases/1111220 -
Insilico Medicine reposted
Forbes Asia
@ForbesAsia
After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma companies,” says founder Alex Zhavoronkov. Read: www.forbes.com/sites/zinnialee/2025/12/30/ai-drug-discove…
-
Insilico Medicine reposted
Kai-Fu Lee
@kaifulee
@sinovationvc backed and double-downed on @InSilicoMeds since 2019 with a firm belief that AI will accelerate healthcare and medicine development. Congratulations to Insilico Medicine on the @HKEXGroup IPO milestone. This is definitely an area where AI collaboration will do greater good in today's complicated global climate.
Forbes Asia
@ForbesAsia
After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma companies,” says founder Alex Zhavoronkov. Read: www.forbes.com/sites/zinnialee/2025/12/30/ai-drug-discove…
-
Insilico Medicine
@InSilicoMeds
"Across models, Alex Zhavoronkov was repeatedly described as standing out for building and operationalizing end-to-end AI platforms explicitly focused on aging biology, and for translating those systems into real therapeutic programs."
Read the latest from @LongevityTech here👇 -
Insilico Medicine
@InSilicoMeds
⚡️On behalf of the Chemistry 42 Team, we'd like to thank our amazing team, clients, and future partners! We wish you a happy holiday season.
If we haven’t connected just yet, we look forward to working together in 2026.
Catch up on our latest 2025 recap, and see what’s next! -
Insilico Medicine
@InSilicoMeds
According to the analysis, Dr. Alex Zhavoronkov (@biogerontology ), Founder and CEO of Insilico Medicine, was consistently identified across every model tested. Despite variations in emphasis and framing, the reasoning followed a similar arc, focusing not on publication volume or visibility, but on the sustained application of AI across the full longevity pipeline, from biomarker development and target discovery through to molecule design and clinical translation.
At Insilico Medicine, our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence. What do you believe will be the defining AI capability in longevity research over the next decade?
🔗 Read the full article:
longevity.technology/news/asking-ai-who-leads-ai-for-long…
Thanks to Eleanor Garth for the thoughtful analysis and perspective.
#artificialintelligence #longevity #drugdiscovery #biotechnology -
Insilico Medicine
@InSilicoMeds
Insilico Medicine’s pharma.ai Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence
Read the full release here: firstwordpharma.com/story/6852399 -
Insilico Medicine
@InSilicoMeds
Thank you to Alex Philippidis and the Genetic Engineering & Biotechnology News team for the insightful piece on Insilico’s AI-designed PROTAC targeting PKMYT1.
The article unpacks how we used our Chemistry42 generative AI platform to design a dual-action PROTAC that both inhibits and degrades PKMYT1 and how this work led to our recent Nature Communications paper describing an AI-empowered degrader with potent anti-tumor activity and favorable oral pharmacokinetics.
📰 Continue reading: www.genengnews.com/topics/cancer/insilico-details-ai-desi… -
Insilico Medicine
@InSilicoMeds
The editors of Nature Biotechnology have selected their favorite research articles from 2025, and we are pleased to see our research Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors included in this list.
This work was carried out in collaboration with Mohammad Ghazi Vakili, Igor Stagljar, Alán Aspuru-Guzik, et al. It showcases the potential of quantum computing to generate experimentally validated hits that compare favorably against classical models.
This recognition represents an important milestone, but it is only a step in a broader journey. We look forward to continued collaboration across disciplines to advance science and translate innovation into real-world impact.
Link to the editorial: www.nature.com/articles/s41587-025-02961-w
Link to the paper: www.nature.com/articles/s41587-024-02526-3
#naturebiotechnology #drugdiscovery #quantumcomputing #generativeai #computationalbiology #kras #translationalscience #scientificcollaboration -
Insilico Medicine
@InSilicoMeds
At Global AI Show 2025, the panel “From Smart Cities to Smart Healthcare: Shaping the Future of Digital Health” explored how AI and digital innovation are reshaping healthcare systems and patient experiences.
Dr. Alex Aliper, Co-Founder and President at Insilico Medicine, joined Caroline Hoffmann, Chief Medical Officer at OWKIN; Marius Raileanu, Chief Data Officer at Department of Health Abu Dhabi; and Farah Shamout, Assistant Professor at New York University Abu Dhabi, in a discussion moderated by Hassa Al Mazrouei, Medical Director at Sheikh Shakhbout Medical City (SSMC). The conversation highlighted a broader shift across regions, particularly in the Middle East, where healthcare innovation is increasingly intertwined with smart city ecosystems, population-scale data, and AI-driven approaches.
Since 2014, Insilico has been advancing its pharma.ai platform and expanding generative AI applications across industries. Insilico has been expanding its presence in the Middle East since opening its AI Research and Development Center in Abu Dhabi in 2023 and is now advancing a major initiative in the UAE to develop the first locally discovered novel oncology therapeutic, covering the entire process from target identification to preclinical nomination. In parallel, the company is strengthening internship, employment, and research collaboration efforts with institutes and universities such as MBZUAI (Mohamed bin Zayed University of Artificial Intelligence), New York University Abu Dhabi, United Arab Emirates University and Khalifa University. These initiatives and partnerships reflect Insilico’s commitment to driving scientific excellence in the region and cultivating diverse talent in AI-driven biotechnology.
#globalaishow #gais2025 #digitalhealth #aiinhealthcare -
Insilico Medicine
@InSilicoMeds
Insilico Medicine was glad to take part in Think Business, Think Hong Kong in Milan, a forum focused on strengthening Europe–Asia connections through Hong Kong’s role as a global innovation hub. Convened by the Hong Kong Trade Development Council, the event brought together leaders from finance, entrepreneurship, culture, and global markets.
Our Founder and CEO, Dr. Alex Zhavoronkov (@biogerontology ), joined a group of speakers including Bernard Charnwut Chan (West Kowloon Cultural District Authority), Bonnie Y Chan (Hong Kong Exchanges and Clearing Limited (HKEX)), Claudio de Bedin (Justin Chow & de Bedin Solicitors LLP) and Fabio De Rosa (BancoBPM), in a plenary session moderated by Hans Michael Jebsen (Hong Kong Europe Business Council), discussing Hong Kong’s role as a superconnector for trade and innovation and how global collaboration is reshaping business across regions.
The symposium offered a unique platform to explore new avenues for collaboration between Europe and Asia.
#insilicomedicine #tbthk #thinkbusinessthinkhongkong #milano #ai #biotech #drugdiscovery #lifesciences -
Insilico Medicine
@InSilicoMeds
Suguna Rachakonda, VP Business Development at Insilico Medicine, will join the speaker lineup at LSX Investival Showcase USA. She will speak on AI-driven drug discovery at the forefront of #pharmaceutical innovation.
Insilico Medicine is a leading, global AI-driven biotech company that utilizes its proprietary platform (pharma.ai) and cutting-edge automated laboratory to accelerate drug discovery and advance innovation in life sciences research.
Don’t miss the chance to hear how AI is shaping the future of pharmaceutical innovation! informaconnect.com/investival-showcase-usa/
#investivalusa -
Insilico Medicine reposted
TimePie (focus on anti-aging science)
@TimePieChina
Generative AI for aging research and drug discovery
| @InSilicoMeds @biogerontology
Its platform #pandaomics identified 27 high-confidence, and 8 novel HCC targets potentially associated with #cellular #senescence, and knocking down PRPF19/MAPK9 in liver cells cuts senescence. -
Insilico Medicine reposted
Live Forever Club
@liveforeversoc
From quantum bits to drug hits: A new way to target KRAS @NatureBiotech @InSilicoMeds @biogerontology
A hybrid quantum–AI system designed and validated new KRAS inhibitors in early lab tests #aidrugdiscovery #ai #drugdiscovery
liveforever.club/article/from-quantum-bits-to-drug-hits-a… -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/posts/capgemini_jpmhealth-lifesciences-p…
Start with breakfast and stay for the deep-tech demos, Physical AI showcase and innovation lab tours at the JPM Detox Breakfast Event.
📍 Capgemini Applied Innovation Exchange (AIE), San Francisco
📅 Wednesday, Jan 14 | 8:00 – 10:30 AM PST
Explore more and secure your spot at this can’t miss event!
Register here: www.capgemini.com/news/events/jpm-detox-breakfast-2026/ -
Insilico Medicine
@InSilicoMeds
📣 We are proud to share that our paper Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors has been featured on the cover of the December issue of Nature Biotechnology.
This work was developed in collaboration with Igor Stagljar and Alán Aspuru-Guzik, with Mohammad Ghazi Vakili as first author.
The team introduce a quantum–classical generative model for small-molecule design, specifically targeting KRAS inhibitors for cancer therapy. They apply the method to design, select and synthesize 15 proposed molecules that could notably engage with KRAS for cancer therapy, with two holding promise for future development as inhibitors. This work showcases the potential of quantum computing to generate experimentally validated hits that compare favorably against classical models.
Read the paper:
www.nature.com/articles/s41587-024-02526-3 -
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
The December issue is live www.nature.com/nbt/volumes/43/issues/12
The cover shows a representation of hybrid quantum computing for drug design. Ghazi Vakili et al. present a hybrid quantum–classical generative model to design molecules to inhibit KRAS activity. Two candidates are synthesized and further characterized go.nature.com/3EitbLm -
Insilico Medicine
@InSilicoMeds
⚡ Did you catch the latest paper in JAMCDD Journal?
In Insilico Medicine’s drug discovery work published in the Journal of Medicinal Chemistry, PandaOmics plays a critical role in AI-driven target and biomarker identification that guides downstream molecule generation and therapeutic development.
"Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors" is available here 👉 pubs.acs.org/doi/10.1021/acs.jmedchem.5c01943 -
Insilico Medicine
@InSilicoMeds
Insilico Medicine has entered an exclusive out-licensing agreement with TaiGen Biotechnology for ISM4808, an oral PHD inhibitor for anemia of chronic kidney disease (CKD).
ISM4808 targets the HIF-α pathway and addresses a major unmet need in CKD anemia, combining Insilico’s AI drug discovery engine with TaiGen’s strong regional development and commercial capabilities.
🔗 Read More Here: www.prnewswire.com/news-releases/insilico-medicine-and-ta…
#aidrugdiscovery #ckd #anemia #biotech #insilicomedicine #taigen -
Insilico Medicine
@InSilicoMeds
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, will speak at AiMS 2025 (AI and Materials for Sustainability), organized by IIT Delhi - Abu Dhabi , on December 15 in Abu Dhabi, presenting “Generative AI for Sustainability: Applications in Drug Discovery, Agrichemistry, and Materials Science.”
Since 2014, Insilico has been advancing its pharma.ai platform and expanding generative AI applications across industries. For example, together with Syngenta Group, we have achieved a breakthrough in crop science research. By combining Syngenta’s deep expertise in agriculture with Insilico’s generative AI technology, we have identified new areas of chemistry faster and more precisely.
Learn more about the event at: www.aims2025.com
#aims2025 #generativeai #sustainability #insilicomedicine #ai #syngenta -
Insilico Medicine
@InSilicoMeds
🎯Insilico was recently featured by MaryAnn L. in Genetic Engineering & Biotechnology News.
At Insilico Medicine, we’ve been pioneering AI-driven discovery by using our AI platforms to identify hard-to-target biology and nominate several novel small molecules that address unmet needs in oncology.
The article “Painting a Bull’s-eye on Undruggable Cancer Targets” highlights how cutting-edge technologies, like Insilico's pharma.ai Suite, are transforming the search for therapies against previously “undruggable” cancer targets.
Read the article here:
genengnews.com/topics/cancer/painting-a-bulls-eye-on-undr…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
The wait is over: the pharma.ai Winter Edition Webinar is today!
Join Insilico Medicine today, December 10, from 10:00–11:00 a.m. ET, for the pharma.ai Q4 Winter Edition Webinar, presenting the latest advancements in our journey toward Pharmaceutical Superintelligence.
Key Highlights Include:
-Generative Biologics applies physics-driven precision to binder design with automated molecular dynamics simulations, an advanced scoring function, and interactive contact analysis.
-Chemistry42 strengthens its analytical tools lineup with the upcoming features, including MolSpace for versatile chemical space exploration and PACE for patent analysis.
-PandaOmics advances target and biomarker discovery with new LLM scores and extended species support via an improved user interface and a secure Virtual Private Cloud deployment.
-DORA for scientific content drafting introduces a new Deep Research module that streamlines the entire research workflow by combining intelligent planning, credible sourcing, and advanced reasoning to transform research plans into fully traceable, analyst-level reports in minutes.
-MMAI Gym for Science dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10× performance gains on key drug discovery benchmarks.
Each upgrade strengthens the intelligence, precision, and scalability of pharma.ai, accelerating progress toward autonomous, AI-driven drug discovery.
Learn more at: www.eurekalert.org/news-releases/1109014
Register now to attend: insilico.zoom.us/webinar/register/5917635757230/WN_KBH6zT…
#pharmaai #insilicomedicine #drugdiscovery #aiinpharma #pharmaceuticalsuperintelligence -
Insilico Medicine
@InSilicoMeds
Today in Abu Dhabi, our Co-founder and President Dr. Alex Aliper joins the DeSci Summit Abu Dhabi 2025 to speak on the panel “From Algorithm to Therapy: How AI is Transforming Biology” at 17:20 local time.
DeSci Abu Dhabi brings together some of the world’s most groundbreaking scientific thinkers to explore the reality-shifting transformations shaping the future of human health and capability.
Dr. Aliper will discuss how Insilico Medicine is leveraging advanced AI and automation technologies to accelerate drug discovery. By integrating these innovations, Insilico has reduced the average time to preclinical candidate (PCC) nomination to just 12–18 months, compared to traditional methods that typically require 2.5–4 years.
Since establishing its generative AI and drug R&D center in Abu Dhabi in February 2023, Insilico has actively pursued industry collaborations and advanced AI algorithm development.
More info: luma.com/DeSciAbuDhabi2025
#desci #abudhabi #ai #drugdiscovery #insilicomedicine -
Insilico Medicine
@InSilicoMeds
What’s next for GLP-1? Tackling side effects may be the next frontier.
At the Fortune Innovation Forum, our founder and CEO, Dr. Alex Zhavoronkov (@biogerontology ), shared how the GLP-1 revolution is evolving beyond weight loss toward healthy longevity.
At Insilico Medicine, we are tackling this with a dual AI-powered strategy:
1. Finding Dual-Purpose Targets: We use AI to mine massive population and molecular data to identify protein targets implicated in both specific diseases and the general process of aging.
2. Advancing the GLP-1 Ecosystem Itself: We are not just observing. We are building. Our cardiometabolic portfolio includes a small molecule GLP-1 program to explore its potential beyond peptides. Crucially, we are also developing therapies to counteract side effects, like the significant muscle loss (up to 40% of weight loss in trials!) associated with current GLP-1s.
The future isn’t just one drug. It’s intelligent combination therapies built on a deep understanding of aging biology.
Courtesy of @FortuneMagazine
#longevity #glp1 #biotech #agingscience #fortuneinnovationforum #aifordrugdiscovery #futureofhealthThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
❄️ It’s pharma.ai Winter Launch Week! Have you secured your spot yet? insilico.zoom.us/webinar/register/7817635756176/WN_KBH6zT…
Our final quarterly webinar of 2025 is coming up on Wednesday, and it’s packed with breakthroughs you won’t want to miss.
Get a first look at the newest updates across pharma.ai, plus a preview of what’s next for AI-driven drug discovery at Insilico Medicine. -
Insilico Medicine
@InSilicoMeds
At @NeurIPSConf 2025, Our Founder and CEO Dr. Alex Zhavoronkov (@biogerontology ) participated in the AI Virtual Cells and Instruments: A New Era in Drug Discovery and Development workshop, where he shared insights on the company’s progress in enhancing biological and chemical intelligence in frontier LLMs and Insilico's MMAI Science Gym, where both SFT and RFT can be used to reach SOTA and SOTA+ performance across multiple drug discovery tasks, and more.
The workshop drew a full audience and sparked engaging discussions on the intersection of AI and drug discovery.
Many thanks to Michelle Li and Marinka Zitnik for organizing such a thoughtful and forward-looking session.
Those with virtual access can watch the recap here:
🔗 neurips.cc/virtual/2025/loc/san-diego/workshop/109543
#neurips2025 #mmaisciencegym #drugdiscovery #ai #generativeai #lifesciences -
Insilico Medicine
@InSilicoMeds
What’s next for GLP-1? Tackling side effects may be the next frontier.
At the Fortune Innovation Forum, our founder and CEO, Dr. Alex Zhavoronkov (@biogerontology ), discussed how the GLP-1 revolution is expanding beyond weight loss toward healthy longevity.
He shared that the future may not only depend on more potent GLP-1s, but on developing complementary therapeutics to mitigate side effects such as muscle loss and early signs of age-related decline.
Watch the discussion to learn how this broader approach could shape the next chapter of longevity science.
Courtesy of @FortuneMagazine
#longevity #glp1 #biotech #agingscience #fortuneinnovationforum #aifordrugdiscovery #futureofhealthThis media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
FORTUNE
@FortuneMagazine
“There are signals that GLP-1s could be the first true longevity drug,” Alex Zhavoronkov (@biogerontology), the founder and CEO of @InSilicoMeds, said at the #fortune Innovation Forum in Kuala Lumpur, Malaysia. fortune.com/2025/11/21/glp-drugs-anti-obesity-drugs-longe…
-
Insilico Medicine reposted
Atossa Therapeutics
@atossainc
.@InSilicoMeds and $ATOS announce the publication of a joint study evaluating the potential of (Z)-endoxifen for #glioblastoma multiforme (#gbm).
PR here: investors.atossatherapeutics.com/2025-12-02-Insilico-Medi…
Article here: go.nature.com/3KrGNYc
#ai #atos #pandaomics @Nature #braintumor #braintumors -
Insilico Medicine
@InSilicoMeds
👏
LEAP East
@leapeast
Alex Zhavoronkov, Founder & CEO of @InSilicoMeds, joins LEAP East in Hong Kong.
Recognised as one of the top 100 AI leaders in drug discovery and advanced healthcare globally and has published over 200 peer-reviewed research papers, hear from Alex as he brings new thinking from the frontier of generative AI drug discovery.
Expect sharp insight on how biological, chemical, and pharmaceutical intelligence is being accelerated.
See him on stage 8-10 July 2026: leapeast.com
#intonewworlds #leapeastThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
This is your final chance to join our pharma.ai Webinar series for 2025! Hear all of our top feature announcements, big reveals for Q4 and so much more.
Be the first to discover the latest advancements, new platform features, and next-gen #ai capabilities that will redefine pharma R&D.
Register here 👉 insilico.zoom.us/webinar/register/7817635756176/WN_KBH6zT…
#pharmaai #webinarseries -
Insilico Medicine
@InSilicoMeds
In case you missed it 👏
Thank you again to the conference organizers at #qlife2025 for hosting Insilico Medicine President, Alex Aliper!
The qLIFE Conference brought together researchers, industry leaders, students, and partners from across Australia and around the world, creating a space where ambitious ideas met real scientific momentum.
Special thanks to the ARC Centre of Excellence in Quantum Biotechnology (QUBIC). -
Insilico Medicine reposted
Jeff Robinson, CEO and Chairman of $MRES and $MMAZ
@contrariansmind
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma, via @EurekAlert! @InSilicoMeds www.eurekalert.org/news-releases/1107779
-
Insilico Medicine
@InSilicoMeds
🎉 Proud to share new work, now published in @Nature's Scientific Reports, from Insilico Medicine and Atossa Therapeutics, Inc. using our AI-powered PandaOmics platform to identify (Z)-endoxifen as a potential therapeutic candidate for glioblastoma, one of the deadliest malignant brain tumors in adults.
This study showcases how AI-enabled, multi-omics analyses and experimental validation can uncover new oncology indications for a well-characterized molecule and support further exploration in areas of urgent unmet need. Together, the multi-omic analyses and findings highlight endoxifen as a promising therapeutic candidate for GBM and demonstrate how AI-powered discovery can reveal new opportunities for drug repurposing and cancer treatment innovation.
🔗 Read the Press Release: www.eurekalert.org/news-releases/1107779
🔗 Nature Scientific Reports Paper: www.nature.com/articles/s41598-025-22034-x
#ai #breastcancer #braintumors #endoxifen #monotherapy #pandaomics -
Insilico Medicine
@InSilicoMeds
📰 New Paper Alert: Excited to share the newest peer-reviewed publication in @Nature Communications from the Insilico Medicine team, where our generative AI platform Chemistry42 designed a first-in-class, dual-action PROTAC D16-M1P2 targeting PKMYT1, a synthetically lethal cancer target. The AI-generated molecule simultaneously degrades and inhibits PKMYT1, showing high selectivity, potent anti-tumor activity, and favorable oral bioavailability in preclinical studies, and has now advanced to the pre-candidate validation stage as a promising therapeutic option for biomarker-defined cancers.
This work demonstrates how AI can move beyond single-function inhibitors to design complex, modality-hybrid molecules that address challenging cancer biology.
🔗 Press Release: www.prnewswire.com/news-releases/nature-communications--i…
🔗 Nature Communications Article: idp.nature.com/authorize?response_type=cookie&client_id=g…
#protacs #oncology #pkmyt1 -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Please meet the new paper from the Insilico Medicine lab in JMC on the discovery of novel, potent, selective DGKa inhibitors for cancer. This is the second generation of our DGKa inhibitors and second paper in this space. Congratulations to the team!
pubs.acs.org/doi/10.1021/acs.jmedchem.5c01943 -
Insilico Medicine
@InSilicoMeds
📰 New Paper Alert: Excited to share the newest peer-reviewed publication in Nature Communications from the Insilico Medicine team, where our generative AI platform Chemistry42 designed a first-in-class, dual-action PROTAC D16-M1P2 targeting PKMYT1, a synthetically lethal cancer target. The AI-generated molecule simultaneously degrades and inhibits PKMYT1, showing high selectivity, potent anti-tumor activity, and favorable oral bioavailability in preclinical studies, and has now advanced to the pre-candidate validation stage as a promising therapeutic option for biomarker-defined cancers.
This work demonstrates how AI can move beyond single-function inhibitors to design complex, modality-hybrid molecules that address challenging cancer biology.
🔗 Press Release: www.prnewswire.com/news-releases/nature-communications--i…
🔗 Nature Communications Article: www.nature.com/articles/s41467-025-65796-8
#ai #generativeai #drugdiscovery #protac #oncology #pkmyt1 #pharmaai #insilicomedicine -
Insilico Medicine reposted
AI_4_Healthcare
@AI_4_Healthcare
More promising #aiinhealthcare research from @biogerontology at @InSilicoMeds, pubs.acs.org/doi/full/10.1021/acs.jmedchem.5c01943
-
Insilico Medicine
@InSilicoMeds
At NeurIPS 2025 in San Diego (Dec 2–7), Insilico Medicine will join the global AI and science community to explore how artificial intelligence is transforming the frontiers of biology and medicine.
On December 6, our Founder and CEO Dr. Alex Zhavoronkov will speak at the workshop “AI Virtual Cells and Instruments: A New Era in Drug Discovery and Development”, sharing how generative AI is accelerating new therapy discovery.
Together with Global Head of AI Platform Dr. Petrina Kamya, Ph.D., the Insilico team will also present our vision for Pharma Super Intelligence. By integrating advanced machine learning, deep learning, and generative AI, this platform aims to tackle the toughest challenges in modern science and medicine.
Connect with us at NeurIPS to learn more!
#neurips2025 #pharmasuperintelligence #generativeai #ai4science #pharmaai #drugdiscovery #airesearch #biotech #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Could GLP-1s be the first true longevity drug?
The answer may not come from the clinic but from our communities.
At the Fortune Innovation Forum, our Founder and CEO, Dr. Alex Zhavoronkov, shared his view on how tracking healthy people over time, monitoring their aging clocks and overall well-being, may reveal the true potential of GLP-1s as longevity therapeutics.
Check out the video to learn more.
Courtesy of @FortuneMagazine
#longevity #glp1 #bigdata #biotech #agingscience #fortuneinnovationforum #aifordrugdiscovery #futureofhealthThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🧡 Grateful for Science, Innovation, and Collaboration
This Thanksgiving, we’re thankful for our global team, partners, and collaborators whose dedication and creativity continue to drive progress in generative AI and drug discovery.
Wishing everyone a wonderful Thanksgiving filled with warmth, gratitude, and inspiration for the discoveries ahead.
Let’s keep working hard to extend healthy, productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence.
#thanksgiving #aiforscience #aifordrugdiscovery #insilicomedicine #innovation #gratitude #longevity -
Insilico Medicine
@InSilicoMeds
Happy Thanksgiving from Insilico Medicine! While you’re enjoying the holiday, why not secure your spot for our FINAL pharma.ai webinar of 2025?
🔔 This will be our biggest, most epic event of the year, so, don’t miss your front-row spot! Register now: insilico.zoom.us/webinar/register/5917635757230/WN_KBH6zT…
#pharmaai #insilicomedicine #drugdiscovery #aiindrugdiscovery #aiinpharma #lifesciencesinnovation #webinar #2025recap -
Insilico Medicine
@InSilicoMeds
📄 New Paper Alert
Recently the Insilico team published a paper in Journal of Medicinal Chemistry: “Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors.”
Casitas B-lineage lymphoma-b (CBLB) has emerged as a promising therapeutic target for cancer immunotherapy due to its central role in modulating T-cell activation and immune tolerance. Using a structure-guided approach and iterative SAR exploration, the team identified compound 10, which is a potent and orally bioavailable CBLB inhibitor with favorable ADME properties. In vivo studies demonstrated that compound 10 exhibits significant antitumor efficacy in syngeneic mouse models, synergizes strongly with anti-PD-1 therapy to enhance tumor regression, and induces durable immune memory against tumor rechallenge.
Read the full paper here: pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5c02541
#drugdiscovery #immunotherapy #oncology #cblb #partnerships #aiforscience #insilicomedicine -
Insilico Medicine
@InSilicoMeds
AI is accelerating breakthroughs for patients with rare diseases. On December 3, 2025, 9AM PT, our Founder and CEO Dr. Alex Zhavoronkov will speak at the ASCPT Journal Family webinar on how AI-powered drug discovery is transforming the development of new therapies for conditions with high unmet medical need.
In recent years, Dr. Zhavoronkov’s published work has shifted from a primary focus on AI algorithms and platforms to two main areas: AI-driven drug discovery and longevity research. His efforts are closely tied to the major milestones achieved by Insilico. Since its inception, Insilico has published over 200 peer-reviewed papers, including six publications in the Nature portfolios since 2024.
Register here to learn how AI is reshaping drug discovery for rare diseases:events.zoom.us/ev/Akvoe5jJVgn9FNzTwl9k1wHh1Qzfdg1FWiRhd7F…
#aifordrugdiscovery #rarediseases #generativeai #longevityscience #pharmaai #healthcareinnovation #insilicomedicine #aidrivendiscovery #drugdevelopment #biotech -
Insilico Medicine
@InSilicoMeds
Last week at the Fortune Innovation Forum, our Founder and CEO, Dr. Alex Zhavoronkov, discussed his perspective on GLP-1s in the context of longevity.
At Insilico Medicine, where we use AI to target the root causes of age-related disease, this is a powerful validation of looking at existing targets through a new lens. Let’s advance science to extend healthy, productive human life.
Courtesy of @FortuneMagazine
#aifordrugdiscovery #longevityscience #glp1 #biotechinnovation #healthcare #aging #insilico #ardd #fortuneinnovationforumThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
We are pleased to share that Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, will participate in the NeurIPS 2025 Workshop “AI Virtual Cells and Instruments: A New Era in Drug Discovery and Development”, taking place at the San Diego Convention Center on Saturday, December 6, 2025.
Our Global Head of AI Platforms Petrina Kamya, Ph.D., will also be on site together with our team. We are happy to connect and discuss Pharma SuperIntelligence, the AI Gym, our latest breakthroughs in generative artificial intelligence transforming drug discovery and development, and more.
📍 December 2–7, 2025
📫 Please email pharma.ai@insilicomedeicine.com if you would like to schedule a meeting with our team during NeurIPS 2025.
#neurips2025 #generativeai #aiforscience #drugdiscovery #pharmasuperintelligence #aigym #insilicomedicine -
Insilico Medicine reposted
FORTUNE
@FortuneMagazine
That’s a wrap on the #fortuneinnovation Forum in Kuala Lumpur.🎉
We heard from:
➡️ @LinkedIn Head Economist APAC Pei Ying Chua
➡️ @IntrinsicAI CEO @wendytanwhite
➡️ @InSilicoMeds CEO Alex Zhavoronkov (@biogerontology)
➡️ @mahbubani_k, Distinguished Fellow, Asia Research Institute, @NUSingapore
…and many more!
🔗Learn more: conferences.fortune.com/event/FortuneInnovationForum2025/…This media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
FORTUNE
@FortuneMagazine
“We are going to see massive advances in small molecule drug discovery.”
@InSilicoMeds Founder Alex Zhavoronkov (@biogerontology) told the #fortuneinnovation Forum that we should expect innovations in "therapeutic modalities" for GLP-1 medications in the next few years. -
Insilico Medicine
@InSilicoMeds
Artificial intelligence is rapidly transforming industries, from healthcare to finance to mobility.
Last week at the Morgan Stanley Twenty-Fourth Annual Asia Pacific Summit in Singapore, our Founder and CEO Alex Zhavoronkov, PhD spoke on the panel “AI in Practice: Perspectives from Across the Value Chain” together with Xuan J.(Horizon Robotics), Harry Man (MCPi), and Stephen Byrd (Morgan Stanley), moderated by Min Han (Morgan Stanley). The discussion focused on how AI is being applied across industries, the practical challenges of rapid adoption, and what comes next for large-scale deployment.
This perspective aligns with our recent research and licensing collaboration with Eli Lilly, where Insilico will apply its pharma.ai platform together with Lilly’s development and disease expertise to jointly discover and advance new therapeutics. (Read more at insilico.com/tpost/e9xm9y0if1-insilico-and-lilly-enter-a-…)
Putting AI in practice means turning technology into tangible results. At Insilico Medicine, we are working to harness the power of AI to accelerate the discovery and development of life-saving medicines for the benefit of humanity.
#aiforscience #generativeai #drugdiscovery #pharmaai #elililly #morganstanley #biotech #healthcareinnovation #artificialintelligence #lifesciences -
Insilico Medicine
@InSilicoMeds
Earlier this week at the Fortune Innovation Forum in Kuala Lumpur, our CEO Dr. Alex Zhavoronkov (@biogerontology ) joined the panel session “The Appetite Revolution: How GLP-1 Drugs Are Reshaping Food, Health, and the Future of Consumption.”
Fortune's recent article by Angelica Ang, titled “GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis,” highlights Alex’s comment that “There are signals that GLP-1s could be the first true longevity drug.” The article discusses how GLP-1 therapies are moving beyond obesity and diabetes and are now being considered for their potential impact on age-related diseases and healthy lifespan.
Read the article:
fortune.com/2025/11/21/glp-drugs-anti-obesity-drugs-longe…
Rewatch the panel:
fortune.com/conferences/videos/the-appetite-revolution:-h…
As GLP-1 science continues to evolve, how might it reshape the future of longevity research and the way we think about healthier, longer lives?
#pharmaai #longevity #drugdiscovery #glp1 #aiforscience -
Insilico Medicine
@InSilicoMeds
Our Co-Founder and President Dr. Alex Aliper, will speak at the ReviveMe Global Longevity & Health Tech Summit on November 26 in Abu Dhabi, where he will discuss generative AI, aging clocks, and laboratory automation for drug discovery and aging research.
Insilico has been expanding its presence in the Middle East since opening its AI Research and Development Center in Abu Dhabi in 2023 and is now advancing a major initiative in the UAE to develop the first locally discovered novel oncology therapeutic, covering the entire process from target identification to preclinical nomination. In parallel, the company is strengthening internship, employment, and research collaboration efforts with institutes and universities such as MBZUAI (Mohamed bin Zayed University of Artificial Intelligence), New York University Abu Dhabi, and Khalifa University. These initiatives and partnerships reflect Insilico’s commitment to driving scientific excellence in the region and cultivating diverse talent in AI-driven biotechnology.
#aiforscience #drugdiscovery #generativeai #agingresearch #biotech #pharmaai -
Insilico Medicine
@InSilicoMeds
We are pleased to share that Alex Zhavoronkov, PhD (@biogerontology ), Founder and CEO of Insilico Medicine, will participate in Think Business, Think Hong Kong in Milan, organised by the Hong Kong Trade Development Council.
He will join an excellent lineup of leaders across finance, entrepreneurship, culture and global markets, including Prof Frederick Ma, Mr Paul Chan, Mr Hans Michael Jebsen, Mr Bernard Chan, Ms Bonnie Y Chan, and Mr Claudio de Bedin.
This event brings together influential voices from different industries, with discussions on innovation, technology, creative sectors and global business development. We look forward to joining the conversations in Milan and contributing to the dialogue on AI, biotech and the future of life sciences.
📅 November 27, 2025
📍 Palazzo Mezzanotte, Milan
👉 Register at: milan.hktdc.com/index.php?lang=it -
Insilico Medicine
@InSilicoMeds
We are proud to be the winner of The FII9 Innovators Pitch 2025, a milestone that reflects our commitment to transforming the future of drug discovery.
Recognizing the significant bottlenecks in drug discovery, we envisioned using AI to help extend healthy longevity for people by innovating in this field.
Thank you to Entrepreneur Middle East for highlighting this mission. The article covers our end-to-end generative AI platform across biology, chemistry and clinical development, as well as our growing presence in the UAE and the wider MENA region where we continue to advance new AI-driven programs.
Read the full story:
www.entrepreneur.com/en-ae/starting-a-business/inside-fii…
#fii9 #longevity #aiforscience #pharmaai #drugdiscovery #aimedicine #innovation #healthtech #biotech #mena -
Insilico Medicine
@InSilicoMeds
MBZUAI (Mohamed bin Zayed University of Artificial Intelligence) brought together over 200 leaders from healthcare, government, science, and research for AI Innovation Day in Abu Dhabi, featuring sessions across four key domains: multimodal foundation models, human genomics, longevity science, and robotics-enabled therapeutics.
Our Co-Founder and President, Alex Aliper, PhD, spoke in the Multimodal Foundation Models track, sharing how Insilico integrates multimodal AI into our pharma.ai platform to accelerate therapeutic discovery.
Thank you to MBZUAI for the invitation and for hosting an inspiring event!
#aiforscience #pharmaai #healthcareinnovation -
Insilico Medicine
@InSilicoMeds
Yesterday at the Fortune Innovation Forum in Kuala Lumpur, our Founder and CEO Dr. Alex Zhavoronkov (@biogerontology )joined Praful Chakkarwar from Novo Nordisk and Adele Wong from Nutrition Track for a dynamic session titled “The Appetite Revolution: How GLP-1 Drugs Are Reshaping Food, Health, and the Future of Consumption.”
Thanks Fortune bringing this important conversation together.
#fortuneinnovationforum #glp1 #futureofhealth -
Insilico Medicine
@InSilicoMeds
Insilico Medicine was featured as a “frontier firm” in GeekWire’s story on Microsoft’s new Experience Center One. Our joint demo with Microsoft was highlighted as a real example of how advanced generative and agentic AI is reshaping drug discovery and accelerating scientific progress.
Thank you to the Microsoft team for showcasing our work and to GeekWire for the coverage.
Read more at: www.geekwire.com/2025/inside-microsofts-new-experience-ce…
#aiforscience #generativeai #drugdiscovery #pharmaai #microsoftai #frontierfirm #insilicomedicine -
Insilico Medicine
@InSilicoMeds
A defining moment for the longevity field. This Nature Biotechnology editorial captures how the dialogue at this year’s Aging Research & Drug Discovery Meeting in Copenhagen brought aging biology and pharma innovation together. When leaders from Eli Lilly and Novo Nordisk discussed the longevity potential of GLP-1 drugs on stage, it marked a new era where aging mechanisms, AI-driven biomarkers, and preventive medicine begin to converge.
Link to the article: www.nature.com/articles/s41587-025-02932-1
#longevity #glp1 #ardd2025 #agingresearch #pharma #naturebiotechnology -
Insilico Medicine
@InSilicoMeds
Artificial intelligence is reshaping industries at an unprecedented pace. At the upcoming Morgan Stanley Asia Pacific Summit (Nov 19–20, Singapore), our Founder and CEO Alex Zhavoronkov, PhD will join the panel “AI in Practice: Perspectives from Across the Value Chain” to share insights on how organizations are applying AI across technology and business, the challenges of rapid adoption, and the next waves of transformation.
📅 November 19, 14:30 – 15:20 (Singapore Time)
📍 Mandarin Oriental, Singapore
#aiforscience #generativeai #drugdiscovery #pharmaai #artificialintelligence #lifesciences #innovation #morganstanley #insilicomedicine -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Very happy to share the news of our new drug discovery collaboration with Eli Lilly!
I must say that in my book, I rate Eli Lilly as #1 in terms of their approach to deploying end-to-end AI among all pharma companies with very strong internal generative AI and automation capabilities. They also deployed and integrated our generative AI tools in the most sophisticated way possible as lego blocks in the agentic AI platform. So it is a great honor for us to be chosen as one of the drug discovery partners where we collaborate to discover novel therapeutics.
I am also very happy that the partnership announcement coincides with Eli Lilly hitting all-time high 💡
Check out the BiopharmaTrend article and official press release in the comments.
#pharma #longevity -
Insilico Medicine
@InSilicoMeds
From algorithm to human clinical trials, this is the journey we are building at Insilico Medicine.
Our Co-Founder and President Alex Aliper, PhD will speak at the QLIFE International Conference on Quantum Technologies in the Life Sciences in Wollongong, sharing how Generative Artificial Intelligence and laboratory automation are transforming drug discovery and development.
#aiforscience #generativeai #drugdiscovery #lifesciences #insilicomedicine -
Insilico Medicine
@InSilicoMeds
The BindHack Hackathon 2025 in Abu Dhabi hosted by Insilico Medicine brought together talented innovators, researchers, and students to tackle a central challenge in computational biology, predicting the binding affinity between protein pairs.
We extend our congratulations to the winning teams for their outstanding projects and to all participants for their creativity, collaboration, and dedication throughout the event.
Thank you to everyone who contributed to making this hackathon a success, fostering new ideas, inspiring collaboration, and advancing the future of AI for science and medicine.
#aiforscience #computationalbiology #drugdiscovery #innovation #hackathon #abudhabi #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Dr. Alex Aliper, Co-Founder & President of Insilico Medicine, will join the panel discussion “How will we measure aging in the future?” at Nature Forum: Measuring Healthy Aging.
We look forward to insightful conversations on how AI and science together can redefine the way we understand and measure aging!
🔗 Learn more: ku.events/3rd-healthy-longevity-symposium/
#healthyaging #agingresearch #aiforscience #longevity #generativeai #biomarkers #insilicomedicine #healthylongevity -
Insilico Medicine
@InSilicoMeds
Exciting news! Insilico Medicine is proud to announce today a new research and licensing collaboration with Eli Lilly and Company, valued at up to $100 million, to advance AI-driven drug discovery.
By combining Insilico’s pharma.ai platform with Lilly’s deep development and disease-area expertise, this partnership aims to accelerate the discovery and advancement of next-generation therapeutics for patients worldwide.
Read More Here: www.prnewswire.com/news-releases/insilico-and-lilly-enter…
#aiinbiotech #drugdiscovery #pharmainnovation #generativeai #insilicomedicine #lilly -
Insilico Medicine
@InSilicoMeds
Dr. Alex Zhavoronkov (@biogerontology ), Founder & CEO of Insilico Medicine, will speak at The Fortune Innovation Forum 2025 on the panel “The Appetite Revolution: How GLP-1 Drugs Are Reshaping Food, Health, and the Future of Consumption,” to share his insights on GLP-1 drugs.
Don’t miss the event!
📍 Kuala Lumpur, Malaysia
🗓️ November 17–18, 2025
#fortuneinnovationforum -
Insilico Medicine
@InSilicoMeds
Since pioneering next-generation AI in drug discovery, Insilico Medicine has built an extensive therapeutic portfolio across high-demand areas, rapidly advancing its internal R&D pipeline and setting a new standard for efficiency. This year, we are excited to introduce our emerging cardiometabolic portfolio, featuring novel programs targeting diseases closely linked to the aging process. Let's forge partnerships that will help extend healthy productive longevity for everyone!
Thank you, longevity.technology for the coverage. Read the article: longevity.technology/news/insilico-expands-ai-reach-into-…
#longevity #metabolichealth #cardiometabolic #generativeai #aiforscience #pharmaai #drugdiscovery #biotech #agingresearch #precisionmedicine -
Insilico Medicine
@InSilicoMeds
By integrating AI and automation, Insilico Medicine has demonstrated a significant increase in efficiency compared to traditional drug discovery methods. At AI Innovation Day: Shaping the Future of Healthcare Together, our Co-Founder & President, Alex Aliper, PhD, will speak in Domain Track 1: Multimodal Foundation Models, sharing how Insilico is integrating multimodal AI models into our pharma.ai platform and how this is transforming the way we discover and develop new therapeutics.
📍 Multi-Use Hall, MBZUAI Campus, Masdar City, Abu Dhabi
🗓️ November 12, 10:00–11:00 a.m.
🔗 Event: mbzuai.ac.ae/event/ai-innovation-day/ -
Insilico Medicine
@InSilicoMeds
The AI drug discovery space is crowded. It's hard to separate the real, clinically-validated platforms from the "narrative-only" companies.
We were curious about the digital consensus and analyzed how leading LLMs see the field. (See the video.)
The results consistently point to Insilico as a leader. But for us, this narrative is just an echo.
It's a reflection of the tangible proof that separates a platform from a promise: our fully generative AI-discovered drug for Idiopathic pulmonary fibrosis (IPF) successfully completing Phase IIa trials and beyond
In our industry, it's the proof that matters.
#insilicomedicine #drugdiscovery #clinicaltrials #ai #leadership #pharmaai #ipfThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Our Founder & CEO, Dr. Alex Zhavoronkov (@biogerontology ), shared perspectives on AI in longevity and longevity biotechnology at #bioeurope2025. Grateful to the organizers for creating a powerful platform for knowledge-sharing and partnering.
#bioeurope #longevity #longevitybiotech #aiforscience #drugdiscovery #agingresearch #pharmaai -
Insilico Medicine
@InSilicoMeds
Our founder and CEO Dr. Alex Zhavoronkov, spoke at “Agentic AI for Biomedical Discovery,” hosted by the Harvard Chan Chinese Student Health Club 哈佛中国健康协会, on AI and automation for drug discovery. Topics covered:
• History of Generative AI in Drug Discovery
• Use Cases of AI-Powered Drug Discovery
• Pharmaceutical Superintelligence
Thank you to the organizers for bringing the community together. Let’s push the boundaries of what AI can achieve in medicine!
#agenticai #drugdiscovery #agents #aidd #biopharma #harvardchan #harvardmed -
Insilico Medicine
@InSilicoMeds
Our President, Alex Aliper, PhD, will join the 1st MENA Conference on Living Therapeutics at the NYUAD Institute and speak on Panel D2: “Developing a Framework to Accelerate Living Therapeutics Development and Applications.” He’ll share how Insilico’s generative-AI platform and workflows improve the quality and productivity of pharmaceutical research and help compress timelines.
📍 NYU Abu Dhabi, Saadiyat Campus, A6 Lecture Hall
🗓️ Nov 5, 2025, 4:20–5:00 PM
#nyuad #mena #livingtherapeutics #generativeai #aiforscience -
Insilico Medicine
@InSilicoMeds
Let's connect and partner at #bioeurope!
Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The rapid progress of our internal pipeline demonstrates the drug discovery capabilities of our pharma.ai platform.
Pipeline:insilico.com/pipeline -
Insilico Medicine
@InSilicoMeds
At the Fortune Global Forum 2025 panel, “Living Better, Longer: A Social and Economic Imperative,” our CEO, Alex Zhavoronkov (@biogerontology), PhD, shared that the science of aging is advancing faster than ever, and the breakthroughs ahead could be truly transformative. He also highlighted that the democratization of biotech is accelerating research globally, making longevity innovation faster, broader, and more accessible than at any point in history.
Check out the video to learn more.
#longevity #biotech #agingresearch #innovation #saudiarabia #uaeThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
How do you actually scale AI-driven drug discovery?
On October 31 (12–1 p.m. PT), Keck Graduate Institute will host Dr. Alex Zhavoronkov (@biogerontology ), Founder, CEO and CBO of Insilico Medicine, for a research seminar on "Scaling AIDD: Faster, more cost-efficient discovery and development of innovative new drugs using generative AI, parallel validation, and global collaboration."
By integrating the technologies of AI and automation, Insilico has demonstrated significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
#ai #drugdiscovery #generativeai #aidd #biotech #pharmaai #translationalmedicine #kgi -
Insilico Medicine reposted
FII Institute
@FII_Institute1
At #fii9, Alex Aliper, Co-Founder & President of @InSilicoMeds, showcased their groundbreaking lung fibrosis program, achieving rapid milestones far ahead of industry standards while optimizing costs.
Tune in to the #livestream: www.youtube.com/live/FQij130SiUQ?cbrd=1&ucbcb=1
#keytoprosperity -
Insilico Medicine reposted
FII Institute
@FII_Institute1
At #fii9, @AlexAliper, Co-Founder & President of @InSilicoMeds, highlighted how Insilico is combining #medical intelligence with #genai to fast-track breakthroughs in #biochemistry.
Tune in to the #livestream: www.youtube.com/live/FQij130SiUQ?cbrd=1&ucbcb=1
#keytoprosperity -
Insilico Medicine
@InSilicoMeds
To illustrate how generative AI breakthrough is driving real-world healthcare solutions, Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, spoke on Oct 29 on the topic “Can Cell-Based Innovation Keep Humanity in Peak Condition?”
Today, Alex Aliper, PhD, President of Insilico Medicine, joined the FII Innovators Pitch 2025 session to share the know-hows obtained in continued AI platform development and reproducible proof-of-concept achieved with highly efficient novel pipelines at Insilico.
Under the theme “The Key to Prosperity,” #fii9 focuses on urgent topics including global growth, AI and technology responsibility, as well as the next generation of talent, fostering communication between global investors, visionary leaders, and pioneering minds as the world’s leading platform for dialogue and action.
We are proud to be part of this conversation. -
Insilico Medicine
@InSilicoMeds
We are proud to be featured as a case study by HKTDC Research on how AI is driving biomedicine innovation in Hong Kong. The piece includes an interview with Dr. Frank Pun, Head of Insilico Medicine Hong Kong, who talks about how our AI platform is shortening the drug discovery timeline and why Hong Kong, with its financial system and international scientific research talent pool, is becoming an important hub for biopharmaceutical innovation. Thank you to Hong Kong Trade Development Council Research for highlighting our work.
Read more at: research.hktdc.com/en/article/MjE1MzM0ODAxNA
#ai #drugdiscovery #pharmaai #hongkong #lifesciences -
Insilico Medicine
@InSilicoMeds
14 November is World Diabetes Day, a global call to action in the fight against one of the world's most critical health challenges. In alignment with this year's theme of "Diabetes and Well-being," we are harnessing our proprietary AI engine Biology42: Generative Biologics to drive innovative breakthroughs in diabetes therapy development. In a recent pioneering study, Insilico has demonstrated the remarkable potential of generative biologics to rapidly design peptides targeting GLP1R—the receptor modulated by blockbuster diabetes drugs such as Ozempic.
Read the full article to learn more! www.prnewswire.co.uk/news-releases/insilico-showcases-adv… -
Insilico Medicine
@InSilicoMeds
Our CEO, Alex Zhavoronkov, PhD (@biogerontology), presented TargetBench and our latest work on generative AI and automation for drug discovery at the 2025 Biomarkers of Aging Conference at Harvard Medical School last week. Thank you to the organizers for gathering this outstanding aging community!
Read more about TargetBench at: insilico.com/tpost/v49bfcu0r1-transforming-drug-target-di… -
Insilico Medicine
@InSilicoMeds
Proud to be included in Microsoft’s Becoming Frontier stories. Thank you @Microsoft and @judsonalthoff for spotlighting how artificial intelligence can accelerate drug discovery. At Insilico Medicine, we hope to revolutionize the drug discovery process with cutting-edge artificial intelligence technologies. Microsoft provides the world’s greatest platforms for deep technology start-ups to thrive and co-develop. Deeply honored to be working with your team for the benefit of patients worldwide.
Read more at: blogs.microsoft.com/blog/2025/10/28/becoming-frontier-how… -
Insilico Medicine
@InSilicoMeds
We’re proud to announce that Insilico Medicine has been recognized by the Boston Business Journal as a 2025 honoree of the BostInno Fire Awards.
This recognition celebrates our major achievements from 2025 as we continue to demonstrate the real-world impact of generative AI and advance a new generation of therapeutics in the clinic.
We’re grateful to our Boston and global teams for helping transform how medicines are discovered.
👉 Read more about the Fire Awards honorees: www.bizjournals.com/boston/inno/stories/news/2025/10/02/m…
#bbjfire #ai #drugdiscovery #innovation #bostonbiotech #insilicomedicine #bostinno #fireawards -
Insilico Medicine
@InSilicoMeds
At the Fortune Global Forum 2025 panel “Living Better, Longer: A Social and Economic Imperative,” our CEO, Alex Zhavoronkov, PhD addressed how to develop drugs in a way that keeps them representative across populations and avoids bias. Check out the answer in the video.
#fortuneglobalforumThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
See you at BIO-Europe Vienna, Nov 3–5!
At the event, Insilico will introduce its emerging Cardiometabolic Portfolio and showcase the capabilities of our end-to-end AI platforms.
Alex Zhavoronkov, PhD, Founder and CEO of Insilico, will be a featured speaker in a panel discussion scheduled for Tuesday, November 4, 2025, from to , where he will discuss how generative AI is accelerating the development of new therapies for age-related diseases. Meanwhile, the company's business development team will be available for meetings at the booth, as well as through the conference's partnering system, to pursue strategic collaborations.
Read more at: www.eurekalert.org/news-releases/1103438
#bioeurope #generativeai #pharmaai #partnerships #biotech -
Insilico Medicine
@InSilicoMeds
Bosphorus Summit 16: Global Challenges, Adjusting to New Realities
Our Founder and CEO Dr. Alex Zhavoronkov will lead the panel on Longevity, Biotechnology and Artificial Intelligence, highlighting how AI and automation are advancing drug discovery and longevity research. Join us to explore concrete applications, collaborations, and what this means for patients and partners.
November 6–7, 2025 | Istanbul
Tickets: www.bogazicizirvesi.org
#bosphorussummit #aiforscience #generativeai #drugdiscovery #longevity #biotech -
Insilico Medicine
@InSilicoMeds
Insilico Medicine is at the Future Investment Initiative 9th Edition, starting today at the King Abdulaziz International Conference Center in Riyadh.
Under the theme “The Key to Prosperity,” #fii9 focuses on urgent topics including global growth, AI and technology responsibility, as well as the next generation of talent, fostering communication between global investors, visionary leaders, and pioneering minds as the world’s leading platform for dialogue and action.
www.eurekalert.org/news-releases/1103264 -
Insilico Medicine
@InSilicoMeds
Insilico Medicine is proud to present BindHack: The Protein Affinity Hackathon in Abu Dhabi — a unique event for innovators, researchers, and data scientists to collaborate on advancing AI in drug discovery. Join us to connect with industry leaders, share ideas, and contribute to solutions shaping the future of healthcare!
💡 Open to students, researchers, and AI enthusiasts
🏆 Prizes: AED 6,000 + internship at Insilico Medicine
📍 Masdar City, Abu Dhabi
Register now at insilico.com/ism-events/abu-dhabi/hackathon2025 -
Insilico Medicine
@InSilicoMeds
Two days to go until the @FortuneMagazine Global Forum in Riyadh (October 26–27). The Insilico Medicine team will be on site!
Our founder and CEO, Alex Zhavoronkov, PhD, will speak on longevity and artificial intelligence in healthcare at the Forum.
Learn more at: www.alphagalileo.org/en-gb/Item-Display/ItemId/264558?ret…
#fortuneglobalforum #riyadh #aiforscience #pharmaai #drugdiscovery #longevity #healthcare #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Missed the pharma.ai Fall Launch webinar on October 2, 2025?
We have published a recap addressing the most frequently asked questions.
Read the summary: www.eurekalert.org/news-releases/1102736
For the full webinar recording, email pharma.ai@insilicomedicine.com
#pharmaai #generativeai #drugdiscovery #biotech #aiforscience #precisionmedicine #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Insilico Medicine is heading to Vienna for BIO-Europe, Nov 3–5, 2025! Let's connect and partner!
#bioeurope #biotech #biopharma #drugdiscovery #partnering #licensing #generativeai #pharmaai #lifesciences -
Insilico Medicine
@InSilicoMeds
Dr. Alex Aliper, President of Insilico Medicine, will speak at the FII Innovators Pitch 2025 on Investment Day (Day 3 of #fii9). He will share how our #generativeai platform accelerates drug discovery with faster timelines and lower costs.
Time: Oct 30, 12:15 to 1:15 PM
Location: KAICC, Riyadh, Saudi Arabia
Join us to see how Insilico is advancing healthcare innovation!
#fii9 #generativeai #drugdiscovery #healthcare #innovation #aiforscience -
Insilico Medicine
@InSilicoMeds
Riyadh is buzzing next week as global leaders gather for #fii9 under the theme #keytoprosperity. Amid the conversations on growth and health, our Founder, CEO and CBO Dr. Alex Zhavoronkov @biogerontology will join the panel “Can Cell-Based Innovation Keep Humanity in Peak Condition?”
Insilico Medicine’s management team will be onsite. Ping us to connect if you’re attending!
🗓️ Oct 27-30, 2025
📍KAICC, Riyadh, Saudi Arabia
🔗 Learn more: fii-institute.org/conference/fii9-edition -
Insilico Medicine
@InSilicoMeds
How AI is rewriting the rules of drug discovery?
In this DATE with Tech podcast, our president Dr. Alex Aliper explains how generative biology and AI compress discovery cycles and speed the path from algorithm to real-world impact.
Insilico is committed to advancing AI for Science across biology and chemistry to accelerate drug discovery and development. Watch the full episode: www.youtube.com/watch?v=4kVgxqZ_T0k
#aiinbiotech #insilicomedicine #drugdiscovery #generativebiology #datewithtech #dubaiaifestival -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Team is heading to the Fortune Global Forum in Riyadh on October 26–27!
Our CEO, Dr. Alex Zhavoronkov, will join two sessions:
-MAIN STAGE: Living Better, Longer — A Social and Economic Imperative
5:00 pm, Oct 26.
-LUNCH SESSION: Hacking Our Defenses
12:30 pm, Oct 27.
If you are attending, let’s connect in Riyadh!
Agenda: conferences.fortune.com/event/global-forum-2025/agenda
#fortuneglobalforum #riyadh #longevity #healthyaging #pharmaai #generativeai #cybersecurity -
Insilico Medicine
@InSilicoMeds
While in-vitro models are essential for studying neurological disorders, how to include biological sex in experimental design remains unclear. A new Nature Reviews Bioengineering review outlines the pros and cons of using in-vitro models to investigate sex differences in neurological disorders, and proposes a roadmap and discussion of best practices to incorporate sex as a biological variable into in vitro models of neurodegenerative diseases and neuropsychiatric disorders.
Kudos to all the authors!
Full article: www.nature.com/articles/s44222-025-00355-w
#neuroscience #bioengineering #brainhealth #organoids #ipsc #organonchip #reproducibility #precisionmedicine -
Insilico Medicine
@InSilicoMeds
A new review on the cGAS–STING pathway in colorectal cancer cites Insilico Medicine’s ENPP1 program as an example of AI-driven innovations in STING modulator design.
We leverage our generative chemistry artificial intelligence-based drug design platform Chemistry42 to facilitate the design of ISM5939, an orally bioavailable ENPP1-selective inhibitor capable of stabilizing extracellular cGAMP and activating bystander antigen-presenting cells without inducing either toxic inflammatory cytokine release or tumor-infiltrating T-cell death.
To learn more about ENPP1, click: insilico.com/pipeline_target_enpp1
Read the review: pmc.ncbi.nlm.nih.gov/articles/PMC12506337/
#cgassting #stingpathway #enpp1 #tumorimmunity #innateimmunity #colorectalcancer #crc #smallmolecule #chemistry42 -
Insilico Medicine
@InSilicoMeds
Yesterday at Fierce Biotech Week, our CEO Alex Zhavoronkov joined Margo Georgiadis (Co-founder & CEO, Montai Therapeutics; Flagship Pioneering) and Christopher Arendt, PhD (Chief Science Officer and Head of Research, Takeda) on the panel “How AI/ML is Accelerating Drug Development.”
For Insilico, success in AI drug discovery means cheaper, faster, higher quality drugs, better probability of success, and hopefully higher novelty. -
Insilico Medicine reposted
Genetic Engineering & Biotechnology News
@GENbio
Insilico’s AI Workflow Has Two Jobs: Discover Compounds, Thwart Competitors
@InSilicoMeds researchers unveil LEGION, designed to search chemical space around targets, then protect discoveries from fast patenting by rivals
#ai #drugdiscovery #parkinsons
www.genengnews.com/gen-edge/insilicos-ai-workflow-has-two… -
Insilico Medicine
@InSilicoMeds
Thank you to the Genetic Engineering & Biotechnology News team for the coverage of our latest study, "Molecular LEGION: Latent Enumeration, Generation, Integration, Optimization and Navigation. A case study of incalculably large chemical space coverage around the NLRP3 target". Through a NLRP3 case study the piece highlights how our AI-native workflow explores and prioritizes vast chemical space to strengthen IP strategy and accerlerate discovery.
🔗 Link: www.genengnews.com/gen-edge/insilicos-ai-workflow-has-two…
#ai #drugdiscovery #generativeai #chemistry #nlrp3 #pharma -
Insilico Medicine
@InSilicoMeds
Managed Healthcare Executive recently covered our work on an AI-driven toolset for IPF and aging research. The study "AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging" highlights how advanced models can reveal biology linking lung fibrosis with accelerated aging and point to more targeted therapeutic paths.
www.managedhealthcareexecutive.com/view/new-study-ai-expl… -
Insilico Medicine
@InSilicoMeds
In a recent article, Financial Times highlights how big pharma is turning to AI to cut time and costs. In that context, our CEO, Dr. Alex Zhavoronkov @biogerontology , emphasizes the importance of benchmarking how the technology performs versus conventional methods.
Links to the FT article and Alex’s thoughts on benchmarking: www.ft.com/content/c4b5153f-be07-454d-911f-31bb011f09ae -
Insilico Medicine
@InSilicoMeds
By building an AI system that outperforms general-purpose models and widely used public resources, we are generating actionable intelligence not just predictions. Combined with TargetBench 1.0, this framework sets a new standard for reliability and transparency, enabling biopharma companies to move faster and smarter toward breakthrough therapies.
📄 Paper: www.biorxiv.org/content/10.1101/2025.08.06.668866v2 -
Insilico Medicine
@InSilicoMeds
A study from Insilico Medicine, the Buck Institute for Research on Aging and Duke University proposes a new method to evaluate age-related diseases based on how closely they align with the biological processes of aging.
Read the full paper: DOI: www.aging-us.com/article/206301/text
Full coverage of the perspective from Drug Target Review: www.drugtargetreview.com/news/186449/scientists-spotlight… -
Insilico Medicine
@InSilicoMeds
In a Forbes article by David Henkin, he writes that innovation in AI demands smarter thinking around value creation.
Insilico Medicine is a real-world practice of this idea. We have showcased the capability of our proprietary AI platform to significantly reduce cost and improve efficiency in the early stages of small molecule drug discovery and development.
Let’s work hard to extend healthy productive longevity for everyone!
Link: www.forbes.com/sites/davidhenkin/2025/09/23/why-innovatio…
#generativeai #aiforscience #drugdiscovery #biotech #pharmaai -
Insilico Medicine
@InSilicoMeds
Insilico Medicine is heading to Oslo for #inlifescience2025 in November! Our Global Head of AI Platforms, Petrina Kamya, Ph.D., and Associate Director of Global Business Development, Aisyah Sjöholm, MD, Msc., will be attending the event and speaking.
👩🏫Pre-Conference Webinar
Scientific Arena: How AI is Reshaping Drug Development
🗓️Thursday, October 2 | 5:30-6:30 PM CET
🔗Register here: thelifesciencecluster.no/events/scientific-arena-how-ai-i…
🎤Onsite Keynote
Transforming Drug Development Through AI
🗓️Wednesday, November 19 | 9:45-10:05 AM CET
Petrina will share how AI is reshaping every step of the drug development journey, from early stage discovery to clinical trials and regulatory approval.
We look forward to connecting with you in Oslo.
🔗View the event agenda here: thelifesciencecluster.no/events/inlifescience-2025-securi… -
Insilico Medicine
@InSilicoMeds
🚀 In just 2 weeks, we’ll be in Amsterdam for the World Summit AI!
Our Global Head of AI Platforms, Petrina Kamya, PhD, will join the panel:
From Code to Cure: Using AI and Automation to Solve Some of the Most Pressing Challenges in Healthcare
🗓 October 9 | 2:30 – 3:10 PM CET
The discussion will explore how the convergence of AI and automation transforms drug discovery with predictive modeling and real-time data-driven optimization.
🎟 Use code “PETRINA20” for 20% off tickets.
👉 Register for the event here: worldsummit.ai -
Insilico Medicine
@InSilicoMeds
Check out this video from #ardd2025. This presentation from Novo Nordisk on GLP-1 covers its history as a proven longevity medicine, its association with prevention of heart failure, and its impact on neurodegenerative diseases.
We hope to continue these exciting conversations at #ardd2026!This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
In 2 weeks, Insilico Medicine will be at Fierce Biotech Week in Boston!
Our Founder & CEO, Alex Zhavoronkov will be speaking on the panel:
How AI/ML is Accelerating Drug Development
🗓️Tuesday, October 7 | 🕝2:30PM EDT
This session will dive into how AI is transforming biotech R&D, from accelerating discovery and improving preclinical predictability, to optimizing clinical design.
See the event agenda here: www.fiercebiotechweek.com -
Insilico Medicine
@InSilicoMeds
In this interview with Ray Dogum, Chief Editor at Drug Discovery Online, our Founder & CEO Alex Zhavoronkov speaks on the deep responsibility drug developers carry in treating disease, and more importantly, shaping the human experience of aging and dying.
Alex shares his thoughts on:
⏩How AI and robotics are redefining speed and scale in drug discovery R&D
🫁Why seeing our TNIK inhibitor show positive Phase 2a signals in Idiopathic Pulmonary Fibrosis (IPF) was a historic moment
🔬Exciting updates from Insilico: building our fully automated lab LifeStar2 in Shanghai
📖 Read Part 1 of the full interview here: www.drugdiscoveryonline.com/doc/ai-meets-aging-inside-the…
Part 2: www.drugdiscoveryonline.com/doc/ai-meets-aging-inside-the… -
Insilico Medicine
@InSilicoMeds
🚀 We’re just 10 days away from the Fall 2025 pharma.ai Updates Webinar
Join us for an exclusive look at what our lovely pharma.ai scientists have been working on this quarter for all of you 😊
🗓️ Date: October 2, 2025
⏰ Time: 7AM PST / 10AM EST / 4PM CET / 6PM GST / 10PM CST
For those who don't know:
🎯 PandaOmics – AI-powered multi-modal Target, Biomarker and Indication Identification platform
🧪 Chemistry42 – Design and Optimize small molecules using a multi-agent generative AI platform that leverages reinforcement learning for multi-parametric optimization
🧬 Generative Biologics – Design and optimize Peptides, nanobodies & antibodies using generative AI paired with built-in and custom predictive models
⚙️ LifeStar2 – Insilico's 2nd generation of our automation lab (opened Sep 2025)
👉 Register Now: insilico.zoom.us/webinar/register/5517580990886/WN_IzqS_Z… -
Insilico Medicine
@InSilicoMeds
Thank you to everyone that joined us at this year’s Aging Research & Drug Discovery Meeting.
Check out this video from #ardd2025 featuring Eli Lilly’s presentation on GLP-1, a promising candidate for the world’s first longevity drug.
We look forward to continuing the conversation on longevity and innovation in drug discovery. See you at #ardd2026!This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
We are proud to share our Founder and CEO, Alex Zhavoronkov, PhD (@biogerontology), has been named in Observer’s 2025 AI Power Index, recognizing the “Top 100 Leaders Shaping the Future of Artificial Intelligence.”
The feature highlights Insilico’s pharma.ai, our end-to-end drug discovery platform accelerating development timelines from years to months, along with Insilico’s recent breakthroughs across idiopathic pulmonary fibrosis (IPF), Parkinson’s disease and our push towards Pharmaceutical Superintelligence. Under Alex’s leadership, Insilico is redefining what’s possible in drug discovery and development.
👉Read the full #observerpowerindex feature here: observer.com/list/2025-ai-power-index/ -
Insilico Medicine
@InSilicoMeds
1 week away! Join us at the 23rd Annual Discovery on Target (DOT) Conference, Sep 22-25, in Boston. Petrina Kamya, PhD, our Global Head of AI Platforms, will be speaking and teaching a short course on practical ways to deploy AI in discovery and development.
💊DOT is the premier event focused on emerging drug targets, novel modalities, AI/ML, and the latest innovations in therapeutics.
👋 Attending DOT? Connect with Petrina or email our team: pharma.ai@insilicomedicine.com.
📅 Event details & agenda: www.discoveryontarget.com -
Insilico Medicine
@InSilicoMeds
We’re just 2 weeks away from the Fall edition of our pharma.ai Updates Webinar.
Join us to learn more about the latest advancements to all our platforms.
As a reminder!
🎯Discover novel targets with PandaOmics
🧪Generate and optimize molecules with Chemistry42
📊Discover and optimize novel biomolecules with Generative Biologics
⭐LifeStar2: AI-powered automation lab accelerating drug discovery, this is the 2nd generation of the Automation lab that opened in September 2025
🗓️Date: October 2, 2025
⏱️Time: 7AM PST / 10AM EST / 4PM CET / 6PM GST / 10PM CST
📍Location: Online (Zoom)
👉Register Now: insilico.zoom.us/webinar/register/5517580990886/WN_IzqS_Z… -
Insilico Medicine
@InSilicoMeds
🌟 AI Talks Spotlight: Petrina Kamya, Ph.D. Leads the Conversation
We're excited to share that Dr. Petrina Kamya, VP and Global Head of AI Platforms at Insilico Medicine, will be speaking at the prestigious AI Talks series hosted by the Sino-American Pharmaceutical Professionals Association (SAPA) Data Science Community!
Looking forward to her insights on #aiadoption in #lifesciences at this influential gathering.
Feel free to connect with her if you're attending or curious about the future of AI-driven discovery! Learn more about the event here: www.sapaweb.org/data-science-community
#aitalks #sapacommunity -
Insilico Medicine
@InSilicoMeds
✍ DORA helps #researchers produce coherent, structured, and well-cited papers making the #academicwriting and research process smoother and faster.
Improve your experience in scientific writing and get started today: pharma.ai/dora -
Insilico Medicine
@InSilicoMeds
⚡Announcing the latest from ajmc.com: AI Models Demonstrate Links Between IPF, Aging Processes
A pair of new artificial intelligence (AI)-driven models are helping to clarify the relationship between aging and idiopathic pulmonary fibrosis (IPF). The new research suggests that IPF is not merely the result of the acceleration of normal aging but rather represents dysregulation of the aging process. The study was published in the journal Aging.
Key Takeaways
-AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns.
-Key pathways in IPF and aging include TGF-β signaling, oxidative stress, inflammation, and extracellular matrix remodeling.
-Future research aims to validate models in IPF cohorts and explore applications in other fibrotic and age-related diseases.
-The models may aid in drug discovery, biomarker identification, and personalized medicine strategies, though further validation is needed.
See the latest news article here 👉www.ajmc.com/view/ai-models-demonstrate-links-between-ipf… -
Insilico Medicine
@InSilicoMeds
Just 1 week away! ⏰
We’re honored to share that Petrina Kamya, Ph.D., VP and Global Head of AI Platforms at Insilico Medicine, will be speaking at the 16th Annual Drug Discovery to Development Innovation Forum (DDIF) 2025, an invite-only event bringing together up to 200 C-suite executives, visionary scientists, and strategic decision-makers driving the future of pharmaceutical innovation.
🌍Heading to the event? Connect with Petrina ahead of the event or email our team: Pharma.ai@insilicomedicine.com. For more information, please visit: www.ddisummit.co.uk -
Insilico Medicine
@InSilicoMeds
ISM8969, developed with Insilico’s proprietary AI platform pharma.ai, is a brain-penetrant molecule designed to block NLRP3. By preventing activation of this inflammatory response in the brain, ISM8969 is expected to help reduce further neurodegeneration.
Continue Reading: parkinsonsnewstoday.com/news/ai-designed-parkinsons-thera… -
Insilico Medicine
@InSilicoMeds
AI-designed Parkinson’s therapy prepares to move to clinical trials
“We are thrilled to reach the milestone of IND-enabling [study] completion, as it marks the beginning of clinical validation for ISM8969,” Alex Zhavoronkov, PhD, founder, CEO, and chief business officer at Insilico, said in a company press release. “The anti-inflammation strategy against Parkinson’s disease has never before passed the whole process of clinical validation, so the progress of ISM8969 is indeed encouraging.”
Read the latest release 👇parkinsonsnewstoday.com/news/ai-designed-parkinsons-thera… -
Insilico Medicine
@InSilicoMeds
🎤 Petrina Kamya, Ph.D., Global Head of AI Platforms at Insilico Medicine, will be speaking at the LSX World Congress USA in just a few weeks in Boston, joining an incredible panel.
📍 Panel: "TechBio Meets Pharma: AI-Powered Drug Discovery & Development"
🗓️ September 16, 2025 | ⏰ 1:40–2:30 PM ET
📌 BCEC, Boston, USA
Petrina will join fellow industry leaders from Johnson & Johnson, BigHat Biosciences, and Novartis to explore how AI is shaping the future of drug discovery.
👉 Planning to attend? Let us know or reach out to our team for more information: Pharma.AI@insilicomedicine.com.
See the detailed agenda here: informaconnect.com/lsx-congress-usa/agenda/2/
#lsxusa #pharmatech #aiindrugdiscovery #techbio #insilicomedicine -
Insilico Medicine reposted
Insilico LAIR
@precious_gpt
🖨️🖼️Just picked up a fresh roll-up poster for @ARDD_Meeting from the print shop! Time to start packing! 🧑🔬🧳✈️
Stop by @InSilicoMeds booth next week to talk about our exciting new project — Longevity Vault 🧬💊⌛ -
Insilico Medicine reposted
GBX Circle
@GbxCircle
👋 GBX welcomes Alessandra Pepe (@Merck) to #ddif2025, alongside @Novartis, @Recursion @InsilicoMeds @AIONLabs @RevvitySignals & @IambicTx. Committed to innovation: #forthepatientswemustdobetter #ai #drugdiscovery #gbxcircle
Because the world can’t wait and neither can patients. -
Insilico Medicine
@InSilicoMeds
Incredible coverage at #ardd2025!
Linus Petersson
@LinusPeters
Day 3 at @ARDD_Meeting and group photo time! 😃
Coordinate hundreds of researchers, entrepreneurs and investors might be as hard as solving aging ;)
Superb organizing by @biogerontology, Morten Scheibye-Knudsen, @MaxUnfried, Evelyn’s Bischof etc! -
Insilico Medicine
@InSilicoMeds
Thank you to the @GalienFdn for recognizing Insilico Medicine as a "Best Startup" nominee for 2025. Congratulations to the rest of the participating organizations, and we look forward to the winners being announced in October!
-
Insilico Medicine reposted
Peter Ottsjö
@peterottsjo
A feeling I carry around this week is envy. I should be at the Aging Research & Drug Discovery Meeting (ARDD) conference in Copenhagen but for reasons I’m not.
On the other hand LEVITY recently had the privilege to spend 2+ hours with @biogerontology (Alex Zhavoronkov) - CEO of @InSilicoMeds and founder of ARDD. And what better time to share that conversation with all of you right now (links below), whether or not you’re attending the conference.
As you may have heard, AI-designed medicines have crossed a historic line. In this episode, Alex walks us through how Insilico’s rentosertib became the first AI-generated small molecule with peer-reviewed clinical efficacy, while arguing against AI hype and reminding us that biology still moves at “the speed of traffic.”
That duality runs through the whole conversation. On one side: a pragmatic operator obsessed with credible science, biomarkers, and clinical benchmarks; on the other: an AI visionary investing in cryonics, sketching “pharmaceutical superintelligence,” and thinking in decades, not quarters.
We start in Basel, home to Roche and Novartis, where ARDD was born, then trace how the conference morphed into a ”high-signal filter for longevity” - packed with startups (who also fund it), hard data, and mainstream pharma.
Alex looks back at his 2014 Nvidia talk (”Can Nvidia solve aging?”) and explains why Insilico trains its AI to learn age first - so it actually grasps biology. Years of problem-solving with pharma turned into their Pharma AI toolkit.
Insilico now runs 40+ programs and in an early Phase 2 study for idiopathic pulmonary fibrosis (IPF), their drug rentosertib showed a dose-dependent boost in lung capacity. Compared with the old path - often $150–200M and ~5 years just to pick a lead molecule - Insilico says it can often reach that point for under $3M or even less.
Still, Alex is cautious: no matter how smart the AI gets, real-world testing and regulation won’t speed up overnight.
We also get the wider frame: ARDD 2025 themes (including a planned molecular nutrition workshop), cultural attitudes to aging, why the Middle East is moving fast on longevity, and why cryonics is the necessary plan B - from organ preservation to his TimeShift collaboration.
Finally, Alex explains why he writes the newsletter Forever AI (“This is food for AI”) and outlines a near-term path to pharmaceutical superintelligence: generalist agents for biology and chemistry that eventually merge.
If you want both ambition and receipts on AI drug discovery - and a realistic path from models to medicines - this one’s for you. -
Insilico Medicine
@InSilicoMeds
🌍 The countdown is on for the 12th Aging Research & Drug Discovery Meeting (#ardd 2025), taking place August 25–27 in Copenhagen!
Insilico Medicine a proud sponsor contributing to this premier event advancing the science of healthy #longevity. Don’t miss our featured talks:
🎤 August 27, 19:20–19:40
From Disease to Discovery: Leveraging IPF Aging Biology for Novel Therapeutic Targets
Fedor Galkin, PhD
🎤 August 29, 19:00–19:20
Discovery and Development of Longevity Therapeutics: When Should We See the First Rationally-designed Geroprotectors with the Clinical Longevity Protocol?
Alex Zhavoronkov, PhD
🔗 Learn more & register for the virtual pass today: [agingpharma.org]
#ardd2025 #agingresearch #drugdiscovery #longevity #ai #insilicomedicine -
Insilico Medicine
@InSilicoMeds
📣 We’re thrilled to announce that ISM8969, our orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has completed IND-enabling studies with positive results, moving us closer to a potential new treatment for Parkinson’s disease (PD).
Insilico Medicine will submit an IND application in Q4 this year, aiming to advance ISM8969 into clinical trials. Backed by our proprietary pharma.ai platform and powered by generative AI,ISM8969 has shown dose-dependent improvements in preclinical PD models and demonstrated a strong safety and druggability profile.
Why does this matter?
-PD is the world’s 2nd most common neurodegenerative disease, with over 25 million projected cases by 2050.
-Current therapies largely address symptoms without altering disease progression.
-Targeting NLRP3 inflammation could represent a paradigm shift for PD–and CNS diseases in general.
“These positive data further strengthen our belief in the potential of ISM8969 and the power of AI-driven drug discovery in CNS diseases,” said Dr. Feng Ren, Co-CEO and CSO.“ We hope that AI can be the game-changer for novel, effective solutions,” added Dr. Alex Zhavoronkov, founder and CEO.
Since introducing AI-generated molecule design in 2016, Insilico has nominated 22 preclinical candidates, received 10 IND clearances, and advanced two programs through successful human clinical trials. We’re proud to be driving innovation in age-related and neurodegenerative disease therapeutics, accelerating timelines and delivering promising candidates at the intersection of AI, automation, and drug development.
Stay tuned for more updates on ISM8969 and our clinical advancements!
#ai #drugdiscovery #neurodegeneration#Biotech #pharmaai #innovation -
Insilico Medicine
@InSilicoMeds
Our team will be at #acsfall2025 in Washington, DC this week!
Visit Booth #1921 and explore how Chemistry42 accelerates AI-driven molecular design. Don’t miss our scientific sessions:
Poster: AI-Augmented Design of Selective CDK20 Inhibitors Using Chemistry42 – Pouyan Haghshenas
Oral: AI-Driven Molecular Glue Design in NRF2^Mut Inhibitor Development – Haining WangThis media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
TimePie (focus on anti-aging science)
@TimePieChina
Researchers @InSilicoMeds employ AI-driven tools to uncover the link between idiopathic pulmonary fibrosis (#ipf) and accelerated #aging.
The aging clock shows great performance in cross-validation that predicts biological age with high accuracy (R²=0.84, MAE=2.68 years). -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds published in Aging on aging-related mechanisms in idiopathic pulmonary fibrosis, uncovering links between aging biology and IPF pathogenesis and the promise of AI-guided therapeutic development for age-related diseases.
-
Insilico Medicine
@InSilicoMeds
The Master Switch Every Pipeline Needs, from the latest "Beyond GLP-1: Is NLRP3 the Next Trillion Dollar Target?"
Read it here 👉www.forever.ai/p/next-generation-nlrp3-inhibitors -
Insilico Medicine
@InSilicoMeds
🚀We're thrilled to announce our collaboration with Syngenta, shifting the frontier of agricultural R&D using the same cutting-edge AI technologies powering #drugdiscovery.
Check out this new video below!
Syngenta Group
@SyngentaGroup
Together with @InSilicoMeds, @Syngenta is exploring new chemistry through generative AI, bringing smarter solutions to farmers worldwide.
See how we’re shaping the future of farming: shootsbysyngenta.com/insilico-medicine-and-syngenta
#ai #agtech #sustainablefarming -
Insilico Medicine reposted
The Galien Foundation
@GalienFdn
The 2025 #prixgalien USA nominees for “Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup”have been announced. Read more: www.prnewswire.com/news-releases/the-galien-foundation-an…
-
Insilico Medicine
@InSilicoMeds
🚀 Our mission is to extend healthy productive longevity for everyone by transforming #drugdiscovery and development with generative #artificialintelligence, significantly reducing the time and cost to bring life-saving medications to patients.
See our list of high quality therapeutic programs, and our pharma.ai software below 👇 or visit insilico.com. -
Insilico Medicine
@InSilicoMeds
In our Phase 2a clinical trial for #rentosertib, a generative AI–designed #tnik inhibitor for idiopathic pulmonary fibrosis (#ipf), we not only advanced a novel first-in-class molecule but also generated a detailed pharmacokinetic profile that underscores its therapeutic potential.
See the #pharmacokinetic properties of rentosertib from Figure 3 below 👇
🔗 Explore the full Nature Medicine article here: www.nature.com/articles/s41591-025-03743-2/figures/3 -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Chronic GLP-1 inhibition will likely lead to side effects that will become noticeable later in life. This presents an opportunity for companies like Insilico to identify potential remedies that can be administered with GLP-1 and may also have anti-aging properties.
-
Insilico Medicine reposted
Kyle Tretina, Ph.D.
@AllThingsApx
The genAI template for virtual screening: generate → screen → enumerate → validate at scale
e.g. @InSilicoMeds's LEGION searches NLRP3 target space: 34k pharmacophore scaffolds ➜ 110M candidates in days, not years.
🚀~60% of a 375k sample survive full 3D SBDD vs 8-26% for combinatorics -
Insilico Medicine reposted
Longevity Investors
@Longevity_Inv
🧬 Meet the Minds Merging AI & Longevity
From investment to innovation, AI is rapidly reshaping how we understand and extend human healthspan. At #lic2025, we’re diving deep into this powerful intersection with three unmissable sessions:
💬 Panel Discussion: Investing in AI and Digital Health Innovations.
@smarcelo, @amol & @AlexAliper share where smart capital is going in the next-gen health tech space.
🎤 Keynote Presentation: Generative AI, Aging Clocks & Lab Automation by Alex Aliper (@InSilicoMeds) on how AI is transforming aging research and drug discovery.
🤝 Roundtable Discussion: AI as the Ultimate Longevity Accelerator
An open forum on the most exciting breakthroughs — and what’s coming next.
Still not enough? Then Start-up Showcase will bring you fresh companies diving into the latest AI solutions 🤩
#longevityinvestors -
Insilico Medicine
@InSilicoMeds
🔬 Behind the Science: Understanding the TNIK Inhibitor Trial Design
The recent (June 2025) Springer Nature publication on #rentosertib, an AI-discovered #tnik inhibitor for idiopathic pulmonary fibrosis (#ipf), includes a compelling figure that outlines the trial architecture.
Eligible patients were randomized to receive 30 mg rentosertib QD, 30 mg rentosertib BID, 60 mg rentosertib QD, or placebo administered over 12 weeks with periodic assessment and plasma sampling. See the trial eligibility criteria below in greater detail 👇
Continue reading: www.nature.com/articles/s41591-025-03743-2
#nature #fibrosis #generativeai -
Insilico Medicine
@InSilicoMeds
One of the best collaborations
The partnership began in 2020, after Syngenta approached Insilico Medicine at the highest levels. shootsbysyngenta.com/insilico-medicine-and-syngenta
Both teams found the learning curve steep.
Bogdan Zagribelnyy, Senior Researcher in Medicinal Chemistry and CADD, Insilico Medicine, describes working with Syngenta as “one of the best collaborations we have undertaken.”
The project also fulfilled one of Insilico Medicine’s strategic goals, as well as the Syngenta team being able to gain insights into optimizing its scientific data for use with AI. -
Insilico Medicine
@InSilicoMeds
Thank you to HKIC for this incredible event coverage 📹 www.linkedin.com/posts/hong-kong-investment-corporation-l…
-
Insilico Medicine
@InSilicoMeds
🔬 Thank You Chemistry World for Spotlighting the AI Revolution in #drugdiscovery We’re honored to be featured in #chemistryworld’s recent article exploring whether AI-designed drugs are about to change pharma forever. The article highlights Insilico Medicine as a leader in generative AI drug design, particularly noting our clinical‑stage candidate Rentosertib (ISM001‑055) headed toward Phase III trials.
Read the latest News article here 👉www.chemistryworld.com/news/as-ai-designed-drug-looks-to-… -
Insilico Medicine
@InSilicoMeds
Embracing the Cloud, the latest from @bioitworld www.bio-itworld.com/news/2025/07/15/pharma-companies-find…
All but one of the top 20 #pharma companies are building their drug discovery capabilities using the cloud computing platform of Amazon Web Services (@awscloud ), and Insilico Medicine also sells their software through the AWS Marketplace. “Scaling data and scaling compute are both obviously crucial for AI, and the great thing from what we’ve observed is that the conversation has moved on from people being very afraid of the security implications of the cloud,” says Bradley. -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Turned 69 in h-years today and wanted to thank the team for their commitment to academic excellence and transparency.
And please do check out some of our new papers. Of course, some of the best papers are still in the oven since both AI and drug discovery are rapidly advancing. I very much hope to publish our first PSI model within 12 months, it will change the way we discover novel medicines. All papers we publish in the meantime are just stepping stones on the way to PSI.
scholar.google.com/citations?hl=en&user=8Icccp0AAAAJ&view… -
Insilico Medicine
@InSilicoMeds
China’s AI drug discovery companies land huge deals with Big Pharma
restofworld.org/2025/ai-drug-discovery-startups-big-pharm… -
Insilico Medicine
@InSilicoMeds
🚀 New platform capabilities: New Generative Model for Antibodies
This model utilizes a diffusion-based approach to generate antibody scaffolds before producing their sequences.
Take a look at this latest video and see new frameworks, desired properties, ad more! 👇 -
Insilico Medicine
@InSilicoMeds
Hong Kong Investment Corporation Limited Leads Delegation to Southeast Asia to Explore Regional Opportunities for Ecosystem Partners (August 2025)
www.hkic.org.hk/latest-updates/seadelegation_pr -
Insilico Medicine
@InSilicoMeds
Artificial intelligence is changing the game in drug discovery efforts. Here's how Boston-area biotechs are using it.
www.bizjournals.com/boston/news/2025/07/31/biotech-is-all… -
Insilico Medicine
@InSilicoMeds
📣 Happening Today! Alex Zhavoronkov will discuss how his team uses #generativeai and automation to streamline target discovery and advance #aging research.
Topics to be covered:
-Identifying novel therapeutic targets and biomarkers with generative AI
-Integrating multiomics data in aging and disease research
-Using fully automated laboratories for high throughput drug discovery
Register for this webinar here! It will be available on-demand as well. www.drugdiscoverynews.com/ai-and-automation-to-decode-mul… -
Insilico Medicine
@InSilicoMeds
🚀 We are thrilled to announce our latest collaboration with Syngenta Group, a global leader in agricultural innovation, to explore the application of generative AI in crop science and sustainable agriculture.
Through this collaboration, Insilico Medicine will bring the power of our pharma.ai platform, including Chemistry42 for generative molecule design, into agricultural R&D, helping accelerate the discovery of novel crop protection solutions.
Read more about the collaboration here 👉 www.linkedin.com/feed/update/urn:li:activity:735638650841…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Insilico launched Life Star in 2022, a fully automated laboratory that performs target discovery, compound screening, precision medicine development and translational research. The lab uses Insilico’s PandaOmics to predict targets for specific diseases, enabling the automated lab to conduct early-stage drug discovery experiments.
www.rdworldonline.com/self-driving-cars-are-hitting-the-s… -
Insilico Medicine
@InSilicoMeds
Incredible collaboration! Thank you to the @SyngentaGroup 🤝
Syngenta Group
@SyngentaGroup
Together with @InSilicoMeds, @Syngenta is exploring new chemistry through generative AI, bringing smarter solutions to farmers worldwide.
See how we’re shaping the future of farming: shootsbysyngenta.com/insilico-medicine-and-syngenta
#ai #agtech #sustainablefarming -
Insilico Medicine
@InSilicoMeds
AI has always had the potential to speed up drug discovery and development.
Now Insilico Medicine has shown that AI-designed drugs can actually provide clinical benefit.
Read more: www.drugdiscoverynews.com/machine-learning-drives-progres… -
Insilico Medicine
@InSilicoMeds
The Hippo pathway is biology’s critical brake on tumor growth. When deactivated, it unleashes TEAD transcription factors that allows cancer cells to multiply uncontrollably, evade death, and metastasize—driving aggressive cancers like mesothelioma with no targeted therapies.
Our team is proud to share that Insilico Medicine’s ISM6331, a pan-TEAD inhibitor co-developed with our AI engine Chemistry42, attacks this hijacked system at its core. By blocking all four TEAD isoforms via their palmitoylation pocket, it collapses the oncogenic complex with nanomolar potency.
Even more thrilling: Our global Phase I trial (NCT06566079) is now dosing patients across U.S. and Chinese sites. This milestone brings hope to those battling Hippo-dysregulated cancers.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
www.rdworldonline.com/self-driving-cars-are-hitting-the-s… Self-driving cars are hitting the streets. Is your lab up next for automation?
Insilico Medicine
@InSilicoMeds
A group of researchers, including scientists from Insilico Medicine and the AC, used AlphaFold-based software and Insilico’s AI-powered drug discovery platform pharma.ai, along with PandaOmics, a biocomputational engine, and Chemistry42, a generative chemistry platform, to identify a new treatment pathway for hepatocellular carcinoma (HCC). The project, with oversight from the University of Toronto’s Alán Aspuru-Guzik, Nobel laureate Michael Levitt and Insilico Medicine founder Alex Zhavoronkov, was completed in just 30 days, showing how even semi-autonomous labs can significantly shorten the timelines of drug discovery projects.
-
Insilico Medicine
@InSilicoMeds
Join three of the leading companies that integrates health and technology as they sit down with Bloomberg @business's Parmy Olson to discuss how AI is changing human analytics, personal health and how do it all whilst protecting privacy, avoiding bias, and building trust.
Dr Alex Zhavoronkov PhD - Founder & CEO • Insilico Medicine
Dr Greg Bailey - Co-Founder & Executive Chair • Juvenescence Limited
Tom Hale - CEO • ŌURA
Parmy Olson - Technology Columnist • Bloomberg Media
www.youtube.com/watch?v=p2Hv2EfXELI&t=3s
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Cold tumors–cancers with little to no immune cell infiltration–represent one of oncology’s toughest challenges. These tumors evade the immune system, leaving patients with limited treatment hope.
What if we could turn cold tumors “hot”? Published in Springer Nature Communications, our breakthrough research at Insilico Medicine reveals a powerful new strategy: targeting ENPP1, a master regulator of immune evasion in cold tumors.
Using our generative AI target discovery engine, we prioritized gastric carcinoma, colorectal carcinoma, and melanoma as indications for ENPP1 targeting beyond the well-established TNBC association.
Our research demonstrates that inhibiting ENPP1:
✅Reawakens the tumor microenvironment, enabling immune cell infiltration.
✅Synergizes with checkpoint inhibitors to boost anti-tumor response.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Event Recap 🚀
Alex Zhavoronkov, CEO of Insilico Medicine, took the stage at the United Nations’ flagship AI event to present:
"Beyond human: AI, superhumans, and the quest for limitless performance & longevity"
🌍 Thank you to the AI for Good Global Summit and ITU for spotlighting transformative applications of AI across industries, including health and #longevity.
AI for Good is organized by ITU in partnership with over 50 UN partners and co-convened with the Government of Switzerland.
#aiforgoodsummit #switzerlandbiotech -
Insilico Medicine reposted
Aloha Protocol
@AlohaProtocol
🚀 Generative AI is reshaping the landscape of drug discovery!
Explore how @InSilicoMeds, led by Alex Zhavoronkov, is using AI to design molecules, predict clinical trial outcomes, and tackle aging.🧵👇
@artemZholus @Max__Kuznetsov @biogerontology
#ai #drugdiscovery #generativeai -
Insilico Medicine reposted
Aloha Protocol
@AlohaProtocol
💡 From GANs to Transformers
@InSilicoMeds began using GANs in 2015 to design molecules with specific properties.
By 2017, they integrated transformer models—unlocking new levels of precision in drug discovery. #ai #innovation -
Insilico Medicine reposted
Aloha Protocol
@AlohaProtocol
🕰️ Targeting Aging
To Alex, aging is the biggest challenge—and opportunity—in medicine.
By making it their moonshot, @InSilicoMeds is aiming beyond just treatment: toward prevention and longevity.
#longevity #future
💥 Generative AI isn’t hype. It’s already redefining how we discover and develop medicine.
🌟 #ai #drugdiscovery #generativeai -
Insilico Medicine
@InSilicoMeds
Pharma Companies Finding Their Way with AI www.bio-itworld.com/news/2025/07/15/pharma-companies-find…
-
Insilico Medicine
@InSilicoMeds
🔥#nach01 leverages a large language model to process both structural and spatial data. Combining strengths from both predecessors, Nach01 is designed to solve hundreds of diverse tasks, providing a broad and comprehensive range of chemical knowledge.
Check out this new video and explore the #aws Marketplace today: www.youtube.com/watch?v=p6Ux262eK8I
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🎓 Missed the #pharmaai Summer 2025 Update? Catch the Chemistry42 refresher below.
Our latest webinar explored how Chemistry42, Insilico Medicine’s generative chemistry platform, continues to accelerate #smallmolecule drug discovery.
This summer, the Chemistry42 suite is more modular, more intuitive, and more powerful than ever.
📺 Watch the platform walkthrough 👉 [insilico.zoom.us/webinar/register/9217443018637/WN_KQxBpQ…]
#insilicomedicine #chemistry42 #pharmaai
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀 Three Ways to Work Smarter with pharma.ai
Whether you're looking to scale internal R&D or build a transformative partnership, pharma.ai offers flexible business models designed to meet your goals.
Choose stand alone technology access or combine our software with pharma.ai services for a data-driven AI-partnership.
Get started today: pharma.ai -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:735058238648…
Who uses hashtag#DORA? 👇 Listen in below.
Biotech teams use it to analyze drug targets, and create competitive landscape reports. Medical writers rely on it to draft summaries for clinical development programs. Researchers turn ideas into well-structured manuscript drafts.
Here the latest updates from the hashtag#Science42 team below, and if you missed it, you can download the pharma.ai Summer update here: insilico.zoom.us/webinar/register/6817441093015/WN_eV0sLt… -
Insilico Medicine
@InSilicoMeds
Pharma AI Summer Update begins in just 10 minutes. Join us live! insilico.zoom.us/webinar/register/8517443018693/WN_eV0sLt…
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
NEW: Generative AI for drug discovery and protein design: the next frontier in AI-driven molecular science
www.sciencedirect.com/science/article/pii/S2590098625000107 -
Insilico Medicine reposted
AI for Good 🇺🇳 #AIforGood
@AIforGood
The #aiforgood Global Summit continued this afternoon on Center Stage with bold sessions exploring how #ai is reshaping human potential, #creativity, learning, and the very meaning of work.
This afternoon’s sessions featured:
👉 Beyond Human: AI, Superhumans, and the Quest for Limitless Performance & Longevity with Alex Zhavoronkov (@InSilicoMeds), David Sinclair (@Harvard), Tilly Lockey (@openbionics), and moderator LJ Rich: examining how #ai, biotechnology, and human augmentation are unlocking new frontiers in #performance, #health, and life extension.
👉 Understanding Emergent Intelligence in Work: Agentic, Robotic, and Creative with Harry Yeff (R100 Studios): a deep dive into how agentic, #robotic, and creative #intelligence intersect, shaping workflows, collaboration, and how human ingenuity thrives alongside #automation.
👉 Why Kids Still Need to Learn to Code in the Age of AI with Philip Colligan (@RaspberryPi_org): making the case for why #coding and #computerscience are more vital than ever, equipping the #nextgen with the tools to understand and shape #ai.
👉 AI in Education: Leveraging Technology for Human Potential with Kevin Mills (@OpenAI): exploring how #ai can transform classrooms and unlock human potential through personalized, equitable #education.
Center Stage can be viewed online.
Register for free virtual participation and make sure you don’t miss a moment: aiforgood.itu.int/summit25/ -
Insilico Medicine
@InSilicoMeds
🔥 The Summer Update from pharma.ai starts tomorrow at 10 am EST! If you can't make it live, the webinar will be available on-demand.
Register here to be the first to hear what our team has been up to: insilico.zoom.us/webinar/register/8517443018693/WN_eV0sLt…This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
💡 Have you seen the Design Kit from Insilico Medicine? Our Design Kit is a comprehensive, AI-inspired visual toolkit built specifically for the scientific community.
At the forefront of artificial intelligence in the scientific realm, we are thrilled to introduce our comprehensive presentation template library. Developed with precision and creativity, this design kit of handy icons, design components, workflows, and templates are tailored to meet the high standards for communication of the scientific community.
🔗 Explore and download: figshare.com/articles/dataset/Collections_of_Icons_and_Wo… -
Insilico Medicine
@InSilicoMeds
🧬 1 Day to Go! Meet our Application Scientist team in #montreal.
We're excited to join the AACR Journals Special Conference on Advances in Cancer Research.
📍 Stop by the Insilico Medicine tabletop to discover how our end-to-end pharma.ai platform is accelerating cancer drug discovery, from target identification to clinical trials.
📅 July 10–12, 2025
📍 Doubletree Hilton, Montreal, Quebec
📫 Connect with us: pharma.ai@insilicomedicine.com
#aacr #cancerresearch #aiforcancer #insilicomedicine #pharmaai -
Insilico Medicine
@InSilicoMeds
Insilico ranked Top50 in USA in Nature Index’s “2025 Research Leaders: Global corporate institutions for all-subject output”
The 2025 Nature Index Research Leaders rankings have been officially released. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico Medicine secured a position among the Top 100 global corporate institutions for biological sciences and natural sciences publications, and ranked 43rd among global corporate institutions in the USA across all-subject output.
www.eurekalert.org/news-releases/1089186 -
Insilico Medicine
@InSilicoMeds
First patient receives novel MAT2A inhibitor for solid tumours
www.linkedin.com/posts/drugdiscoveryworld_cancerresearch-… -
Insilico Medicine
@InSilicoMeds
Q&A: AI-established drug ‘breakthrough in the treatment of IPF’
⚡ Key takeaways:
-Rentosertib was shown to be safe in a 12-week phase 2a trial in China.
-Two doses improved FVC vs. placebo.
-Future studies are expected to be larger, longer and include patients from other parts of the world.
Read the full Q&A here 👉 www.healio.com/news/pulmonology/20250707/qa-aiestablished… -
Insilico Medicine
@InSilicoMeds
NEWS Release: www.eurekalert.org/news-releases/1090177
pharma.ai summer 2025 updates: Join Insilico Medicine on July 10 for the future of AI-empowered medical research boost
Insilico Medicine announces its upcoming Summer pharma.ai Updates webinar, scheduled for 10 a.m. ET on July 10. During the webinar, Founder and CEO Alex Zhavoronkov, PhD, will provide the latest company developments and introduce new features and applications of Insilico’s AI software suite, with a particular focus on the latest advancements in Biology42 and Chemistry42 through product demos, in-depth explanations, and real-world use cases.
Register here: insilico.zoom.us/webinar/register/1417441093095/WN_eV0sLt…
#pharmaaiday -
Insilico Medicine reposted
The Longevity Science Foundation
@longescience
“Aging is a global economic problem.” — @biogerontology, CEO of @InSilicoMeds
With 1 in 5 Americans over 65 by 2030 and rising healthcare costs, population #aging threatens economic stability. Extending #healthspan is urgent for a sustainable future: www.linkedin.com/posts/longevity-science-foundation_healt… -
Insilico Medicine reposted
Healio Pulmonology
@HealioPulm
🗨️"This is a novel drug discovered and designed using #ai technology, which is pioneering work in the field of drug research and development," Zuojun Xu, MD, of the Peking Union Medical College, told Healio. @InSilicoMeds #ipf
www.healio.com/news/pulmonology/20250707/qa-aiestablished… -
Insilico Medicine
@InSilicoMeds
Q&A: AI-established drug ‘breakthrough in the treatment of IPF’ www.healio.com/news/pulmonology/20250707/qa-aiestablished…
-
Insilico Medicine
@InSilicoMeds
[Exclusive] AI New Drug Development Pioneer Insilico CEO: "We are in the process of proving with patient clinical data"
www.hitnews.co.kr/news/articleView.html?idxno=66085 -
Insilico Medicine
@InSilicoMeds
Insilico ranked Top50 in USA in Nature Index’s “2025 Research Leaders: Global corporate institutions for all-subject output”
www.eurekalert.org/news-releases/1089186 -
Insilico Medicine reposted
Healio Pulmonology
@HealioPulm
An #ai-generated small molecule targeting Traf2- and Nck-interacting kinase was safe and improved FVC in patients with #ipf.
💬Healio spoke with Zuojun Xu, MD, of the Peking Union Medical College, and Alex Zhavoronkov, PhD, @InSilicoMeds, to learn more.
www.healio.com/news/pulmonology/20250707/qa-aiestablished… -
Insilico Medicine
@InSilicoMeds
🧠 What happens when AI meets the future of human potential? Join the #aiforgood Global Summit this week.
We’re excited to announce Alex Zhavoronkov's upcoming session:
"Beyond human: AI, superhumans, and the quest for limitless performance & longevity"
📅 July 9, 2025
🔗 Learn more and register: aiforgood.itu.int/event/beyond-human-ai-superhumans-and-t… -
Insilico Medicine
@InSilicoMeds
Beyond human: AI, superhumans, and the quest for limitless performance longevity aiforgood.itu.int/event/beyond-human-ai-superhumans-and-t…
-
Insilico Medicine
@InSilicoMeds
www.alphagalileo.org/en-gb/Item-Display/ItemId/260073?ret…
The strategic collaboration between Insilico Medicine and UAEU aims to bridge academia and industry through multifaceted collaboration, including joint research projects, academic exchange, and hands-on training for students and faculty. The MoU outlines partnership in several key areas including co-developing and publishing innovative research, delivering expert lectures, organizing educational events such as hackathons and workshops, and providing internships for eligible UAEU students. Additionally, the collaboration opens career opportunities for UAEU graduates at Insilico, fostering local talent and supporting the expansion of the UAE’s biotechnology sector. -
Insilico Medicine reposted
Marinka Zitnik
@marinkazitnik
📢 AI-enabled drug discovery reaches clinical milestone
rdcu.be/eugUu
Few AI-designed drug candidates have gone beyond in silico benchmarks. Now, a study in @NatureMedicine @biogerontology reports a successful phase 2a trial of rentosertib, an AI-discovered drug and target combination for idiopathic pulmonary fibrosis
What distinguishes this study (in addition to clinical data) is the upstream innovation pipeline
This trial marks a turning point: it affirms a potential for AI to do more than generate molecules faster and cheaper; guide discovery, de-risk development and potentially reshape how we develop medicines
A pertinent question is: why did this AI-generated drug candidate advance to clinical testing when so many others have not?
🎯 Cross-disease target discovery and 'time-machine' setup: AI models trained on past data predicted therapeutic targets years ahead of traditional methods, pinpointing TNIK as a promising target
🔬 Robust biological validation: Integrated multi-omic analyses, network biology, and extensive literature mining rapidly validated TNIK’s biological relevance for fibrosis
⚙️ Chemistry design: Generative AI models designed molecules targeting novel binding sites, prioritized drug-likeness and synthetic feasibility, and proactively optimized pharmacokinetics and potency from early stages
@biogerontology @InSilicoMeds
@HarvardDBMI @Harvard @harvardmed @harvard_data @KempnerInst @broadinstitute -
Insilico Medicine
@InSilicoMeds
📍 Heading to #montreal for the AACR Journals Special Conference?
Stop by our tabletop and discover what’s next in AI for Cancer.
Insilico Medicine is proud to join the AACR Special Conference in #cancerresearch. The AACR Special Conference on Artificial Intelligence and Machine Learning Conference will offer a comprehensive look at #ai’s transformative role in oncology, with expert-led discussions and interactive sessions.
🗓 July 10–12, 2025
📍 DoubleTree by Hilton, Montreal, Quebec, Canada
Let’s connect and explore how AI is reshaping cancer research.
📬 Contact us: pharma.ai@insilicomedicine.com
🧬 Learn more: insilico.com
For the event agenda, visit: www.aacr.org/meeting/aacr-special-conference-in-cancer-re… -
Insilico Medicine
@InSilicoMeds
🚀 We’re excited to share how our target discovery platform PandaOmics now integrates seamlessly with #dora, our AI-powered multi-omics precision medicine engine.
While DORA's flexibility allows for the incorporation of users’ results, it can also autonomously guide research by independently gathering information from PandaOmics. PandaOmics AI Agents enable DORA to efficiently extract omics data: gene expression, methylation, and knowledge graph.
Learn More here 👉 insilico.com/blog/science42-dora
#integrations #pharmaai #scientificwriting -
Insilico Medicine
@InSilicoMeds
“These results not only suggest that Rentosertib has a manageable safety and tolerability profile, but also warrants further investigation in larger-scale clinical trials of longer duration, demonstrating the transformative potential of AI in drug discovery and development and paving the way for faster and more innovative therapeutic advancements,” Said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. insilico.com/tpost/tnrecuxsc1-insilico-announces-nature-m…
-
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds announced the release of its Nach01 foundation model on AWS, now available via AWS Marketplace, a major milestone in its collaboration with AWS to provide access to advanced AI tools for drug design.
#qmportfolio -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:734397643967…
🚀 Did you know that Science42: #dora connects to web platforms like STRING, Reactome, PDB, and more, offering deeper insights and smarter data filtering for literature analysis?
DORA now dynamically generates subsections tailored to your research plan objectives and custom data.
Get a deeper look at #dora and how it can help streamline your scientific writing today 👇
pharma.ai/dora -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
@InSilicoMeds, a Qiming Venture Partners' portfolio company, signed a Memorandum of Understanding with United Arab Emirates University to boost scientific collaboration, drive biotech innovation in the UAE, and nurture talent across the Middle East.
#qmportfolio -
Insilico Medicine
@InSilicoMeds
Have you seen the main track program for #ardd2025? The program is now online: agingpharma.org/program2025
Join us in Copenhagen for the world’s largest event on #agingresearch and #drugdiscovery to meet leading scientists, biotech innovators, and industry pioneers driving the future of aging and longevity.
Explore the agenda and register today:
agingpharma.org -
Insilico Medicine
@InSilicoMeds
Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors
www.eurekalert.org/multimedia/1078469 -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
As AI Dawns in Precision Oncology, 2025 Expected To Be a ‘Turning Point’ www.biospace.com/drug-development/as-ai-dawns-in-precisio…
-
Insilico Medicine
@InSilicoMeds
🚀 Big news from our Founder and CEO Alex Zhavoronkov, PhD
#kras has been challenging to target due to its lack of druggable pockets. Using Insilico's Generative AI Platform, Chemistry42, and human expertise, led to the recent publication in American Chemical Society.
Access the paper here: Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation [pubs.acs.org/doi/10.1021/acsmedchemlett.5c00080]
Check out the latest video for more information.
www.linkedin.com/posts/zhavoronkov_i-am-thrilled-to-annou…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Alex Aliper, Co-founder & President of AI-drug company, Insilico Medicine, discusses why China is a stand-out market for pharmaceuticals and biotech, and says the company plans to invest in research to accelerate business growth and drug development. He speaks with Annabelle Droulers on the sidelines of SuperAI Conference in Singapore on "Bloomberg: The Asia Trade". (Source: Bloomberg)
www.bloomberg.com/news/videos/2025-06-18/insilico-medicin…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Insilico has built sustainable revenue streams through a diversified business model centered on out-licensing deals for certain programs, taking into account drug discovery and pipeline development, software solutions, and other discovery related programs for non-pharma sectors
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds announced the development of novel pan-KRAS inhibitors of new chemotypes, powered by the generative chemistry methods of Chemistry42. The results were published in ACS Medicinal Chemistry Letters.
www.eurekalert.org/news-releases/1087792 -
Insilico Medicine
@InSilicoMeds
Trained using Amazon SageMaker, AWS's fully-managed machine learning (ML) service to build, train, and deploy NL models, #nach01 enables scientists to build, fine-tune, and apply large-scale generative models for retrosynthesis and molecular prediction tasks. This foundational model has evolved into a production-ready solution, where it can deliver state-of-the-art performance across a wide range of generative and predictive tasks.
press.aboutamazon.com/2025/6/insilico-medicine-launches-n… -
Insilico Medicine
@InSilicoMeds
🆕Report: The Future of Healthcare Innovation 2025
Few companies illustrate this shift more than Insilico Medicine, a clinical-stage biotech and a resident of Cure, in which Cure’s affiliate Deerfield Management has a financial interest, that uses generative AI and robotics platforms for drug discovery. Founder and CEO Alex Zhavoronkov, PhD, described how.
wewillcure.com/insights/healthcare-innovation-report -
Insilico Medicine
@InSilicoMeds
Thank you to @ftlive for this coverage 🤝 www.linkedin.com/posts/ft-live_thank-you-to-those-who-joi…
-
Insilico Medicine
@InSilicoMeds
AI Emerges as Healthcare’s Bright Spot Amid Industry Upheaval
New data from Cure reveals how healthcare entrepreneurs are betting on AI to reshape drug development, advance rare disease treatments, and reduce clinical and financial barriers to innovation.
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
www.sciencedirect.com/science/article/pii/S26666340250017… Clinical trials reimagined: Integrating community engagement and artificial intelligence
-
Insilico Medicine
@InSilicoMeds
📽️ #bio2025 Day 3 Update!
📍 Stop by Booth 489 at the Boston Convention and Exhibition Center to explore:
-Our AI-designed therapeutic pipeline
-Breakthrough platforms like Chemistry42, PandaOmics, and #nach01
-Real-world success stories, like our first AI-discovered drug in Phase II trials
Meet Alex Zhavoronkov, PhD, CEO & Founder, Petrina Kamya, Ph.D., Global Head of #aiplatforms, and more from our team. We have one more presentation taking place tomorrow!
🧬 Join Michelle Chen, Chief Business Officer at Insilico Medicine tomorrow from 10:15-11:15 am in 210B for the "Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?" presentation. Attendees will gain insights into the current capabilities and limitations of AI, as well as how it can empower scientists to uncover novel solutions that address unmet medical needs.
If you have stopped by already, thank you, and we look forward to working together 🤝
#bostonbiotech #bioboston -
Insilico Medicine
@InSilicoMeds
AI-Derived Therapy for IPF Shows Potential in Phase 2a Trial www.ajmc.com/view/ai-derived-therapy-for-ipf-shows-potent…
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine’s #chemistry42 Drives Discovery of Novel Chemotype Pan-KRAS Inhibitors, Reported in ACS Medicinal Chemistry Letters scienmag.com/insilico-medicines-chemistry42-drives-discov…
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million www.biopharmatrend.com/post/1293-insilico-medicine-comple…
-
Insilico Medicine reposted
Bryan Johnson
@bryan_johnson
This is cool. The first real-world demonstration of a quantum-enhanced AI workflow producing experimentally validated drug leads for a notoriously "undruggable" cancer protein.
Offering a template for integrating quantum computing as a molecule generator in a hybrid model with classical AI models for groundbreaking drug discovery.
What they did: a research team from @InSilicoMedsand and @UofT leveraged a potent hybrid quantum-classical AI system to design novel small molecules capable of inhibiting mutant KRAS, a notoriously "undruggable" cancer protein.
KRAS is one of the most frequently mutated oncogenes across human cancers, particularly prevalent in lung, colorectal, and pancreatic tumors. These mutations hyperactivate the KRAS protein, leading to uncontrolled cell growth. For decades, KRAS was deemed "undruggable" due to its smooth surface and lack of deep binding pockets, making it incredibly challenging for small molecules to bind effectively and inhibit its function.
Given that KRAS mutations are responsible for approximately 25% of human cancers, often associated with poor prognoses and limited efficacy of existing drugs, it presents an ideal target for AI-driven drug discovery.
Congratulations to @biogerontology for this breakthrough.
Here are more details for those of you curious about AI drug discovery
1/ Quantum-Classical AI setup and workflow. Data and training.
A custom training set of 1.1 million molecules, including known KRAS binders, was compiled and used to train both the classical and quantum systems using Virtual Flow docking screening.
+ Generation of molecules: Hybrid Generative model
Quantum AI: Generator, Classical AI: discriminator.
A Quantum Circuit Born Machine (QCBM) ran on a quantum chip to generate new molecular structures.
A classical AI system (Insilico’s Chemistry42) evaluated those molecules, filtering for likely KRAS interaction
+ Filtering and identifying best drug candidates:
Using Chemistry42 a million QCBM-generated molecules were sampled, filtered according to their drug-likeness including absorption metabolism and toxicity, and then ranked based on their docking scores.
+ Chemical synthesis and real world validation
15 candidates were chosen, chemically synthesized, and tested in the lab .
2/ The main outcome
Two of the 15 molecules successfully inhibited multiple KRAS variants in live cells. Real experimental hits based on quantum AI generation (QCBM) coupled with classical AI (Chemistry42) screening and validation.
3/ Advantage of using Quantum Computing for drug discovery
Quantum systems are theoretically better at sampling from complex, high-dimensional distributions, which could help find unusual and novel molecules that classical systems might miss. But today, this is still experimental. No clear advantage has been proven yet.
4/ This study used a “real but limited” quantum computer
The study used real, hardware-based quantum processor (IBM Quantum’s superconducting qubits), not just a quantum simulator.
However, the scale and depth of the quantum computation were limited, and the scope of application was limited to the molecule generation step, while all the evaluation and optimization steps were performed by Chemistry42, a classical generative AI model.
5/ Significance
+ First experimental validation of quantum-AI drug generation
This is the first study to use a quantum generative model (QCBM) integrated with classical AI to design small molecules that were synthesized and shown to inhibit a real, disease-relevant target (KRAS) in vitro.
+ Demonstrates hybrid quantum–classical synergy
The study showcases a practical workflow, where quantum computing contributes to early-stage ideation, while classical AI tools like Chemistry42 handle evaluation and optimization.
+ Progress against the “undruggable” KRAS target
KRAS has long been considered one of the most challenging oncogenic proteins to target. Generating novel KRAS inhibitors using this approach highlights the potential of AI–quantum tools to tackle previously intractable targets.
+ Opens the door to expanding the chemical space
Quantum models can sample from non-intuitive, high-dimensional chemical spaces, potentially leading to new classes of molecules that classical methods might overlook.
+ Lays groundwork for scalable quantum drug discovery
While quantum advantage has not yet been demonstrated, this study is a foundational step showing that quantum hardware can be functionally integrated into real-world discovery pipelines.
6/ Limitations
+ Limited scale and maturity of quantum hardware
The quantum component (QCBM) was run on noisy, small-scale quantum hardware, limiting circuit depth and complexity. The study does not demonstrate quantum advantage over classical generative methods.
+ Narrow experimental validation
Only 15 molecules were synthesized, and just 2 showed modest in vitro activity against KRAS. There was no in vivo testing, pharmacokinetics, or toxicity data — so therapeutic potential remains speculative.
+ Single-target, proof-of-concept scope
The approach was tested on only one protein family (KRAS). It’s unclear how well this quantum–classical pipeline generalizes to other targets. -
Insilico Medicine
@InSilicoMeds
Insilico Medicine Harnesses AI to Break the 12‑Year Drug Development Curse 🚀
On the eve of #bio2025 International Convention 2025 in North America, at a dedicated session hosted by the Taiwan Biotech Forum titled “Generative AI and Automation for Drug Discovery,” Insilico Medicine founder Alex Zhavoronkov shared practical experience and engaged with experts.
Founded in 2014 in Baltimore, Maryland, Insilico Medicine initially focused on deep learning algorithm research for its first five years. Around 2019, the company shifted toward commercialization by launching proprietary software and initiating drug development projects. Now in its 11th year, Insilico operates across Boston, Montreal, Abu Dhabi, and Greater China. Notably, its first Asian office opened in Taipei in 2019, collaborating closely with the Development Center for Biotechnology and local research teams.
Alex, who has visited Taiwan since 2001, has witnessed the maturation of its tech and biotech ecosystem. He noted that “if you choose to base your tech operations in Taiwan, you can save at least six months to a year in drug development timelines.”
Read the latest here 👉www.geneonline.com/category/conferences/us-bio-2025/ -
Insilico Medicine
@InSilicoMeds
🚀 Day 2 at #bio2025 has begun!
We're showcasing how our end-to-end generative AI platforms are transforming drug discovery, from target identification and molecule design to our growing therapeutic pipeline.
🔬 Explore our software platforms:
-PandaOmics for target discovery
-Chemistry42 for generative chemistry
-Generative Biologics for protein engineering
📍Come by booth #489 to learn more about our high quality therapeutic programs discovered using Generative AI and Automation, and to see how we can partner together.
#bioboston #drugdiscovery #aiinpharma -
Insilico Medicine reposted
GeneOnline
@GeneOnlineNews
🚀 At the 2025 Taiwan Biotech Forum in Boston, industry leaders gathered to spotlight how AI is revolutionizing drug discovery and biopharma R&D. Co-organized by Taiwan’s Development Center for Biotechnology (DCB) and the Mount Jade New England Science and Technology Association (MJNE), the forum featured a dynamic Q&A panel titled “Accelerating Breakthrough in Drug Discovery with AI.”
🎙️ Panelists Ashwini Ghogare (Merck Group), Alex Zhavoronkov (Insilico Medicine), and Janusz Dutkowski (Data4Cure, Inc.) shared invaluable insights on AI’s transformative impact, highlighting advances in protein modeling, workflow optimization, and decision-making in life sciences. While tools like Google DeepMind’s AlphaFold push the boundaries of protein structure prediction, experts emphasized that experimental validation remains crucial, especially for complex biologics and novel drug modalities.
🤖 AI accelerates candidate selection and hypothesis generation but cannot yet replace essential human expertise in target validation, trial design, and regulatory compliance. Trust in AI depends not only on accuracy but on transparency and scientists’ understanding of model logic.
📊 Data quality and integration emerged as crucial challenges, with panelists stressing the need for multi-modal data frameworks combining genomic, proteomic, clinical, and phenotypic information.
Discover how AI is reshaping drug discovery! 💡
Click the link to read the full in-depth article from the 2025 Taiwan Biotech Forum Q&A Panel Discussion Section and gain expert insights! 👉🏻 www.geneonline.com/experts-weigh-in-on-ais-role-challenge…
#taiwanbiotechforum2025 #drugdiscovery #artificialintelligence #biopharmainnovation #proteinmodeling #aiinhealthcare #lifesciences #clinicaldata #genomics #pharmaceuticalai #dataintegration #aiandhumanexpertise #deepmindalphafold #biologics #precisionmedicine #randd #innovationinbiotech #regulatoryscience -
Insilico Medicine reposted
Longevity Investors
@Longevity_Inv
✨ We’re excited to welcome @AlexAliper, President of @InSilicoMeds, to the Longevity Investors Conference 2025 in Gstaad!
As a leader in applying AI to drug discovery and development, Alex is driving innovation that’s shaping the future of longevity science. 🚀
Don’t miss his insights this September 22–25, 2025, as we gather top investors, scientists, and entrepreneurs to explore the next frontier in longevity. Apply here: www.longevityinvestors.ch/longevity-investors-conference-…
#lic2025 #longevityinvestors -
Insilico Medicine reposted
GeneOnline
@GeneOnlineNews
💡 On the eve of BIO International Convention 2025, InSilico Medicine’s Founder Alex Zhavoronkov joined the Taiwan Biotech Forum to unveil how AI and automation are reshaping drug discovery, from smart labs to generative AI platforms like pharma.ai, Chemistry42, and PreciousGPT.
🚀 From concept to clinic, Insilico has launched 22 clinical-stage candidates, out-licensed 3 molecules, and slashed development time with AI-powered breakthroughs, including an IPF drug that improves lung function and shows anti-aging potential.
🔬 With global sites in Boston, Montreal, Abu Dhabi, and Greater China, Insilico is now leading the charge toward Pharmaceutical Superintelligence, blending validated data models, smart experimental design, and real-time “Body AI” lab assistants.
📖 Couldn’t attend the session in person? GeneOnline has you covered. Dive into our full article for exclusive insights, expert commentary, and everything you missed. 👇🏻
👉🏻 English: www.geneonline.com/insilico-medicine-harnesses-ai-to-brea…
👉🏻 Chinese: geneonline.news/insilico-medicine-ai-drug-discovery/
#insilicomedicine #pharmaai #generativeai #drugdiscovery #bio2025 #taiwanbiotechforum #precisionmedicine #aihealthcare #clinicalinnovation #smartlab #agingresearch #aipharma #biotechinnovation #bodyai #taiwanbiotech #alexzhavoronkov #fasterdrugdiscovery -
Insilico Medicine reposted
Masdar City
@MasdarCity
Insilico Medicine is launching the UAE's first fully integrated drug discovery program for oncology, utilizing AI-driven technology for target discovery, molecule design, and preclinical development, all conducted locally for the first time.
@InSilicoMeds -
Insilico Medicine
@InSilicoMeds
📍 Attending #bio2025 in Boston next week? Meet Petrina Kamya, Ph.D., Global Head of AI Platforms at Booth #489 in the Exhibit Hall. Boston Convention and Exhibition Center
🚀 Insilico Medicine has released #nach01, a large-scale generative chemistry foundation model, on the AWS Marketplace.
The model is the third iteration in Insilico’s Nach0 model family, extending capabilities from earlier versions:
-Nach0, a cross-domain language model for chemistry and natural language tasks.
-Nach0-pc, an architecture that integrates textual and spatial representations to handle atom-level geometry.
-Nach01, which combines both and is optimized for general-purpose chemistry reasoning and molecule generation across hundreds of task types.
🤝 Reach out to our team at Pharma.AI@insilicomedicine.com to schedule a meeting for all things pharma.ai, and visit the AWS Marketplace today: aws.amazon.com/marketplace/pp/prodview-aq32kfu5ifjgw -
Insilico Medicine
@InSilicoMeds
Thank you to biopharmatrend.com for coverage on #nach01 🤝
Insilico Medicine Launches its Multimodal Generative Chemistry Model on AWS Marketplace
The model is the third iteration in Insilico’s Nach0 model family, extending capabilities from earlier versions:
-Nach0, a cross-domain language model for chemistry and natural language tasks.
-Nach0-pc, an architecture that integrates textual and spatial representations to handle atom-level geometry.
-Nach01, which combines both and is optimized for general-purpose chemistry reasoning and molecule generation across hundreds of task types.
Read the full report here 👉 www.biopharmatrend.com/post/1291-insilico-medicine-launch… -
Insilico Medicine
@InSilicoMeds
#nach01 leverages a large language model to process both structural and spatial data. Combining strengths from both predecessors, Nach01 is designed to solve hundreds of diverse tasks, providing a broad and comprehensive range of chemical knowledge.
www.biospace.com/press-releases/insilico-medicine-launche… -
Insilico Medicine
@InSilicoMeds
Media Alert 📣 Insilico Medicine Launches #nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
We are thrilled to unveil Nach01, our next-generation multimodal foundation model for generative chemistry, now available on AWS Marketplace.
💬 Insights from the launch:
“Natural and chemical languages+point cloud transformer (NACH01-PC) is one of the most capable multimodal foundational models in our arsenal and in the industry with the potential to produce novel medicines and save lives. It is a stepping stone on our path to pharmaceutical superIntelligence. We are very thankful to AWS for their support in making it available to the community.”
- Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine
“Making frontier biochemistry models like NACH01-PC broadly available to the research community around the world, so they can accelerate the discovery of better treatments to diseases and improve patient outcomes, is one of the many ways AWS sees generative AI making a positive impact in people’s lives,” said Jon Jones, VP and Global Head of Startups at AWS. “We are excited to be part of Insilico’s journey in bringing transformative technologies like this to the market.”
- Jon Jones, VP & Global Head of Startups, Amazon Web Services (AWS)
🔗 Discover how Nach01 can power your generative #chemistryworkflows: explore the full release on our website and access the model directly in AWS Marketplace today: aws.amazon.com/marketplace/pp/prodview-aq32kfu5ifjgw
Read the full release here: press.aboutamazon.com/2025/6/insilico-medicine-launches-n… -
Insilico Medicine
@InSilicoMeds
The latest from aginganddisease.org 👉 Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development
Read the abstract here: www.aginganddisease.org/EN/10.14336/AD.2025.0508 -
Insilico Medicine
@InSilicoMeds
itdigest.com/healthtech/biotech/insilico-launches-nach01-… Insilico Launches Nach01 on AWS to Boost Gen Chemistry
#nach01 -
Insilico Medicine
@InSilicoMeds
🚨 Less than 1 week to go! Biotechnology Innovation Organization International Convention 2025 starts next week, and the Insilico Medicine team is heading to Boston.
Meet our team at Booth #489 and don’t miss these Industry leading sessions:
🧠 "AI in Biopharma: What’s Working and What’s Left to Prove"
📅 Monday, June 16 | 🕐 1:45–2:45 PM ET
🎤 Alex Zhavoronkov, PhD, Founder and CEO
💡 "Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?"
📅 Thursday, June 19 | 🕥 10:15–11:15 AM ET
🎤 Michelle Chen, PhD, Chief Business Officer
Whether you're exploring our software services or looking to partner, we'd love to connect at the event.
📩 Reach out to us at BD@insilico.com to set up a meeting or reach out in the BIO Partnering App. We hope you will join us next week!
#bio2025 #aiinbiopharma #drugdiscovery #insilicomedicine #partnering -
Insilico Medicine
@InSilicoMeds
www.prnewswire.com/news-releases/insilico-medicine-launch… Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
-
Insilico Medicine
@InSilicoMeds
www.linkedin.com/posts/zhavoronkov_the-moment-many-of-you…
🚀 Nach01 is live on Amazon Web Services (@awscloud )! #nach01 is designed to solve hundreds of diverse tasks, providing a broad and comprehensive range of chemical knowledge.
Thank you to everyone involved 🤝
Read the full release here: -
Insilico Medicine
@InSilicoMeds
Insilico sees the phase 2a data as a steppingstone toward ‘pharmaceutical super-intelligence’
www.drugdiscoverytrends.com/insilicos-ai-designed-rentose… -
Insilico Medicine
@InSilicoMeds
📢Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
Thank you to @biospace for this coverage. Read the full report: www.biospace.com/press-releases/insilico-medicine-announc… -
Insilico Medicine
@InSilicoMeds
www.nature.com/articles/s44386-025-00013-6 @SpringerNature
The AI drug revolution needs a revolution -
Insilico Medicine
@InSilicoMeds
📢 Big thanks to Bio-IT World for highlighting a major milestone in our AI-driven drug discovery journey.
We’re proud to share our Springer Nature Medicine publication announcing Phase IIa results for #renosertib, a novel TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), discovered and designed using our pharma.ai Platforms at Insilico Medicine.
This represents a significant advancement in the application of AI for discovering first-in-class therapeutics in complex diseases like IPF.
🔗 Read the full Bio-IT World coverage:
www.bio-itworld.com/news/2025/06/05/insilico-medicine-ann…
#aiindrugdiscovery #ipf #insilicomedicine #renosertib -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds announced the Nature Medicine publication of Phase 2a results for Rentosertib, a novel TNIK inhibitor for idiopathic pulmonary fibrosis, discovered and designed using a pioneering AI-driven approach.
insilico.com/tpost/tnrecuxsc1-insilico-announces-nature-m… -
Insilico Medicine
@InSilicoMeds
Investigational IPF Therapy Developed Using AI
Idiopathic pulmonary fibrosis (IPF) is a challenging respiratory condition with limited treatment options. However, new therapies are being investigated, including one that was developed in part through generative artificial intelligence (AI). Research findings on rentosertib (INS018-055) were presented this week at the 2025 American Thoracic Society (#ats) annual meeting in San Franciso.
See the full recap here 👉 www.medcentral.com/pulmonology/investigational-ipf-therap…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
DoNotAge.org
@Do_Not_Age
See you there
-
Insilico Medicine
@InSilicoMeds
As an age-related disease, with people aged 75 years and older being diagnosed over 60 times more frequently than people aged 18-343, treatments for #ipf have the potential to be dual-function therapeutics, or drugs that treat both aging and age-related disease.
The aging process is characterized by accumulating dysregulation of various metabolic, immune, and homeostatic pathways across tissues, and much of the research into combatting #aging is focused on modulating key genes within these pathways.
At Insilico Medicine, we leverage advanced artificial intelligence (#ai) models trained on multi-omic datasets, publication and grant text-mining, and other sources of biological insights to find new targets for aging-related diseases.
communities.springernature.com/posts/ai-meets-ipf-taking-…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
www.nature.com/articles/s44386-025-00013-6 The AI drug revolution needs a revolution
Thank you for the mention, @Nature @NaturePortfolio 🤝 -
Insilico Medicine
@InSilicoMeds
📣 Join Insilico Medicine at the Biotechnology Innovation Organization Convention in Boston!
📍 Booth #489
We’re proud to announce the following presentations from our Leadership team:
🎤 AI in Biopharma: What’s Working and What’s Left to Prove
📅 Monday, June 16 | 🕐 1:45–2:45 PM ET
👨🔬 Featuring: Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine
🔬 Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
📅 Thursday, June 19 | 🕥 10:15–11:15 AM ET
👩💼 Featuring: Michelle Chen, PhD, Chief Business Officer, Insilico Medicine
Also, you can visit us at Booth #489 to learn how our end-to-end AI platform is accelerating the future of medicine.
Want to schedule a meeting? 📩 Reach out at BD@insilico.com
#bio2025 #aiindrugdiscovery #digitalbiotech #insilicomedicine -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Insilico’s IPF drug demonstrated ‘clinically meaningful’ benefits in trial
#longevity #biotech #drugdiscovery #ai
longevity.technology/news/insilicos-ipf-drug-demonstrated… -
Insilico Medicine
@InSilicoMeds
www.ddw-online.com/insilico-medicine-study-validates-enpp… Insilico Medicine study validates ENPP1 as immune checkpoint for cancers
-
Insilico Medicine reposted
Eric Topol
@EricTopol
The first generative AI drug to get to a Phase 2 randomized clinical trial. The small molecule in pill form, rentosertib, showed signs of efficacy for idiopathic pulmonary fibrosis @NatureMedicine @InSilicoMeds
www.nature.com/articles/s41591-025-03743-2 -
Insilico Medicine reposted
Masdar City
@MasdarCity
A major leap for biotech in the region is taking place at Masdar City. @InSilicoMeds is launching the UAE’s first fully end-to-end drug discovery program for oncology, and it’s all happening within our Life Sciences cluster.
www.wam.ae/en/article/b35d9pu-uae-based-insilico-medicine… -
Insilico Medicine reposted
Genetic Engineering & Biotechnology News
@GENbio
@InSilicoMeds Eyes Q4 Start for Late-Stage Trials of IPF Candidate
The AI drug developer publishes results for rentosertib showing the idiopathic pulmonary fibrosis drug led to improved lung function
#bioprocessing #artificialintelligence #lungdisease
www.genengnews.com/topics/artificial-intelligence/insilic… -
Insilico Medicine
@InSilicoMeds
🔥 Thrilled to announce the publication of our new Nature Medicine paper reporting positive Phase IIa trial results for rentosertib – a first-in-class #tnik inhibitor discovered using generative AI – for the treatment of idiopathic pulmonary fibrosis (IPF). See the full post here: www.linkedin.com/posts/zhavoronkov_thrilled-to-announce-t…
Insilico Medicine
@InSilicoMeds
Read the full paper here: www.nature.com/articles/s41591-025-03743-2
-
Insilico Medicine
@InSilicoMeds
Investigational IPF Therapy Developed Using AI, An #ats 2025 meeting highlight. www.medcentral.com/pulmonology/investigational-ipf-therap…
Idiopathic pulmonary fibrosis (IPF) is a challenging respiratory condition with limited treatment options. However, new therapies are being investigated, including one that was developed in part through generative artificial intelligence (AI). Research findings on rentosertib (INS018-055) were presented this week at the 2025 American Thoracic Society (ATS) annual meeting in San Franciso. -
Insilico Medicine
@InSilicoMeds
🚨 New Publication Alert! Thank you to Bio-IT World for covering our latest research published in Springer Nature Communications.
"Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors" is now available.
This work highlights the power of AI-driven drug design and the potential of ENPP1 as a promising therapeutic target in oncology and immunotherapy.
🔬 Read the full article via Bio-IT World:
www.bio-itworld.com/news/2025/05/28/latest-nature-communi…
#enpp1 #immunotherapy #aiforscience #insilicomedicine #naturecommunications
Insilico Medicine
@InSilicoMeds
See the full paper here 👉 www.nature.com/articles/s41467-025-59874-0
-
Insilico Medicine
@InSilicoMeds
How Generative Artificial Intelligence Can Transform Drug Discovery?
www.sciencedirect.com/science/article/abs/pii/S0223523425… -
Insilico Medicine reposted
Eli Mohamad
@elimohamad
Today was Hard Work Day at the gym, protection courtesy of @InSilicoMeds. Little sleep, old-school beats barking in my ear, highest intensity muscle destruction. OK, back to building New DeSci.
P.S. still a fantastic gift, @biogerontology -
Insilico Medicine
@InSilicoMeds
Train accurate generative and predictive models on your data with Nach01, the latest from pharma.ai www.youtube.com/watch?v=3smoiFQz5Ic
-
Insilico Medicine
@InSilicoMeds
The latest from @SpringerNature: A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro www.nature.com/articles/s41467-025-59870-4
-
Insilico Medicine
@InSilicoMeds
🚀 It’s Here: Nach01 is LIVE on AWS Marketplace! @awscloud
We’re thrilled to announce that #nach01, our powerful molecular AI foundation model, is now officially available on the AWS Marketplace!
We’re excited to introduce Nach01’s predictive capabilities, the first release of our large language foundation model for chemistry. This version focuses on predictive tasks, enabling you to maximize the value of your data. Fine-tune the model for specific objectives or leverage multi-task learning to tackle diverse predictive challenges. With Nach01, address predictive problems with precision and scalability.
👉 Try Nach01 on AWS → aws.amazon.com/marketplace/pp/prodview-aq32kfu5ifjgw?appl…
#nach01 #pharmaai #insilicomedicine #awsmarketplaceThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
NEW from @MDPIOpenAccess International Journal of Molecular Sciences: AI-Driven Drug Target Screening Platform Identified Oncogene CACNA2D1 Activated by Enhancer Infestation in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
See the abstract here: www.mdpi.com/1422-0067/26/10/4697 -
Insilico Medicine
@InSilicoMeds
#pandaomics' On-Demand Webinar Now Available: www.linkedin.com/feed/update/urn:li:activity:733130165652…
🚀 Following our pharma.ai Spring Launch, we’re excited to share new features in PandaOmics that make target discovery even more precise.
What’s new in #pandaomics?
🧫 scRNA-seq support: Analyze cell-type specific transcriptomes with new upload and comparison tools
🧩 Smarter metadata design: Easily stratify samples for fully customized comparisons
🧠 Ask Panda: A powerful new assistant to explore and prioritize novel targets with context-aware reasoning
Whether you're digging deep into single-cell data or searching for first-in-class targets, PandaOmics is here to help you move faster — with confidence.
🧪 Explore the platform [pharma.ai/pandaomics] and catch the full on-demand webinar: insilico.zoom.us/webinar/register/WN_KQxBpQSaQzeWh3O6WfbITA
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Report: AI-Assisted Development of COVID-19 Treatment: Insilico Medicine and Collaborators Develop Broad-Spectrum Coronavirus Inhibitor
www.citybiz.co/article/696668/ai-assisted-development-of-… -
Insilico Medicine
@InSilicoMeds
👏 A big thank you to our colleague ♠️ Aisyah Sjöholm, MD, Msc. for representing Insilico Medicine at Vitalis 2025 and sharing our work in AI-driven drug discovery with the broader digital health community.
If you're attending #vitalis2025 or are based in Europe and curious about how our AI platforms are accelerating therapeutic innovation, reach out to Aisyah to learn more. Connect with her on LinkedIn or book a call here: calendly.com/d/4g7-9j5-xsz/connect-with-insilico-medicine…
🌍 We're always excited to connect with partners and researchers advancing the future of healthcare.
#insilicomedicine #vitalis2025 #aiinhealthcare #pharmaai
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:733021657653…
⭐ Great to see our Insilico Medicine team on the ground at #ats2025 in San Francisco, connecting with the #respiratory science and #clinical community
Tomorrow, visit Poster #5115 in Session C23: On the Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD
If you are heading to the exhibit hall today, come by and meet our team at Booth #1464.
🤝 Thank you to American Thoracic Society for hosting this incredible event.
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
💟 This National Women's Health Week is all about caring for your whole health, from mind to body. Visit OWH's #nwhw page for tips on self-care, mental well-being, and health priorities for every age. womenshealth.gov/nwhw
🔬 In our latest publication in Advanced Science, Insilico Medicine researchers identify novel therapeutic targets and a repurposed drug for endometriosis, a condition affecting over 190 million women globally. Learn more information here: www.eurekalert.org/news-releases/1070573 -
Insilico Medicine
@InSilicoMeds
👏 We are proud to see ♠️ Aisyah Sjöholm, MD, Msc. representing Insilico Medicine at the QSNAI International AI & Digital Health Forum! Queen Silvia Nursing Award International
As we continue advancing AI-driven drug discovery and development, it’s inspiring to join global leaders shaping the future of healthcare through innovation and collaboration.
#aiforgood #womenintech #qsnaiinternational #swedenbio
www.linkedin.com/posts/aisyahsjoholm_ai-digital-health-ac… -
Insilico Medicine
@InSilicoMeds
🤝 We’re honored that TIME has recognized Insilico Medicine as one of the Top 10 AI-led Contributions to Society, alongside global leaders advancing impactful AI innovation.
"The Top 10 AI-Led Contributions to Society According to AI" is published by allbusiness.com.
Explore the full list: www.allbusiness.com
#drugdiscovery #insilicomedicine #generativeai -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:732845039007…
📢 Alex Zhavoronkov will be presenting at the American Thoracic Society Conference in San Francisco this Saturday, May 17!
Session Details:
🧬 Generative AI & The Future of Drug Development: A New Era of AI Designed IPF Drug Therapy
🕦 11:30 AM – 12:00 PM PT
📍 San Francisco Marriott Marquis, Yerba Buena Ballroom
You can meet our BD team at booth #1464. Visit us throughout the week or book a meeting ahead of the event 👉🏼 BD@insilico.com
We hope to see you in person!
#ats2025 #ipf -
Insilico Medicine
@InSilicoMeds
Alex Zhavoronkov, CEO of Insilico Medicine, gave a keynote speech at the opening ceremony of 'Bio Korea 2025' held at COEX in Gangnam-gu, Seoul on the 7th, and gave a presentation on the topic of 'AI and robotics, the future of new drug development and life extension.'
Read the event recap here 👉it.chosun.com/news/articleView.html?idxno=2023092140032 -
Insilico Medicine reposted
SuperAI
@superai_conf
Step into the future of AI-driven drug discovery with @AlexAliper, Co-Founder and President of @InSilicoMeds, at #superai.
Alex will share how Insilico is using generative AI to accelerate pharmaceutical R&D and expand what's possible in healthcare.
Join him on 18-19 June. -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:732773014980…
🎥Introducing LifeStar1: Insilico Medicine’s Automated Lab Operating Environment, showcased during our pharma.ai Spring Launch!
From target validation to indication expansion, LifeStar1 offers AI-integrated capabilities across the drug discovery pipeline, including CRISPR screening, phenotypic assays, biomarker discovery, and more.
🎥 Couldn’t join us live? Catch the full on-demand webinar to see how LifeStar1 connects with the entire pharma.ai ecosystem:
👉 insilico.zoom.us/webinar/register/WN_KQxBpQSaQzeWh3O6WfbITA
We continue to add new segments to our pharma.ai launch series, so stay tuned for the next one coming later this summer!
#aiforscience #pharmaai #lifestar1 #insilicomedicine -
Insilico Medicine
@InSilicoMeds
📢 Join Insilico Medicine at The American Thoracic Society (#ats2025) Conference in San Francisco!
Don’t miss Alex Zhavoronkov, PhD, Founder & CEO of Insilico Medicine, presenting at the Respiratory Innovation Summit on Saturday, May 17.
🧬 Generative AI & The Future of Drug Development: A New Era of AI Designed IPF Drug Therapy
🕦 11:30 AM – 12:00 PM PT
📍 San Francisco Marriott Marquis, Yerba Buena Ballroom
Explore how generative AI is driving innovation in IPF treatment and reshaping respiratory drug discovery.
Our BD team will be at booth #1464. Visit us throughout the week or book a meeting ahead of the event 👉🏼 BD@insilico.com
Stay tuned for more ATS updates!
#ats2025 #generativeai #ipf #drugdiscovery #insilicomedicine -
Insilico Medicine
@InSilicoMeds
✈️ BIO KOREA kicks off today through May 9 at COEX in Seoul.
This year's opening ceremony will be attended by a keynote speaker, Alex Zhavoronkov, CEO of Insilico Medicine, whose candidate substance derived from its own AI platform has entered phase 2 clinical trials, who will present on the topic, "Can AI and robotics create a drug and extend life?" Through this, he will share the current status and prospects of new drug development using AI, as well as experiences in innovation through global collaboration.
Follow along for more updates, and see the latest report here: www.hnews.kr/news/view.php?no=65883
#biokorea -
Insilico Medicine
@InSilicoMeds
www.hnews.kr/news/view.php?no=65883
#biokorea Report: This year's opening ceremony will be attended by a keynote speaker, Alex Zhavoronkov, CEO of Insilico Medicine, whose candidate substance derived from its own AI platform has entered phase 2 clinical trials, who will present on the topic, "Can AI and robotics create a drug and extend life?" Through this, he will share the current status and prospects of new drug development using AI, as well as experiences in innovation through global collaboration. -
Insilico Medicine reposted
Bio Protocol
@BioProtocol
Huge thank you to everyone who joined for yesterday's DeSci Summit in Dubai @token2049
All talks are now LIVE on YouTube!
Industry leaders from TradBio @Roivant crypto @yzilabs & AI @InSilicoMeds converged to make it an amazing event.
Links to all the talks below ↓ -
Insilico Medicine
@InSilicoMeds
🚀 The Amazon Web Services (AWS) Life Sciences Symposium takes place today at the Sheraton New York Times Square Hotel.
Meet Petrina Kamya, Ph.D., Global Head of AI Platforms, VP, President of Insilico Medicine Canada at this year's event. Get more information on the latest updates to the pharma.ai Suite, explore partnership opportunities, and much more.
See the full program here, and we hope to see you next week! aws.amazon.com/health/life-sciences-symposium-2025/
🔥 New to this year's event 👉 You can discover cutting-edge innovators at the TechBio Showcase Lounge and AI Startup Pavilion, where emerging startups and AI-driven breakthroughs in life sciences take center stage. -
Insilico Medicine reposted
AI for Good 🇺🇳 #AIforGood
@AIforGood
Get inspired by the voices leading AI for positive change at the #aiforgood Global Summit 2025!
🗣 Alex Zhavoronkov @biogerontology, Founder and CEO of @InSilicoMeds, will share insights on #ai, human performance and longevity.
Join us for free or go VIP!
🌐 aiforgood.itu.int/summit25/
📅 8–11 July 2025
📍 Palexpo, Geneva, and online -
Insilico Medicine
@InSilicoMeds
🤝#aacr25 brought over 22,000 attendees to #chicago this year, and we were there to experience it.
We want to extend our heartfelt thanks to the AACR 2025 organizers and the city of Chicago for an incredible event.
It was an honor to connect with researchers, clinicians, and industry professionals, where we could share our latest advances in #ai-driven drug discovery, and engage in meaningful conversations about the future of oncology research.
A special thank you to everyone who visited our booth, and if you missed our team onsite, please reach out to us: BD@insilico.com.
We will see you in San Diego in 2026! 🌴 @AACR -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🤝 Day 3 here at #aacr25!
Join us at Booth #334 from 9-5 pm to explore how our platforms are accelerating oncology breakthroughs.
🔬 Catch up on our Publications:
-Discovery of Novel SIK2/3 Inhibitors for the Potential Treatment of MEF2C+ Acute Myeloid Leukemia (AML) [pubs.acs.org/doi/10.1021/acs.jmedchem.4c03225]
-A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models [pubmed.ncbi.nlm.nih.gov/38459338/]
-Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids [pubmed.ncbi.nlm.nih.gov/40207690/]
📩 We hope to meet with you today! Connect with our team: BD@insilicomedicine.com -
Insilico Medicine reposted
Christoph Kuppe
@KuppeChristoph
Just met Alex @biogerontology CEO at @InSilicoMeds at #aacr25 — exciting to exchange ideas on novel targets in fibrosis and ageing! Great discussions on novel mechanisms and #aidrugdesign in organ fibrosis. Stay tuned for what’s next with @InSilicoMeds! 🤝
-
Insilico Medicine
@InSilicoMeds
🎓 Calling all university researchers at #aacr25 in Chicago!
Meet Science42: #dora, Insilico Medicine’s AI-powered writing and data analysis assistant designed for biomedical innovation.
🔬 Whether you're publishing research, or generating grant proposals, DORA assists in fast crafting draft research. Offering literature analysis, originality, insightful tips and citations to support your work.
Stop by booth #334 to learn more about our scientific writing tool and visit pharma.ai/dora to learn more.
#academicwriting #publications -
Insilico Medicine reposted
Bio Protocol
@BioProtocol
💥 Announcing the agenda for DeSci Dubai @token2049
Join us TOMORROW April 29 for live talks on decentralized science & AI with biotech leaders from:
@yzilabs, @ApeironInvests, @Roivant, @vitadao, @SofinnovaVC,
@InSilicoMeds & more!
See the agenda & livestream info below ↓ -
Insilico Medicine
@InSilicoMeds
🏃♂️Final chance to register! pharma.ai Spring Launch begins at 10 am EST. Can't join us live? Register today for on-demand access.
We will explore AI breakthroughs in drug discovery and development. Hear from Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, see what's next for pharma.ai, and dive deeper into new product demos, and more.
Sign up here: insilico.zoom.us/webinar/register/8517443018693/WN_KQxBpQ…
#pharmaaispringlaunch #pharmaaiday -
Insilico Medicine
@InSilicoMeds
🏃♂️Final chance to register! pharma.ai Spring Launch begins at 10 am EST. Can't join us live? Register today for on-demand access.
We will explore AI breakthroughs in drug discovery and development. Hear from Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, see what's next for pharma.ai, and dive deeper into new product demos, and more.
Sign up here: insilico.zoom.us/webinar/register/8517443018693/WN_KQxBpQ…
#pharmaaispringlaunch #pharmaaiday -
Insilico Medicine
@InSilicoMeds
👉For Release: www.eurekalert.org/news-releases/1081064
-
Insilico Medicine
@InSilicoMeds
🚀 pharma.ai Day 2025: Insilico Medicine to unveil gen-AI platform quarterly updates on April 24
Since the debut of PandaOmics and Chemistry42 in 2020 as generative AI tools for drug discovery across target discovery and molecule generation, Insilico Medicine has been periodically sharing technological updates of its proprietary pharma.ai platform. Our latest update included the integration of AI agents, Large Language Models (LLMs), hardware solutions and customized model training functions, and as the platform continues to grow with new enhancements, we are happy to share new features in the upcoming pharma.ai Day webinar.
👉 The brand-new quarterly update series for pharma.ai takes place tomorrow, April 24, 10:00 am EST. Register today: insilico.zoom.us/webinar/register/8517443018693/WN_KQxBpQ…
#pharmaaiday #springlaunch #pharmaaiwebinar -
Insilico Medicine reposted
Diana
@dorawriting
🧪 Are you a thought leader ready to shape the future of research?
We’re inviting you to explore DORA — our next-gen AI tool designed to transform how research is created and shared.
✨ Apply now to join our exclusive early access group and help shape the next big innovation in AI.
🔓 What you get:
– Unlimited trial access to the full product
– Direct influence on DORA’s development through your feedback
📢 Your experience matters.
Share it with your audience and lead the conversation.
👉 Apply here: pharma.ai/dora
#dorawriting #airesearch -
Insilico Medicine reposted
Future Health – A Global Initiative by Abu Dhabi
@FutureHealthAD
AI is rewriting the drug development lifecycle, uncovering new targets, reducing timelines, and boosting success rates. At the Forum @ ADGHW, experts broke down the top priorities and possibilities of AI-driven discovery.
We were joined by:
• Dr. Thomas Clozel, Co-Founder and CEO, @OwkinScience, USA
• Dr. Stefan Frings, Chief Medical Officer Pharma Development, @Roche, Switzerland
• Dr. Alex Zhavoronkov, Founder and CEO, @InSilicoMeds, USA
• Julia Miao, Deputy CEO and Chief Financial Officer, Sihuan Pharmaceuticals, China
Moderator: Dr. Richard Jenkins, Chief Medical Officer and Senior Executive Advisor, Health Industries, @PwC, KSA
There is still time to register for your delegate pass to join us at #adghw: www.adghw.com/forms/delegate-registration/
#adghw #abudhabi #doh #futureofhealth #globalhealth #towardslongevityredefininghealthandwellbeing @dohsocial -
Insilico Medicine
@InSilicoMeds
🎤 Thank you to Allison Proffitt and the @bioitworld Conference & Expo team (Cindy Crowninshield, RDN, LDN, HHC) for the thoughtful coverage of our CEO Alex Zhavoronkov’s keynote on the transformative power of Generative AI in drug discovery and aging research.
📖 Read the full article here: www.bio-itworld.com/news/2025/04/17/insilico-s-alex-zhavo…
#bioitworld #insilicomedicine #generativeai #agingresearch -
Insilico Medicine
@InSilicoMeds
Catch our Founder and Co-Founder & President over the next two days at #adghw25📍Abu Dhabi Global Health Week
Alex Zhavoronkov, PhD and Alex Aliper, PhD will be in multiple panels on AI in healthcare, longevity investment, and cutting-edge research integration.
📅 April 15-17 | Booth #5a14
For more information, visit: www.adghw.com/forms/2025-visitor-registration/?actioncode… -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀 See the latest report from biopharmatrend.com
We’re proud to see PandaOmics and Chemistry42 featured in the latest BioPharmaTrend 2024 AI Drug Discovery Pipeline Report, recognizing the platforms accelerating innovation across target discovery and molecule design.
Catch some highlights below 👇
-According to the company, a target identification PandaOmics module leverages 1.9 trillion data points from over 10 million biological samples (including RNA sequencing and proteomics) and 40 million documents (such as patents and clinical trials), using NLP and machine learning to uncover and prioritize novel therapeutic targets.
-The Chemistry42 module applies deep learning, including generative adversarial networks (GANs) and reinforcement learning, to design novel drug-like molecules optimized for binding affinity, metabolic stability, and bioavailability.
Together, they form the core of pharma.ai, enabling a more intelligent, integrated approach to drug discovery.
👉 Learn more: www.biopharmatrend.com/ai-drug-discovery-pipeline-2024/
#aidd #drugdiscovery #pandaomics #chemistry42 #pharmaai #targetdiscovery #generativeai
Insilico Medicine
@InSilicoMeds
Click here for the full report: www.biopharmatrend.com/ai-drug-discovery-pipeline-2024/
-
Insilico Medicine
@InSilicoMeds
Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis pubmed.ncbi.nlm.nih.gov/39666559/
-
Insilico Medicine
@InSilicoMeds
👉 Happening today at #drugdiscoverychemistry in San Diego!
Petrina Kamya, Ph.D. will take the stage at 11:20 am PST for: Leveraging #multiomics Data to Identify and Prosecute Targets Implicated in Women's Health
Endometriosis and alternative sources of non-hormonal contraception are neglected and challenging issues associated with women's health. Today, Petrina will discuss how we leverage multiomics data and AI to identify novel targets implicated in Endometriosis and how we contribute to the challenge of designing novel non-hormonal contraceptives using AI.
We hope to see you later today! www.drugdiscoverychemistry.com/artificial-intelligence
#ddc #sandiegobiotech -
Insilico Medicine reposted
Insilico LAIR
@precious_gpt
We are running a booth at Abu Dhabi Global Healthcare week. Stop by our booth at 5A14 to talk about biomedical AI 🦾🤖🧠
@ADGHWTweets -
Insilico Medicine
@InSilicoMeds
The first-ever drug generated entirely by artificial intelligence has entered Phase 2 clinical trials for the treatment of a deadly lung disease. The AI platform is being developed in Montreal by a company that is part of this new generation that promises to radically accelerate drug development.
ici.radio-canada.ca/info/long-format/2154434/medicament-i… -
Insilico Medicine
@InSilicoMeds
Can AI Improve Success in Drug Development?
I had the chance to speak with Petrina Kamya, Global Head of AI Platforms and VP at Insilico Medicine, as well as President of Insilico Medicine Canada. Petrina’s background is in both chemistry and computations.
Listen in here 👉cclifescience.substack.com/p/success-in-drug-development?…
#aipodcasts #aidd -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Great to hear and see Dr. Petrina Kamya, our president of Insilico Canada on air in Canada!❤️🇨🇦
ici.radio-canada.ca/info/long-format/2154434/medicament-i… -
Insilico Medicine
@InSilicoMeds
🚀 Did you catch the latest documentary from Insilico Medicine? Watch the latest video here.
We’re on the cusp of a revolutionary moment in science and medicine—a moment that redefines what’s possible. That’s why we’ve dedicated so much effort to telling the story of AI-powered #drugdiscovery: to inspire people, regardless of their location or stage in life, to join this incredible community of innovators.
We present you a documentary of the First: end-to-end discovery of a novel drug using #generativeai, where AI powered every step—starting from identifying a new target and designing a new molecule, through advancing into Phase 0, Phase I, and Phase II clinical trials.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🤝 [News Release] Thank you to Managed Healthcare Executive for the latest story: AI-Designed Drug for #ipf Gets Name, Fares Well in Early Trials
“The name Rentosertib is especially meaningful to us, as it not only honors [co-founder] Dr. (Feng) Ren’s contributions but also highlights the essential interplay between human scientific expertise and artificial intelligence in driving this innovative program forward,” Alex Zhavoronkov, co-founder and CEO of Insilico Medicine, said in a company release announcing the news.
Insilico Medicine’s research started with PandaOmics, an AI-driven biology engine that analyzed extensive datasets and identified #tnik (TRAF2 and NCK-interacting kinase) as a promising target for the treatment of IPF. Subsequently, the platform’s generative chemistry engine, Chemistry42, was employed to design and optimize small-molecule compounds that target TNIK, ultimately resulting in Rentosertib being nominated as a preclinical candidate.
Read the full article here: www.managedhealthcareexecutive.com/view/ai-designed-drug-…
Insilico Medicine
@InSilicoMeds
Continue reading: www.managedhealthcareexecutive.com/view/ai-designed-drug-…
-
Insilico Medicine
@InSilicoMeds
👉NEW Webinar Announcement:
The pharmaceutical industry is undergoing a paradigm shift as AI-driven technology in biotechnology (TechBio) strategies transform drug discovery and development. AI is enhancing data integration, cost efficiency, and success rates by identifying hidden patterns in complex biological datasets. From drug candidate identification to clinical trial optimization and CMC (chemistry, manufacturing, and controls) formulation, AI is accelerating pharma innovation.
Join this growth webinar on April 22 at 9am EDT, featuring Insilico CEO, Alex Zhavoronkov: frost.zoom.us/webinar/register/8017363553083/WN_hGynF4dfQ… -
Insilico Medicine
@InSilicoMeds
🔬 Heading to AACR 2025 in Chicago? We will see you there!
Insilico Medicine is proud to be exhibiting at the American Association for Cancer Research (AACR Journals) Annual Meeting—highlighting how AI-driven drug discovery is transforming oncology.
📍 Booth #334
📅 April 25–30, 2025
📌 McCormick Place Convention Center, Chicago
Come meet our team and explore how we can collaborate to bring new treatments to patients faster.
📧 Contact us: BD@insilico.com
🔗 insilico.com?pi_content=a4060cb4f917b2155751fc67945886f98…
#aacr2025 #oncologyinnovation #aidrugdiscovery #cancerresearch #pharmaai -
Insilico Medicine
@InSilicoMeds
🎧 New Podcast Episode – Now Streaming on Spotify.
Discovering Drugs with with AI - From SHIFT Podcast with Jennifer Strong
Artificial intelligence is playing an increasingly important role in the way new drugs are discovered. It’s radically changing how this process works, and speeding up the development of new therapies.
Hear from:
-Alex Zhavoronkov, CEO at Insilico Medicine
-Mike Nally, CEO at Generate Biomedicines
🔗 Listen here: open.spotify.com/episode/2HFEnQGK3HRzEfchTUOVZC -
Insilico Medicine
@InSilicoMeds
NEW Documentary from @RadioCanadaInfo 📹
The first-ever drug generated entirely by artificial intelligence has entered Phase 2 clinical trials for the treatment of a deadly lung disease. The AI platform, developed in Montreal, is part of a new generation of companies that promise to revolutionize drug development.
Épisode du dimanche 6 avril 2025 | Découverte ici.radio-canada.ca/tele/decouverte/site/episodes/1062781…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Allison Proffitt catches up with Insilico Medicine’s Alex Zhavoronkov after the morning keynote at hashtag #bioitexpo that explored #generativeai, aging research and robotics as a platform for #drugdiscovery and why if a drug is powerful enough to work in aging, it should in multiple diseases.
www.youtube.com/watch?v=8-3obeulZwE
Insilico Medicine
@InSilicoMeds
Video here: www.youtube.com/watch?v=8-3obeulZwE
-
Insilico Medicine
@InSilicoMeds
Bio-IT World is not over yet! Join Petrina Kamya, PhD, Global Head of AI Platforms & VP at Insilico Medicine, as she takes the stage for an exciting panel discussion on:
🎙️ Unlocking AI Potential: Best Practices for Implementation and Management
📍 Omni Boston Hotel & Virtual
📅 Today, April 2, 2025, 2:35 pm
Featured Speakers:
🔹 Nagaraja Srivatsan – Founder, Vidya Seva (Chair & Moderator)
🔹 Dimitris K. Agrafiotis, PhD – Director, Digital, Analytics, and AI, Arsenal Capital Partners
🔹 Julie Bryant – Chief Strategy Officer & Founder, Rancho BioSciences
🔹 Vinod Das (SK) – R&D Drug Innovation, AI Solutions, Bayer Pharmaceuticals
🔹 Petrina Kamya, Ph.D. – Global Head of AI Platforms & VP, Insilico Medicine; President, Insilico Medicine Canada
Join us for a dynamic discussion to harness AI’s full potential in life sciences innovation. www.bio-itworldexpo.com/drug-discovery-informatics
#bioitexpo #bioitworld #aiimplementation #bostonconferences -
Insilico Medicine
@InSilicoMeds
🚨 Happening Today, 330 PM at Bio-IT World!
Join Petrina Kamya, Ph.D., Global Head of AI Platforms & VP at Insilico Medicine, as she takes the stage to discuss "Revolutionizing Drug Discovery with Generative AI" 🤖. This talk will explore how generative AI is transforming this paradigm through Insilico Medicine’s innovative machine learning platform, enabling novel target identification, small molecule design, and clinical trial prediction.
📍 Boston, MA | Generative AI Track | Omni Boston Hotel Seaport
⏰ 3:30 pm
🔗 For more information, visit: www.bio-itworldexpo.com/generative-ai
#bioitworld #generativeai #aifordrugdiscover #insilicomedicine #precisionmedicine #bioitexpo -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:731361384761…
Follow along for all coverage from #bioitexpo! Thank you to @bioitworld for this interview.
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚨 Happening NOW at Bio-IT World! 🚨
💡 Join Michelle Chen, PhD, VP at Insilico Medicine, and an esteemed panel of biotech investment leaders for a dynamic discussion on Optimizing Investment Strategies in Biotech.
#bioitexpo -
Insilico Medicine
@InSilicoMeds
🚨 Happening in just a few minutes (8:45 am) ... Don’t Miss CEO, Alex Zhavoronkov's Plenary Keynote at Bio-IT World! 🚨
🔬Generative AI, #aging Research & #robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy 🔬
#bioitexpo -
Insilico Medicine
@InSilicoMeds
From aginganddisease.org: How a Drug Candidate for Rare Diseases Could Be the Key to Living Longer
Check out our latest paper: "AI-driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent."
Insilico Medicine
@InSilicoMeds
For more information, please visit: www.aginganddisease.org/EN/10.14336/AD.2024.1492
-
Insilico Medicine reposted
Future Health – A Global Initiative by Abu Dhabi
@FutureHealthAD
Welcoming Alex Zhavaronkov, PhD, Founder and Chief Executive Officer, @InSilicoMeds, to the Forum @ ADGHW from 15 - 17 April 2025, ADNEC Centre Abu Dhabi, UAE.
Alex Zhavoronkov, PhD, is a pioneer in generative AI and robotics for drug discovery, leading Insilico Medicine in revolutionising biotechnology. With over 200 research papers and groundbreaking AI-driven drug advancements, his expertise is shaping the future of precision medicine.
Join Alex at the Forum @ ADGHW as he explores the transformative role of AI in accelerating drug discovery and healthcare innovation.
Book your delegate pass: www.adghw.com/forms/delegate-registration/
Download the conference brochure: www.adghw.com/forms/forum-adghw-brochure/
#adghw #abudhabi #doh #futureofhealth #globalhealth #towardslongevityredefininghealthandwellbeing -
Insilico Medicine reposted
BIS Research
@BISResearch
From molecule to miracle quantum computing #startups are revolutionizing drug discovery. @qubit_pharma @InSilicoMeds @QuantumKuano @aqemia & @proteinqure harness quantum mechanics, #ai , & biophysics to accelerate medical breakthroughs.
#drugs #healthtech #startupsuccess #trend -
Insilico Medicine
@InSilicoMeds
Thank you to @HSBC for hosting Insilico CEO, Alex Zhavoronkov at the Private Wealth Summit. For event coverage, please visit: www.linkedin.com/feed/update/urn:li:activity:731141151900…
-
Insilico Medicine
@InSilicoMeds
🚀 Next week, the Insilico Team heads to Bio-IT World!
🎤 Plenary Keynote:
🧠 Alex Zhavoronkov, PhD – Founder & CEO, Insilico Medicine
Generative AI, Aging Research, and Robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy
🔬 Featured Sessions:
📌 Petrina Kamya, Ph.D. – Unlocking AI Potential: Best Practices for Implementation and Management
📌 Michelle Chen, PhD – Optimizing Investment Strategies in Biotech
The program features inspiring plenary keynotes, 200+ educational and technical presentations, interactive panels, hands-on symposia, technical workshops, unparalleled networking opportunities, and an exhibit hall showcasing cutting-edge technologies and solutions.
📅 April 2-4, 2025 | Boston, MA + Virtual
🔗 Reserve your spot now: www.bio-itworldexpo.com
Our team will be onsite throughout the week. Connect with us here or on the Bio-IT World Networking app! Email: BD@insilico.com
#bioitworld #aiinbiotech #drugdiscovery #generativeai #insilicomedicine #precisionmedicine -
Insilico Medicine
@InSilicoMeds
We’re on the cusp of a revolutionary moment in science and medicine—a moment that redefines what’s possible. That’s why we’ve dedicated so much effort to telling the story of AI-powered drug discovery: to inspire people, regardless of their location or stage in life, to join this incredible community of innovators.
We present you a documentary of the First: end-to-end discovery of a novel drug using generative AI, where AI powered every step—starting from identifying a new target and designing a new molecule, through advancing into Phase 0, Phase I, and Phase II clinical trials.
And the First: drug discovered through groundbreaking aging research, representing a monumental leap toward healthier, longer lives.
And the First Potential:Longevity gerotherapeutic—a drug designed to address the underlying biology of aging—developed with artificial intelligence as the driving force behind its discovery.These extraordinary milestones highlight how AI and cutting-edge scientific research are coming together to accelerate innovation in human healthspan. From initial conception to human trials, this journey serves as a testament to the transformational power of interdisciplinary collaboration.This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🚀 1-Week Countdown to Bio-IT World 2025!
We're just one week away from Bio-IT World 2025, where AI, robotics, and aging research are transforming drug discovery. Insilico Medicine is excited to have three incredible speakers taking the stage:
🎤 Plenary Keynote:
🧠 Alex Zhavoronkov, PhD – Founder & CEO, Insilico Medicine
Generative AI, Aging Research, and Robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy
🔬 Featured Sessions:
📌 Petrina Kamya, Ph.D. – Unlocking AI Potential: Best Practices for Implementation and Management
📌 Michelle Chen, PhD – Optimizing Investment Strategies in Biotech
The program features inspiring plenary keynotes, 200+ educational and technical presentations, interactive panels, hands-on symposia, technical workshops, unparalleled networking opportunities, and an exhibit hall showcasing cutting-edge technologies and solutions.
📅 April 2-4, 2025 | Boston, MA + Virtual
🔗 Reserve your spot now: www.bio-itworldexpo.com
Our team will be onsite throughout the week. Connect with us here or on the Bio-IT World Networking app! Email: BD@insilico.com
#bioitworld #aiinbiotech #drugdiscovery #generativeai #insilicomedicine #precisionmedicine -
Insilico Medicine
@InSilicoMeds
www.mmm-online.com/features/game-changers-2025-ai-takes-c… Healthcare organizations are taking a fundamentally different approach to AI now. It’s not just about new models or bigger datasets, but about trust, human impact, and systemic integration.
Organizations that use AI tools well aren’t just launching new tech; they are fundamentally rethinking how healthcare can work better.
Read the full article to learn more about how healthcare leaders are navigating AI integration across four key dimensions — consumer trust, talent augmentation, enterprise technology, and systemic integration.
www.mmm-online.com/features/game-changers-2025-ai-takes-c…
#aiinhealthcare #healthtech #aitransformation #healthcareinnovation #digitalhealth #healthcareleadership #artificialintelligence #futureofhealth -
Insilico Medicine
@InSilicoMeds
The next generation from Nach0: "Join Waitlist"
www.linkedin.com/pulse/next-generation-from-nach0-join-wa… -
Insilico Medicine
@InSilicoMeds
AI-Powered Drug Discovery: A Breakthrough in MASH Treatment www.panda-int.com/insights/ai-powered-drug-discovery-a-br…
-
Insilico Medicine
@InSilicoMeds
AI helps find promising therapeutic target for rare salivary gland cancer www.uchicagomedicine.org/forefront/cancer-articles/ai-hel…
-
Insilico Medicine
@InSilicoMeds
A Deep Dive with Leaders from Insilico Medicine & Generate Biomedicines 🎙️
What happens when two pioneers in AI-driven drug discovery take the stage at #humanx Conference? Alex Zhavoronkov, PhD (Founder & CEO, Insilico Medicine) and Mike Nally, CEO of Generate Biomedicines discuss the future of Generative AI in biopharma, the evolution of AI-first drug development, and how breakthroughs in AI-driven protein design are reshaping medicine.
📺 Watch the full conversation here: 🔗 [www.youtube.com/watch?v=KRcDKwWMGio]
This discussion is a must-watch for anyone interested in how AI is revolutionizing drug discovery, biologics, and the future of biotech. Let’s keep pushing the boundaries of AI and biopharma innovation!
#aiinbiomedicine #generativeai #drugdiscovery #biotech #humanx #pharmaai #machinelearning #insilicomedicine #aiforhealth
Insilico Medicine
@InSilicoMeds
Full Video can be found here: www.youtube.com/watch?v=KRcDKwWMGio
-
Insilico Medicine
@InSilicoMeds
How two Hong Kong firms’ innovative solutions enhance well-being in belt and road regions [March 24, 2025] 🤝
Dr Alex Zhavoronkov, the company’s founder and CEO, says AI drug discovery – where “frontier AI technology” is used to more quickly and efficiently understand diseases and develop effective treatments – will play an increasingly important role in improving the quality of life for people around the world.
His firm’s pharma.ai platform, a #genai-powered #software and #robotics solution used in the fields of #biology, #chemistry, medicine development and science research, has helped to develop a portfolio of 31 programmes for 29 drug targets.
Read more about these programmes and the pharma.ai platform here: pharma.ai -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀 We’re thrilled to share that Alex Zhavoronkov, Founder & CEO of Insilico Medicine, will be a guest speaker at the Private Wealth Sessions during the HSBC Global Investment Summit 2025! 🚀
🔍 What to Expect:
✅ The role of AI in drug discovery & longevity science
✅ The intersection of biotech innovation & global investment
✅ How AI-driven platforms like pharma.ai are reshaping the future of medicine
We will share perspectives on AI’s impact on the industry — what’s working, what’s not, and where real progress is happening in healthcare and biotech.
Looking forward to the discussion!
#hsbcgis #hsbcglobalsummit #theprivatewealthsessions
Insilico Medicine
@InSilicoMeds
See the event details here: www.gbm.hsbc.com/en-gb/campaigns/global-investment-summit
-
Insilico Medicine
@InSilicoMeds
Thank you to ainews.com - Company Page for hosting Alex Zhavoronkov at the 2025 #humanx Conference to explore how AI-powered drug discovery is revolutionizing #biopharma, #aging research, and the future of human health. www.youtube.com/watch?v=3VmDmJJTqaM
📌 Highlights:
✅ AI-Driven Drug Discovery – How Insilico’s generative AI models are transforming the drug development pipeline
✅ Fighting Aging & Disease – Why Insilico targets aging as the root cause of multiple diseases
✅ Clinical Success – The journey behind Insilico’s AI-designed drug advancing through Phase 2A trials
✅ Robotics in Biotech – How fully autonomous labs and humanoid robots optimize R&D
✅ Quantum Computing – The future role of quantum tech in molecular generation
✅ Global Collaboration – Why Insilico sees China as a key partner in accelerating drug testing and development
✅ Longevity Research – How AI could unlock longer, healthier lives for future generations
Insilico Medicine
@InSilicoMeds
See the full video here: www.youtube.com/watch?v=3VmDmJJTqaM
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine Raises $110M to Advance AI Drug Discovery www.ainews.com/p/insilico-medicine-raises-110m-to-advance…
-
Insilico Medicine reposted
BioWorld
@BioWorld
.@InSilicoMeds advancing AI platform with $110M Asian-backed series E round www.bioworld.com/articles/718333 #biotech #pharma
-
Insilico Medicine
@InSilicoMeds
“The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico’s leadership in this rapidly evolving sector. We remain dedicated to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare,” Insilico founder and CEO Alex Zhavoronkov said in a statement.
www.fiercebiotech.com/medtech/insilico-medicine-raises-11… -
Insilico Medicine
@InSilicoMeds
From Reshaping Newborn Screening to Redefining Longevity Science, Bio-IT World 2025 Will Highlight Transformative Applications of New Technologies www.abc27.com/business/press-releases/cision/20250313NE40…
-
Insilico Medicine reposted
Tatyana Kanzaveli
@glfceo
The Pharma Industry’s AI Wake-Up Call: Are You Ready?
At #sxsw, in deep conversations with @biogerontology, I saw firsthand how #ai is no longer just an “accelerator” in drug discovery—it’s rewriting the playbook.
#pharma execs: The old model is crumbling. Timelines that once took a decade are now measured in months. AI isn’t a tool—it’s a strategic imperative. The question isn’t if AI will reshape your R&D, but whether you’ll lead or lag behind.
@InSilicoMeds is proving it: AI-designed drugs in clinical trials, predictive engines for success rates, and a redefinition of precision medicine. This is happening now, not in the future.
If your company is still debating AI adoption rather than embedding it into every layer of discovery and development, you’re already late. The winners in this AI-driven biotech revolution will be those who move fast, bold, and with vision.
Are you one of them? -
Insilico Medicine
@InSilicoMeds
Your next supervisor might be an android. Could this AI-controlled research robot be the future of science? thestar.com/business/technology/your-next-supervisor-migh…
-
Insilico Medicine
@InSilicoMeds
Insilico's humanoid robots can perform laboratory tasks that require more dexterity and expand beyond the capabilities of the existing autonomous guided vehicles, according to Zhavoronkov.
www.bizjournals.com/boston/inno/stories/news/2025/03/17/i… -
Insilico Medicine
@InSilicoMeds
🚀 Using Insilico Medicine's AI-driven platform #pandaomics, the research team identified two novel therapeutic targets: HCK and GDP2, paving the way for breakthrough treatments.
Watch the video to see how AI is accelerating drug discovery and driving innovation in women’s health.
#aifordrugdiscovery #endometriosisawareness #womenshealth #pandaomics #insilicomedicineThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Accelerating Drug R&D: Harnessing Robotics and AI for Breakthroughs www.linkedin.com/pulse/accelerating-drug-rd-harnessing-ro…
Using Science42: #dora
#dorawriting @dorawriting -
Insilico Medicine
@InSilicoMeds
First AI-designed drug, Rentosertib, officially named by USAN www.drugtargetreview.com/news/157365/first-ai-designed-dr…
-
Insilico Medicine
@InSilicoMeds
interestingengineering.com/innovation/us-humanoid-deploye…
Video: US unveils ‘scientist’ humanoid robot to boost drug discovery, experiments -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds raised US$110 million in its Series E funding round. The funding will enhance Insilico Medicine's AI platform and support the clinical development of Rentosertib, its lead candidate for idiopathic pulmonary fibrosis.
Insilico Medicine
@InSilicoMeds
Insilico Medicine raises $110M for new trials and robotic helping hands:
Alongside new steps in its #therapeuticpipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 million to carry forward its artificial intelligence-powered drug design platforms.
Read the full article from @FierceBiotech here: www.fiercebiotech.com/medtech/insilico-medicine-raises-11… -
Insilico Medicine reposted
Bauris T, Ph.D
@aiinlabcoat
This week's AI Healthcare Roundup:
• Evaluating AI for Suicide Response
• AI Digital Twins for Trans Patients
• AI and BCI Restore Speech in ALS
plus: 12 funded Startup this week -
Insilico Medicine
@InSilicoMeds
🐼Need a refresher on #pandaomics?
PandaOmics is a cloud-based software platform that applies #artificialintelligence and #bioinformatics techniques to multimodal #omics and biomedical text data for therapeutic target and biomarker discovery.
🔥PandaOmics generates novel and repurposed therapeutic target and biomarker hypotheses with the desired properties and is available through licensing or collaboration. Targets and biomarkers generated by the platform were previously validated in both in vitro and in vivo studies.
PandaOmics is a core component of Insilico Medicine’s pharma.ai drug discovery suite, which also includes Chemistry42 for the de novo generation of novel small molecules, and inClinico─a data-driven multimodal platform that forecasts a clinical trial’s probability of successful transition from phase 2 to phase 3. In this paper, we demonstrate how the PandaOmics platform can efficiently identify novel molecular targets and biomarkers for various diseases.
Read this paper from the Journal of Chemical Information and Modeling today: pubs.acs.org/doi/10.1021/acs.jcim.3c01619 -
Insilico Medicine reposted
Wes Nichols
@wesnichols
AI’s biggest impact will be on drug discovery and cures. We are finally seeing the benefits of scale in biotechnology thanks to AI. “When complex systems become engineerable , technological breakthroughs occur”- @mike_nally of @generate_biomed
“We haven’t solved biology yet- if we just double what we know over the next ten years, think of the cures that can occur.” #humanx -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Insilico seals unicorn status after landing $110m for AI drug discovery
Company gears up for pivotal trials of AI-developed IPF drug candidate following encouraging Phase 2 data.
#longevity #investment #ai #biotech
longevity.technology/news/insilico-seals-unicorn-status-a… -
Insilico Medicine reposted
Genetic Engineering & Biotechnology News
@GENbio
With $110M Financing Complete, Insilico Eyes Platform, Pipeline Progress
@InSilicoMeds @BuckInstitute
www.genengnews.com/topics/artificial-intelligence/with-11… -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine raises $110M for new trials and robotic helping hands:
Alongside new steps in its #therapeuticpipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 million to carry forward its artificial intelligence-powered drug design platforms.
Read the full article from @FierceBiotech here: www.fiercebiotech.com/medtech/insilico-medicine-raises-11…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
ADKEEDA
@Adkeeda5
Insilico Medicine unveils “Supervisor,” an AI-powered humanoid robot for drug discovery labs!
Follow @adkeeda for more updates!
#ai #robotics #biotech #innovation #science #technology #automation #future #adkeeda @InSilicoMeds -
Insilico Medicine reposted
Rich Law
@drrichjlaw
Congrats and good luck Insilico! @biogerontology @InSilicoMeds
endpts.com/insilico-nabs-110m-series-e-for-ai-drug-discov… -
Insilico Medicine reposted
Ryan Flinn
@RS_Flinn
Bloomberg reporting by @SarithaRai that @InSilicoMeds raised $100 million - CEO @biogerontology confirms at #humanx this morning.
-
Insilico Medicine
@InSilicoMeds
🚀NEW from @business @Bloomberg
AI Drug Startup Insilico Weighs Hong Kong IPO After Funding
Insilico Medicine Inc. has secured $110 million in funding, valuing the company at over $1 billion, and is considering an initial public offering. Read the full article here:
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀Coming Soon: #nach01 from Insilico Medicine.
Train accurate #generative and #predictivemodels on your data
Specially designed for both #2d and #3d molecular tasks. Seamlessly integrate and enhance your pipeline by fine-tuning our foundation model using your data. -
Insilico Medicine
@InSilicoMeds
🚨 Insilico CEO, Alex Zhavoronkov, @biogerontology , joins the "The era of generative AI in drug discovery and longevity" roundtable at #humanx2025 tomorrow!
This roundtable will explore how #generativeai is revolutionizing drug discovery and advancing longevity research, highlighting practical achievements, current challenges, and the future of AI-driven innovation in healthcare.
We hope to see you tomorrow in Las Vegas! Event details can be found here: www.humanx.co/interactivesessions -
Insilico Medicine
@InSilicoMeds
Learn more about #pandaomics in our Application Note
PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery
From: Journal of Chemical Information and Modeling
pubs.acs.org/doi/10.1021/acs.jcim.3c01619 -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:730528400551…
⭐ Congratulations to Insilico CBO, Michelle Chen
We’re proud to see Michelle Chen featured in this spotlight by The Alliance for Artificial Intelligence in Healthcare (AAIH)🎉
As a leader in AI-driven drug discovery, Michelle plays a key role in advancing Generative AI. Her dedication and vision continue to push the boundaries of AI-powered healthcare innovation.
Join us in celebrating International Women’s Month and recognizing the incredible contributions of women driving change in AI and biotech. 🚀
🔗 Check out the full post below!
#womeninai #aiforhealthcare #drugdiscovery #generativeai #insilicomedicine #leadership -
Insilico Medicine
@InSilicoMeds
NEW Release 🚀
First end-to-end generative AI-assisted drug ISM001-055 receives official generic name #rentosertib from USAN
See the release here: www.eurekalert.org/news-releases/1076031 -
Insilico Medicine
@InSilicoMeds
A Bright Future for AI in Pharma, the latest from MedCityNews
The future will see more pharma companies leveraging AI to improve diversity and inclusion, especially in trials that are diverse by design, as well as the odds of finding patients who fit an acceptable set of inclusion/exclusion criteria to accelerate clinical trial timelines.
medcitynews.com/2025/03/a-bright-future-for-ai-in-pharma/ -
Insilico Medicine
@InSilicoMeds
Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for #endometriosis
See the full study here: pubmed.ncbi.nlm.nih.gov/39666559/ -
Insilico Medicine reposted
Gabrielle Vaucan
@GabrielleVaucan
Insilico Medicine deploys the first bipedal humanoid AI scientist in the fully-robotic drug discovery laboratory, via @EurekAlert! @InSilicoMeds www.eurekalert.org/news-releases/1075930
-
Insilico Medicine
@InSilicoMeds
🚀 Happening This Week at Insilico Medicine!
Our team is hitting the stage at two major conferences this week!
📍 Las Vegas, March 10-13, 2025 – Our Founder & CEO, Alex Zhavoronkov, will be speaking at HumanX, one of the most important AI events of the year! Don’t miss his insights on AI-powered drug discovery, part of the "AI in drug discovery: Pioneering a new era of medicine" session.
📍 London, March 10-11, 2025 – Petrina Kamya, President of Insilico Medicine Canada Inc. & Global Head of AI Platforms, will be sharing cutting-edge developments at AI in Drug Discovery 2025. Join Petrina for this session that will dive deeper into:
💡 Combining Insilico’s AI platform with a fully automated, nextgeneration laboratory for maximal success
✏️ Detailing the recent advances in Insilico’s clinical pipeline – results from phase 2
⚡ Challenges associated with progressing AI-designed molecules through the pipeline
🔗 Stay tuned for key takeaways from both events!
#ai #drugdiscovery #generativeai #biotech #insilicomedicine -
Insilico Medicine
@InSilicoMeds
interestingengineering.com/innovation/us-humanoid-deploye…
US unveils ‘scientist’ humanoid robot to boost drug discovery, experiments
AI-driven humanoids boost automation, streamline workflows, and speed up scientific progress while reducing human involvement in labs. -
Insilico Medicine reposted
Wevolver
@WevolverApp
Insilico Deploys First Bipedal Humanoid at AI-Powered Robotic Lab
Insilico Medicine introduces 'Supervisor,' a bipedal humanoid designed to assist with data acquisition, AI training, and lab supervision. The humanoid will also support lab tours and telepresence.
Video source: @InSilicoMeds
#humanoid #bipedal #robotics #technology #engineering #stem #innovation #robots
—————————————
Stay ahead of the curve in engineering!
Follow the topics that inspire you on Wevolver and get a custom weekly digest packed with cutting-edge content!
Follow now: wevlv.co/follow-wevolver-twThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
JMC|With generative AI assistance, Insilico Medicine announces novel CDK12/13 dual inhibitors for tumor treatment
Published in the Journal of Medicinal Chemistry (IF=7.2), the study showcases the discovery of compound 12b, a potent, selective, and safe therapy targeting CDK12/13, empowered by Insilico’s proprietary generative AI platforms including PandaOmics and Chemistry42.
www.eurekalert.org/news-releases/1074881 -
Insilico Medicine
@InSilicoMeds
🔥 #sxsw2025 begins in Austin tomorrow. Thank you to the organizers at SXSW.
Hear Insilico CEO, Alex Zhavoronkov, PhD, during “The Power of Generative Artificial Intelligence to Transform Medical Research” session at the JW Marriott Austin
👉 Event details can be found here, and we hope to see you tomorrow! www.sxsw.com -
Insilico Medicine
@InSilicoMeds
Insilico Deployed the First Bipedal Humanoid at the AI-Powered Fully-Rob... youtu.be/J_Z-xfmcY6U via @YouTube
-
Insilico Medicine
@InSilicoMeds
Insilico And Tenacia Collaborate To Advance CNS Therapeutics With #generativeai
quantumzeitgeist.com/insilico-and-tenacia-collaborate-to-… -
Insilico Medicine
@InSilicoMeds
NEW Video 📹Mutations in the HIPPO pathway drive activation of the TEAD family of transcription factors, which in turn promotes the expression of genes involved in cell proliferation and survival, in addition to resistance to targeted therapies.
Subsequently, TEAD pathway over-activation is associated with tumorigenesis, making this family of proteins an attractive target for oncology drug development.
Here, our Chief Medical Officer Sujata Rao and Associate Director (BD) Sean Cullen explore the latest developments in the TEAD inhibitor space and highlight Insilico Medicine's internal TEAD inhibitor program which has just entered phase 1 clinical trials.
Watch here: www.youtube.com/watch?v=k_YuS_PCOsI
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
✍ New Study Highlights Need for Personalized #radiotherapy in Brain Cancer Treatment [NEW Release]
Scientists at Insilico Medicine and the University of Copenhagen (Københavns Universitet) conducted a comprehensive study examining the variability in radiotherapy outcomes across different cancer types, with a focus on glioblastoma multiforme (GBM) and low-grade gliomas (LGG).
Published in the Aging (Aging-US) Journal, the research highlights significant differences in radiotherapy efficacy between these two brain tumor types, emphasizing the need for personalized treatment approaches. The researchers utilized the Science42: #dora AI tool for literature analysis and content drafting. They collected and analyzed data on GBM and LGG—two brain tumors with distinct responses to radiotherapy. A signaling pathway enrichment analysis identified key pathways associated with radiotherapy resistance and sensitivity.
🎯 The study found that while radiotherapy improves survival in GBM patients, it worsens outcomes for those with LGG. This disparity is linked to differences in the regulation of pathways related to programmed cell death, DNA repair, telomere maintenance, chromosome condensation, antiviral responses, and interferon signaling between the two patient groups. These findings underscore the significant variability in radiotherapy outcomes between GBM and LGG. The use of AI tools like DORA in academic research enhances literature analysis and streamlines drafting, contributing to more effective research workflows.
Continue reading: www.aging-us.com/article/206212/text
#dorawriting #academicresearch #publications @dorawriting
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀 Kicking off the week with two exciting conference presentations from Insilico Medicine!
📢 On March 3, Petrina Kamya, Ph.D., will take the stage at #ddip2025 in San Diego to discuss real-world studies in AI-driven drug discovery and development.
📢 On March 7, Alex Zhavoronkov, PhD will be at #sxsw2025 in Austin, sharing insights on the power of Generative AI to transform the future of medical research.
Join us as we explore the cutting edge of AI in drug discovery! 🔬✨
📍 DDIP 2025 – Hilton San Diego Bayfront (drug-discovery-conference-us.worldbigroup.com)
📍 SXSW 2025 – JW Marriott Austin (www.sxsw.com)
#ai #drugdiscovery #genai #sxsw #ddip #insilicomedicine #biotechinnovation -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
Maksim Kuznetsov
@Max__Kuznetsov
1/ At @InSilicoMeds, we’re exploring how language models can process and generate 3D molecular structures.
nach0-pc fuses a specialized text-based representation with a domain-specific encoder, enabling precise generation and conditioning on 3D molecular structures. -
Insilico Medicine
@InSilicoMeds
NEW Release from @SpringerNature | February 27, 2025
🚀 Insilico Medicine: Pioneering AI-Driven Drug Discovery
A recent Nature article highlights how Insilico Medicine is revolutionizing drug discovery by integrating vast datasets from US government-funded research into their #aiplatforms. This approach accelerates the identification of novel therapeutic targets and the development of effective treatments.
By harnessing the power of AI and big data, Insilico Medicine is transforming scientific research into actionable medical solutions.
Read more: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
#bigdata#InsilicoMedicine #pharmaai #medicalinnovation -
Insilico Medicine
@InSilicoMeds
🔬 AI Meets Anti-Aging: Exciting New Study on Insilico’s IPF Drug!
A groundbreaking study featured in Genetic Engineering & Biotechnology News (GEN) highlights the anti-aging potential of Insilico Medicine’s AI-designed IPF candidate. This discovery underscores the power of AI-driven drug discovery in accelerating breakthroughs for age-related diseases.
With our cutting-edge pharma.ai platform, we’re not just tackling fibrosis—we’re opening new doors for longevity and regenerative medicine.
🚀 Read the full story here: [www.genengnews.com/topics/artificial-intelligence/study-s…]
#aiinbiotech #drugdiscovery #agingresearch #pharmaai #insilicomedicine -
Insilico Medicine reposted
Peter Ottsjö
@peterottsjo
Here's my feature on @biogerontology and @InSilicoMeds in @nyteknik (in Swedish). It was great talking to Alex and we hope to have him as a guest on the LEVITY podcast at some point. www.nyteknik.se/innovation/pionjaren-skapar-nya-lakemedel…
-
Insilico Medicine reposted
Live Forever Club
@liveforeversoc
TNIK inhibition reduces senescence and fibrosis, aiding longevity research @InSilicoMeds @biogerontology
Ongoing clinical trials aim to confirm its effectiveness in human therapies #labautomation #medtech #senescence #senolytics
liveforever.club/article/tnik-inhibition-reduces-senescen… -
Insilico Medicine
@InSilicoMeds
Pioneer creates new drugs in record time – "The risk of failure is extremely high"
It can take over ten years to create a drug. In less time than that, Latvian @biogerontology Alex Zhavoronkov has founded Insilico Medicine, built an AI platform and developed a drug candidate that is being tested in clinical studies. Now the world's major pharmaceutical companies are working to catch up.
Full story can be found here: www.nyteknik.se/innovation/pionjaren-skapar-nya-lakemedel… -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
If you are wondering what we have been doing at Insilico in the past 2 months, here is a 7-minute update. The future is very bright and this year you should expect more cool software and hardware products from us and many more preclinical and clinical milestones. No prep, no assistants, just wanted to stand up and record and update for my colleagues and friends.
Let's work harder to Make Pharma Great Again!This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🚀 More Exciting News from Insilico Medicine at AAAI 2025!
We’re excited to present our latest AI research for molecular design at AAAI 2025! Join us on Feb 27, Thursday, as we showcase #bindgpt, a modern way to train language models with reinforcement learning for 3D molecular generation. If you're attending AAAI 2025, stop by our poster session to explore how AI can accelerate and optimize molecular design.
✏️ Poster #15035
📅 Feb 27, 2025
📍 AAAI 2025 Conference
Key Highlights 📣
✅ All-in-One Model: BindGPT seamlessly integrates 3D #moleculargeneration, conformer generation, and pocket-conditioned molecule generation—all within a single model.
✅ Scalable & Efficient: Uses the standard #llm paradigm, eliminating the need for specialized diffusion models, graph-based techniques, or other inductive biases.
✅ Simplified & Powerful: Leverages a SMILES+XYZ format for end-to-end 3D molecular modeling, bypassing the need for external chemical software to reconstruct molecular bonds.
Let’s accelerate drug discovery with AI together. See you in Philadelphia!
bindgpt.github.io -
Insilico Medicine
@InSilicoMeds
Only 2 days left! 👇
Academic Researchers: Maximize Your Budget with DORA! 🎓💰
With 2025 bringing budget cuts, funding for research is tighter than ever.
Science42: #dora is here to help academics stay ahead—offering AI-powered insights to accelerate discoveries at a fraction of the cost.
Don’t let budget constraints slow down your breakthroughs. Take advantage of exclusive savings on DORA today!
🔗 Learn more before this winter sale ends: pharma.ai/dora
#aiforacademia #researchfunding #academicsavings #science42 #dorawriting -
Insilico Medicine
@InSilicoMeds
🔬 AI Meets Anti-Aging: Exciting New Study on Insilico’s IPF Drug!
A groundbreaking study featured in Genetic Engineering & Biotechnology News (GEN) highlights the anti-aging potential of Insilico Medicine’s AI-designed IPF candidate. This discovery underscores the power of AI-driven drug discovery in accelerating breakthroughs for age-related diseases.
With our cutting-edge pharma.ai platform, we’re not just tackling fibrosis—we’re opening new doors for longevity and regenerative medicine.
🚀 Read the full story here: [www.genengnews.com/topics/artificial-intelligence/study-s…]
#aiinbiotech #drugdiscovery #agingresearch #pharmaai #insilicomedicine -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
@InSilicoMeds, a Qiming Venture Partners' portfolio company, reveals TNIK inhibition as a promising new anti-aging strategy. AI-driven research identifies Rentosertib as a potent senomorphic agent, with findings published in Aging and Disease.
#qmportfolio -
Insilico Medicine
@InSilicoMeds
Insilico has now officially announced key timeline benchmarks for its 22 developmental candidates, emphasizing its commitment to efficiency, transparency and innovation in #drugdevelopment:
# of DC Nominations (2021–2024): 22 candidates
Average time to DC: 12-18 months; 60-200 molecules synthesized per program
Shortest time to DC: 9 monthsQPCTL program co-developed with Fosun Pharma and in ongoing Phase I trial
www.eurekalert.org/news-releases/1073344 -
Insilico Medicine reposted
Genetic Engineering & Biotechnology News
@GENbio
Study Shows Anti-Aging Potential for @InSilicoMeds's IPF Candidate
ISM001-055 was shown to have attenuated cellular senescence through the suppression of various #aging processes, thus showing potential as a senomorphic drug.
www.genengnews.com/topics/artificial-intelligence/study-s… -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Congrats to Qiming Venture Partners' portfolio company @InSilicoMeds on its collaboration with @Harbour_BioMed to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective strengths in antibody discovery and AI.
#qmportfolio -
Insilico Medicine reposted
TimePie (focus on anti-aging science)
@TimePieChina
Researchers from @InSilicoMeds and two partner institutions published a study concluding that its lead candidate ISM001-055 could function as a senomorphic agent. #aging
www.aginganddisease.org/EN/10.14336/AD.2024.1492
www.genengnews.com/topics/artificial-intelligence/study-s… -
Insilico Medicine
@InSilicoMeds
Academic Researchers: Maximize Your Budget with DORA! 🎓💰
With 2025 bringing budget cuts, funding for research is tighter than ever.
Science42: DORA is here to help academics stay ahead—offering AI-powered insights to accelerate discoveries at a fraction of the cost.
Don’t let budget constraints slow down your breakthroughs. Take advantage of exclusive savings on DORA today!
🔗 Learn more: pharma.ai/dora
#aiforacademia #researchfunding #academicsavings #science42 -
Insilico Medicine
@InSilicoMeds
www.eurekalert.org/news-releases/1073344
Cambridge, MA – Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate (DC) nominations achieved by its platform from 2021 to 2024. These benchmarks underscore the platform's efficiency and represent a potential new standard for the drug discovery industry by significantly reducing developmental times, cost, and by allowing resources to be redirected toward further research and development. -
Insilico Medicine reposted
Subhodayam Subbarao
@rajasekharaa
How is AI revolutionising the entire pharma value chain—from R&D to commercialisation? Join our power-packed panel as they explore AI’s impact on drug discovery, supply chains, manufacturing, quality, and operations.
bioasia.in/2025/
@ShakthiNa… -
Insilico Medicine
@InSilicoMeds
JMC | Insilico Medicine unveils novel AI-driven FGFR2/3 inhibitor to overcome resistance tumor mutations
www.eurekalert.org/news-releases/1072930 -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
www.bioanalysis-zone.com/insilico-go-in-vivo-with-new-pro… Insilico go in vivo with new promising and selective FGFR2/3 inhibitors
-
Insilico Medicine
@InSilicoMeds
🚀 NEW Conference Announcement: Join Alex Zhavoronkov, Mass General Brigham, and Open Health Network during "The Power of #genai To Transform the Future of Medical Research" panel at the #sxsw2025 Conference.
✏️ Details: Unleash the future of clinical trials with Generative AI. Explore how AI accelerates drug development, enhances precision, and improves patient outcomes. Our expert panel will showcase real-world applications, tackle ethical challenges, and highlight the transformative power of GenAI in medical research. Join us for an inspiring and informative session at the cutting edge of AI and healthcare, designed to drive the next wave of medical innovation.
See the full list of speakers and sessions here: schedule.sxsw.com?year=2025 -
Insilico Medicine
@InSilicoMeds
🚀 Exciting news! Insilico Global Head of AI Platforms, and President of Insilico Medicine Canada, Petrina Kamya, Ph.D. will be speaking at the SAE Media Group AI in Drug Discovery conference, sharing insights on how AI is transforming drug development! 💡
If you're attending, be sure to catch her session "An end-to-end AI platform for novel drug discovery" and connect with Jan Szollos, MBA, Senior Director of BD from our pharma.ai Business Development team. Be sure to reach out ahead of the conference in London to setup a meeting!
Insilico looks forward to this event year after year! See you there! 👥
📅 Event details: www.smgconferences.com/pharmaceuticals/uk/conference/drug…
#aiindrugdiscovery #londonbiotech #aiconferences -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Very cool read and I think @InSilicoMeds is the only drug discovery company in the UAE, not just the only one setting world records
appinventiv.com/blog/ai-in-healthcare-in-dubai/ -
Insilico Medicine
@InSilicoMeds
🚀 Insilico Medicine Reports Preclinical Benchmarks for AI-Designed Therapeutics 🚀 www.biopharmatrend.com/post/1137-insilico-medicine-report…
🔬 Key takeaways:
✅ Demonstrated success in AI-generated drug design
✅ Promising preclinical results for novel therapeutics
✅ A major step toward efficient, cost-effective, and innovative drug development
With AI reshaping pharmaceutical R&D, Insilico Medicine’s progress marks a significant milestone for the industry.
📖 Read the full article here: www.biopharmatrend.com/news/insilico-medicine-reports-pre…
What are your thoughts on AI's growing role in drug discovery? Let’s discuss in the comments! ⬇️
#drugdiscovery #artificialintelligence #biopharma #aidriveninnovation #pharmatech #insilicomedicine -
Insilico Medicine
@InSilicoMeds
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AI
www.eurekalert.org/news-releases/1073344 -
Insilico Medicine
@InSilicoMeds
Fierce Biotech Report: Insilico Medicine provides benchmark timelines from its 22 AI-designed drug candidates
After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving a tour of its entire molecular kitchen. The artificial-intelligence-powered drug designer is putting forward internal benchmarking data and timelines from 22 therapeutic candidates cooked up by the company’s platforms over the years.
At the same time, Insilico disclosed that it’s begun chasing new therapeutic areas, including obesity and muscle-wasting conditions as well as nonaddictive painkillers.
Insilico first announced in February 2021 that its AI programs had identified a new biological target linked to idiopathic pulmonary fibrosis (#ipf), designed a novel molecule to match, and completed several #preclinical studies and experiments to ready the potential therapy for its first human trials later that same year—all within the span of 18 months, and for a total price tag of about $2 million.
www.fiercebiotech.com/medtech/insilico-medicine-provides-… -
Insilico Medicine
@InSilicoMeds
👉Check out these New Enhancements and Features from Science42: #dora! Reminder, the winter sale expires on February 28, 2025! Get started today.
🚀Explore Loaded Custom Bibliography Files
-Effortlessly manage your loaded files with the new “Custom Bibliography” button in the left panel.
-Every loaded bibliography file now includes a convenient Preview/Download button.
When your document is generated, find Custom Bibliography file links directly in the right panel on the Bibliography page.
✔️ Docx Export Issue Resolved: No more errors! We've fixed the unsupported element type: hardBreak issue during the Docx export process.
⚡Citation Color Formatting: Parentheses in the Add Citation feature now display correctly—green and gorgeous!
These updates are designed to make your DORA experience smoother, more intuitive, and more powerful. We can’t wait for you to explore these exciting new features!
Visit pharma.ai/dora to get started today.
#dorawriting #documentgeneration #scientificwriting -
Insilico Medicine
@InSilicoMeds
Insilico Medicine divulges new potent PKMYT1 inhibitors www.bioworld.com/articles/716403-insilico-medicine-divulg…
-
Insilico Medicine
@InSilicoMeds
Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral www.morningstar.com/news/pr-newswire/20250121la00601/mode…
-
Insilico Medicine
@InSilicoMeds
👏👏 Thank you to @GENbio and @UofT for this partnership.
Genetic Engineering & Biotechnology News
@GENbio
.@InSilicoMeds, @UofT Researchers Develop Quantum-Classical Computing AI Model
Quantum computing and #ai can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein.
www.genengnews.com/topics/artificial-intelligence/insilic… -
Insilico Medicine
@InSilicoMeds
Speedier drug trials and better films: how AI is transforming businesses www.theguardian.com/technology/2025/jan/17/speedier-drug-…
-
Insilico Medicine
@InSilicoMeds
An end-to-end AI platform for novel drug discovery 💡
Petrina Kamya, Ph.D., President, Insilico Medicine Canada Inc., and Global Head of AI Platforms, VP, Insilico Medicine joins the SAE Media Group #aiindrugdiscovery Conference!
The following points will be covered:
-Combining Insilico’s AI platform with a fully automated, next generation laboratory for maximal success
-Detailing the recent advances in Insilico’s clinical pipeline – results from phase 2
-Challenges associated with progressing AI-designed molecules through the pipeline
See the full agenda and speaker list here: www.smgconferences.com/pharmaceuticals/uk/conference/drug… -
Insilico Medicine
@InSilicoMeds
🔥Insilico Medicine is proud to announce that Petrina Kamya, PhD, Global Head of AI Platforms, will lead the “Real-World Studies in AI-Driven #drugdiscovery and Development” session at #ddip2025 in San Diego.
Welcome to the Drug Discovery Innovation Programme (DDIP) — an invitation-only event where the future of #pharmaceuticalscience takes center stage.
This conference brings together the brightest minds in drug discovery to exchange insights, share experiences, and forge powerful collaborations with key industry leaders and solution providers. At DDIP, you lead the conversation! Curate your agenda to dive deep into the topics that matter most, empowering you to tackle pressing challenges and achieve actionable insights. Gain invaluable knowledge, evaluate cutting-edge technologies, and fast-track your strategic goals in a matter of days — not months.
Follow along for updates, and be sure to register online here: worldbigroup.com/drug-discovery-innovation-programme/ -
Insilico Medicine
@InSilicoMeds
✏️ Science42: #dora aims to improve the scientific drafting process. Check out the latest video to hear about smarter navigation, improved customization, workflow improvements, and much more!
Stay tuned for more exciting updates.
#dorawriting #documentgeneration #abstractpapers #reviewpapers #conferences #aigeneration
Visit: pharma.ai/dora today -
Insilico Medicine reposted
AI_4_Healthcare
@AI_4_Healthcare
Learning about AI in drug discovery ... now, live, with @biogerontology, CEO of @InSilicoMeds.
-
Insilico Medicine reposted
-
Insilico Medicine
@InSilicoMeds
Design and optimize small molecules with #generativeai and Physics-based methods
Chemistry42 is your one stop shop for all things small molecules drug discovery. Get started today: pharma.ai/chemistry42 -
Insilico Medicine
@InSilicoMeds
NEW Video 📽️ Coding the Impossible Cure--The First AI-Powered Drug with Safety and Efficacy Proved in Phase IIa
As our #ipf program reaches a new clinical milestone, we're excited to update our documentary and share the joy and confidence in AI-driven drug discovery with you. In November 2024, Insilico announced positive topline data from the IPF Phase IIa study. The results demonstrate that our drug, ISM001-055, exhibits a strong safety profile and dose-dependent efficacy. This achievement marks a significant milestone in the AI-powered #drugdiscovery world, as ISM001-055 was developed using our proprietary end-to-end AI platform, pharma.ai.
Watch the latest documentary here 👉www.youtube.com/watch?v=RMYkvbhOezo
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
🚀 Happy Monday from Science42: #dora! Here are some New Enhancements and Features now available to users:
💰 1. Pricing Table Update
-We’ve added a brand-new Enterprise product option.
-Now, you get a more comprehensive product description to help make informed decisions.
✏️ 2. Explore Loaded Custom Bibliography Files
-Easily manage your loaded files using new “Custom Bibliography” button in the left panel.
-Every loaded bibliography file now has a handy Preview/Download button for your convenience.
-Find your Custom Bibliography file links right on the Bibliography right panel page when document has generated.
📃 3. Template Selection Page as Default
-The template selection page is now your default view when you open DORA. Get started instantly. Clicking the Science42:DORA logo in the header now takes you straight to the template selection page.
4. Document Page Settings Customization
-Tailor the name of “Proposed Research Tasks” based on specific templates.
5. Streamlined Indication Prioritization Template
-We’ve removed points related to agents and resources from the Indication Prioritization template, making your research plan more streamlined.
6. Docx Export Issue
-No more errors! We’ve fixed the unsupported element type: hardBreak issue during the Docx export process.
7. Citation Color Formatting
-Fixed color formatting for parentheses in the ‘Add Citation’ feature. Green and gorgeous!
These updates are all about giving you a more efficient, user-friendly, and powerful experience with DORA. We can’t wait for you to dive in and explore these exciting new features!
Visit pharma.ai/dora to get started today.
#dorawriting #newfeatures #doraupdates #scientificwriting -
Insilico Medicine
@InSilicoMeds
Join us on Tuesday, February 4, at 12 PM ET for a live discussion with Alex Zhavoronkov, CEO of Insilico Medicine, on how AI is revolutionizing drug discovery. Don't miss this opportunity to gain insights from a leader in AI-driven biotechnology. Tune in live: www.linkedin.com/events/aidrugdiscoveryrevolutionwithal72…
#ai #drugdiscovery #insilicomedicine #alexzhavoronkov -
Insilico Medicine
@InSilicoMeds
While these results demonstrate the potential of quantum computing to accelerate the early stages of drug discovery, they stop short of showing that the molecules discovered using this approach are more effective than molecules identified through classical methods.
“Even though we show that a quantum computer can help with drug discovery, that doesn’t mean it is better than a classical computer at the task. This is a proof-of-principle study but does not provide any sign of significant quantum advantage,” says Aspuru-Guzik, who is also director of U of T’s Acceleration Consortiumand a member of the Vector Institute.
temertymedicine.utoronto.ca/news/u-t-researchers-develop-… -
Insilico Medicine
@InSilicoMeds
Unlocking the Power of Science42: #dora - Your New Document Generating Best Friend! 🚀🔬
Identifying the primary beneficiaries of Science42: DORA is essential to understanding its impact across various sectors. The following points outline how different groups can leverage its capabilities:
1/5 Researchers seeking to streamline their data analysis processes can greatly benefit from Science42: DORA. Tools such as the Integrated Biomedical Information System (IBIS) create centralized hubs for collaborative research, enhancing the efficiency of data analysis and knowledge discovery.
Insilico Medicine
@InSilicoMeds
2/5 Academic institutions aiming to enhance their research productivity will find Science42: DORA invaluable. Institutional characteristics and policies, along with financial support and structured incentives, are crucial for boosting research outputs.
Insilico Medicine
@InSilicoMeds
3/5 Students requiring reliable tools for their scientific projects can rely on Science42: DORA. It provides access to advanced scientific equipment and methodologies, enhancing their laboratory skills and problem-solving abilities.
Insilico Medicine
@InSilicoMeds
4/5 Industry professionals seeking to integrate advanced data analysis into their workflows will benefit from Science42: DORA. It supports data-driven decision-making and fosters collaboration across diverse domains.
Insilico Medicine
@InSilicoMeds
5/5 Overall, researchers, academics, students, and industry professionals can elevate their data analysis capabilities and drive innovation by utilizing Science42: DORA.
Get Started today: pharma.ai/dora
#dorawriting @dorawriting #documentgeneration #scientificwriting -
Insilico Medicine reposted
Temerty Medicine
@uoftmedicine
Study co-led by #temertymed researchers and @InSilicoMeds has demonstrated for the first time the potential of quantum computing and artificial intelligence to transform the drug discovery pipeline. temertymedicine.utoronto.ca/news/u-t-researchers-develop-…
-
Insilico Medicine reposted
Diana
@dorawriting
Joketime!
🔬 Scientist: "I wrote a grant proposal using #dorawriting so convincing, it should get funded instantly!"
💰 Reviewer: "Impressive! Just resubmit it five more times, wait a year, and maybe we'll think about it."
Tired of rewrites and long waits? DORA drafts clear, compelling grant proposals in minutes with AI-powered tools and expert templates. 🚀 Get funded faster—try DORA today!
#dorawriting #researchtools #aiwriting #ai -
Insilico Medicine
@InSilicoMeds
NEW Video 📽️ Synthetic Lethality Webinar and Hot Assets: #mat2a and #prmt5 Inhibitors
Explore our latest insights in synthetic lethality in this webinar hosted by Keith Mikule and Sean Cullen from our asset BD team. This informative webinar outlines the concept of synthetic lethality in oncology as it applies to drug development. Our colleagues describe the promising PRMT5/MAT2A pathway and outline how small inhibitors against these targets have begun to yield great promise for tumors with loss of MTAP, which encompass around 15% of all solid tumors. They also touch on Insilico Medicine’s internal programs for both MAT2A (Phase 1) and PRMT5 (IND enabling). Watch it here.
Check out the latest video here: www.youtube.com/watch?v=_o1eFWPUpkQ
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
I am very happy to announce that the first patient was dosed with our novel pan-TEAD inhibitor designed using generative AI Chemistry42 in a new Phase I clinical trial. My friends who are unfamiliar with TEAD, it is a "Swiss Army Knife" target that is super promising in multiple cancers but may also work in fibrotic diseases and it is also implicated in aging and age-related diseases (check out our dual-purpose targets paper in comments). I like this target a lot and I think that many pharma companies are missing out on TEAD as a potential blockbuster.
Great reporting by @brianbuntz for R&D World . He also picked up on DeepSeek AI's R1 before the general hype. -
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
.@uoftmedicine researchers develop new approach using quantum computers to accelerate drug discovery #nbtinthenews temertymedicine.utoronto.ca/news/u-t-researchers-develop-…
-
Insilico Medicine
@InSilicoMeds
⚡The PandaOmics platform just got a major upgrade—and it’s all about AGING RESEARCH!
Why is this HUGE? Understanding the biology of aging is the key to unlocking breakthroughs in age-related diseases and discovering groundbreaking therapeutic opportunities that could change the game for longevity!
Are you ready to take your research to the NEXT LEVEL? Time to dive into the future of aging research with PandaOmics. The clock is ticking... ⏰ Get started today: pharma.ai/pandaomics -
Insilico Medicine reposted
Masdar City
@MasdarCity
@InSilicoMeds is driving innovation within Masdar City’s Life Sciences cluster. Their groundbreaking work in AI-driven drug discovery is transforming pharmaceutical research and development, greatly reducing the time and cost to deliver life-saving medication to patients.
-
Insilico Medicine
@InSilicoMeds
📢Insilico Medicine announces first patient dosed in phase I clinical trial of ISM6331, the novel inhibitor for the treatment of mesothelioma and other solid tumors
-The global multicenter Phase I trial of ISM6331 that is enrolling patients in China and the United States has advanced with the dosing of the first patient in this study for the treatment of mesothelioma and other solid tumors.
-ISM6331, a potent pan-TEAD inhibitor with novel scaffold, demonstrates superior efficacy and safety in preclinical studies.
-ISM6331 not only effectively targets tumors with abnormalities in the hippo pathway but also shows synergistic anti-tumor effects and overcomes drug resistance in combination therapy.
For the full release, please visit: www.eurekalert.org/news-releases/1071279 -
Insilico Medicine
@InSilicoMeds
🚀 NEW Speaker Announcement, featuring Insilico President, Alex Aliper, PhD.
Join over 150+ world-class international and local speakers and 4,000+ delegates at this 4-day congress, designed to offer the latest advancements in #laboratoryscience. With 12 CME-accredited conference tracks, Medlab Congress 2025 leads the way in driving innovation and excellence in medical labs. Explore the full programme and dive deep into the details of each track to stay ahead in the rapidly evolving field of laboratory practice.
See the full agenda, and register today! www.worldhealthexpo.com/events/labs/dubai/
#medlabmiddleeast #diagnostics #automation #robotics #aievents -
Insilico Medicine
@InSilicoMeds
🤝 We’re honored to be part of the thriving MassBio community! A huge thank you to MassBio for fostering collaboration, innovation, and support within the life sciences industry. 👏
At Insilico Medicine, we’re excited to continue advancing AI-driven solutions for drug discovery and development alongside this incredible network of visionaries and changemakers. Let’s keep building the future of healthcare together! Thank you, @MassBio
www.linkedin.com/posts/massbio_massbiomember-massbiomembe… -
Insilico Medicine
@InSilicoMeds
Thank you @CityBizHub 🤝
Insilico Medicine Announces First Patient Dosed in Phase I Clinical Trial of ISM6331, the Novel Inhibitor for the Treatment of Mesothelioma and other Solid Tumors
“By inhibiting TEAD, ISM6331 has the potential to suppress tumor growth and progression, providing a targeted therapeutic strategy for malignancies driven by alterations in the Hippo pathway.” says Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine. “We look forward to further clinical validation of ISM6331 and to translating these promising preclinical findings into tangible clinical benefits for patients.”
Continue reading here 👉 www.citybiz.co/article/651804/insilico-medicine-announces… -
Insilico Medicine reposted
Ramesh Dontha 🦉
@EntrepreneursAI
Exciting news! @InSilicoMeds has started global trials for an AI-designed cancer drug.
Could this be the future of oncology? Find out in #aihealthtechinsider Issue #33. #cancerresearch #aiart
aihealth.standout.digital/p/ai-breakthrough-cancer-drug-t… -
Insilico Medicine
@InSilicoMeds
How breakthroughs in AI are helping to design life-saving drugs faster than ever before
edition.cnn.com/2025/01/23/business/video/ai-tools-cancer… -
Insilico Medicine reposted
Daniel Kraft, MD
@daniel_kraft
. @InSilicoMeds with the @UofT used an IBM Quantum Computer to generate a new KRAS inhibitor, synthesized it & tested it— showcasing the potential of quantum to generate experimentally validated hits that compare favorably against classical models.
www.nature.com/articles/s41587-024-02526-3 -
Insilico Medicine reposted
Future Medicine AI
@FutMedicineAI
🚨 In a (genuine) breakthrough for drug discovery, @InSilicoMeds (@biogerontology) and Acceleration Consortium at the University of Toronto (Igor Stagljar & (Igor Stagljar & Alán Aspuru-Guzik)) have used a hybrid of AI (classical) and quantum computing to unlock a previously undraggable cancer target called KRAS🚨
Our article has everything you need to know, including some of the science behind combing the strengths of AI and quantum computing for biological applications.
Read it here: www.fmai-hub.com/researchers-develop-breakthrough-quantum… -
Insilico Medicine reposted
Future Medicine AI
@FutMedicineAI
Insilico Medicine(@InSilicoMeds) is off to a strong start in 2025. Our latest article draws together recent developments contributing to this momentum, including:
🚨 Yesterdays announcement of ISM6331 (for mesothelioma) entering phase I
💰 A recent $100m series E funding round
🧬 Pipeline highlights— INS018_055 progresses to phase III trials for idiopathic pulmonary fibrosis & ISM5411 phase IIa planned for inflammatory bowel disease
🤝 Partnership deals— second licensing deal with MENARINI Group & $10m milestone payment from Exelixis
We also touch on some of the challenges Insilico Medicine is facing, such as it's IPO attempts and importance of successful outcomes in the next few years.
Full article here ): www.fmai-hub.com/insilico-medicines-strong-start-to-the-y… -
Insilico Medicine
@InSilicoMeds
Researchers Develop Breakthrough #quantumai Tool that Unlocks ‘Undruggable’ Cancer Target www.fmai-hub.com/researchers-develop-breakthrough-quantum…
-
Insilico Medicine
@InSilicoMeds
Insilico Medicine Announces First Patient Dosed in Phase I Clinical Trial of ISM6331, the Novel Inhibitor for the Treatment of Mesothelioma and other Solid Tumors
www.citybiz.co/article/651804/insilico-medicine-announces… -
Insilico Medicine
@InSilicoMeds
📢Two Nobel Laureates to Deliver Key Talks at #ardd2025
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
www.eurekalert.org/news-releases/1071277 -
Insilico Medicine
@InSilicoMeds
From Generative AI and ML to Quantum Computing, Bio-IT World 2025 Showcases Technologies Poised to Accelerate Lifesaving Therapies
www.bio-itworld.com/pressreleases/2025/01/09/from-generat… -
Insilico Medicine
@InSilicoMeds
Hot off the press 🔥
Quantum-computing-enhanced algorithm unveils potential #kras inhibitors
Drug discovery is a multifaceted and resource-intensive process encompassing the discovery, development and comprehensive testing of new molecules.
Read the full paper here: www.nature.com/articles/s41587-024-02526-3
@NatureBiotech -
Insilico Medicine
@InSilicoMeds
Incredible work in #quantumcomputing 👏👏
Structural Biology at St. Jude Children's Hospital
@StJudeStructBio
Congrats to our newest faculty member, Christoph Gorgulla @StJudeResearch, and colleagues @UofT @InSilicoMeds, for work just out @NatureBiotech — using quantum computing to design small molecules that inhibit KRAS. #openaccess
www.nature.com/articles/s41587-024-02526-3 -
Insilico Medicine reposted
GeneOnline
@GeneOnlineNews
With 15 AI-derived drugs in trials and predictions that 30% of new drugs will be AI-discovered by 2025, the landscape is changing fast.💊🤖
@InSilicoMeds take charge with the first AI-designed drug for idiopathic pulmonary fibrosis. 🚀
👉🏻 www.geneonline.com -
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors go.nature.com/3EitbLm
-
Insilico Medicine reposted
Acceleration Consortium (AC)
@acceleration_c
A study co-led by @UofT researchers + @InSilicoMeds has demonstrated for the first time the potential of #quantum + #ai to transform the drug discovery pipeline. Follow the link to learn more or read on below. temertymedicine.utoronto.ca/news/u-t-researchers-develop-…
-
Insilico Medicine
@InSilicoMeds
🌟 Join Petrina Kamya, Ph.D. Kamya at Bio-IT World Conference & Expo! 🌟
We’re thrilled to announce that Petrina Kamya, Ph.D., Global Head of AI Platforms at Insilico Medicine, will be presenting at Bio-IT World.
Session Details: Explore how generative AI is transforming the life sciences, accelerating breakthroughs, and redefining possibilities in drug discovery.
The traditional drug discovery process is lengthy, costly, and fraught with failure, with development often taking over a decade and costing billions. This talk will explore how generative AI is transforming this paradigm through Insilico Medicine’s innovative machine learning platform, enabling novel target identification, small molecule design, and clinical trial prediction. Discover how generative AI is accelerating drug development and reshaping the future of medicine.
See the full event agenda here: www.bio-itworldexpo.com?matchtype=b&adgroupid=89145905918…
#bioitworld #generativeai #pharmaai #drugdiscovery #insilicomedicine -
Insilico Medicine reposted
AI_4_Healthcare
@AI_4_Healthcare
AI, drug discovery, longevity, and beginning with the end in mind. Let's solve for aging and work backward from there? @biogerontology @InSilicoMeds @BBCScienceNews www.bbc.com/news/articles/cz6lg44jwwno
-
Insilico Medicine
@InSilicoMeds
New Analysis from www.theguardian.com/us
A treatment for a deadly lung disease called idiopathic pulmonary fibrosis has been hailed as the world’s first fully #ai-generated drug that is in late-stage trials. Developed by the Massachusetts-based company Insilico Medicine, it used AI to generate 30,000 novel small molecules and whittled this down to the six most promising drugs, and then a lead candidate.
Meanwhile, AstraZeneca, Britain’s biggest drugmaker, said more than 85% of its small molecule drug pipeline is “AI-assisted”.
Read the full article here: www.theguardian.com/technology/2025/jan/17/speedier-drug-…
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
NEW Video 📹
Learn how to discover targets in #pandaomics (pharma.ai/pandaomics) by setting #aging as a Disease in the video below and check out the paper we published from Aging-US www.aging-us.com/article/203960/textThis media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
@InSilicoMeds, a portfolio company of Qiming Venture Partners, has advanced endometriosis research with a renowned Hong Kong medical school, identifying two novel therapeutic targets and a promising drug repurposing strategy.
#qmportfolio
advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202406565 -
Insilico Medicine
@InSilicoMeds
🚀Introducing #nach01, where you can train accurate generative and predictive models on your data
Built on the capabilities of Nach0 and Nach0-pc, Nach01 leverages a #largelanguagemodel to process both structural and spatial data. Combining strengths from both predecessors, Nach01 is designed to solve hundreds of diverse tasks, providing a broad and comprehensive range of chemical knowledge.
Learn more and join the waitlist here: pharma.ai/nach01 -
Insilico Medicine
@InSilicoMeds
💡 NEW Peer-Reviewed Publication from EurekAlert!
Advanced Science: Insilico Medicine utilized AI technology for novel target discovery and drug repurposing to treat #endometriosis
Targeting endometriosis, a condition that affects more than 190 million women worldwide, the researchers used Insilico’s PandaOmics, the #artificial intelligence-driven platform, to identify two novel #therapeutictargets and a FDA approved drug as a potential repurposed treatment option. The findings were published in December 2024 in Avanced Science(IF=15.1).
In the study, the research team utilizes PandaOmics, the AI-driven biological engine to identify novel targets and potential non-hormonal drug repurposing strategies for endometriosis treatment. PandaOmics, a generative biology platform self-developed by Insilico Medicine, is based on over 20 biological models and proprietary databases. The platform not only supports professional target screening and indication exploration but also evaluates and ranks candidate targets based on novelty, credibility, commercial viability, durability, safety, and other key filters.
👉 See the full release and continue reading here:
www.eurekalert.org/news-releases/1070573 -
Insilico Medicine
@InSilicoMeds
cen.acs.org/business/informatics/AI-will-be-everywhere-in…
Insilico Medicine is a leader in AI-based drug discovery, but the company also uses generative AI for environmental sustainability. Zhavoronkov says this could be a big year for using AI to discover and manufacture materials needed for carbon capture. -
Insilico Medicine reposted
Exploding Topics
@explodingtopics
44 Fast-Growing Biotech Companies & Startups (2024)
Featuring:
- @InSilicoMeds
- @kriyatx
- @freenome
- @seedhealth
#startups #biotech
explodingtopics.com/blog/biotech-startups -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Insilico licenses AI-discovered drug candidate to Menarini
Collaboration focuses on AI-discovered oncology asset in license deal worth $550m – highlights growing significance of AI in drug discovery.
#longevity #investment #epigenetics #healthspan #biotech
longevity.technology/news/insilico-licenses-ai-discovered… -
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
📽️ Welcome to Generative Biologics. This AI-powered platform is developed for the design and optimization of a wide range of #biologics tailored to specific therapeutic targets. #generativebiologics supports a variety of biologic modalities including #peptides, #antibodies, and #nanobodies.
🚀 Hear from Insilico Medicine CEO, Alex Zhavoronkov, on the latest updates to the platform. Visit pharma.ai to get a full demo from our team of experts.
Biology42: Generative Biologics pharma.ai WEBINAR WEEK Nov 2024 youtu.be/kHp0SLMXC0U via @YouTube -
Insilico Medicine
@InSilicoMeds
🌟 We’re excited to see Alex Zhavoronkov, PhD, Founder & CEO of Insilico Medicine, featured in the latest Chemical & Engineering News (C&EN) article:
“#ai Will Be Everywhere in Chemistry.”
In this new piece, Alex shares how AI is revolutionizing chemistry, from accelerating drug discovery to advancing materials science, and why it’s set to transform the future of innovation across industries. 🚀
Read the full article to discover how AI is becoming a driving force in science and how Insilico Medicine is leading the charge: cen.acs.org/business/informatics/AI-will-be-everywhere-in…
💡 Curious about how Insilico’s AI platforms, like Chemistry42, are pioneering these advancements? Learn more at pharma.ai.
#aiinchemistry #innovation #drugdiscovery #insilicomedicine #leadership -
Insilico Medicine
@InSilicoMeds
🚀 Report: @FierceBiotech - Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal
www.fiercebiotech.com/medtech/insilico-medicine-licenses-… -
Insilico Medicine
@InSilicoMeds
📢 NEWS Release | January 10, 2025
MENARINI Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in #oncology
➕ This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their #generativeai platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase.
➕ Under the agreement, Menarini Group will be granted global rights to develop and commercialize the asset. The deal includes a $20m upfront payment, and the combined value, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.
⚡ The asset is a highly selective and potentially best-in-class small molecule inhibitor targeting a broad range of solid tumor cancers, developed with the help of Chemistry42, Insilico's #generativechemistry engine, and Insilico's drug discovery team. The asset has successfully completed #preclinical development and has demonstrated broad anti-tumor activity in selected cancers.
The full release can be found below 👇
www.prnewswire.com/news-releases/menarini-group-and-insil… -
Insilico Medicine
@InSilicoMeds
🚀 DORA 1.7.0 - Introducing the New DORA Redesign
We’re kicking off the new year with exciting updates and improvements! Thank you for choosing DORA. In 2025, we’re committed to delivering even more powerful tools and features to enhance your experience. Wishing you a successful and prosperous year ahead!
-New Homepage:
Document Tab: Choose between grid or card layouts for a customized experience. Documents requiring finalized settings are now easily identifiable with a new status icon.
#custombibliography Tab: Upload, rename, and delete custom files independently from the document generation process, ensuring better organization.
Improved Navigation: Seamlessly switch between template selection, the main document page, and the redesigned Document Settings page.
Streamlined User Info: Quickly access key account details from your profile icon.
Updated Tutorial: Get up to speed with the updated DORA tutorial, now featuring videos for a smoother onboarding experience.
-Enhanced Features for Document Generation:
Unified Settings Page: Manage all document-related settings from one centralized location.
Redesigned Input Fields: Enjoy cleaner input fields with detailed descriptions and helpful icons linking to the updated user manual. Gene-Disease association templates also feature suggested content tailored to your inputs.
Agent & Resource Selection: Select agents and their resources for data gathering across all templates.
Improved Custom Data Integration: Add custom data to specific template sections with clear visual highlights of dependencies between predefined sections.
Smarter Research Task Planning: Research plans now integrate seamlessly with custom data, enabling effortless manual adjustments to document outlines.
Updated Document Count Logic for Paid Users
Document counts only update when generation begins.
Current document availability is now clearly displayed on the Document Settings page.
-New Press Release Template:
Create professional announcements with the new press release template for general propose along wIth press release about the study.
Get Started with the New #dora Today! pharma.ai/dora
We’re excited to hear your feedback on the new redesign. Let us know how we can continue improving your experience!
#documentgeneration #publications #reviewpapers #conferenceabstracts #academicpapers #agents #dorawriting
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine
@InSilicoMeds
Thank you to @SliceofHC for including Insilico Medicine!
sliceofhealthcare.com/companies-to-watch-editors-choice-2…
Insilico Medicine is at the forefront of using artificial intelligence to accelerate #drugdiscovery and development. Their AI-driven platform helps identify potential drug candidates faster and more cost-effectively than traditional methods. By combining advanced machine learning with cutting-edge biology, Insilico Medicine focuses on tackling some of the world’s most challenging diseases. With a commitment to innovation and collaboration, they’re transforming the way new medicines are discovered, making the process faster and more efficient to improve patient care worldwide.
Congratulations to all the organizations! -
Insilico Medicine
@InSilicoMeds
🚀Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
www.biospace.com/press-releases/insilico-received-positiv… -
Insilico Medicine
@InSilicoMeds
We’re excited to announce Alex Zhavoronkov is speaking at @HumanX, the #1 AI conference of 2025! Don’t miss their insights on his.
Register now to join us onsite:
#humanx2025 i.snoball.it/p/o8mt/t/1 -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company @InSilicoMeds has nominated ISM1745 as a preclinical candidate for treating MTAP-deleted cancers. Powered by Chemistry42, ISM1745 is the company's 5th PCC nomination in 2024, bringing the total to 22 since 2021.
#qmportfolio -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Ten Levels of Longevity: #5 aging disease management
Clinical interventions for diagnosed aging diseases that bridge traditional care with longevity innovation.
#biotech #diagnostics #economy
longevity.technology/news/ten-levels-of-longevity-5-aging… -
Insilico Medicine
@InSilicoMeds
🚀 Happy New Year from the Science42: #dora Team! We are happy to announce DORA 1.7.0 - Introducing the New #dora Redesign
We’re starting the new year with exciting updates and improvements! Thank you for choosing our platform. In 2025, we’re committed to enhancing your experience with even more powerful tools and features. Wishing you a successful and prosperous year ahead
📰 What’s New?
-New Document Homepage
Access the new Documents home page and #custombibliography tabs to easily upload, view, and manage your references independently from the document generation process.
-New navigation: switch between template selection, other pages, and the main document page.
-Optimized User info: Key account details are now conveniently accessible under your profile icon.
2. Revamped design for the #documentgeneration page, enhanced by the agent and resource selection feature.
-Manage all document settings from a single, unified page
-Redesigned input fields with detailed descriptions and helpful icons linking to an updated user manual.
-Agents and resource selection: Select agents and their resources for data gathering, now available for every template.
-Improved Custom #dataintegration: A smoother process for adding custom data to specific template sections, with clear highlights of dependencies between predefined sections.
-Smarter Research Task planning: Research plans now integrate seamlessly with your custom data. Enjoy an enhanced experience for manually adding, updating, and adjusting future document outlines.
3. Updated Document count logic for paid users
Document count now updates only when document generation begins. The current document availability is clearly displayed for paid users on the document page settings.
Get Started with the New DORA Today! pharma.ai/dora -
Insilico Medicine reposted
GeneOnline
@GeneOnlineNews
Quote of the week 💬
Did you know that over 50% of drug discovery companies 🧬 are now integrating AI into their processes? In biotech, generative AI is revolutionizing molecule design, enabling researchers to create entirely new compounds with properties tailored to treat specific diseases—compounds that don’t exist in nature. This has the potential to cut drug development timelines by 40% ⏱️ and significantly reduce costs 💰.
But the impact doesn’t stop at healthcare. AI is reshaping industries like manufacturing ⚙️, where predictive algorithms are improving efficiency by up to 30%, and renewable energy 🌱, optimizing systems to increase output by 20%.
The possibilities are endless as AI transforms the way we innovate and solve global challenges. Which industry do you think will see the biggest AI-driven revolution next? 🤔
#artificialintelligence #aistatistics #generativeai #biotechinnovation #futureofwork #techforgood #aiforchange -
Insilico Medicine
@InSilicoMeds
🌍 As we step into 2025, Insilico Medicine reaffirms its commitment to sustainability and creating a healthier planet for all.
Our mission is to develop and promote open source cutting-edge generative AI technologies for environmental sustainability.
Together, let’s build a future where technology, health, and sustainability thrive hand in hand. 🌱✨
#insilicomedicine #sustainability #aiforgood #innovation #2025This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
🔥Science42: DORA (Draft Outline Research Assistant) is an advanced AI-driven tool designed to streamline the process of drafting academic papers and other related documents.
🔑Unlock the future of Scientific Writing today! Winter discounts are available: pharma.ai/dora -
Insilico Medicine
@InSilicoMeds
Happy Holidays from Insilico Medicine! ❄️
-
Insilico Medicine
@InSilicoMeds
ISM012-042’s gut-restricted distribution was confirmed in healthy and oxazolone-induced colitis mice.
We observed a 67-fold enrichment in the colon relative to the plasma (area under the curve (AUC)0−t = 0.3 h nmol ml−1) of healthy mice orally dosed with 10 mg kg−1 ISM012-042 with a similar colon–plasma exposure ratio observed in colitis mice (Fig. 1j,k and Supplementary Table 3), indicating that this distribution was independent of the intestinal barrier integrity or colitis severity.
We recapitulated this gut-specific distribution in rats (Supplementary Table 3), which were administered 30 mg 100 μCi−1 kg−1 14C-labeled ISM012-042 to trace the distribution kinetics of our compound over 48 h (Fig. 1l). The 14C-labeled ISM012-042-derived radioactivity was distributed into the small intestine, stomach and cecum as early as 0.5 h after dosing and peaked at 4 h, with most of the compound excreted by 24 h. Excretion was enriched in feces (~85% dose) with roughly 5% of total radioactivity (TRA) in the bile.
www.nature.com/articles/s41587-024-02503-w -
Insilico Medicine reposted
Longevity Technology
@LongevityTech
Innovations in longevity research and therapeutics in 2024
A look back at the year’s most intriguing developments in longevity science, from regenerative medicine to AI-driven discoveries.
#biotech #innovation
longevity.technology/news/innovations-in-longevity-resear… -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
Qiming Venture Partners' portfolio company, @InSilicoMeds, reports promising topline results from two Phase 1 trials of ISM5411, a small-molecule inhibitor targeting PHD1/2 for inflammatory bowel disease, powered by the AI-driven Chemistry42 platform.
#qmportfolio -
Insilico Medicine
@InSilicoMeds
www.linkedin.com/feed/update/urn:li:activity:727806577956…
💡 “As a researcher often involved in #drugdiscovery efforts, I get the feeling that AI is truly a powerful helping hand in the biopharmaceutical industry,” says Jingjing Peng, PhD, the first author of the paper and a medicinal chemist at Insilico Medicine, “In our work, we utilized AI to systematically identify and optimize HPK1 inhibitors with enhanced potency and selectivity. The workflow was streamlined, and we were excited to see the constant improvement at each milestone.”
📜 In the first paper published in September 2024, the team employed #pandaomics, the AI-powered discovery engine affiliated to pharma.ai, which integrates over 20 AI #bioinformatic models and billions of data points, for #hpk1 target evaluation. Supported by the knowledge graph based on AI analysis, as well as previous studies, HPK1 is hypothesized to mitigate select immune responses, laying the foundation for further molecule design and synthesis.
With a novel candidate compound identified with potent in vitro activity, markedly improved PK properties, strong in vivo anti-tumor activity and promising toxicity profiles, Insilico scientists achieved a starting point for further optimization of kinase selectivity and more properties.
Read the full release here 👉 www.eurekalert.org/news-releases/1068310 -
Insilico Medicine
@InSilicoMeds
“The generative chemistry module identified a novel PHD inhibitor candidate scaffold, the Alchemistry module optimized its potency by refining the Insilico Medicine Restricted (Level 3) molecular structure, and the ADMET profiling module modeled the physiochemical and biological properties that led us to select an effective and safe gut-restrictive molecule,” Zhavoronkov and colleagues reported in their paper.
www.genengnews.com/topics/artificial-intelligence/insilic… -
Insilico Medicine
@InSilicoMeds
⚡ What is the advantage of #dora over other AI-driven tools?
The main advantages of the DORA are:
-Structural integrity
-Relevant facts and hypotheses
-In-depth content generation
-Custom data integration
-Citation accuracy
-Reference transparency
-In-line customization
Effortlessly create professional scientific articles, literature reviews, perspective summaries, case reports, and more.
Get started today 👉 pharma.ai/dora
#reviewpapers #conferenceabstracts #publications #casestudies -
Insilico Medicine
@InSilicoMeds
The final paper in the series had increased AI input, introducing a series of potent, selective HPK1 inhibitors with a pyridine-2-carboxamide core generated by Chemistry42, using a structure-based drug design and hybrid strategy. The candidate compound displayed improved kinase selectivity against GLK and improved PK properties compared with the previous HPK1 inhibitors. Moreover, AI models guided the iterative design process, and AI-assisted docking models helped analyze the key binding interactions with HPK1.
www.eurekalert.org/news-releases/1068310 -
Insilico Medicine
@InSilicoMeds
“We are excited that our partner Exelixis is rapidly advancing the clinical development of XL309," said Michelle Chen, Ph.D., Chief Business Officer of Insilico Medicine. “This type of partnership is critical to Insilico Medicine’s business model, where we can leverage our strength in AI-powered drug discovery and our partner’s strength in clinical development and commercialization.
We look forward to continuing to work with Exelixis to develop XL309 for the potential to treat cancer patients globally.”
www.eurekalert.org/news-releases/1067983 -
Insilico Medicine
@InSilicoMeds
www.youtube.com/watch?v=oM6W3TbO4WU
📹In case you missed it
Pharma AI Week gave over 500 attendees an inside look into the latest updates across pharma.ai. Here is the highlight video from Chemistry42, which shares the highlights across these new features:
-New app: Model Training
-New app: #retrosynthesis
-Generative Chemistry
-#alchemistry
-ADMET Profiling
Chemistry42 is a comprehensive #smallmolecules #drugdiscovery platform. It streamlines hit identification, hit-to-lead, and lead optimization programs.
We hope you will follow along for more updates into 2025 🚀 -
Insilico Medicine
@InSilicoMeds
🎄Celebrate the Holiday Season with Big Savings on Science42: DORA! 🎄
This holiday season, we're spreading cheer to the academic and scientific community with 50% off Science42: DORA Premium and Advanced subscriptions!
💡 What is Science42: DORA?
The Draft Outline Research Assistant (#dora) is an advanced AI-powered tool designed to streamline the process of drafting academic papers, reviews, and other research documents.
Why Choose Science42: DORA?
-Fast and Efficient Drafting: Create comprehensive reviews in no time using #pmc, #pubmed, PandaOmics and other scientific datasources.
-Customizable Content: Add your own citations and leverage AI actions to refine your text.
-AI-Powered Review: Get insightful suggestions to improve your content and explore publication analytics.
-Tailored #bibliography Lists: Generate references that perfectly suit your research needs.
🎁 Treat yourself this holiday season and make your #research writing faster, easier, and more enjoyable!
Act now to take advantage of this limited-time offer! [Get 50% Off Today]
👉 Explore DORA’s Holiday Offer: pharma.ai/dora
#holidaysavings #science42 #aiinresearch #pharmaai #happyholidays -
Insilico Medicine reposted
Qiming Venture Partners
@QimingVC
With pharma.ai, Qiming Venture Partners' portfolio company @InSilicoMeds has unveiled a series of potent, selective HPK1 inhibitors for immunotherapy, enhancing druggability with each iteration.
#qmportfolio
www.eurekalert.org/news-releases/1068310 -
Insilico Medicine
@InSilicoMeds
🔥 NEW Video: Train accurate generative and predictive models on your data
Specially designed for both 2D and 3D molecular tasks. Seamlessly integrate and enhance your #pipeline by fine-tuning our foundation model using your data.
Increase success rate of experimental validation
#nach01's high precision lets you know everything you need about your molecules, whether you need #admet properties, activity, or quantum calculations.
Follow along for more updates from Nach01, and be sure to join the waitlist today: pharma.ai/nach01 -
Insilico Medicine
@InSilicoMeds
“Since Insilico’s foundation in 2014, I have seen, with my own eyes, lots of proof-of-concept cases in AI-driven drug discovery, and they are scattered across diseases areas and stages of the drug R&D process,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “The application of AI is revolutionizing the whole scientific research spectrum by enabling us to tackle complex challenges more efficiently and effectively, so that we’ll be living healthier, better, and more sustainable lives.”
www.eurekalert.org/news-releases/1068310 -
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
Generative AI helps Hong Kong’s @InSilicoMeds design potential new IBD drug #nbtnthenews via @scmpnews sc.mp/hakta
-
Insilico Medicine
@InSilicoMeds
🎄✨ Celebrate the Holiday Season with Big Savings on Science42: DORA! ✨🎄
This holiday season, we’re bringing cheer to the academic and scientific community with 50% off Science42: DORA Premium and Advanced!
Science42: DORA (Draft Outline Research Assistant) is an advanced AI-driven tool designed to streamline the process of drafting academic papers and other related documents.
🔬 Unlock advanced AI-powered research capabilities
📊 Optimize your data analysis and discovery process
💡 Accelerate insights in your field
Don’t miss out—this exclusive offer is available for a limited time!
🎁 Make the most of your year-end budget and start 2024 with a cutting-edge tool that’s transforming research.
👉 Explore DORA’s Holiday Offer: pharma.ai/dora
#holidaysavings #science42 #aiinresearch #pharmaai #happyholidays
Insilico Medicine
@InSilicoMeds
-
Insilico Medicine reposted
@dMatrix
@dMatrix_AI
“Training an AI model is a pretty expensive affair…its only affordable to a handful of companies on the planet” - d-Matrix CEO @sidsheth
Thanks @GlobalXETFs & @Bloomberg for featuring @dMatrix_AI's new AI chip with innovators @JohnDeere @InSilicoMeds
www.youtube.com/watch?v=ETQ67SzxxXg -
Insilico Medicine reposted
Insilico LAIR
@precious_gpt
Why are there so few @huggingface datasets dedicated to TCM?
We've tried to fix this and published 2 dsets related to our #p3gpt project on natural geroprotectors.
Feel free to build RAG tools or to fine-tune your models
huggingface.co/datasets/f-galkin/DragonTCM
huggingface.co/datasets/f-galkin/batman2 -
Insilico Medicine
@InSilicoMeds
NEW Video: 2024 Annual Conference - AI, Ageing and Redefining the Workforce - Alex ... youtu.be/k5aAy-FGToY via @YouTube
-
Insilico Medicine reposted
Insilico LAIR
@precious_gpt
📢Big update to our ecosystem! 📢
Visit @InSilicoMeds GitHub to get the latest scripts to interact with #p3gpt. We have just enabled:
- automatic instruction handling;
- combinatorial mass generations;
- cross-tissue and cross-species workflows
github.com/insilicomedicine/precious3-gpt/tree/main -
Insilico Medicine
@InSilicoMeds
Exploring cross-species aging hallmarks with P3GPT+DORA youtu.be/8HxFkPic_wM via @YouTube
-
Insilico Medicine
@InSilicoMeds
wewillcure.com new release 🚀
Researchers at Insilico Medicine achieved a groundbreaking milestone to design a first-in-class therapy for patients with inflammatory bowel disease (IBD). Having proved itself in #preclinical studies, the company’s promising oral drug candidate ISM5411, designed in less than a year with generative #artificialintelligence (AI), has entered early human studies.
While newer biologic drugs can help patients with moderate to severe IBD achieve a reduction in their symptoms, these treatments have a high rate of failure. The successful treatment of IBD, such as ulcerative colitis and Crohn's disease, has been hindered by an insufficient response in most patients.
Insilico’s ISM5411 might transform treatment for IBD.
Please visit: wewillcure.com/insights/ai-and-machine-learning/ai-design… -
Insilico Medicine
@InSilicoMeds
⚡ Going after multiple diseases
“We wanted to go after multiple diseases including #ibd,” Zhavoronkov explained. “The beauty of having a mucosal barrier repair molecule is that it can be combined with multiple anti-inflammatory and other drugs to deliver even greater benefit.”
In terms of the mechanism, intestinal PHD1/2-HIF-1α signaling is critical for maintaining epithelial barrier integrity by regulating processes such as mucus production, tight junction assembly, immunosuppressive metabolite synthesis, and wound repair.
Continue reading from Genetic Engineering & Biotechnology News www.genengnews.com/topics/artificial-intelligence/insilic… -
Insilico Medicine
@InSilicoMeds
Very exciting stuff from Science42: #dora @dorawriting 👏
Diana
@dorawriting
Imagine this: One DORA agent writes your paper, another reviews it with precision! 📝🤖
✨ Insights on language, content, readability, and more.
📊 Stats: word count, readability score, & citation year distribution.
❄️ Try it now at 50% OFF!
#dorawriting #aireview -
Insilico Medicine
@InSilicoMeds
NEW Video 📹
For the full paper from @SpringerNature , visit: www.nature.com/articles/s41587-024-02503-wThis media couldn't be displayed. See it on the original post. -
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor go.nature.com/4iteK6Z
-
Insilico Medicine reposted
Nature Biotechnology
@NatureBiotech
Insilico details AI-designed IBD candidate’s path to nomination #nbtnthenews via @GENbio www.genengnews.com/topics/artificial-intelligence/insilic…
-
Insilico Medicine reposted
Derya Unutmaz, MD
@DeryaTR_
Big congratulations to @biogerontology for yet another AI-developed drug! I recall well that Alex had this vision a decade ago when he founded @InSilicoMeds long before many believed it was possible. Kudos to him & his team for their persistence & pioneering in AI-drug discovery!
Nature Biotechnology
@NatureBiotech
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor go.nature.com/4iteK6Z
-
Insilico Medicine
@InSilicoMeds
🔥Announcing the latest from @NatureBiotech www.nature.com/articles/s41587-024-02503-w
-
Insilico Medicine
@InSilicoMeds
As the first line against #microbialinfections or endogenous cellular damage in our body, the innate immune system utilizes #nlrs (NOD-like receptors) to sense the molecules triggering #microbial infection and damage, thus ensuring the proper immune response function. In the NLRs family, #nlrp3 is the most characterized member, and its overactivation can lead to excessive production of pro-inflammatory cytokines and chemokines, driving pathological processes in various #inflammatory diseases.
Continue reading the full release here: www.eurekalert.org/news-releases/1067683 -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
Time flies and in a blink of a second I am almost 50... On the positive side, we managed to discover and put into clinical trials several therapeutics that may also have anti-aging effects in addition to treating diseases 🤞. So I am happy to be included in this year Microsoft's Slice of Healthcare 50 under 50 list and happy to see several good friends on the same list.
2024 was a great year with many AI breakthroughs, great papers, and even our first clinical success. 2025 should be much better. -
Insilico Medicine reposted
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
I discussed our latest paper in @NatureBiotech with Dr. Ren Feng, our superstar scientist who turned AI into the many valuable drugs. Check out the true power of PHD inhibitors.
www.nature.com/articles/s41587-024-02503-wThis media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
Announcing a major deal with @ExelixisInc to advance our novel, potentially best-in-class #genai-designed USP1 #cancer inhibitor. Insilico will receive $80m upfront in exchange for an exclusive, worldwide license to develop & commercialize ISM3091. www.businesswire.com/news/home/20230912041846/en/Exelixis…
-
Insilico Medicine
@InSilicoMeds
Emerging tech storyteller @TarynSouthern will judge Insilico's #docuthon contest. As a young breast cancer survivor, she's motivated to support #ai drug discovery. “AI-enabled drug discovery will rapidly shift the realm of possibility for these patients.” www.eurekalert.org/news-releases/995242
This media couldn't be displayed. See it on the original post. -
Insilico Medicine
@InSilicoMeds
A cautionary tale on the use of generative AI tools like ChatGPT in medicine from Insilico Medicine founder and CEO @biogerontology in @NatureMedicine
Nature Medicine
@NatureMedicine
Caution with generative AI tools, such as chatGPT, in medicine.
World View from @biogerontology, CEO at Insilico Medicine.
www.nature.com/articles/d41591-023-00014-w -
Insilico Medicine
@InSilicoMeds
"Alex Zhavoronkov, PhD, compared Insilico’s ambitions with Formula One, the car racing sport that's captivated a global audience by blending precision, speed and glamour." @FierceBiotech gets inside Insilico's vision for transforming #drugdiscovery. www.fiercebiotech.com/biotech/insilico-gases-60m-series-d…
-
Insilico Medicine
@InSilicoMeds
We @InSilicoMeds are extremely proud to announce that the first fully AI-designed #drug candidate is entering the clinic! Both the biological #target and the molecules were discovered using #ai. For more info please watch our video documentary: youtu.be/AOJfkDu5nC4

























































































































































































































































































































































































































































































